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CHAPTER I 
 
INTRODUCTION 
 
Overview: Inflammatory bowel disease and colitis-associated carcinoma 
Cancers of the digestive tract are a significant healthcare burden. In America in 
2008 alone, more than 135,000 are estimated to have died of cancers of the digestive 
system (1).  A large percentage of cancers of the digestive system arise because of chronic 
inflammation including hepatocellular carcinoma which can result from viral hepatitis, 
esophageal adenocarcinoma, which often arises from Barrett’s esophagus, gastric cancer, 
frequently caused by Helicobacter pylori-induced gastritis, and colon cancer, which can 
result from inflammatory bowel disease (IBD) (2). IBD is comprised of two types of chronic 
inflammatory disorders of the intestine: Crohn’s disease (CD) and ulcerative colitis (UC). 
IBD affects approximately 1.4 million Americans with typical onset occurring between 15 
and 30 years of age (3). While the etiology of IBD is incompletely understood, evidence 
suggests that IBD is the result of inappropriate inflammatory responses to intestinal 
microbes which is dependent on genetic susceptibility in the host (4). In fact, prevailing 
thought presents the model that 1) microbes or other undefined environmental 
exposure, 2) genetic susceptibility, and 3) inappropriately sustained and severe 
autoimmune inflammatory response leads to repetitive inflammatory injury to the 
gastrointestinal tract. 
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There is constant debate in the field regarding the level of risk for colorectal cancer 
(CRC) in patients with IBD which is greatly dependent on the set-up and analysis of 
epidemiological data. A large single academic center study focused on histopathology of 
IBD patients and risk of CRC demonstrated that histologically severe inflammation was 
present in 41.4% of patients with dysplasia and 24.1% with CRC, but only 4.3% in controls. 
Moreover, annual risk for dysplasia or CRC was increased 4.5% with longer disease 
duration implicating disease severity and duration in risk of developing CRC (5). Patients 
with IBD (standardized incidence ratio (SIR), 2.2; 95% confidence interval (CI) 1.5-3.0) and 
long-standing extensive colitis (SIR, 7.0; 95% CI 4.4-10.5) are at increased risk for CRC, 
although the risk is lower among patients receiving thiopurine therapy (6) indicating that 
treatment should be taken into account when analyzing risk of CAC.  
A meta-analysis of population-based data on cancer risk in CD revealed that there 
is an increased risk of CRC among people with CD (SIR, 1.9; 95% CI 1.4-2.5) (7) while a 
similar study analyzing UC revealed that men with UC have a greater risk of CRC (SIR, 2.6; 
95% CI 2.2-3.0) than women (SIR, 1.9; 95% CI 1.5-2.3) and that young age at disease onset 
(SIR, 8.6; 95% CI 3.8-19.5) and extensive colitis (SIR, 4.8; 95% CI 3.9-5.9) were both risk 
factors for CRC (8) implicating sex, age, and extent of colitis in risk determination. The 
risks outlined in the above studies represent values that are lower than those historically 
noted for CAC risk in IBD, but the risk depends on age of IBD diagnosis, disease duration, 
disease severity, and efficacy of therapies and IBD management (9-13). Moreover, more 
effective anti-inflammatory treatment as well as more effective surveillance has likely led 
to the decrease in the observed association. Importantly, increased disease activity is 
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associated with increased risk so understanding modifiers of IBD severity and CAC risk 
factors are of paramount importance. 
Unlike sporadic CRC there is no established genetic alteration associated with CRC 
predisposition in IBD. It is hypothesized that it is the chronic inflammation characteristic 
of IBD that causes cancer. In support of his hypothesis, CAC incidence increases with 
longer duration and greater extent of colitis, the concomitant presence of  
 
Figure 1.1 Tumor promotion by the tumor microenvironment. The cells within the tumor 
microenvironment form the niche for the tumor-initiating cells by producing tumor-promoting 
cytokines and chemokines. These create a supportive environment that supports the uncontrolled 
growth of initiated cells (promotion). The microbiota on the luminal side of the epithelium also 
contributes to the niche and is responsible for barrier defects and maintenance of chronic 
inﬂammation. The tumor microenvironment and epithelial cells interact with one another. Figure 
obtained from Quante et al (14). 
 
inflammatory symptoms including primary sclerosing cholangitis, and CAC incidence 
decreases in response to anti-inflammatory treatment (5, 15). This inflammation likely 
contributes to tumorigenesis via cytokine and chemokine production by infiltrating 
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immune cells which support tumor initiation and promotion (Figure 1.1) (16). In fact, 
disruption of the NLRP3 inflammasome increases tumorigenesis in a mouse model of 
colitis-associated carcinoma (17). Cytokines and growth factors produced by immune cells 
can contribute to all stages of tumorigenesis, from initiation to progression and 
metastasis, by promoting tumor cell proliferation, inhibiting apoptosis, suppressing anti-
tumor immunity and augmenting tumor blood vessel formation (14). 
Inflammatory cells, including activated macrophages and neutrophils, produce 
reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI), which are both 
highly reactive and mutagenic (18-21). As opposed to the early adenomatous polyposis 
coli (APC) mutations seen in sporadic CRC, early oncogenic events in CAC include p53 gene 
mutations. This occurs in both carcinoma and dysplasia, as well as in inflamed, but 
otherwise normal intestinal mucosa (22), suggesting that this mutation is an initiating 
event in development of CAC. Furthermore, epigenetic changes have been increasingly 
noted in relation to IBD and CAC. In fact, several groups have identified epigenetic 
modulation of histones and DNA within the loci of tumor suppressor genes including APC 
and p16(INK4a) and p19(ARF) as well as genes controlling DNA stability, such as MutL-
homolog (MLH) (23-28). Indeed, most of the effects of inflammation discussed above, 
such as the ability to cause mutations and epigenetic changes and promotion of cellular 
regeneration in response to injury, continue to enhance oncogenesis during the tumor 
promotion stage. Accumulation of subsequent genetic and epigenetic changes including 
mutations in K-Ras and BRAF enhance tumorigenesis by reducing apoptosis, increasing 
proliferation, and reducing growth factor dependence (29). Furthermore, several crucial 
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signaling pathways in the promotion of tumorigenesis are activated in response to 
inflammation in IBD including NF-κB (30), TGFβ (31) STAT3 (32, 33), IL-23 (34, 35), COX2 
(36), and IL-18 (37) to name a few. 
Chronic inflammation present during CAC development can also influence 
metastatic dissemination (38, 39). The acquisition of a mesenchymal or dedifferentiated 
phenotype by tumor epithelial cells, known as epithelial-mesenchymal transition (EMT), 
apart from being controlled by TGFβ signaling, can also be enhanced by NF-κB and/or 
STAT3 signaling (40, 41). Additionally, TNF signaling stabilized the transcription factor 
Snail, which is pivotal for EMT (42). TNF also promoted survival and dissemination of 
single cancer cells in circulation as well as their successful extravasation and growth in the 
secondary site (43). Inflammation also regulates various proteases, whose activity was 
implicated in remodeling of extracellular matrix and in metastatic process (38, 44). 
Overexpression of various matrix metalloproteases (MMP), such as MMP7 and MMP9, is 
a hallmark of colon cancer (44), essential for tumor growth and progression. Thus, a more 
detailed understanding of modifiers of inflammation in IBD as well as factors that 
influence aberrantly regulated pathways in CAC is essential for the development of 
preventative strategies in patients with IBD at risk to develop CAC. The nutrients and 
proteins of focus in this work are strong targets for risk identification as well as treatment 
options in the progression from IBD to CAC. 
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Selenium, selenoproteins, and human health 
In 1817, the element selenium (Se) was discovered by J.J. Berzelius (45). Initially 
considered toxic and later understood to be an essential micronutrient, it was not until 
the discovery of the first animal selenoprotein, glutathione peroxidase, in 1973 (46) that 
the Se mechanism of action began to be elucidated. Se is incorporated into proteins, 
known as selenoproteins, as selenocysteine (Sec) the twenty-first amino acid. Metabolic 
labeling studies reveal that 80% of bodily Se is incorporated into selenoproteins (47). To 
date, 25 genes encoding selenoproteins have been discovered within the human genome 
(48), the majority of which were discovered because Sec requires a very specialized 
mechanism for its incorporation into selenoproteins. Sec is encoded by a UGA codon in 
the selenoprotein mRNA. In most proteins, the UGA codon encodes a stop signal but cis-
acting sequences in the selenoprotein mRNA recruit specialized trans-acting factors that 
are dedicated to Sec incorporation. As can be imagined, selenoprotein production is 
dependent upon availability of Se (49) and the importance of particular selenoproteins to 
human health can be hypothesized based on the hierarchy of selenoprotein expression 
that is reliant on this Se requirement. Se dietary intake depends on the bioavailability and 
content of Se in crop plants that is contingent on Se content in soil. As an essential 
micronutrient, Se plays a significant role in many human health processes and has even 
been linked to cancer suppression. In the subsequent chapter, a detailed explanation of 
Sec incorporation into selenoproteins as well as a broad description of the roles of Se and 
selenoproteins in human health will be discussed. 
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Selenium metabolism 
Decoding of UGA as Sec is a well-conserved process, occurring in all three domains 
of life. The Sec incorporation mechanism has been largely worked out within prokaryotes. 
The Sec insertion site is identified by the presence of a stem-loop structure within the 
selenoprotein mRNA. This sequence is termed the selenocysteine insertion sequence 
(SECIS) and, in Escherichia coli, the SECIS resides directly downstream of the Sec UGA 
codon. In fact, movement of the SECIS by as few as three nucleotides can abolish Sec 
incorporation (50). In archea and eukarya, on the other hand, stem-loops are still required 
for the SECIS but sequence and structure requirements differ from prokaryotes. The SECIS 
is located within the 3’ untranslated region (UTR) of the mRNA and can be located a 
significant distance from the Sec codon (49). This distance is required so that the single 
SECIS can recode multiple UGA codons as opposed to a single, contiguous UGA codon as 
is seen in prokaryotes (51, 52). In fact, a minimal spacing requirement of ~60 nucleotides 
must exist (53).  
In addition to the cis-acting SECIS elements described above, Sec incorporation 
requires supplementary trans-acting factors including the selenocysteine-specific tRNA 
(tRNA[Ser]Sec) (54) as well as the enzymes required for the biosynthesis of the Sec-charged 
tRNA, selenophosphate synthetase, phosphoseryl kinase, and selenocysteine synthase 
(55-57). Also required are an elongation factor (EF) specific for the tRNA and a SECIS-
binding protein, SBP2, which recruits the EF to the selenoprotein mRNA (Figure 1.2) (58).  
Moreover, the recent discovery of mammalian Trit1 as a tRNA[Ser]Sec- isopentenyl-
transferase which is also indispensable for selenoprotein expression (59) demonstrates 
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that we are still learning about the complete mechanism of Sec incorporation into 
selenoproteins. 
Figure 1.2 A schematic demonstrating Sec incorporation in eukaryotes. The model shows the 
hairpin structure of the SECIS as well as the trans-acting factors that are integral to Sec insertion 
including the elongation factor (eEFSec), Sec-binding protein 2 (SBP2) and the Sec-tRNA. Figure 
obtained from Driscoll et al (49). 
 
Se metabolism takes place within the liver and ingested Se enters the liver via 
portal vein blood (60). Those selenoproteins synthesized by the liver include the Se 
transport protein selenoprotein P (Sepp1) which is exported to the circulation as well as 
selenoenzymes that support liver function (60). The liver also releases Se in the form of 
1β-methylseleno-N-acetyl-D-galactosamine, which is the major urinary selenium 
metabolites and has been identified in rat liver and in rat and human urine (61). Finally, 
the liver produces methylated excretory forms (62) and non-specifically incorporates 
selenomethionine into proteins. Of those forms of Se produced by the liver, Sepp1 is 
important for the distribution of Se to other tissues and production of other 
selenoproteins. 
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Sepp1 has ten selenocysteines incorporated into its primary structure, nine of 
which exist within a putative Se transport domain of Sepp1. This Se-rich C-terminal 
domain is necessary for the delivery of Se to the brain and testis (63) via apoER2-mediated 
endocytosis of Sepp1 (64, 65) and to the kidney via megalin, a lipoprotein receptor 
localized to the proximal tubule epithelium (65). Knockout of Sepp1 in hepatocytes 
decreases plasma Sepp1 concentrations by 90%, thus decreasing whole-body and tissue 
Se concentrations, further validating a role for Sepp1 in Se transport to tissues besides 
the brain, testis, and kidneys. Moreover, 75Se-labeled selenite tracing of metabolically 
available Se reveals that deletion of hepatocyte Sepp1 more than doubles 75Se excretion 
in urine and increases liver 75Se by 25% in mice lacking hepatic Sepp1 compared to 
controls, suggesting increased incorporation of metabolically available Se into liver 
selenoproteins consistent with there being competition for 75Se between synthesis of 
Sepp1 and production of excretory metabolites (Figure 1.3) (66).  
 
Figure 1.3 Model for the proposed fate of metabolically available Se. Hepatocytes can further 
metabolize several sources of Se. Synthesis of sec-tRNA[ser]sec ① competes with methylation 
reactions ② for Se and synthesis of Sepp1 ③ for export to the plasma competes with synthesis 
of intracellular selenoproteins ④. Furthermore, liver selenoproteins turn over ⑤ to release Se. 
The asterisks indicate the preferred path of Se during Se deficiency. Figure obtained from Hill et al 
(66). 
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Because Se is required for the production of selenoproteins, Se deficiency causes 
a substantial decrease in Sepp1 secretion. Moreover, Se deficiency also leads to 
decreased expression of other selenoproteins. During Se deficiency, mRNA stability 
contributes to the determination of what selenoproteins will be preferentially produced. 
The relative stability of mRNAs has been determined to be glutathione peroxidase-4 
(Gpx4) > Sepp1 > thioredoxin reductase 1 (TrxR1) > type I deiodinase (D1) > glutathione 
peroxidase-1 (Gpx1) (67). This hierarchy of mRNA expression likely relates to the relative  
importance of the selenoproteins in cellular homeostasis. Additionally, Se retention and 
selenoprotein expression are differentially regulated within different tissues, thus 
providing further hierarchical regulation of selenoprotein expression (68, 69).  
 
Selenium in human health 
The importance of Se to human health is most obvious when considering diseases 
common in areas of the world with Se-poor soil. Se deficiency has been identified as a 
factor in Keshan disease, a cardiomyopathy (70), which can be prevented by dietary Se 
supplementation. Se supplementation also prevents and treats Kashin-Beck disease, a 
deforming osteoarthritis (71). Both of these diseases are found in areas of China in which 
soil Se concentrations are low. The importance of selenoproteins to human health is 
demonstrated by humans with genetically impaired biosynthesis of selenoproteins who 
develop a multisystem disorder characterized by failure of the latter stages of 
spermatogenesis, axial muscular dystrophy, increased cutaneous ROS and susceptibility 
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to ultraviolet radiation-induced oxidative damage, impaired T lymphocyte proliferation, 
abnormal mononuclear cell cytokine secretion, and telomere shortening (72), giving some 
of the best evidence for the varied roles of selenoproteins in maintenance of human 
health.  
Furthermore, epigenetic evidence reveals that low levels of Se are linked to a 
number of health problems including decreased survival in people infected with HIV (73), 
epileptic seizures (74) and age-associated neurological disorders (75). Moreover, dietary 
Se supplementation contributes to the prevention of neurodegenerative and 
cardiovascular diseases related to chronic oxidative stress as well as in the treatment of 
inflammatory disorders including autoimmune thyroid disease (76), viral diseases and 
sepsis (77-79), suggesting a link between Se and inflammation. In fact, a higher risk of CD 
was noted in individuals with low baseline Se levels. 
 While low Se status has been linked to several diseases, there is also risk 
associated with supranutritional Se status. At the most extreme, Se poisoning can result 
in hair loss, skin lesions, and deformities and as selenosis progresses, decreased cognitive 
function, weakness, paralysis, and ultimately death can occur (80). Se poisoning to this 
extent is rare, though, so it is the detrimental effects of slightly increased Se levels that 
are most worrisome. A secondary analysis of the Nutritional Prevention of Cancer (NPC) 
trial revealed that Se-enriched yeast supplemented individuals whose baseline plasma Se 
levels exceeded 122 ng/ml were at increased risk of developing type 2 diabetes compared 
to those assigned placebo (81). Though the mechanism of this increased risk is not clearly 
understood, the expression of selenoenzymes such as Gpx1, which act as antioxidants, 
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may interfere with insulin-regulated cellular pathways via hydrogen peroxide (H2O2) 
reduction (82), as H2O2 normally enhances the early insulin signaling cascade and 
stimulates insulin-induced glucose uptake (83, 84). Moreover, both Se compounds and 
Sepp1 are capable of attenuating insulin-induced phosphorylation of protein kinase B 
(Akt) (85, 86), and insulin downregulates hepatic biosynthesis of Sepp1 (85, 87), thus 
providing a potential feedback loop. Thus, there is a very small window in which Se 
supplementation is beneficial to human health, beyond which there are also detrimental 
effects.    
 
Optimal recommended daily selenium intake 
 Se availability is the most important determinant for biosynthesis of 
selenoproteins. Therefore, optimized expression of selenoproteins through Se 
supplementation represents both a key objective and a biomarker of Se-replete status in 
intervention trials (88). As suggested in the previous section, there is a narrow target for 
beneficial Se supplementation. Animal studies demonstrated an inverted “U”-shaped 
curve of optimal Se intake where too little or too much Se can be detrimental to health 
(89). Further complicating matters, a number of studies designed to determine optimal 
Se supplementation arrived at very different conclusions based on the method of Se 
determination, study goals, and the population in which the study was conducted. In the 
U.S., where Se is available at sufficient levels in crops, the recommended dietary 
allowance for Se is 55 μg/day for healthy adults (90), while other studies have 
recommended that adequate Se intake ranges between 30 and 85 μg/day, with a 
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tolerable upper intake level of 300-450 μg/day (77, 91). These values have been 
determined based on various Se status parameters.  
Traditionally, the Se content in hair, toenails or plasma has been measured; 
however, plasma levels of the two extracellular selenoproteins plasma glutathione 
peroxidase (Gpx3) and Sepp1 are considered to be preferable as biomarkers. Maximal 
Gpx3 activity is achieved at an intake of ~70 μg Se/day or plasma Se levels of 90 ng/ml 
(92). Sepp1 plasma levels plateau at ~105 μg Se/day and plasma Se levels of 124 ng/ml 
(93). As full expression of Sepp1 requires a greater Se intake than does Gpx3, it is the 
better indicator of Se nutritional status (94). On the basis of the Se intake needed for 
optimal Sepp1 expression based on the aforementioned parameters, ~75 μg Se/day is 
recommended for U.S. residents (95), but even this value comes with several stipulations. 
For instance, effects of Se-enriched milk protein and Se-yeast on rectal selenoprotein 
mRNA levels have been compared in Australians with adequate Se status (basal plasma 
Se levels of ~100 ng/ml) and while plasma Se levels increased similarly in both Se-
supplemented groups, dairy-Se was more effective at stimulating selenoprotein 
expression (96), suggesting that the form of Se supplemented has an impact on the 
efficiency of incorporation.  
Genetic polymorphisms also have a significant impact on Se utilization, meaning 
that the Se requirement for optimum human health can vary among individuals (97-102). 
Finally, the health process that is being modified by Se supplementation must be 
considered. For example, people with IBD demonstrate a decreased ability to absorb 
nutrients and thus have an increased risk of Se deficiency. Se supplementation in these 
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patients would need to be carefully monitored for Se biomarkers to insure adequate 
supplementation. Additionally, other diseases in which inflammation and ROS exceed the 
ability of the redox system to maintain balance might require higher levels of Se to insure 
proper maintenance of selenoptroteins.  
In conclusion, when considering successful Se supplementation, four points 
should be considered: 1) the genetic and metabolic determinants that may affect 
efficiency of dietary Se supplementation, 2) differences in metabolization and, therefore, 
biological impact of the different Se compounds, 3) Se absorption and usage within 
individuals, and 4) potential adverse health effects of high Se intake (103). 
 
Selenoproteins as modifiers of tumorigenesis 
The vast majority of the characterized selenoproteins are enzymes that catalyze 
oxidation-reduction reactions and contain Sec in their active sites (104). Though Sec is 
structurally identical to cysteine (Cys) with the exception of a Se replacing the sulfur, the 
selenol group in Sec is more fully ionized than the thiol of Cys at physiological pH, making 
it a more potent antioxidant (105). Due to its antioxidant role as well as a plethora of 
epidemiological evidence pointing towards selenium as a suppressor of tumorigenesis, it 
is predicted that selenoproteins contribute to suppression of a multitude of cancer types. 
Within the following sections, the functions of selenoproteins as they relate to tumor 
modifying properties will be discussed with a particular focus on the two plasma 
selenoproteins, Gpx3 and Sepp1. 
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Selenium and selenoproteins in oxidative stress response and cancer 
Populations with low Se status are at increased risk for several cancers including 
prostate, breast, lung, laryngeal and colorectal (106-108) and increased cancer-specific 
mortality has been seen in renal cancer patients (109). Moreover, animal models have 
demonstrated that Se supplementation can reduce the incidence and severity of liver, 
esophageal, pancreatic, prostatic, colon, and mammary carcinogenesis (110). In support 
of a potential role for Se in cancer suppression, several novel drugs are in development. 
Synthetic organoselenium compounds have been generated to promote anti-tumor 
activity (111), and encapsulated elemental Se nanoparticles are in production to increase 
anti-tumor efficacy and decrease toxicity compared to Se compounds commonly used in 
dietary supplements (112). 
Interestingly, despite a consistent pattern in epidemiology, there are questions as 
to whether Se supplementation is of potential value in reducing cancer risk. An early 
intervention study of high-selenium yeast in humans demonstrated protection against 
prostate and other cancers (113, 114). The Wheat Bran Fiber Trial, the Polyp Prevention 
Trial, and the Polyp Prevention Study corroborated that variations in Se status may affect 
CRC risk as adenoma recurrences were significantly lower in the quartile with the highest 
plasma Se levels (150 ng/ml) versus the quartile with the lowest Se (113 ng/ml) (115). A 
Spanish study reported significantly lower serum Se levels in two groups of patients with 
large-size colorectal adenomas or CRC compared to healthy control subjects only for the 
age group ≤ 60 years (116), suggesting that age may be a confounding factor in several 
studies. Furthermore, a U.S. cancer screening trial identified a significant inverse 
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association between serum Se levels and the occurrence of advanced colorectal 
adenomas only among the high-risk group of recent smokers (117) implicating lifestyle 
decisions such as smoking as potential modifiers of study outcome.  
In contrast, two larger U.S. case-control studies did not find any clear association 
between serum Se levels and the risk of recurrent CRC (118, 119), and a meta-analysis of 
intervention trials concluded that oral administration of antioxidants including Se were 
not effective in the prevention of colorectal neoplasia in the general population (120). As 
has been mentioned, though, there are limiting factors when considering Se 
supplementation in otherwise healthy people in areas like America where Se status is 
already sufficient for complete selenoprotein production. In support of this, in a meta-
analysis of randomized controlled trials of Se supplements and cancer prevention, there 
was sufficient evidence to support the use of Se supplements in populations with high risk 
of cancer and low baseline Se levels (121).  
There were several lines of evidence that point towards mechanisms for Se 
modification of tumorigenesis. Several intracellular selenoproteins metabolize reactive 
oxygen intermediates and thereby defend the cell against oxidative injury. In fact, it 
appears that over one third of all known selenoproteins are antioxidant in nature (122) 
and the antioxidant activity of selenoproteins is essential in minimizing the levels of 
hydroperoxides (123, 124). Thus, Se deficiency increases endogenous cytosolic oxidative 
stress (125). Rat models have shown that Se deficiency can lead to liver necrosis and lipid 
peroxidation in response to small doses of the redox-cycling compound diquat (126). 
Importantly, injection of Se ten hours prior to diquat injection prevents the injury via the 
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selenoprotein Sepp1 (127, 128). Alterations in oxidative stress have varied and far-
reaching consequences in terms of tumor modulation. Most directly, high levels of ROS 
can promote cancer development through direct oxidative damage to DNA by species 
such as the hydroxyl radical (129). However, more recent evidence suggests that other 
actions of ROS, such as effects on p53, Nrf2, and Wnt signaling, cell proliferation, and 
invasiveness might be important to cancer susceptibility (130, 131).  
As many intermediate steps in both the Nrf2 and Wnt pathways can be modulated 
by hydroperoxides, Se deficiency activates these pathways. In fact, the oxidation sensor 
Keap1, which maintains Nrf2 in the cytosol until its modification by 
hydroperoxides/electrophiles, is the link between Se and Nrf2 signaling. Wnt signaling, on 
the other hand, is activated by the oxidation sensor nucleoredoxin (Nrx), which is 
associated with disheveled (Dvl). Se deficiency results in oxidation of both sensors and 
the ultimate activation of both pathways (130), which are key players in the pathogenesis 
of cancer (132-134). Moreover, by a likely feedback mechanism, the selenoproteins Gpx2, 
TrxR2, and TrxR3 are regulated by Wnt signaling. Thus Se, which is essential for the 
biosynthesis of Wnt-dependent selenoproteins, is likely important during carcinogenesis 
(135). 
As oxidative stress causes DNA damage, Se also impacts protection against DNA 
damage. Supplementation of either tissue culture media, animal or human diets with 
even moderate levels of Se compounds protect against the formation of DNA adducts, 
DNA/chromosome breakage, chromosome gain or loss, mitochondrial DNA damage, and 
telomere length and function alterations, and it is proposed that Se might do so through 
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more direct mechanisms than just reduction of hydroperoxides. Se has been proposed to 
enhance the DNA damage response, increase the activity of repair enzymes such as DNA 
glycosylases, and augment DNA damage repair pathways that involve p53, BRCA1 and 
Gadd45 (136). 
Se is also thought to suppress tumor progression through inhibition of metastasis. 
Se has been linked to inhibition of angiogenesis, the formation of new blood vessels 
within and around a tumor through which metastatic cells can enter the blood stream, in 
mammary cancer. Se does so via inhibition of endothelial proliferation and survival as well 
as matrix degradation through enhancing production of Mmp7 (137). Moreover, other 
aspects of metastasis are inhibited by Se including cell motility, migration and invasion 
(138). Thus, Se not only inhibits tumor growth but also progression. 
Experimentally, there is a plethora of evidence for a role of selenoproteins in 
protection from tumorigenic processes. In a murine model of chemically-induced 
hepatocarcinogenesis, tumorigenesis is increased in mice expressing a mutant Sec tRNA 
gene (TrspA37G) compared to wild-type mice (139), but Se supplementation decreased 
tumor size via augmentation of transforming growth factor-alpha (TGFα) signaling (140). 
Specific selenoproteins have also been tested for their impact on tumorigenesis in several 
models. For instance, in a mouse model of inflammation-associated carcinogenesis, 
glutathione peroxidase-2 (Gpx2) and Se decreased both inflammation and tumorigenesis 
(141) and knockout of the 15 kDa selenoprotein protected against aberrant crypt 
formation (ACF) during chemically-induced colorectal carcinogenesis (142). Moreover, 
epidemiological evidence exists for the involvement of selenoproteins in human 
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tumorigenesis. Loss of heterozygosity of the GPX1 locus has been identified in breast, 
lung, head and neck, and colon cancers (143-145). A second glutathione peroxidase, Gpx3, 
is a biomarker for ovarian tumors and is frequently methylated in prostate cancer and 
esophageal adenocarcinoma arising in the setting of Barrett’s esophagus (146, 147). 
Within the thioredoxin reductase system, both Trx and TrxR1 are overexpressed in non-
small cell lung carcinoma, T-cell acute lymphoblastic leukemia, malignant pleural 
mesothelioma, colorectal cancer, breast carcinoma, hepatocellular carcinoma, gastric 
carcinoma, and cervical carcinoma. Moreover, increased cellular proliferation, decreased 
patient survival, and chemotherapeutic resistance are associated with overexpression of 
the thioredoxin system (148). Additionally, several selenoprotein single nucleotide 
polymorphisms (SNPs) have been associated with CRC (Figure 1.4). Of particular interest 
in their modification of cancer phenotypes are the plasma selenoproteins GPx3 and Sepp1 
as they could potentially impact both intra- and extracellular redox activities.  
 
Plasma glutathione peroxidase (Gpx3) in cancer 
 Gpx3 is expressed in a wide range of tissues, localizing to the cytoplasm and nuclei 
of cells and secreted into the blood stream (149). Due to its nuclear localization as well as 
its broad and unique substrate spectrum, including lipid and thymine hydroperoxides, 
Gpx3 is hypothesized to play an important role in Se-dependent chemoprevention. Gpx3 
specifically reduces lipid peroxide concentrations in cell membranes and downregulates 
the eicosanoid biosynthesis pathway. This pathway increases inflammation, cancer 
growth, and metastasis suggesting that Gpx3 might inhibit tumorigenesis (150). 
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Figure 1.4 Colorectal functions modified by selenoproteins and their SNPs. The schematic shows 
the identified genetic interactions in the context of selenoprotein subcellular localization and  
biological function. Pictograms illustrate SNPs where rs numbers are defined in the legend in the 
upper right. Black arrows indicate the delivery of Se to the different selenoproteins. Figure 
obtained from Meplan et al (99). 
 
 
There is inconsistent data regarding the roles of Gpx4 gene variants within the human 
population. The gene variant rs713041, which is located in the 3’UTR of GPX3, has been 
loosely associated with increased CRC risk (151). A second polymorphism in the GPX3 
gene causes a T-C substitution in the 3’UTR bordering the SECIS element (152). In vitro, 
the C variant promotes reporter gene expression to a greater extent than the T variant 
and competes more strongly for one or more proteins involved in Se incorporation, 
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possibly through modification of the structure of the 3’UTR in the vicinity of the SECIS 
(153). Likely due to these alterations in Gpx3 expression, the C variant has also been 
associated with increased mortality in breast cancer patients (154). Moreover, breast 
cancer patients have impaired basal Gpx3 gene expression and a reduced ability to induce 
Gpx3 expression in response to oxidative stress (155).  
In perinatal mice Gpx3 loss in the epidermis causes hyperplasia, dermal 
inflammatory infiltrate, dysmorphic hair follicles, and alopecia. These phenotypes are at 
least partially due to increased lipid peroxidation and COX2 levels (156). Moreover, 
ectopic Gpx3 expression in pancreatic tumor cell lines as well as L929 cells suppresses 
tumor progression by reducing proliferation, tumor growth in semisolid media and in 
orthotopic xenografts (157, 158). These data indicate that Gpx3 might suppress 
tumorigenesis, especially in the context of high inflammation and oxidative stress. 
 
Selenoprotein P (Sepp1) in cancer 
 Based on its Sec location, Sepp1 has two domains. The first, and larger domain 
extends from the N-terminus through the residue just before the second Sec (residues 1-
244). This N-terminal domain contains one Sec and seven Cys residues and the Sec exists 
within a UXXC motif that catalyzes the oxidation of glutathione (GSH) by a 
phosphatidylcholine hydroperoxide (159). The smaller domain extends from the second 
selenocysteine to the C-terminus (residues 245-366). It contains nine Sec and ten Cys 
residues (160) and serves as a Se transport domain (63). 
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Although Sepp1 is expressed almost ubiquitously in many tissues and cell lines 
(161), most research has focused on liver-secreted plasma Sepp1 (160). Interestingly, 
Sepp1 is abundantly expressed in normal colonic mucosa, and SEPP1 mRNA and 
accompanying activity is significantly reduced in colon tumors (162). Similarly, it is 
dramatically reduced in human prostate tumors, mouse tumors, and in the androgen-
dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cell lines (163). 
Several SNPs have been identified in SEPP1 that might contribute to decreased expression 
in tumors. For instance, there is an association between rs7579 genotype in SEPP1 and 
prostate cancer risk (164). Furthermore, four variants in SEPP1 were significantly 
associated with advanced colorectal adenoma risk including the variant SEPP1 -4166G, 
which exists within the promoter region, two loci in the 3’ region of SEPP1, and a third 
locus in the 3’ region of SEPP1, which was inversely associated with risk of colorectal 
adenoma (165). Also, though a novel (TC)3 polymorphism within a complex (A)4-C-(A)4-
GG-(A)8-GCT-(TC)5-(T)17 (bp – 429 to bp – 477) repeat structure of the SEPP1 promoter 
confers significantly reduced basal promoter activity, there is not a definitive link between 
this polymorphism and cancer risk. Additionally, genetic instability was observed within 
the (T)17 repeat motif in CRC to the mutator phenotype. Thus, this SEPP1 complex repeat 
structure may be of functional relevance to Sepp1 gene expression and thus modify 
tumorigenesis (98). 
Experimentally, there is evidence supporting a role of Sepp1 downregulation in 
mechanisms of tumor promotion. Sepp1 knockdown in Pr-111 cells resulted in increased 
ROS and subsequent cell growth inhibition upon H2O2 exposure. In support of Sepp1 loss 
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being the driver of these phenotypes, administration of exogenous Sepp1 was able to 
buffer ROS and rescue growth inhibition (166). Sepp1 has also been implicated in 
inflammatory processes that play substantial roles in tumorigenesis. The cytokine TGF-β1 
which is overexpressed in colon cancers (167) exerts an inhibitory effect on Sepp1 
secretion as well as represses Sepp1 transcription (168). Additionally, treatment of HepG2 
cells with the cytokines interleukin 1β (IL-1β), tumor necrosis factor α (TNFα), and 
interferon γ (IFNΥ) repress promoter activity (169). These data suggest that Sepp1 is 
downregulated in response to inflammation and that this mechanism might contribute to 
Sepp1 downregulation during tumorigenesis. Another mechanism of Sepp1 regulation 
might depend on inhibition of Sepp1 transactivation by the glucocorticoid receptor which 
is increased during development, differentiation, and under conditions of critical illness 
(170). 
Differentiation, a process often reversed during the course of tumorigenesis, is 
also influenced by Sepp1. During enterocytic differentiation, Sepp1 gene expression and 
secretion are both strongly upregulated through increased binding of hepatocyte nuclear 
factor-4α (HNF-4α) to an upstream promoter element in Sepp1 (171). Additionally, 
knockdown of Sepp1 in 3T3-L1 cells inhibits adipogenic differentiation, likely via 
concomitant upregulation of proinflammatory cytokines (172). These data suggest that 
Sepp1 promotes differentiation, a process that is generally associated with tumor 
progression. Thus, Sepp1 appears to be a contributor to suppression of tumorigenesis in 
multiple cancer types. 
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Transcriptional corepressors with functions in gut development  
and epithelial wound repair: Myeloid translocation genes 
 The analysis of translocation breakpoints in acute leukemia has identified several 
gene regulatory proteins that are critically involved in cellular proliferation, 
differentiation, apoptosis and stem cell properties; all processes that contribute to the 
leukemic phenotype (173). For example, the reciprocal translocation between the 8th and 
21st chromosomes (t(8;21)) associated with acute myeloid leukemia (AML) has enabled 
the discovery of AML-1 on chromosome 21 and myeloid translocation gene 8 (MTG8, 
otherwise known as eight twenty-one; ETO) on chromosome 8 (174). t(8;21) retains the 
AML-1 DNA binding domain which is fused to the majority of the MTG8 protein. Knock-in 
of the AML-1/ETO translocation demonstrates that the fusion protein acts in a dominant 
manner to inhibit AML-1 targets (175). This suggests that MTG8 serves to form repression 
complexes which contribute to repression of targets bound by AML-1. In support of this, 
biochemical and molecular studies reveal a role for MTG8 as a component of histone 
deacetylase (HDAC) complexes which are recruited to AML-1 target genes (176-178). 
 After the discovery of MTG8, two other MTG family members were identified: 
myeloid translocation gene on chromosome 16 (MTG16) and myeloid translocation gene 
related protein-1 (MTGR1) (179-182). MTGR1 was characterized within the L-G murine 
myeloid cell line as an AML-1/ETO interacting protein. MTGR1 is an 85 kDa 
phosphoprotein that is recognized by MTG8 antibodies (182). Moreover, this gene was 
validated in randomly sequenced human cDNA (EST) database searches based on the 
MTG8 cDNA search probe. As such, MTGR1 is also termed ETO homologous on 
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chromosome twenty (EHT) (180). MTG16 is a second, less common, translocation 
involving chromosome 21, t(16;21), which was identified in therapy-related AML. 
Characterization of MTG16 cDNAs revealed a high degree of homology to MTG8 (181).  
The MTG family of proteins are defined by four evolutionarily conserved domains 
called nervy homology regions (NHR) 1-4. The NHR1 and NHR2 domains are protein-
interaction motifs (177, 183, 184). NHR1, homologous to the Drosophila transcriptional 
co-activator TBP-associated factor 110 (TAF110) (185), can positively or negatively 
regulate transcription through interaction with either co-repressors or transcriptional 
activators (186). The NHR2 domain contains a hydrophobic heptad repeat that mediates 
MTG dimerization as well as binding to the transcriptional co-repressor SIN3A (182, 187). 
The function of the NHR3 domain is not well understood but it is hypothesized that it may 
be involved in contacting certain co-repressors (188). The NHR4 domain contains a ring 
finger motif, which mediates protein interactions including those with N-CoR/SMRT 
(Figure 1.5) (176, 178, 189). The association of MTG family members with AML 
translocations and HDACs indicate that MTGs may be important in both normal 
physiology and pathology. The subsequent sections will explore the functions of MTGs 
and how they can be subverted in malignancy. 
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Figure 1.5 MTG8 family proteins are defined by their evolutionarily conserved domains, termed 
nervy homology regions. A) Schematic of MTG8 illustrating the positions of the NHR regions. 
Percentages represent the percent homology between MTG8, MTG16, MTGR1, and Drosophila 
nervy within each NHR. B) Schematic of MTG8 interaction domains and binding partners. 
Abbreviations: growth factor independence-1 (Gfi-1), promyelotic leukemia zinc-finger (PLZF), 
histone deacetylase (HDAC), nuclear co-repressor (N-CoR), silencing mediator of retinoic acid and 
thyroid hormone receptors (SMRT). The asterisk indicates that the binding domain for atrophin-1 
has not been determined. Figure obtained from Davis et al (190). 
 
Myeloid translocation genes in normal physiology 
 The MTG family is ubiquitously expressed, though individual members are 
expressed differentially, which may influence their activities within different tissues. 
MTG8 is expressed in the human brain, heart, and peripheral blood as well as in the 
human hematopoietic cell line (HEL; human erythroleukemia) (191-194) and the CD34+ 
compartment of human bone marrow cells (195). MTG16, on the other hand, is expressed 
A 
B 
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at high levels in the heart, pancreas, skeletal muscle, spleen, thymus, colon, and in 
peripheral blood leukocytes (181). Interestingly, substantially increased expression of 
MTG16 is observed during hematopoietic differentiation suggesting that its temporal 
regulation is important to the process of differentiation (196). MTGR1 is expressed in a 
vast number of human cell types including those within the adult heart, brain, skeletal 
muscle and to a lesser extent in placenta, kidney, pancreas, spleen, thymus, prostate, 
testis, ovary, small intestine, and colon (180, 197, 198).  
The MTGs serve as scaffolding proteins upon which transcriptional repression 
complexes are built. Amongst those co-repressors recruited by MTG8 are N-CoR/SMRT, 
SIN3A, and HDACs -1, -2, and -3 (176, 178, 187-189). MTG16 also binds SIN3 as well as 
HDACs -1, -2, -3, -6, and -8 (187). As MTGs do not bind DNA directly, they must interact 
with DNA-binding transcription factors. Several MTG-recruiting proteins have been 
identified that illustrate the physiological processes in which MTGs are involved. MTG8, 
for example, is recruited by the promyleocytic leukemia zinc finger (PLZF) protein, which 
is involved in cell cycle progression and has been identified in translocations in acute 
promyelocytic leukemia. The PLZF and MTG8 proteins associate in vivo and in vitro and 
MTG8 enhances transcriptional repression by PLZF (192). This implicates MTG8 in yet 
another leukemia-associated interaction. In fact, the majority of proteins with which 
MTGs interact are involved in hematologic differentiation, proliferation, and 
malignancies. For instance, MTG8 and B cell lymphoma-6 (Bcl-6), a protein that is 
frequently translocated and hypermutated in diffuse large B cell lymphoma, are 
coexpressed in normal and malignant lymphoid tissue where they interact and colocalize. 
 28 
 
MTG8 cooperates with Bcl-6 to repress the transcription of Bcl-6 targets via forming a 
complex on the promoters of Bcl-6 endogenous target genes (199). Furthermore, gene 
expression analysis indicates that Mtg16 is required for suppression of the cell-cycle 
regulating E protein E2F2 (200) implicating Mtg16 in regulation of processes associated 
with cellular growth. Notch receptors are determinants of cell lineage allocation, 
commitment, and differentiation. Dysfunction of Notch signaling characterizes malignant 
conditions such as leukemias (201-206). MTG16 interacts with the intracellular domain of 
the Notch receptor, suggesting a role in the regulation of Notch-dependent lineage 
allocation in hematopoiesis (207). 
MTGs also interact with proteins involved in non-hematopoietic malignancies. 
MTG16 overexpression leads to decreased transcription of genes involved in tumor cell 
metabolism including 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4, and 
pyruvate dehydrogenase kinase isoenzyme 1 (PDK1). As a result of this downregulation, 
glycolytic metabolism is decreased while mitochondrial respiration and formation of ROS 
is increased, ultimately resulting in proliferation inhibition and decreased fraction of cells 
in the S-phase indicating that Mtg16 might serve as a tumor suppressor (208). Moreover, 
Mtgr1 interacts with TCF4 and can oppose β-catenin-dependent transcriptional activation 
leading to overexpression of the oncogene c-Myc (209), again potentially linking MTG 
family members to tumor modulation. One of the more interesting novel functions of 
MTG family members is in regulation of RNA-dependent effects on chromatin 
modification. There is increasing evidence that non-coding RNA plays a role in the 
epigenetic control of chromatin (210-212). Remarkably, all MTG proteins can bind RNA 
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through the zinc finger domains of the NHR4 domain and a short basic region upstream 
of the NHR2 domain resulting in a potential RNA component in MTG-mediated chromatin 
regulation (213). 
Several functions of the MTG proteins have been elucidated by the analysis of 
genetic models of MTG gene deletion. For instance, mice carrying an inactivating insertion 
of LacZ in exon 2 of the MTG8 locus demonstrate severely impaired viability as the result 
of failure in formation of the majority of the intestine, from the distal duodenum to the 
greater part of the colon. Of those Mtg8-/- pups that survive past 48 hours, 60% die by 21 
days after birth and are 30-50% smaller than their littermates. The surviving Mtg8-/- mice 
are smaller than littermates but outwardly normal otherwise. Microscopic analysis of 
these mice, though, reveals small intestinal defects where marked intraluminal distention 
and blunted, disorganized villi are observed (214). Based on observations in these mice, 
Mtg8 seems to play an important role in the development of the midgut, likely due to 
effects on intestinal stem cell function. 
The Mtg16-/- mouse is mildly anemic at birth with a predominance of the 
granulocyte/macrophage lineage at the expense of the megakaryocyte/erythroid 
lineages, as expected, linking Mtg16 to hematopoietic lineage allocation (215). Similar to 
Mtg8, Mtg16-/- mice display a gut phenotype. Mtg16-/- colons display increased 
enterocyte proliferation and augmented intestinal permeability. Similar to immune 
alterations identified in the whole body, the colon exhibits an increase in adaptive 
immune signatures with skewing towards Th1 responses (216). 
 30 
 
Finally, Mtgr1-/- mice are smaller than their littermates throughout their lifespan 
but display no other overt phenotype. When analyzing the small intestine, though, a 
significant alteration is identified. Mtgr1-/- mice display a progressive reduction in the 
secretory cell lineage, including goblet, Paneth, and enteroendocrine cells beginning at 
weaning and continuing to 6-8 weeks of age. Moreover, there is a subtle colonic 
phenotype with increased proliferation and mild crypt expansion (217). Collectively, the 
gene knockout studies in Mtg8-, Mtg16-, and Mtgr1-deficient mice suggest that MTG 
transcriptional co-repressors play critical roles in intestinal biology and likely function in 
influencing stem cell behavior. 
 
Myeloid translocation genes in pathology 
As previously mentioned, MTG8 and MTG16 are both involved in chromosomal 
translocations that fuse them to the AML-1 gene on the 21st chromosome. The MTG8 
translocation has been identified in 8-20% of all cases of AML and is even more prevalent 
in the French-American-British class M2 AML with a 30-50% occurrence. The t(16;21) is 
associated with therapy-related AML (181, 218-221). These translocations are non-
random as breakpoints for both occur between exons 5 and 6 in AML-1 and between 
exons 1 and 2 or 3 and 4 of MTG family members (181). MTGR1, on the other hand, maps 
to chromosome 20q11. This region is deleted in a small percentage of myelodysplastic 
syndromes and 3% of AML (180). 
As transcription factors are frequently involved in hematologic malignancies, it is 
possible that many different molecular mechanisms lead to malignant transformation. As 
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such, some of these proteins might interact and mechanistically link different diseases. 
The members of the MTG family of transcriptional co-repressors are excellent candidates 
as such common factors because they are normally expressed in human hematopoietic 
cells, bind to HDACs, and interact with several proteins involved with hematological 
malignancies including PLZF, Bcl-6, PLZF/RARα, T-cell acute lymphocytic leukemia 1 
(TAL1), growth factor independent 1 transcription repressor (Gfi1), and human B-HLH 
factor (HEB) (184, 199, 222, 223). MTG family members are likely involved in more 
tumorigenic processes than just those associated with hematologic malignancies. 
 In vitro, there is evidence for a role of MTG family members in malignancy. The 
ability of MTG8 to bind to HDACs probably plays a significant role in t(8;21)-containing 
leukemia (224). In fact, the addition of phenylbutyrate, an inhibitor of HDAC activity, to 
the t(8;21)-containing Kasumi cell line results in an increase in differentiated cells from 
20% to 60% after 1 week (225). Moreover, the mouse models that were essential to 
developing an understanding of the physiological functions of the MTGs have been used 
to explore the pathology associated with absence of these proteins. Under conditions of 
hematopoietic stress, Mtg16-/- marrow demonstrates attenuated multi-lineage expansion 
capabilities resulting in an inability of Mtg16-/- marrow to form splenic colonies in 
recipient mice. Moreover, Mtg16-/- bone marrow fails to rescue radiation-induced 
marrow clearance in bone marrow transplant assays. Upon removal of bone marrow cells 
from knockout mice, Mtg16-/- stem cells continue to show defects in stem cell renewal 
assays (200). These observations implicate MTG16 in regulation of hematopoietic stem 
cell programs that are essential for lineage allocation (215).  
 32 
 
Considering the gut phenotypes identified in MTG knockout mice at baseline, they 
were also stressed to uncover subsequent phenotypes. Mtg16-/- mice develop increased 
clinical symptoms including weight loss, diarrhea, mortality, and histological colitis as well 
as increased innate (Gr1+, F4/80+, CD11c+, and MHCII+;CD11c+) and Th1 adaptive (CD4+) 
immune cells in response to dextran sodium sulfate (DSS) treatment. Additionally, there 
is an increase in apoptosis and compensatory increase in proliferation in DSS-treated 
mice. As another model of colonic injury, treatment of Mtg16-/- mice with C. rodentium 
results in augmented colitis and increased bacterial colonization. Finally, in support of 
more severe damage in response to injury, in human ulcerative colitis, MTG16 mRNA 
levels are reduced (216).  
Loss of Mtgr1 also sensitizes the colonic epithelium to the effects of DSS, at least 
partially due to an increase in epithelial apoptosis rates. Significantly, Mtgr1-/- mice 
demonstrate impaired regeneration of colonic crypts, even ten weeks after a single DSS 
administration, suggesting a role for Mtgr1 in the colonic stem cell (226). When 
considering these knockout experiments in combination, these data suggest that MTG 
loss might contribute to increased tumorigenesis as well as severity of colitis. In support 
of this, MTG16 has been mapped to the 16q24.3 breast cancer loss of heterozygosity 
(LOH) region. Moreover, the expression of MTG16 is significantly reduced in a number of 
breast cancer cell lines and in primary breast tumors when compared to nontransformed 
breast epithelial cell lines and normal breast tissue and reintroduction of MTG16 into 
breast tumor cell lines with low MTG16 expression reduces colony growth on plastic and 
in soft agar (227). Furthermore, a genome-wide screen identified MTG8 as a candidate 
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cancer gene in CRC and breast cancer and four mutations within the NHR domains of 
MTG16 have been identified in CRC (228, 229). Taken together these data implicate MTG 
family member downregulation in tumor-promoting processes and indicate that loss of 
MTG family members might contribute to tumorigenesis. 
 
A transcriptional repressor that modifies Wnt signaling: Kaiso 
 In mammalian genomes, transcriptional regulation relies on both a complex 
combinatorial interplay of transcription factors and epigenetic mechanisms. The former 
involve the building of protein complexes upon promoters of target genes based on 
specific DNA target sequences. The latter involve chromosomal and DNA structural 
alteration and are maintained within the progeny of a cell (230). DNA methylation is one 
of the epigenetic signatures common in regulation of gene expression. The transcription 
factor Kaiso not only binds to a consensus Kaiso binding site (KBS), TCCTGCNA (231), but 
also uses its three Krϋppel-like C2H2 zinc fingers to bind methylated CpGs (232). Kaiso is a 
member of the zinc finger and BTB domain containing (ZBTB) protein family, within the 
broader poxvirus and zinc finger (POZ)-zinc finger (POZ-ZF) family. Two family members, 
ZBTB4 and ZBTB38 contain Kaiso-like zinc fingers and, like Kaiso, bind methylated DNA in 
vitro and in vivo, but unlike Kaiso, they can bind to single methylated CpGs (233). Kaiso 
and its family members have been implicated in cancer and development (234) and, as 
such, likely serve as targets for tumor modification. Interestingly, Kaiso is implicated in 
Wnt repression and shares several targets with the MTG family members described 
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previously suggesting that these two protein families might interact within a repression 
complex, which might serve as an important target for cancer therapeutics. 
 
Kaiso targets and implications 
 Kaiso, like MTG16, is a component of an N-CoR complex. In vitro, the Kaiso/N-CoR 
complex is able to bind specific CpG-rich sequences in a methylation and sequence-
specific manner. In vivo, Kaiso targets the N-CoR complex to several promoters including 
that of the metastasis-associated 2 (MTA2) gene in a methylation-dependent manner 
(235). Regulation of MTA2 is especially important as this protein is closely related to a 
protein that has been correlated with the metastatic potential of certain carcinomas (236) 
and MTA2, itself, represses p53 (237). Furthermore, Kaiso interacts with the CTC-binding 
factor (CTCF), a DNA binding protein that plays essential roles in regulating gene 
expression through its role as an enhancer blocker, through its POZ domain (238). CTCF 
modifies 3D chromatin architecture giving it a broad impact on a vast array of genes. 
Interestingly, CTCF has been identified as a tumor suppressor in breast cancer (239).  
 Perhaps one of the most well-studied roles of Kaiso is as a transcriptional 
repressor involved intimately in Wnt signaling. Wnt activation has been closely linked to 
colorectal tumorigenesis. Kaiso is a repressor of both canonical and non-canonical Wnt 
signals through both its methylated and sequence-specific DNA binding modalities. Kaiso 
regulates TCF/LEF1-activity by modulating HDAC1 and β-catenin-complex formation 
(240). Moreover, Kaiso associates with the Mmp7 promoter via its KBS ultimately allowing 
for the abrogation of β-catenin-mediated activation of the Mmp7 promoter upon Kaiso 
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binding (241). Mmp7 is a Wnt downstream effector protein that has been heavily 
implicated in the progression of many cancer types, especially CRC (242-244). Kaiso 
interacts with p120-catenin (p120ctn), an E-cadherin-associated protein that affects E-
cadherin function and stability. Interestingly, in response to Wnt3a, p120ctn is 
phosphorylated at two sites, Ser268 and Ser269, disrupting the interaction with E-
cadherin resulting in enhanced binding of p120ctn to Kaiso and preventing Kaiso-mediated 
inhibition of the β-catenin-TCF4 transcriptional complex (245).  
 
Kaiso in pathology 
 POZ-ZF proteins have been implicated in many biological processes, including but 
not limited to B cell fate determination, cell cycle progression, DNA damage responses 
and developmental events such as gastrulation, limb formation, and hematopoietic stem 
cell fate allocation (Table 1.1). As a result, dysfunction of POZ-ZF proteins such as Kaiso 
have been linked to developmental disorders and tumorigenesis (246). Both Kaiso and its 
closely-related family member ZBTB4 are downregulated in cancer (247, 248) and a study  
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Protein 
Name 
Repressor, 
activator, or both? 
Putative function(s) 
PLZF Repressor Limb development; gene regulation in APL 
Bcl-6 Repressor 
Plasma cell fate; germinal center formation; germ cell apoptosis; gene 
regulation in B cell lymphoma 
FAZF Repressor 
T cell proliferation; cytokine production; hematopoietic stem cell 
proliferation 
MIZ-1 Both 
Gastrulation; cell cycle progression; regulator of Myc-mediated gene 
regulation 
HIC-1 Repressor 
Tumor suppressor; craniofacial development; DNA damage responses; 
inhibition of Wnt signaling 
ZBTB7 Repressor 
Proto-oncogene; regualtor of oncogenesis; stimulator of HIV1 Tat 
activity 
Kaiso Both 
Gastrulation; canonical and non-canonical Wnt signaling; regulator of 
synapse formation 
BAZF Repressor Activation of naïve T cells 
APM-1 Repressor 
Possible tumor suppressor; cell growth inhibition; downregulated in 
cervical carcinoma cell lines 
Nac-1 Repressor 
Neuronal apoptosis; behavioral sensitization to cocaine; regulation of 
p53 levels 
ZBTB38 Repressor Expression in late postmitotic neurons; function unknown 
ZBTB4 Repressor Ubiquitous expression; function unknown 
 
Table 1.1 Putative cellular roles of POZ-ZF family transcription factors. Here, Kaiso is bolded for its 
relevance to this work. Table adapted from Kelly et al (246).  
 
to examine the expression pattern of Kaiso in human tumor tissue did not reveal an overt 
alteration in expression but did note a change in Kaiso localization. In human cancer 
tissues, Kaiso often localized to the cytosol rather than the nucleus. Interestingly, when 
cultured cells with nuclear Kaiso localization are xenografted into nude mice, localization 
of Kaiso shifts to the cytoplasm and, in some cells, Kaiso expression is completely 
abolished (249). Such expression and localization changes suggest that Kaiso expression 
is detrimental to tumorigenesis. In support of this hypothesis, increased p120ctn 
expression reduces Kaiso nuclear localization, which results in enhanced expression of 
Cyclin D1 ultimately leading to p120ctn-dependent regulation of proliferation and cell 
cycle in lung cancer cells through Kaiso (250).  
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Interestingly, contrary to the aforementioned hypothesis, there are also instances 
in which increased Kaiso expression and/or nuclear localization are related to increased 
tumorigenic potential. For one, development of a Kaiso-/- mouse crossed with the well-
characterized Apcmin/+ mouse that acquires intestinal polyps revealed that the absence of 
Kaiso leads to delayed polyposis (251). Moreover, Kaiso repressed methylated tumor 
suppressor genes, including the CDKN2A gene in human colon cancer cell lines. 
Significantly, knockdown of Kaiso induced tumor suppressor gene expression and 
increased susceptibility to cell cycle arrest and cell death in response to chemotherapy 
(247). Finally, nuclear localization of Kaiso has been identified as a risk factor in high-grade 
and triple-negative invasive breast cancer (252). Taken together, these data suggest that 
the impact of Kaiso on tumorigenesis is multifactorial and may depend on localization, 
cancer type, and cancer stage. 
 
Experimental overview 
 The activities of each of the proteins outlined above are involved in pivotal roles 
in stem cell activity and inflammatory and injury response. Because colitis-associated 
carcinoma not only depends upon altered growth and differentiation properties within 
the cell, but is also reliant upon inflammatory injury, we predicted that selenoproteins, 
myeloid translocation genes, and Kaiso would modify development of colitis-associated 
carcinoma. In order to test this hypothesis, we take advantage of the murine 
azoxymethane (AOM), repeated dose dextran sodium sulfate (DSS) model of 
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inflammatory carcinogenesis to test the impact of loss of these proteins on tumor 
development as well as inflammatory injury.  
 Until 2003, inflammatory injury and subsequent tumorigenesis were modeled 
using the DSS injury model. DSS-induced colitis is characterized by pro-inflammatory 
cytokine and chemokine (IL-1, IL-6, KC, TNF-α, and IFNλ) induction (253, 254) and 
downregulation of anti-inflammatory cytokines such as IL-10 (254-257), likely at least in 
part due to induction of macrophage infiltration into the colonic epithelium (258). DSS 
induces colonic injury but its mechanism of action is only beginning to be understood. It 
has been demonstrated that DSS can cause inhibition of reverse transcriptase activities 
by competing with poly (U) ultimately resulting in the disruption of major cellular 
functions (259). Moreover, DSS inhibits ribonuclease activity disturbing mRNA translation 
(260, 261). It is thought that DSS penetrates epithelial cells of the colon by establishing 
linkages with medium-chain-length fatty acids such as dodecanoate which form 
nanometer-sized vesicles in the cytoplasm that activate intestinal inflammatory signaling 
pathways (262). The end result of DSS administration is inflammatory injury within the 
distal colon, which after several administrations over a long period of time leads to the 
development of colitis-related tumorigenesis, albeit, with low incidence and multiplicity 
(263). In 2003, though, Tanaka et al. combined the inflammatory injury resulting from DSS 
administration with initial injection of a potent carcinogen, AOM, to enhance 
tumorigenesis (264). When mice were given a low dose of AOM followed by one week of 
exposure to 2% DSS and 20 weeks of incubation, they developed adenocarcinomas with 
100% penetrance and approximately 6 adenocarcinomas per mouse and adenomas with 
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38% incidence and less than one adenoma per mouse, and these neoplasias 
demonstrated positivity for β-catenin, COX2, and iNOS, but not p53 (264). This protocol 
has been modified, increasing DSS concentration administered as well as number of 
administrations and amount of AOM and has allowed for a deeper understanding of 
modifiers of inflammation and inflammation-related carcinogenesis (33, 265-267).  
 The AOM/DSS model for colitis-associated cancer is used in the subsequent 
chapters to determine the impact of altered dietary Se intake, loss of the plasma 
selenoproteins Gpx3 and Sepp1, loss of Mtgr1, and knockout of Kaiso in combination with 
Mtg16 on severity of inflammation and inflammatory carcinogenesis. Our modification of 
this protocol, to be used in the Se and selenoprotein experiments, involves injection with 
12.5 mg/kg AOM intraperitoneally as described in (265, 268, 269). After a 3-day recovery 
period, the animals are started on the first of 3 cycles of 3% DSS ad libitum. Each cycle is 
4 days in length and separated by a 16-day recovery period. After the last cycle, animals 
are sacrificed following 26 days of recovery. We note that, in response to the 
aforementioned protocol though, absence of Mtg16 results in a phenotype so severe that 
it leads to extremely high morbidity. For this reason, the Mtg16 and Kaiso protocols utilize 
10 mg/kg AOM and two administrations of 2% DSS. 
 In addition to the inflammatory injury protocol employed, there are several 
experiments that are specific to the nutrient or protein being analyzed. In Chapter II, mice 
are depleted of selenium via dietary mechanisms and tested, not only for tumor burden 
effects, but also for response to DSS-induced injury as a single modality. Moreover, in 
order to determine alterations in reactive oxygen species in response to inflammation, 
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F2-Isoprostanes are analyzed. Furthermore, cytokines and chemokines are analyzed to 
determine how selenium deficiency impacts extent of inflammation.  
In Chapter III, because Gpx3 has been implicated in antioxidant activity, oxidative 
stress genes and oxidative DNA damage within tumors are analyzed. Caco2 cells are also 
utilized to test for ROS production, DNA damage, and apoptosis in response to Gpx3 
knockdown and H2O2 administration as well as colony formation post-Gpx3 knockdown. 
In Chapter IV, a novel model of epithelial stem cell function, organoid culturing, is utilized 
to analyze the effects of Sepp1 loss on response to oxidative stress as well as baseline 
proliferation and stem cell phenotypes, establishing an epithelial cell-autonomous role 
for Sepp1 in protection from oxidative stress and alteration of Wnt tone. Furthermore, 
bone marrow macrophages are activated in order to determine how Sepp1 loss, either 
partial or complete, impacts macrophage polarization. In Chapter V, in situ hybridization 
is utilized to measure MTGR1 expression alterations in tumors compared to normal 
adjacent tissue. Bone marrow transplant is also employed to determine whether the 
Mtgr1-/- tumor effect is hematopoietic cell autonomous. Finally, in Chapter VI, an 
interaction between MTG16 and Kaiso is established via yeast two hybrid, 
immunofluorescent colocalization, and coimmunoprecipitation and the role of this 
interaction in the transcriptional repression of Mmp7 is established using luciferase 
reporter assays, chromatin immunoprecipitation, and expression analysis, ultimately 
suggesting that this interaction might influence inflammatory carcinogenesis resulting in 
the experiments performed in Chapter VII, which test the impact of either Mtg16 or Kaiso 
loss or absence of both proteins on inflammatory carcinogenesis. The experiments 
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described in this work have been performed with the goal to identify modifiers and 
potential therapeutic targets in the treatment of colitis-associated carcinoma. 
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CHAPTER II 
 
DIETARY SELENIUM DEFICIENCY EXACERBATES DSS-INDUCED EPITHELIAL INJURY AND 
AOM/DSS-INDUCED TUMORIGENESIS1 
 
Introduction 
The essential micronutrient selenium (Se) is of fundamental importance to human 
health. Se, through selenoproteins, has antioxidant roles, influences immune activity, and 
its levels are inversely correlated with cancer risk (73) and inflammatory bowel disease 
(IBD) (270-272). In the case of IBD, red blood cell glutathione peroxidase activity (273), a 
Se-dependent activity and mRNA levels of Sepp1 (274), a selenoprotein, are reduced.  
IBD is an autoimmune inflammatory disease of the GI tract affecting as many as 
1.4 million people in the United States (275). IBD carries numerous and serious medical 
complications: stricture and fistula formation, infection, severe pain, anemia, and 
malnutrition (276-279). The pathophysiology of IBD is thought to be multifactorial in 
origin. Genetic, microbial, and environmental factors have all been implicated, but the 
fundamental etiology remains unclear. Nutritional deficiencies have been a major 
concern in the management of IBD for decades and numerous studies have documented 
decreased levels of Se in IBD compared to control patients (280-283). Moreover, as Se 
                                                        
1 This work has been published under Caitlyn W. Barrett, Kshipra Singh, Amy K. Motley, Mary K. 
Lintel, Elena Matafonova, Amber M. Bradley, Wei Ning, Shenika V. Poindexter, Bobak Parang, 
Vishruth K. Reddy, Rupesh Chaturvedi, Barbara M. Fingleton, Mary K. Washington, Keith T. Wilson, 
Sean S. Davies, Kristina E. Hill, Raymond F. Burk, Christopher S. Williams. (2013) Dietary selenium 
deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis, PLoS One, 8, 
e67845 (7). 
 43 
 
deficiencies are often seen in IBD, downregulation of several selenoproteins have also 
been identified. Serum selenoprotein P (Sepp1) levels are significantly lower in patients 
with Crohn’s disease (274) and glutathione peroxidase 1 mRNA is significantly 
downregulated in mononuclear cells from patients with IBD (284). Defects in epithelial 
integrity contribute to IBD pathogenesis and understanding mechanisms affecting 
epithelial homeostasis is a priority (285). In this regard, Se has been directly linked to WNT 
signaling (286) and the intrinsic apoptosis pathway (287), suggesting that it may play a 
role in epithelial integrity in response to injury. 
Several epidemiological studies suggest that Se status is inversely correlated with 
cancer incidence and mortality (288-291), but Se supplementation trials failed to show 
benefit, possibly due to the fact that the advantages of Se supplementation are 
dependent on several factors including baseline Se status, genetic background (e.g. the 
existence of polymorphisms in selenoprotein genes), type of cancer, as well as the 
metabolic conversion and dose of Se supplements (103). Furthermore, several 
selenoproteins have been correlated with cancer risk. Mutation of the selenocysteine 
transfer RNA gene which results in decreased expression of some selenoproteins results 
in reduction in murine colon cancer risk (292). More specifically, elevated glutathione 
peroxidase-2 (Gpx2) expression has been detected in colorectal adenomas (162, 293-
295). Subsequently, double knockout of Gpx1 and Gpx2 leads to bacterial-induced 
intestinal inflammation and, ultimately, ileal tumor formation (296) and Gpx2 decreases 
inflammation and tumors in response to inflammatory carcinogenesis (297). Expression 
levels of selenoproteins including Gpx1, Gpx3, and Sepp1 are significantly decreased in 
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colorectal cancer, with lowered Sepp1 expression correlating most significantly with 
tumor stage (298). As such, we have shown that Gpx3 serves as a tumor suppressor in the 
AOM/DSS model of CAC (268). Thus, both Se and selenoproteins may play pivotal roles in 
tumor modulation, especially in the setting of inflammatory carcinogenesis. 
There may be sub-populations of CRC patients who would benefit from Se 
supplementation. IBD may fall into this category as it is characterized by chronic 
inflammation and oxidative stress (299) and ulcerative colitis and Crohn’s colitis patients 
are at increased risk for developing colon cancer (300). Experimental studies 
demonstrating that Se deficiency exacerbates intestinal injury and tumorigenesis are not 
definitive. The aim of these studies was to determine whether Se deficiency exacerbates 
colitis and promotes inflammation-associated carcinogenesis. Mice were rendered Se-
deficient via maintenance on a tightly controlled Se-deficient diet. Se-deficient mice had 
exacerbated colitis after DSS injury, resulting in a pro-tumorigenic microenvironment with 
increased cytokines, oxidative stress, and DNA damage. Furthermore, when inflammatory 
carcinogenesis modeling was performed, Se-deficient mice had increased tumorigenicity 
and more advanced lesions compared to Se-sufficient cohorts. Thus, Se supplementation 
in Se-deficient IBD patients may protect from mucosal injury and malignant degeneration. 
 
Materials and Methods 
Ethics Statement. This study was performed in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Institute of Animal Care and Use 
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Committee at Vanderbilt University (protocol number: M/10-355). Every effort was made 
to minimize suffering.  
Murine DSS morbidity and inflammatory carcinogenesis modeling. Experimental diets 
were Torula yeast-based and identical except for their Se contents. The basal diet 
contained less than 0.01 mg Se per kg (Se-deficient) and the Se-sufficient diet was the 
same diet supplemented with 0.25 mg Se as sodium selenite per kg. Se-deficient and -
sufficient diets were prepared and pelleted to our specifications (301) by Harlan-Teklad 
(Madison, WI, USA). Upon weaning, Wild-type (WT) C57BL/6 mice were maintained on 
the experimental diets for 12 weeks prior to initiation of DSS or AOM/DSS experiments to 
ensure Se deficiency.  
DSS at a molecular weight of 40,000-50,000 was obtained from USB Corporation 
(Cleveland, OH, USA). A single lot was used for all experiments described in this 
publication. A 3% w/v DSS solution was made in distilled water and filtered through a 0.22 
μm cellulose acetate filter. This solution was then substituted for animal drinking water 
and barriers were placed on the automatic watering systems within each cage.  
For the DSS morbidity experiments, Se-sufficient (n=15) and Se-deficient (n=10) 
mice were treated with DSS (Figure 2.1A) until their weight loss reached 20% of their 
original weights, at which time they were sacrificed. Animals were weighed daily and 
stools were examined for consistency and the presence of blood. Stool consistency scores 
ranged from 0-2, with 0 = hard, normal stools, 1 = soft and spread, 2 = diarrhea-like. 
Presence of blood was scored with a 0 = no blood, 2 = blood present, 4 = copious amounts 
of blood. Values were added for each mouse.  
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For the murine inflammatory carcinogenesis protocol (results shown in Figures 5-
6), Se-sufficient (n=18) or -deficient (n=20) C57BL/6 WT mice were injected with 12.5 
mg/kg AOM (Sigma-Aldrich) intraperitoneally as described in (265, 268, 269). After a 3-
day recovery period, the animals were started on the first of 3 cycles of 3% DSS ad libitum 
(see schematic in Figure 2.5A). Each cycle was 4 days in length and was separated by a 16-
day recovery period. Eight days into each recovery period, murine endoscopy was 
performed to monitor colitis severity and tumor burden (302). After the last cycle, animals 
were sacrificed following 26 days of recovery. Mice were anesthetized with isofluorane 
prior to exsanguination from the inferior vena cava. Blood was treated with 15 μl of a 1 
mg/ml solution of disodium EDTA to prevent coagulation and plasma was separated by 
centrifugation for 2 minutes at 12,000xg. The colon was removed, flushed with PBS, and 
opened longitudinally and gross tumor counts were conducted using a dissecting 
microscope at 15x magnification and size measurements obtained using digital calipers. 
Microscopic analysis was conducted by an experienced gastrointestinal pathologist (M.K. 
Washington) for dysplasia on H&E stained “Swiss rolled” colons (processed by the 
Vanderbilt Translational Pathology Shared Resource core). Low-grade dysplasia (LGD) 
refers to preinvasive pedunculated, sessile, or flat plaque-like lesions with simple 
glandular outlines, without loss of cellularity polarity. High-grade dysplasia (HGD) are 
adenomas with architectural complexity, increased cytologic atypia, and loss of tumor cell 
polarity (303, 304). Sections of tumor and normal adjacent colon were collected and 
stored in RNAlater (Qiagen, Valencia, Santa Clarita, California, USA) and a section of the 
most distal colon above the anus was collected and flash frozen in liquid nitrogen for 
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protein analysis and/or determination of Se content. The remainder of the colon was 
“Swiss Rolled”, formalin fixed overnight, and sectioned for histological analysis. 
Colonic selenium measurements. The determination of colonic Se was carried out using a 
modification of the fluorometric assay of Koh and Benson (305) and Sheehan and Gao 
(306). Briefly, tissue was digested in nitric and perchloric acids and Se was complexed with 
diaminonaphthalene. Selenium-diaminonaphthalene was extracted into cyclohexane and 
fluorescence was measured in a Perkin-Elmer LS 55 fluorometer. 
Plasma glutathione peroxidase activity assay. Plasma collected from mice was subjected 
to a glutathione peroxidase (Gpx) activity assay using a modified protocol (307) based on 
the method of Paglia and Valentine (308). In short, 800 μl of reaction cocktail (50mmol/L 
potassium phosphate, pH 7.0, 1mmol/L EDTA, 1mmol/L NaN3, 0.2mmol/L glutathione) 
was mixed with 10 μl plasma and 90 μl water in a clear plastic cuvette and incubated at 
room temperature for 5 minutes. Next, 100 μl of H2O2 substrate (0.25mmol/L H2O2 in 
H2O) was added to the reaction mixture to initiate the reaction. Gpx activity was assessed 
by measuring the rate of change of A340 during the linear phase of the reaction. The rate 
of change was then converted to the number of μmoles of NADPH oxidized/minute using 
the extinction coefficient of 6.2 x 103 L mol-1 cm-1 for NADPH at 340 nm. Blank reactions 
with distilled water were subtracted from each assay. 
F2-Isoprostane analysis. DSS-treated mice (WT C57BL/6 fed Se-sufficient diets n=3, WT 
C57BL/6 fed Se-deficient diets n=3, 3% DSS ad libitum for 3 days) were housed in 
metabolic cages and urine was collected for 12 hours on days 0 and 3 of DSS 
administration. Urinary F2-isoprostanes were measured by stable isotope dilution gas 
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chromatography mass spectrometry using [2H4]15-F2t-isoprostane as internal standard 
as previously described (309). Values were normalized to mg creatinine in urine.  
Histological injury analysis. A colitis damage score was generated from digital images of 
H&E stained sections, by first measuring the distance around the intact muscularis using 
AVP Universal Desktop Ruler software (as performed by (272, 310)). The areas of 
ulceration were then measured and given scores of 1, 2, 3, or 4, where a score of 1 
represents injury involving the lower 1/3 of the crypt, 2 equaling injury to the lower 2/3rds 
of the crypt, 3 equaling total crypt loss however the epithelial lining remains intact and 4 
equaling total crypt and complete epithelial loss. The ulceration score was then multiplied 
by the length of the involved colon, summed, and divided by the total colon length to give 
a measure of ulceration severity/colon length. Measurements were performed in a 
blinded fashion in all colons from mice subjected to the DSS morbidity protocol. 
Cytokine array analysis. RNA from Se-sufficient or -deficient DSS morbidity colons 
(collected on day nine of DSS treatment) was isolated using the RNeasy Mini Kit (Qiagen, 
Valencia, Santa Clarita, California, USA). cDNA was synthesized using the iScript cDNA 
synthesis kit (Bio-rad, Hercules, California, USA) from 1 μg of total RNA. 1 μl of the 20 μl 
cDNA produced through the iScript reaction was used as a template in each subsequent 
PCR reaction. SYBR green qRT-PCR was performed using mouse cytokine array libraries I 
(Cat #: MCA-I) and II (Cat #: MCA-II) purchased from RealTimePrimers.com (Elkins Park, 
Pennsylvania, USA) according to manufacturer’s instructions. Individual cytokines were 
analyzed using the delta-delta Ct method and normalized to Hypoxanthine-Guanine 
Phosphoribosyltransferase (Hprt). Those showing significant differences were plotted 
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using Graphpad Prism. In order to develop the heat map, data was incorporated into the 
free web-based PCR array analysis software provided by SABiosciences (Qiagen). 
Immunohistochemistry and immunofluorescence staining. Five-micrometer sections were 
cut, dewaxed, and hydrated. Antigen retrieval was conducted using Antigen Unmasking 
Reagent (Vector Laboratories, Inc., Burlingame, California, USA) according to 
manufacturer’s instructions. After blocking, primary antibody was added [α-Ki67 
(NeoMarkers RB-1510-P, Fremont, California, USA), 1:1,000; α-8-hydroxy-
2′deoxyguanosine (8-OHdG, Abcam ab26842, Cambridge, Massachusetts, USA) 1:50] and 
incubated overnight at 4°C. Isotype-matched antibodies were included as negative 
controls. Sections were then incubated for one hour at room temperature in secondary 
antibody (Ki67: Goat α-Rabbit-cy3, Invitrogen A10520; 8-OHdG: α-mouse-FITC, Sigma F-
0257). Identification of apoptotic cells was conducted using the ApopTag Plus Peroxidase 
In Situ Apoptosis Kit (Chemicon, Temecula, California, USA) according to the 
manufacturer's protocol. Control slides were obtained by omitting the terminal 
transferase (TnT) enzyme. For immunofluorescence staining of proliferation and DNA 
damage, slides were counterstained and mounted with ProLong Gold antifade including 
4′,6-diamidino-2-phenylindole (DAPI, Invitrogen, Grand Island, New York, USA). DNA 
damage indices were generated by counting the number of positive cells per colon length 
within each high-powered field, with 5 high-powered fields counted per colon, starting at 
the most distal colon. Apoptosis, and proliferation indices were generated by counting 
either the number of positive cells per high-powered field (HPF; 40x objective) within each 
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tumor or the number of positive cells per longitudinal crypt section in 20 crypts per mouse 
by a blinded observer. The average score was then calculated for each Swiss-rolled colon. 
Statistical methods. Differences between Se-deficient and -sufficient mice were 
determined utilizing Graphpad Prism and analysis with the Student’s t-test. The survival 
curve was analyzed using the Log-rank (Mantel-Cox) test. Differences in stool scores and 
percentage weight loss were determined using two-way ANOVA for repeated 
measurements over time. Urine F2-isoprostane analysis of all four groups was analyzed 
using one-way ANOVA with a Newman-Keuls post-test to determine variances between 
columns. Finally, statistical analysis of high-grade dysplasia was performed using the 
Fisher’s Exact test.  
 
Results 
Dietary selenium maintains epithelial integrity.  
Se, through selenoproteins, has antioxidant roles, influences immune activity, and 
has been inversely correlated with IBD (272, 311) and cancer risk (73). Because oxidative 
stress compromises mucosal integrity (312), and Se deficiency has been shown to increase 
oxidative stress (125), we determined whether dietary Se deficiency influences the 
severity of colitis following treatment with 3% DSS ad lib (Figure 2.1A). Animals were fed 
either Se-sufficient or -deficient diets for 12 weeks, an extended period of time sufficient  
 
 
 51 
 
Figure 2.1 Dietary selenium depletion reduces colon selenium levels and plasma glutathione 
peroxidase activity. A. Schematic for the DSS morbidity protocol. At day 0, mice were weighed and 
then given a 3% DSS solution in lieu of drinking water. Each day, mice were weighed and stools 
were obtained for analysis of blood and stool consistency (weight and stool analyses times 
indicated by black diamonds). Individual mice were sacrificed if their weights fell below 80% of 
their original weights. B. Selenium sufficient (n=7) and deficient (n=7) colons were analyzed for 
selenium concentrations. ***P<0.0001. C. Plasma glutathione peroxidase activity is quantified. 
***P<0.0001. 
 
to ensure Se deficiency which we confirmed via measurement of colonic mucosal Se levels 
at the end of the DSS experiment (333.1 ± 16.5 vs 60.6 ± 4.1 ng/g, P<0.0001, Figure 2.1B)  
and plasma glutathione peroxidase (Gpx) activity (215.4 ± 31.6 vs 18.9 ± 27.8 nmol 
NADPH/ml.min, P<0.0001, Figure 2.1C). In this experiment, mice were maintained on 3% 
DSS until their weight reached 80% of their original weights (survival endpoint). Se 
deficient mice median survival was 9 days in comparison to Se-sufficient whose median 
survival was 12 days (P=0.003, Figure 2.2A). Additionally, Se-deficient mice had worsened 
diarrhea and increased blood in stools (stool scores at day 9: 2.7 ± 0.7 vs 5.7 ± 0.3, P=0.02, 
Figure 2.2B), had accelerated weight loss (84.3 ± 1.2 vs 77.4 ± 1.2% of starting body weight 
at day 9, P=0.01, Figure 2.2C), and had more severe colitis/epithelial injury (2.1 ± 0.2 vs 
A 
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2.9 ± 0.1, P=0.006, Figure 2.2D). These results indicate that Se is protective against DSS-
induced colonic injury.  
Figure 2.2 Selenium deficiency exacerbates colonic injury after DSS treatment. A. Se-sufficient 
(n=15) and -deficient (n=10) mice were subjected to the DSS morbidity protocol (see Figure 1A) 
and percent survival was tracked. P=0.003, Log-rank (Mantel-Cox) test. B. Stool scores were 
analyzed for Se-sufficient and -deficient mice on the DSS morbidity protocol. The graph depicts the 
average stool score for each dietary group on each day of DSS administration. P<0.001, 2-way 
ANOVA. C. Percent of original weight averaged for each dietary group on each day of DSS 
administration. P<0.01, 2-way ANOVA. D. Colitis damage scores (described in Materials and 
Methods) for each dietary group analyzed at the completion of the experiment (left) and 
representative images of Swiss rolled colons from each group (right). Top and bottom of box 25th 
and 75th percentile, bar represents the median value, whiskers minimum and maximum values. 
**P=0.006, Students-t test.  
 
Pro-tumorigenic microenvironment is promoted by selenium deficiency. 
 Inflammation, a component of the epithelial and tumor microenvironment, is a 
contributing factor that predisposes to malignancy and, as we had observed increased 
injury in response to DSS administration in Se-deficient mice, we wanted to determine 
whether chemokine and cytokine signaling was aberrantly regulated in Se-deficient mice 
A B 
C D 
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in response to injury. Therefore, we analyzed Se-sufficient and -deficient colons for 
cytokine mRNA expression using a mouse cytokine array. Because the RNA isolated for 
analysis was isolated from whole colon, the source of these cytokines and chemokines 
would include epithelial and stromal components. This analysis yielded alterations in 
several chemokines and cytokines that are displayed as a heat map for all genes tested 
(Figure 2.3). Significantly altered cytokines were grouped according to function using  
Figure 2.3 Cytokines are aberrantly regulated in selenium-deficient mice subjected to DSS. A. Heat 
map of mouse cytokine library I and B. mouse cytokine library II gene expression in Se-deficient 
(n=4) versus -sufficient (control, n=4) colons post-DSS morbidity (left) and a chart of represented 
cytokines (right). Green=underexpression, Red=overexpression where intensity of color indicates 
increasing distance from 0; Grey=qRT-PCR yields were undetectable. 
A 
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PANTHER Pathway Analysis software (313). Transforming growth factor beta (TGF-β) 
signaling was altered with increased Tgf-β1 and -β2 transcripts and decreased growth  
Figure 2.4 Cytokine expression is aberrantly regulated in selenium deficient mice post-DSS. A. 
mRNA expression changes in Se-sufficient (n=4) and -deficient (n=4) mice on from day nine of the 
DSS morbidity protocol. Genes were grouped based on pathways identified by PANTHER pathway 
analysis software. Expression was normalized to Hprt. A. TGF-β pathway alterations include 
Bmp8b=bone morphogenetic protein 8b, Gdf1=Growth differentiation factor-1, 
Tgfβ1=transforming growth factor beta-1, Tgfβ2=transforming growth factor beta-2. B. EGF 
pathway alterations include Egf=epidermal growth factor, Igf1=insulin-like growth factor 1, 
Nrg4=neuregulin 4. C. Developmental pathway alterations include expression changes in 
Lta=lymphotoxin alpha, Efnb2=ephrin-B2, Efnb3=ephrin-B3, Fgf22=fibroblast growth factor 22. D. 
The gene altered within the group titled antioxidant activity is Tpo=thyroid peroxidase. E. Immune 
system process alterations are demonstrated in Cxcl13=chemokine (C-X-C motif) ligand 13, 
Ifnk=interferon kappa, Ctf1=cardiotrophin 1, Ccl27=chemokine (C-C motif) ligand 27, 
Ccl20=chemokine (C-C motif) ligand 20, IL17c=interleukin 17c, IL23a=interleukin 23a. *P<0.05, 
**P<0.01, ***P<0.001. 
 
differentiation factor-1 (Gdf1) and bone morphogenetic protein 8b (Bmp8b) (Figure 2.4A). 
Additionally, the EGF pathway was altered (Figure 2.4B), as were components of 
developmental programs (Figure 2.4C). Levels of thyroid peroxidase (Tpo), PANTHER 
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classified as an antioxidant, was increased (0.01 ± 0.003 vs 9.1 ± 6.3 fold change, P=0.04, 
Figure 2.4D), consistent with a decrease in Se leading to aberrant regulation of thyroid 
hormone production (314). Supporting immune system process activation there was 
increased chemokine (C-X-C motif) ligand 13 (Cxcl13), interferon kappa (Ifnk), 
cardiotrophin 1 (Ctf1), chemokine (C-C motif) ligand 27 (Ccl27), chemokine (C-C motif) 
ligand 20 (Ccl20), interleukin 17c (Il-17c), and interleukin 23a (Il-23a) messenger RNA in 
Se-deficient states (Figure 2.4E). Collectively, multiple factors capable of promoting tumor 
development were upregulated after DSS treatment in a Se-deficient state. 
 
Lipid peroxidation, a marker of oxidative stress, is increased in the urine of selenium-
deficient mice after DSS induced colitis. 
DSS administration in the drinking water causes colonic epithelial injury and a 
robust innate inflammatory response producing an environment enriched in reactive 
oxygen and nitrogen species (315). Oxidative injury is quantifiable by measuring F2-
isoprostanes (F2-IsoPs), one of the most reliable measures of in vivo lipid peroxidation, a 
marker of oxidative stress (309, 316). We measured F2-IsoPs using stable isotope dilution 
gas chromatography mass spectrometry methodology. F2-IsoP levels were not different 
at baseline between Se-sufficient and -deficient mice (0 time point, Figure 2.5A). 
However, increased urine F2-IsoPs were observed in mice fed a Se-deficient diet when 
compared to mice on a Se-sufficient diet, after 3 days of 3% DSS (6.0 ± 0.3 vs 9.1 ± 1.0 
ng/mg creatinine, P=0.05, Figure 2.5A), indicating that Se protects from lipid peroxidation 
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in this model. Therefore, F2-IsoPs effectively quantitate oxidative stress levels in the DSS 
model and Se-deficiency increases whole animal oxidative stress after DSS-induced injury. 
Figure 2.5 Selenium deficiency induces oxidative stress as measured by F2-isoprostanes and DNA 
damage A. Selenium-sufficient (n=3, white bars) and -deficient (n=3, black bars) mice were given 
3% DSS ad lib. and maintained in metabolic cages. Urine was collected at days 0 and 3 of DSS 
administration and F2-isoprostanes were measured and normalized to mg of creatinine. *P=0.05, 
1-way ANOVA. B. 8-OHdG (FITC) staining was performed in Se-sufficient (n=12) and -deficient 
(n=12) mice post-DSS morbidity protocol and quantified based on number of positive cells per high-
powered field (HPF, 40x) length (left). Representative staining is shown on the right. ***P<0.0001. 
 
DNA damage is increased in selenium-deficient mice in response to DSS.  
As inflammatory injury and lipid peroxidation were upregulated in Se-deficient 
mice, and because Se has been linked with DNA damage repair (136, 317), we next 
determined whether DNA damage was increased in these mice. Colonic epithelial 8-OHdG 
A 
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staining, which identifies oxidative damage to DNA, was significantly increased in Se-
deficient mice after DSS injury (13.2 ± 1.3 vs 28.8 ± 1.6 8-OHdG+ cells/HPF length, 
P<0.0001, Figure 2.5B). Thus, Se-deficiency exacerbated colitis and was associated with 
increased pro-inflammatory and pro-tumorigenic cytokines and increased DNA damage. 
These changes collectively produce a microenvironment primed for tumorigenesis.  
 
Dietary selenium protects from inflammatory carcinogenesis.  
Because Se deficiency promoted an activated pro-tumorigenic microenvironment 
and DNA damage after DSS treatment, we next determined if Se status modified 
inflammatory carcinogenesis.  AOM is a procarcinogen that is metabolically activated to 
a potent alkylating agent forming O6-methyl-guanine (318). Its oncogenic potential is 
markedly augmented in the setting of chronic inflammation, such as that induced by 
repeated cycles of DSS treatment (319, 320). 
To determine if dietary Se modifies CAC, we modeled inflammatory 
carcinogenesis in Se-deficient or –sufficient C57BL/6 mice using AOM/DSS (Figure 2.6A). 
At necropsy, Se-deficient mice demonstrated increased tumor multiplicity (3.4 ± 0.4 vs 
7.6 ± 0.9 tumors/mouse, P=0.0002, Figure 2.6B) as well as a higher degree of dysplasia 
(P<0.0001, Figure 2.6C) compared to Se-sufficient mice. Consistent with the morbidity 
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Figure 2.6 Selenium protects against tumor initiation and progression in inflammatory 
carcinogenesis. A. Schematic of the AOM/DSS CAC protocol. Mice are injected with AOM 4 days 
prior to beginning the first of three 4-day cycles of DSS. There are 16 days between each DSS cycle 
and mice are sacrificed 26 days after their last cycle of DSS. Black circles indicate periods at which 
mice are endoscopically analyzed. B. Selenium sufficient (n=18) and deficient (n=20) mice were 
subjected to the AOM/DSS protocol and tumor number was analyzed. ***P=0.0002. C. Tumors 
were analyzed (by pathologist M.K. Washington) for dysplasia grade (LGD=low-grade dysplasia, 
HGD=high-grade dysplasia) and quantified based on percent of tumors demonstrating each grade 
(left, HGD ***P<0.0001, Fisher’s exact test). Representative H&E stained colons are displayed on 
the right. 
 
studies (Figure 2.2), there was an increase in morbidity in Se-deficient mice in response 
to the AOM/DSS protocol (Figure 2.7A), though this difference was not statistically 
significant. We did not detect alterations in colon weight or length, however, suggesting 
that Se-deficient mice did not sustain chronic inflammatory changes in response to the 
AOM/DSS protocol (Supplementary Figure 2.7B and C), at least when evaluated after the 
26-day recovery period. Taken together, these data suggest that Se serves as a tumor 
suppressor that exerts its influence at the levels of tumor initiation and progression.  
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Figure 2.7 Selenium levels do not significantly impact survival, colon weight, colon length, or 
mouse weight in response to AOM/DSS. A. Survival curve of Se-deficient and -sufficient mice in 
response to the AOM/DSS protocol. B. Colon weight (g) and C. colon length (mm) post-AOM/DSS 
protocol. D. Mouse weight (g) throughout the AOM/DSS protocol measured on days 0, 1, 3, 4, and 
7 of DSS administration during each DSS cycle. E. DSS consumption/mouse during the four days of 
DSS administration. 
 
Selenium deficiency results in increased intratumoral proliferation and a general increase 
in DNA damage. 
 Several selenoproteins have been identified as direct WNT targets (135) and Se 
deficiency activates WNT signaling (286), implicating Se deficiency in a proliferation 
pathway that is aberrantly regulated in colorectal cancer. Furthermore, mitochondrial 
selenoproteins have been implicated in the regulation of mitochondrial-dependent cell 
death (287). As we noted an increase in tumor number in Se-deficient mice, we 
determined whether cellular proliferation or apoptosis indices were altered. 
Proliferation, as measured by Ki67 staining, was increased in the tumors of Se-deficient 
A 
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mice (26.0 ± 1.9 vs 39.5 ± 2.9 Ki67+ cells/tumor HPF, P=0.0008, Figure 2.8A). Apoptosis 
was quantified by TUNEL staining and no difference was seen between the two groups.  
 
Figure 2.8 Selenium deficient colons demonstrate increased intratumoral proliferation and DNA 
damage in response to inflammatory carcinogenesis. Swiss-rolled colons of Se-sufficient and –
deficient mice post-AOM/DSS protocol were analyzed for proliferation and DNA damage. A. Ki67 
immunohistochemistry was conducted to identify actively proliferating cells. Intratumoral 
proliferation index calculated from number of Ki67-positive cells per HPF (top, Se-sufficient n=15, 
Se-deficient n=20, 40x). B. Immunofluorescence for 8-OHdG was conducted according to Materials 
and Methods. Staining is quantified per longitudinal crypt section in 20 crypts of each mouse (top) 
and representative images are shown (bottom). C. 8-OHdG staining is quantified per tumor HPF 
(top, Se-sufficient n=19, Se-deficient n=20, 40x) and representative images are shown (bottom). 
**P=0.009, ***P<0.0001. 
 
Interestingly, an increase in intratumoral proliferation is generally associated with an 
increase in tumor size and not number. For this reason, and due to the fact that DSS 
A B C 
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results in DNA damage (268, 321) which can lead to changes in the initiation frequency, 
we stained crypts and tumors of Se-sufficient and -deficient mice with 8-OHdG. Consistent 
with what was observed in the DSS morbidity study, Se deficiency led to a significant 
increase in DNA damage within crypts (0.83 ± 0.04 vs 1.1 ± 0.08 8-OHdG+/crypt, P=0.009, 
Figure 2.8B), as well as tumors (23.7 ± 1.5 vs 46.8 ± 3.7 8-OHdG+/tumor HPF, P<0.0001, 
Figure 2.8C). Indicating augmented DNA damage, potentially contributing to the 
increased tumorigenesis observed in Se-deficient mice.  
 
Discussion 
The essential trace element Se may be useful for the prevention and/or 
abrogation of several diseases related to oxidative stress including neurodegenerative, 
cardiovascular diseases (78). In these diseases, Se deficiency is uncommon and thus 
therapeutic approaches targeting Se would require supranutritional amounts of Se for 
treatment. This point is important because harmful side-effects of supranutritional Se 
have been identified including increased risk for diabetes (81). In contrast, IBD is a disease 
characterized by chronic inflammation, high oxidative stress and Se deficiency making it 
a potential target for Se supplementation, with the goal being to restore Se nutritional 
status to the normal range. In support of this concept, our results demonstrate that, in 
fact, Se sufficiency protects against DSS-induced injury when compared to Se deficiency 
as morbidity, weight loss, and mucosal injury in response to DSS were all significantly 
increased in mice fed a Se-deficient diet. Moreover, Se may protect against mucosal injury 
by decreasing expression of pro-inflammatory cytokines; as such we detected increased 
 62 
 
mRNA expression of the B cell chemoattractant chemokine (C-X-C motif) ligand 13 
(Cxcl13), the T cell inflammation associated Chemokine (C-C motif) ligand 27 (Ccl27), the 
lymphocyte chemoattractant Chemokine (C-C motif) ligand 20 (Ccl20), as well as 
interleukin (Il)-17c which can promote Th17 cell responses (322). Of particular interest is 
the upregulation of Il-23a, as Il-23 has been shown to be a pro-inflammatory factor and 
target protein for inhibitory therapy in Crohn’s disease, since it has major effects on Th17 
cell differentiation (323). These data suggest that restoration of normal Se levels may be 
a therapeutic option in IBD. 
DSS-induced colonic injury, like ulcerative colitis, results in increased oxidative 
stress, which is at least partly attributable to immune cell infiltration and the release of 
inflammatory mediators (324, 325). One method to quantify oxidative injury is to assess 
lipid peroxidation via measurement of F2-isoprostanes (F2-IsoPs), non-enzymatic 
derivatives of arachidonic acid (309). It is important to note that, although lipid 
peroxidation is an indirect measure of oxidative stress, the Biomarkers of Oxidative Stress 
Study (BOSS) identified F2-IsoPs as the most reliable index of in vivo oxidative stress when 
compared against other known biomarkers (316). Other labs have demonstrated 
increased F2-IsoPs in response to DSS using the Cayman assay (326, 327). We utilized 
stable isotope dilution gas chromatography mass spectrometry analysis of F2-IsoPs to 
demonstrate that Se deficiency further augments the effects of DSS, indicating that DSS-
induced lipid peroxidation, an indicator of oxidative injury, is increased in response to Se 
deficiency upon DSS administration and implicating Se in protection from lipid 
peroxidation in the DSS model. 
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Chronic inflammation and cyclic epithelial injury characteristic of IBD results in 
increased cancer risk, although the magnitude of this risk is unclear (300). In our studies 
we found that Se deficiency leads to increased colonic injury and inflammation. 
Additionally, several TGF-β signaling components were aberrantly expressed in Se-
deficient mice after DSS treatment. Transcripts for bone morphogenetic protein 8b 
(Bmp8b), which important for primordial germ cell determination (328), and a second 
TGF-β family member, growth differentiation factor 1 (Gdf1), were downregulated in DSS-
treated Se-deficient mice. Gdf1 is correspondingly underexpressed in salivary gland 
adenoid cystic carcinoma (329) suggesting a potential role as a tumor suppressor. 
Furthermore, Tgf-β1 gene expression is upregulated in Se-deficient mice and has been 
implicated in the pathogenesis of colorectal neoplasia and several polymorphisms have 
been identified in colorectal adenoma which lead to Tgf-β1 overexpression (330, 331). 
Tgf-β2, also identified as overexpressed in Se-deficient mice, has been linked with tumor 
promotion as it is upregulated in colorectal, breast, pancreatic, and brain cancer (332). 
Transcripts of the EGF pathway are also upregulated in Se-deficient mice with 
pathway members including epidermal growth factor (Egf), insulin-like growth factor 1 
(Igf1) and neuregulin 4 (Nrg4) all demonstrating increased expression in Se-deficient 
compared to -sufficient mice subjected to the DSS morbidity protocol. EGF is upregulated 
nearly 3-fold in colorectal carcinoma (333) and the EGF signaling pathway is intimately 
linked to promotion of solid tumor growth (334). These data coupled with the fact that 
we also see increased expression of the ephrins Efnb2 and Efnb3, which are known to 
contribute to tumor promotion as well as progression (335), suggest that the signaling 
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cascades and inflammation resulting from Se deficiency after DSS injury may result in  
increased cancer risk. 
Beyond activation of oncogenic signaling pathways, Se deficiency may promote 
tumorigenesis via affecting genomic integrity (129). Supplementation with moderate 
levels of Se compounds both in vivo and in vitro is thought to protect against the 
formation of DNA adducts and maintain chromosomal stability and telomere length and 
function (136). In support of this we found that Se deficiency did, in fact, increase DNA 
adduct formation, a marker of DNA damage, after DSS-induced colonic stress, suggesting 
another mechanism by which Se might inhibit tumorigenesis in CAC.  
Two prior studies report on the effects of reduced dietary Se in inflammatory 
colon tumorigenesis. Both have demonstrated a subtle, non-significant, increase in 
tumorigenesis with decreased dietary selenium (141). There are several potential 
explanations for why we observed a significant increase in tumor burden in our studies; 
1) Differences in model selection, 2) strain of mice studied, and 3) degree and magnitude 
of Se deficiency. Our mice were fed Se-deficient diets (less than 0.01 mg Se/kg) for 12 
weeks prior to the initiation of our protocols. This extensive time-frame was selected 
because our group has previously determined that this will ensure Se deficiency (336). In 
our current studies we confirmed Se deficiency by measuring plasma Gpx activity and 
colonic Se levels. In contrast, the prior studies used low Se diets (0.02 and 0.086 mg Se/kg, 
respectively) for shorter time periods before protocol initiation. Our AOM/DSS protocol 
employs a single injection of AOM followed by cyclical administration of 3% DSS. Using 
this protocol, we achieved a tumor penetrance of 100% revealing a significant role of Se 
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deficiency in inflammatory carcinogenesis. Furthermore, our data suggest that Se may 
also protect from tumor progression as more advanced lesions occurred in the setting of 
Se deficiency.  
There is considerable epidemiological evidence indicating that Se levels and 
cancer are inversely correlated (103, 288, 290, 337). Dietary intervention studies targeting 
Se have been inconsistent, however. Our findings suggest that Se supplementation, as a 
therapeutic intervention, should be targeted to patient populations, or individual 
patients, with demonstrable Se deficiency. Importantly, our data indicate that patients 
with IBD, a disease in which Se deficiency occurs, might benefit from Se supplementation 
to prevent CAC. Beyond IBD and CAC, there needs to be a concerted effort towards fully 
understanding the molecular basis for how Se protects from tumorigenesis, in what 
cancers Se is important, at what dietary levels Se is most beneficial, and in which patient 
populations selenium supplementation might have a beneficial impact. 
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CHAPTER III 
 
TUMOR SUPPRESSOR FUNCTION OF THE PLASMA GLUTATHIONE PEROXIDASE GPX3 IN 
COLITIS-ASSOCIATED CARCINOMA2 
 
Introduction 
 Inflammatory bowel disease (IBD), which affects 1 in 600 Americans, is 
characterized by severe and chronic inflammation. Such inflammation is a known 
contributor to cancer as it promotes an environment rich in chemokines, cytokines, and 
reactive oxygen species (ROS) influencing epithelial proliferation and survival programs 
and impacting genomic integrity (15, 299). For example, patients with IBD demonstrate 
increased nitric oxide production via activated macrophages and granulocytes and 
increased plasma levels of the marker for DNA damage 8-hydroxydeoxyguanosine (299, 
338). As such, the risk for cancer is increased 6-fold in patients with IBD compared with 
the general population, and cancer, or risk thereof, is a cause of significant morbidity in 
IBD (300).   
 Selenium is a necessary trace element that is present in the primary structure of 
selenoproteins as selenocysteine. Several epidemiological studies have inversely 
correlated nutritional selenium status with colon and prostate cancer risk, although this 
is somewhat controversial. The effect of selenium status in IBD has not been definitively 
                                                        
2 This work has been published under *Caitlyn W. Barrett, *Wei Ning, Xi Chen, J. Joshua Smith, Mary 
K. Washington, Kristina E. Hill, Lori A. Coburn, Richard M. Peek, Rupesh Chaturvedi, Keith T. Wilson, 
Raymond F. Burk, Christopher S. Williams (2013) Tumor suppression function of the plasma 
glutathione peroxidase Gpx3 in colitis-associated carcinoma, Cancer Research, 73, 1245-55 (3). 
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evaluated. It is proposed that the effect of selenium on carcinogenesis is realized by the 
selenoproteins into which it is incorporated. In support of this, mouse models with 
impaired selenoprotein expression demonstrate increased aberrant crypt foci, a 
preneoplastic colon lesion, and breast cancer incidence (292, 339). The selenocysteine 
present in the catalytic triad of glutathione peroxidases is optimized by hydrogen bonding 
with glutamine and tryptophan residues, enhancing its activity and, in the case of certain 
glutathione peroxidases such as GPX1, this allows it to exert antioxidant activity (68, 340). 
One mechanism, though by no means the only, by which glutathione peroxidases may 
reduce cancer risk is by blunting the tumor-promoting effects of oxidative stress. 
 Gpx3, or plasma glutathione peroxidase, is the only known selenocysteine-
containing extracellular form of glutathione peroxidase (Gpx) and accounts for nearly all 
of the glutathione peroxidase activity in plasma (341). Gpx3 mRNA is expressed in a tissue-
specific manner by the kidney, heart, lung, liver, brain, adipose tissue, breast, and 
gastrointestinal tract, but the majority of plasma Gpx3 is kidney-derived (342-344). It is 
likely that other organs contribute to plasma Gpx3 as nephrectomized rats retain 30% of 
original glutathione peroxidase activity (345). Gpx3 is transported via circulation where it 
binds to the basement membranes of epithelial cells such as those in the gastrointestinal 
tract (346). Gpx3 promoter hypermethylation and downregulation is commonly seen in 
human cancer (298, 347-349). In prostate cancer, hemizygous and homozygous deletions 
as well as methylation of the first exon of Gpx3 frequently occur (349). Promoter 
hypermethylation insures decreased expression of Gpx3 in gastric, cervical, thyroid, head 
and neck, and lung cancers, and in melanoma (347, 348) suggesting that Gpx3 serves as a 
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tumor suppressor in these cancers. Genetic evidence supports a role for GPX enzymes in 
IBD with Gpx1;Gpx2 double knockout mice developing spontaneous ileocolitis (350) and 
intestinal carcinoma that is associated with bacteria-induced inflammation (351). In fact, 
Gpx2 alone may have a protective role in inflammatory carcinogenesis (141). The role of 
Gpx3 in these processes has never been directly tested. 
    We hypothesized that loss of Gpx3 would enhance tumorigenesis in 
inflammatory carcinogenesis, a process rich in ROS production and chemokine/cytokine 
driven pro-proliferative stromal signals (15, 299, 352-354). In order to test this we applied 
the azoxymethane/dextran sodium sulfate (AOM/DSS) murine inflammatory 
carcinogenesis model to Gpx3-/- mice. This model has been used to identify modifiers of 
colitis-associated carcinoma including NF-B (265), TLR4 (266), TNF (355), and Mtgr1 
(269), as well as innate immune responses (33) and intestinal microflora (356). We found 
a striking increase in tumor number in the absence of Gpx3, indicating a direct impact of 
Gpx3 on tumor initiation. In support of an initiating role, Gpx3-/- mice demonstrated 
increased DNA damage. Tumors in Gpx3-/- mice demonstrated increased inflammation as 
well as increased infiltration of M2 macrophages, proliferation, and nuclear -catenin. 
Gpx3-/- tumors were also more advanced. As expected, knockdown of Gpx3 in the human 
colon cancer cell line Caco2 resulted in increased ROS production and DNA damage. Thus 
we provide genetic evidence that Gpx3 behaves as a potent tumor suppressor during 
inflammatory carcinogenesis in vivo likely by decreasing the ROS and DNA damage that 
lead to tumor initiation.  
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Materials and Methods 
Murine Inflammatory Carcinogenesis and Chronic Colitis Protocols. 7-8 week old C57Bl/6 
WT (n=17) or congenic Gpx3-/- (n=20) mice were injected with 12.5 mg/kg of AOM (Sigma-
Aldrich) intraperitoneally as described in Greten, et al (265). After a three-day recovery 
period the animals were started on the first of four cycles of 3% DSS ad libitum (see 
Schematic in Figure 3.1A). Each cycle lasted 5 days and was separated by a 16-day 
recovery period. A second DSS-only control arm was included for C57Bl/6 WT (n=14) and 
Gpx3-/- (n=19) that followed the same protocol outlined above excluding the AOM 
injection. After the last cycle, animals were sacrificed following a 26-day recovery period. 
Tumor counts and measurements were performed in a blinded fashion under a stereo 
dissecting microscope. Each colon was then bisected longitudinally and half was Swiss 
rolled for microscopic analysis and the other half was partitioned into normal and tumor 
tissue and saved for protein and RNA analysis. Microscopic analysis was performed by a 
gastrointestinal pathologist (MKW) for severity of inflammation (357) and dysplasia on 
haematoxylin and eosin (H&E) stained “Swiss rolled” colons (processed by the Vanderbilt 
Translational Pathology Shared Resource core). Four days after the third cycle of DSS, 
murine endoscopy was utilized in order to monitor colitis severity (358) and tumor 
burden. All in vivo procedures were carried out in accordance with protocols approved by 
the Vanderbilt Institutional Animal Care and Use Committee.   
Plasma Glutathione Peroxidase Activity Assay. Blood was collected from mice via the vena 
cava and plasma was separated from erythrocytes (K3EDTA) by centrifugation at 12,000 
rpm for 1 minute. Glutathione peroxidase activity was determined according to a 
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modified protocol (307) based on the method of Paglia and Valentine (308). Briefly, 800 
l reaction cocktail (50 mM potassium phosphate, pH 7.0, 1 mM EDTA, 1 mM NaN3, 0.2 
mM NADPH, 1 E.U./ml GSSG-reductase, and 1mM GSH) was mixed with 20 l plasma and 
80 l water in a clear plastic cuvette and incubated at room temperature for 5 minutes. 
100 l hydrogen peroxide (H2O2) substrate (0.25 mM H2O2 in H2O) was added to the 
reaction mixture to initiate reaction. Gpx activity was assessed by measuring the rate of 
change of A340 per minute over a 3 minute time period after the addition of H2O2 to the 
reaction mixture. The enzymatic reaction is linear during this time period. The rate of 
change was then converted to the number of µmol NADPH oxidized per minute using the 
extinction coefficient of 6.2 x 103 L mol-1 cm-1 for NADPH at 340 nm. Blank reactions with 
plasma replaced by distilled water were subtracted from each assay. 
Oxidative stress gene RT-PCR. RNA was made from 30 mg WT water treated colons and 
normal adjacent tissue from AOM/DSS colons using the RNeasy Mini kit (Qiagen), 
according to the manufacturer’s directions. cDNA was then made using the SuperScript 
cDNA kit (Invitrogen). RT-PCR was then performed using an oxidative stress primer library 
(HOSL-1, Realtimeprimers.com). Reactions were performed according to the 
manufacturer’s recommendations. Analysis was performed using the delta-delta-Ct 
method. 
Immunohistochemistry and immunofluorescence. Five-micrometer sections were cut, 
dewaxed, hydrated and endogenous peroxidase activity quenched with 0.03% hydrogen 
peroxide in MeOH. Antigen retrieval was performed using the boiling sodium citrate 
method in a microwave (20 mmol sodium citrate pH 6.5) for 16 minutes at 30% power. 
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After blocking, primary antibody was added (α-Ki67, (NeoMarkers), 1:1000; α-8-hydroxy-
2’ deoxyguanosine (Abcam) 1:50; α--catenin, (BD Transduction Laboratories), 1:1000; α-
arginase I (Arg1), (Santa Cruz), 1:500; α-IL-1β, (R&D Systems), 1:50; FITC--F4/80 
(eBioscience), 1:1000) and incubated overnight at 4°C. Isotype-matched antibodies were 
included as negative controls. The Vectastain ABC Elite System (Vector Labs) was used to 
visualize staining for immunohistochemistry. Identification of intratumoral apoptotic cells 
was performed using the ApopTag Plus Peroxidase in situ Apoptosis Kit (Chemicon) 
according to the manufacturer's protocol. Control stains were obtained by omitting the 
terminal transferase (TnT) enzyme. For immunofluorescence staining of macrophage 
markers and DNA damage, slides were counterstained and mounted with ProLong Gold 
antifade including DAPI (Invitrogen). Gpx3 staining was performed as described (346). 
Immune cell, apoptosis, and proliferation indices were generated by counting the number 
of positive cells per high-powered field (HPF; 40× objective) within each tumor by a 
blinded observer. A β-catenin index was employed, as previously reported (269). This 
index is generated by multiplying the staining intensity (on a scale of 1-4) by percentage 
of the cells demonstrating nuclear staining. The average score was then calculated for 
each Swiss rolled colon. 
Cell Culture and shRNA Knockdown. Caco2 human colon tumor cells were obtained from 
ATCC (HTB-37) and had morphologic characteristics consistent with their known identity. 
Formal authentication was not performed. Caco2 cells were maintained in DMEM 
supplemented with 10% FBS and penicillin/streptomycin (P/S). HEK293T cells were 
maintained in RPMI1640 supplemented with 10% FBS and P/S. HEK293T packaging cells 
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were transfected with Mission shRNA constructs (Sigma-Aldrich) specific for human Gpx3 
(clone ID: TRCN0000273651-NM, TRCN0000273684, and TRCN0000008678) as well as the 
PAX2 and pMD2.G plasmids using the Calcium Phosphate transfection method. Twenty-
four hours post-transfection, medium was removed from the HEK293T cells and passed 
through a 0.45 M filter. 4 g/ml Polybrene (Millipore) was added to the filtered media. 
Growth medium was removed from Caco2 cells and replaced with infection medium. 
After 6 hours, the infection medium was replaced with normal growth medium and the 
infection process was repeated 24 hours later. Cells were selected for knockdown using 5 
g/ml Puromycin (Invitrogen) over a 3-day period. Knockdown was analyzed by the delta-
delta-CT method following RT-PCR using Gpx3-specific Taqman probes (Invitrogen) and 
by Western blotting using rabbit anti-mouse Gpx3 8096 (dilution 1:5000; custom-made 
by Rockland). 
ROS Determination. Caco2 cells infected with either scrambled or Gpx3-specific shRNA 
were pre-treated with 500 U/ml PEGylated catalase (PEG-CAT, Sigma) one hour prior to 
1.5 hour treatment with 200 M H2O2. Either ROS detection reagent 6-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) (DCFH2, Invitrogen) or the 
oxidation insensitive analog of DCFH2 (DCF, Invitrogen) was used to stain treated cells 
according to the manufacturer’s protocol for flow cytometry analysis. In short, cells plated 
on a 6-well plate in phenol red-free medium were washed with 500 μl PBS. Cells were 
then resuspended in 1 μM DCFH2 or 0.5 μM DCF in pre-warmed PBS and incubated for 
either 20 minutes or 5 minutes at 37°C, respectively. Cells were then washed twice with 
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PBS and centrifuged at 1600 rpm for 6 minutes between washes. Cells were analyzed for 
positivity by flow cytometry. 
Detection of DNA Damage and Active Caspase-3 by Flow Cytometry. Caco2 (sh-scrambled) 
and Caco2 (sh-hGpx3) cells were treated with H2O2 (100 M) for 4 hours and washed with 
PBS, fixed in 0.1% paraformaldehyde, and permeabilized with 100% methanol on ice. 
Levels of DNA damage and active caspase-3 were assessed as described previously (359). 
In brief, cells were incubated with rabbit anti-active caspase-3 antibody conjugated with 
phycoerythrin (PE; dilution 1:50; BD Biosciences) and 8-oxoguanosine–binding peptide 
conjugated with fluorescein isothiocyanate (dilution 1:100) for 30 minutes at room 
temperature. Cells were acquired with a BD LSRII system (BD Biosciences) and analyzed 
using FlowJo software (Star tree, Ashland, OR). 
Matrigel Colony Formation Assay. The day prior to Matrigel plating, Matrigel (BD, 354234) 
at 9 mg/ml was thawed overnight in ice at 4°C. For each well of a 48-well plate, 50 μl ice 
cold Caco2 media (DMEM supplemented with 10% FBS and pen/strep) was mixed with 50 
μl Matrigel. Plates were then allowed to solidify at 37°C for thirty minutes. Caco2 cells 
were trypsinized, washed with PBS, and diluted to 10,000 cells/ml in 2 ml media. A 1:1 
mixture of cells and Matrigel was added to the wells in the prepared 48-well plate and 
incubated at 37°C for thirty minutes. To avoid drying, 200 μl complete Caco2 media was 
added to each Matrigel-filled well. Cells were maintained at their normal growth 
conditions and media was changed every 2-3 days. On day 22, cells were counted using 
GelCount (Oxford Optronix, Oxford, UK). 
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Results 
Glutathione peroxidase activity is decreased and oxidative stress is increased in AOM/DSS-
treated mice.  
Gpx3 is often downregulated in cancer (298, 347-349) and we sought to determine 
whether its expression or activity was altered in the AOM/DSS model of inflammatory 
carcinogenesis. For these experiments, 7-8 week old mice were injected with AOM and 
treated with 4 cycles of DSS as defined in the Methods section and shown in Figure 3.1A. 
During the course of this protocol, six Gpx3-/- mice died (lost over 20% of original body 
weight and were sacrificed), two after cycle 1, two after cycle 2, and two during cycle 4 of 
DSS. Whereas, as is typical with this protocol, two WT mice died, both after cycle 4, a time 
when we usually see mortality. These mice were not included in the final analysis. This 
increased morbidity suggests that Gpx3 may protect the mucosa from DSS induced injury.  
As decreased Gpx3 levels are commonly seen in cancer, we first tested plasma 
Gpx3 activity in mice receiving water only versus mice post the AOM/DSS protocol to 
determine if Gpx3 activity might be altered. Measurement of oxidation of NADPH allowed 
us to determine that AOM/DSS leads to diminished plasma glutathione peroxidase 
activity (497.7 ± 56.9 versus 239.4 ± 40.8 nmol NADPH oxidized/ml plasma/min, P=0.0013, 
Fig. 3.1B). We next wanted to determine if local Gpx3 mRNA levels were affected in 
AOM/DSS tumorigenesis. There was no difference in Gpx3 mRNA expression between 
matched tumor and adjacent normal mucosa samples, but other oxidative stress  
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Figure 3.1 Plasma Gpx3 activity is decreased and oxidative stress genes are increased in mice 
subjected to the AOM/DSS protocol. A, schematic of the AOM/DSS protocol. Animals injected with 
12.5 mg/kg AOM at day 0 followed by 4 cycles of 3% DSS ad libitum separated by 16 days of 
recovery on water. B, plasma glutathione peroxidase activity determined after the completion of 
the AOM/DSS protocol. WT water treated, N = 10; WT AOM/DSS, N = 11; **, P = 0.0013. C, tumor 
tissue mRNA expression of oxidative stress genes (ATOX1, ATX1 antioxidant protein 1 homolog; 
CSDE1, cold shock domain containing E1, RNA binding; GSTM2, glutathione S-transferase M2, 
muscle; GSTT1, glutathione S-transferase theta 1; NCF2, neutrophil cytosolic factor 2; OXSR1, 
oxidative-stress responsive 1; SOD3, superoxide dismutase 3, extracellular) in WT water treated 
(N = 4) vs. WT AOM/DSS (N = 4); ***, P < 0.001; **, P < 0.01; *, P < 0.05. 
 
response genes were upregulated in normal adjacent colon tissue from AOM/DSS mice 
(Fig. 3.1C) suggesting an increase in oxidant stress resulting from the protocol. Finally, we 
wanted to determine if GPX3 expression varied in a large colorectal cancer expression 
array dataset, and in this case GPX3 was markedly and consistently underexpressed as 
early as the adenoma stage (Fig. 3.2A).  We confirmed this observation with 10 matched 
normal/colon cancer samples by qRT-PCR, and in a second set of 10 matched samples by 
protein analysis, finding reduced GPX3 levels in 80% of the samples (Fig. 3.2B & C). These 
A 
B C 
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results support previous studies (298) and suggest that GPX3 may serve as a tumor 
suppressor in colorectal cancer. 
 
 
Figure 3.2 Gpx3 expression is downregulated in human colon cancer samples. A) GPX3 expression 
is significantly downregulated in adenomas and colorectal cancer patients compared with normal 
adjacent colon tissues. **P<0.01 for each stage relative to normal. B) GPX3 expression in matched 
human normal and tumor samples. Error bars represent standard deviation of samples performed 
in duplicate. C) Western blot of GPX3 protein expression in matched human normal and tumor 
samples. Quantification is presented as fold change intensity controlled for -actin. 
 
Gpx3 is a tumor suppressor in inflammatory tumorigenesis.  
Utilizing the Gpx3-/- mouse, we directly tested whether Gpx3 was a tumor 
suppressor in the AOM/DSS model. 7-8 week old WT or Gpx3-/- mice were placed on the 
AOM/DSS protocol (Fig. 3.1A). As expected, mice lost weight and had looser stools as the 
result of DSS administration in both the DSS and AOM/DSS arms of the experiment, 
A B 
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though there was no significant difference between genotypes in these parameters. Gpx3 
protein is normally seen in the colon binding the basement membrane on the basolateral  
Figure 3.3 Gpx3 functions as a tumor suppressor in inflammatory carcinogenesis. A, 
immunofluorescence staining of normal WT colon. Gpx3 (red), F-actin (phalloidin, green), and 
Hoescht (blue) staining is shown (left). Immunoglobulin G (IgG) control is shown on the right (×60 
magnification). B, representative colonoscopic images from WT (top left) or Gpx3−/− (top right) 
mice after 3 cycles of DSS and murine endoscopic colitis scoring using the murine endoscopic index 
of colitis severity. **, P < 0.01. C, representative gross specimens from the indicated genotype 
(left). Tumor multiplicity (top right) and polyp burden (bottom right) are shown; results were 
determined via calculation of the combined surface area (Σitot SAi = Li × Wi) of all lesions in each 
colon. DSS only WT, N = 13; Gpx3−/−, N = 18, AOM/DSS WT, N = 12; Gpx3−/−, N = 11. ***, P < 0.001 
between WT and Gpx3−/−. fff, P < 0.001 DSS only versus AOM/DSS groups. 
A B 
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surface (346) (Fig. 3.3A). Gpx3-/- mice demonstrated an increased endoscopic colitis score 
(302) during both DSS and AOM/DSS protocols (Fig. 3.3B) with colonic thickening, vascular  
changes, evidence of fibrin, increased granularity, and softer stools than wild type mice 
(DSS: 12.1 ± 1.4 N=6 versus 6.8 ± 1.0, N=6; AOM/DSS: 12.1 ± 1.2, N=4 versus 6.9 ± 0.8; 
N=6, P<0.01 for both comparisons).  Twenty-six days after the last DSS cycle the animals 
were sacrificed. Consistent with a role for Gpx3 in tumor suppression, quantification of 
tumor number in AOM/DSS mice demonstrated increased tumor multiplicity in Gpx3-/- 
mice (21.1 ± 1.6 tumors/mouse N=11 versus 10.8 ± 1.5 tumors/mouse N=12, P<0.0001). 
In addition, there was a trend towards increased tumor number and size in Gpx3-/- mice 
receiving DSS only without AOM when compared to wild-type mice (1.0 ± 0.3 
tumors/mouse N=18 versus 0.4 ± 0.2 tumors/mouse, N=13, P=0.1, Fig. 3.3C).  
Histologic examination by a gastrointestinal pathologist (MKW) of H&E stained 
sections from colons prepared as  “Swiss Rolls” revealed increased injury severity based 
on a multi-parameter histologic injury score (357) in Gpx3-/- AOM/DSS mice (16.2 ± 2.6 
N=14 versus 7.8 ± 0.92 N=16, P=0.003, Fig. 3.4A & B) with significant increases in 
inflammation, inflammation extent, and crypt damage/regeneration (Fig. 3.4C). Tumors 
were also analyzed for grade and Gpx3-/- adenomas demonstrated increased propensity 
for high-grade dysplasia characterized by loss of polarity and a more complex tumor 
growth pattern than WT tumors (Fig. 3.4D). In fact, one Gpx3-/- tumor demonstrated local 
invasion (Fig. 3.4A & D), a property rarely seen in response to AOM/DSS. These results 
suggest that Gpx3 loss results in increased colonic injury and inflammation and 
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contributes to tumor promotion and progression in the AOM/DSS model of inflammatory 
carcinogenesis. 
Figure 3.4 Increased histologic injury in Gpx3−/− colons. A, representative H&E staining from WT 
(×10 top, ×20 bottom left) or Gpx3−/− (×10 top, ×20 bottom right) colons. There is evidence for 
invasive adenocarcinoma in the Gpx3−/− tumor. B, histologic injury score for DSS only or AOM/DSS 
tissues. **, P < 0.01. C, division of the histologic injury scores from B into pathologic inflammation, 
extent, and crypt damage/regeneration scores for DSS only or AOM/DSS tissues. ***, P < 0.001. 
D, dysplasia grading (conducted by M.K. Washington) in WT and Gpx3−/− tumors expressed as 
invasive, high-grade dysplasia (HGD), low-grade dysplasia (LGD), or regenerative crypt. Results 
represent percentage of total tumors for each group within each grade. 
 
Altered intratumoral proliferation in the absence of Gpx3.  
Tumor number may be modified by increased cellular proliferation and/or survival 
or decreased apoptosis of transformed cells. Intratumoral proliferation rates were 
analyzed using in situ Ki67 staining. Gpx3-/- mice demonstrated an average of 163.9 ± 14.1 
A B 
C D 
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Ki67+ cells/tumor high-powered field (HPF). WT mice, on the other hand, displayed 73.9 
± 15.1 Ki67+ cells/tumor HPF (P=0.0003, Fig. 3.5A & B) indicating a significant increase in 
proliferation in Gpx3-/- tumors. No differences were seen in apoptotic indices as 
determined by TUNEL staining. 
 
Figure 3.5 Increased intratumoral proliferation and nuclear β-catenin in Gpx3−/− tumors. α-Ki67 
immunohistochemistry was conducted to identify actively proliferating cells. A, representative 
images of Ki67 staining in WT or Gpx3−/− tumors (×40 magnification). B, intratumoral proliferation 
index calculated from number of Ki67-positive cells per HPF in 20 HPF per mouse. *** P = 0.0003. 
C, β-catenin expression and localization was determined via immunohistochemistry with β-catenin 
as per Materials and Methods (Gpx3−/−, N = 10, WT, N = 10 tumors). Representative staining for β-
catenin from WT or Gpx3−/− tumors (left, ×10 magnification; right, ×40 magnification). D, 
intratumoral β-catenin index calculated as described in Materials and Methods. * P = 0.03. 
 
 
A B 
C D 
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Increased nuclear and total -catenin in Gpx3-/- tumors.  
Selenium deficiency in mice is predicted to stimulate the Wnt pathway (286). As 
the Wnt pathway is known to drive pro-proliferative and survival processes and is often 
hyperactive in the AOM/DSS model (264), we hypothesized that Wnt signaling, as 
evidenced by altered -catenin localization, might be further perturbed in the absence of 
Gpx3. Therefore, we stained Gpx3-/- tumors for -catenin localization. Gpx3-/- tumors 
demonstrated a significant increase in both nuclear and total -catenin, suggesting that 
the Wnt pathway is upregulated in these mice, even above that typically seen in AOM/DSS 
tumors (Fig. 3.5C & D, P=0.03). 
  
Increased M2 macrophage infiltrate and DNA damage in Gpx3-/- tumors.  
Macrophages are major modifiers of inflammation and resolution in response to 
injury. Their activity and motility is also significantly modified by selenium and 
selenoprotein modulation (360). Since Gpx3-/- mice demonstrate increased injury and 
inflammation in response to AOM and DSS (Fig. 3.3B & C), Gpx3 loss may influence 
intratumoral macrophage composition. Gpx3-/- tumors demonstrated increased F4/80+ 
and Arg1+ pro-tumorigenic M2 macrophages (17.1 ± 1.7 versus 9.7 ± 1.5 F4/80+/Arg1+ 
cells/tumor HPF, P=0.005; Fig. 3.6A & B, bottom) and decreased F4/80+ and IL-1+ anti-
tumorigenic M1 macrophages (10.1 ± 1.7 versus 18.6 ± 1.8 F4/80+/IL-1β+ cells/tumor HPF, 
P=0.003; Fig. 3.6A & B, top) compared to WT mice, suggesting that Gpx3 may have an 
impact on macrophage polarization, promoting a skewing towards pro-tumorigenic 
macrophage distribution. 
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Figure 3.6 Increased M2 macrophages and evidence for oxidative DNA damage in Gpx3−/− tumors. 
Immunofluorescence for M1 (IL-1β+, F4/80+) and M2 (Arg1+, F4/80+) macrophage markers and 8-
OHdG was conducted according to Materials and Methods. A, example images from WT top row 
or Gpx3−/− tumors. B, quantification of M1 (top) or M2 (bottom) macrophages per tumor HPF. ** 
P < 0.01. C, example images from WT (top row) or Gpx3−/− (bottom row) tumors. White arrow 
indicates positive staining in epithelial cells, yellow arrow indicates nonspecific staining. D, 8-
OHdG quantification. **P < 0.01. All images taken at ×40 magnification. 
 
ROS is produced during the AOM/DSS protocol as evidenced by increased 
expression of oxidative stress response genes (Fig. 3.1C and (361)). Because ROS can 
A B 
C 
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directly induce DNA damage via oxidation and deamination of DNA bases (362), and 
because DNA damage is an indicator of tumorigenesis risk, we wanted to determine 
whether loss of Gpx3 would lead to increased DNA damage. 8-hydroxyguanine (8-OHdG) 
staining was performed to determine intratumoral DNA damage. In fact, Gpx3-/- tumors 
demonstrated evidence for increased DNA damage compared to WT tumors (10.0 ± 0.8 
versus 7.1 ± 0.4 8-OHdG+ cells/HPF, P=0.002, Fig. 3.6C). 
 
GPX3 knockdown in vitro leads to increased ROS levels and DNA damage.  
To determine whether knockdown of GPX3 in vitro would recapitulate results seen 
in vivo we used shRNA to GPX3 in the human colon cancer cell line Caco2. Caco2 cells 
were used as a model cell line because they express high levels of endogenous GPX3 
compared to other colon cancer cell lines. shRNA-mediated knockdown resulted in 
decreased GPX3 expression both at the mRNA and protein levels (Fig. 3.7A). At baseline, 
knockdown of GPX3 had no impact on ROS production or DNA damage, though 
stimulation with hydrogen peroxide (H2O2) resulted in a significant increase in ROS (16.1% 
versus 7.3%, P=0.0019), which was abolished with pre-treatment with the H2O2 scavenger 
PEG-CAT. Furthermore, GPX3 knockdown had no effect on the activity of the oxidation-
insensitive DCFH2+ analog, DCF+ (Figure 3.7B, right graph, compare white to black bars), 
indicating the results obtained with DCFH2+ were due to changes in hydrogen peroxide 
concentrations as opposed to changes in uptake, ester cleavage, or efflux of the probe. 
There was also a concomitant increase in DNA damage (1401 versus 766 8-oxoguanosine 
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MFUs, P<0.05, Fig. 3.7C) in GPX3 knockdown cells, consistent with data seen in tumors of 
Gpx3-/- mice. Thus, GPX3 does not seem to impact baseline oxidant parameters in vitro  
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Figure 3.7 Increased ROS, DNA damage, and apoptosis and decreased soft agar colony formation 
post-GPX3 knockdown. A, GPX3 mRNA and protein (inset) expression after knockdown with GPX3-
specific shRNA constructs in Caco2 cells. **, P < 0.01. B, quantification of percentage of ROS-
positive cells (DCFH2+) post-GPX3 knockdown in untreated or 200 μmol/L H2O2-treated Caco2 cells 
after pretreatment with the H2O2 scavenger PEG-CAT (left). **, P < 0.01. Quantification of 
percentage of DCF+ (oxidation-insensitive analog) cells post-Gpx3 knockdown in untreated or H2O2-
treated Caco2 cells (right). C, DNA damage as measured by 8-oxoguanosine–FITC flow cytometry 
in cells treated with scrambled or Gpx3-specific shRNAs and with or without H2O2 treatment. *, P 
< 0.05; f, P < 0.05. D, apoptosis, assessed as staining for active caspase-3 by flow cytometry (side-
scatter-A; SSC-A). The percentage positive cells are shown. **, P < 0.01; ff, P < 0.01. E, colony 
formation assay in Matrigel in Gpx3 knockdown and scrambled control Caco2 cells with and 
without H2O2 treatment. ***, P < 0.001 Scr versus shGPX3 control. 
 
without application of a stressor, suggesting that its primary role is to buffer excessive 
hydrogen peroxide concentrations. 
 
Knockdown of GPX3 in vitro leads to increased apoptosis and decreased contact-
independent growth.  
Because our data suggest that Gpx3 functions as a tumor suppressor in colitis-
associated carcinoma (CAC) in vivo, we wanted to determine whether it modified cellular 
growth properties in vitro in the acute setting in an established colon cancer cell line. In 
contrast to in vivo modeling where there was no effect of Gpx3 deletion on apoptosis, 
knockdown of GPX3 in Caco2 cells led to increased apoptosis (26.8% versus 15.6%, 
P<0.001, Fig. 3.7D) and no difference in proliferation when exposed to the stressor H2O2. 
Also of note, knockdown of GPX3 led to decreased contact-independent growth in 
Matrigel colony formation assays (7.3 versus 16.1 colonies, P<0.001, Fig. 3.7E), indicating 
the potential for a dual role for Gpx3 as a tumor suppressor in chronic inflammatory 
carcinogenesis while its loss in already established tumor cells (such as Caco2 cells) is 
detrimental to them.  
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Discussion 
 Chronic inflammation, as seen in ulcerative colitis and Crohn’s colitis, predisposes 
to malignancy (15). In fact, the risk for cancer is increased 6-fold in patients with IBD 
compared with the general population (300). Although the relationship between chronic 
inflammation and carcinogenesis is complicated and imprecisely understood, it is 
hypothesized that the excess ROS and reactive nitrogen species (RNS) accompanying 
inflammation contribute to malignancy. During chronic inflammation superoxide is 
produced at rates that overwhelm antioxidant systems (363, 364). When reactive oxygen 
and nitrogen species are not cleared efficiently, they begin to react with lipids, proteins, 
and DNA (365). More specifically, oxidative DNA damage leads to C/G base pair mutations 
which lead to an increased frequency of C:GT:A transversion (366), a mutation which is 
most frequently observed in mutated proto-oncogenes and tumor suppressor genes 
(367). GPX3 is an extracellular glutathione peroxidase that is able to abrogate ROS and is 
postulated to protect from carcinogenesis via these activities, although this has up to now 
not been rigorously tested using reverse genetics. We applied this approach to define the 
role of Gpx3 in inflammatory carcinogenesis and now demonstrate that Gpx3 is indeed a 
potent inhibitor of tumor promotion and progression. The impact of Gpx3 loss on 
tumorigenesis is likely mediated by increased inflammation and DNA damage as well as 
increased intratumoral proliferation that probably results from an increase in -catenin 
nuclear translocation and Wnt stimulation. Loss of Gpx3 in the AOM/DSS CAC model leads 
to increased tumor number, but not size. Gpx3-/- tumors also demonstrated increased 
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tumor staging suggesting that its loss also contributes to progression. In fact, one Gpx3-/- 
tumor demonstrated local invasion, a characteristic that is not normally seen as the result 
of the AOM/DSS protocol. This is significant because it supports epidemiological data that 
demonstrates that throughout the course of colorectal cancer progression, GPX3 
expression is decreased (298).  
 While the in vivo reverse genetic experiments using the Gpx3-/- mice in the 
AOM/DSS protocol model allowed us to decipher the cumulative effects of the absence 
of Gpx3 throughout the full spectrum of transformation from normal cells to tumor cells, 
in vitro experiments were conducted in established cancer cells (Caco2) to isolate the 
contribution of GPX3 to maintenance or promotion. As noted in vivo, GPX3 loss resulted 
in increased DNA damage. Of interest, knockdown of GPX3 in Caco2 cells resulted in a 
decrease in contact independent growth and increase in apoptosis in response to H2O2, 
indicating that the acute absence of Gpx3 is detrimental to established carcinoma growth. 
 Our data show that there is increased inflammation and crypt damage and 
regeneration in Gpx3-/- AOM/DSS mice compared to WT mice. Further, this inflammation 
occurred despite a decrease in M1 and increase in M2 macrophages. It is theorized that 
M1 macrophages, which normally serve as pro-inflammatory cells, are tumoricidal and 
downregulated during cancer development while M2 macrophages, which normally aid 
in the resolution of the inflammatory response, are pro-tumorigenic and upregulated 
within the tumor microenvironment (368). Thus Gpx3 loss likely contributes to differential 
macrophage activation or recruitment that further supports tumor growth and survival. 
This is an interesting finding as selenoprotein deficiency leads to diminished macrophage 
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migration (360) and selenium enhances the capacity of a host to generate cytotoxic 
lymphocytes and macrophages to destroy tumor cells (369, 370). Thus, our data suggest 
that at least part of the immune cell modifying properties of selenium are actuated by 
Gpx3. 
 Thus far, our data support a tumor suppressor role for Gpx3 via clearance of ROS. 
Upon knockdown of Gpx3 in the human colorectal cancer cell line Caco2, we saw an 
induction of ROS as well as an increase in DNA damage resulting from hydrogen peroxide 
treatment that supports our in vivo data. Contrary to what was originally expected, 
knockdown of Gpx3 did not alter proliferation at baseline or during stress as was seen in 
vivo. Instead, apoptosis was increased in response to H2O2 administration, a result that 
would be expected in cells that do not harbor the capacity to deal with oxidative stress 
due to the loss of the antioxidant Gpx3. Even at baseline, knockdown of Gpx3 in Caco2 
cells resulted in a decrease in contact-independent cell growth, a marker of 
tumorigenicity. This is contrary to our in vivo findings in which Gpx3 served as a tumor 
suppressor. Though initially surprising, we hypothesize that the tumor suppressive role of 
Gpx3 exists in its ability to prevent the initiation and malignant transformation in vivo, but 
in cells that are already malignant, Gpx3 is able to promote tumorigenesis by protecting 
them from apoptosis. This also likely explains why, despite having higher proliferation 
rates, the tumors of Gpx3-/- mice are not larger than those of WT mice. It may be that, 
upon the application of a stressor such as DSS, malignant cells in Gpx3-/- mice are dying 
more rapidly than those in WT mice and stabilizing the tumor size. 
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 In conclusion, we demonstrate that removal of Gpx3 enhances inflammation and 
injury, proliferation, nuclear -catenin, and DNA damage in tumors of mice subjected to 
an inflammatory carcinogenesis protocol. The net effect of these changes leads to an 
increase in tumor promotion in response to Gpx3 loss. Thus, Gpx3 appears to serve as a 
tumor suppressor in CAC. These studies provide insight into disease pathogenesis and 
indicate that at least one of the selenoproteins that modifies carcinogenesis is Gpx3 and 
that it may serve as a substrate for translational investigations in colitis-associated 
carcinoma.  
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CHAPTER IV 
 
ABSENCE OF SELENOPROTEIN P PROMOTES STEM CELL PROPERTIES, AUGMENTS ROS-
INDUCED DAMAGE AND PROMOTES COLITIS-ASSOCIATED TUMORIGENESIS 
 
Introduction 
Selenium is a trace mineral that is incorporated into proteins as selenocysteine 
encoded by a UGA codon in the selenoprotein mRNA.  UGA is normally read as a stop 
codon so selenocysteine incorporation relies on a cis-acting sequence within the mRNA 
(selenocysteine insertion sequence) and trans-acting factors dedicated to selenocysteine 
incorporation (such as selenocysteine-charged tRNA) (49).  Selenoprotein synthesis is 
dependent on Se levels resulting in a hierarchy of selenoprotein expression during times 
of Se deficit.  Even under conditions of severe Se deficiency, the majority of Se is used to 
synthesize selenoprotein P (Sepp1) (160).  In fact, the bulk of Se is released into the 
plasma from the liver in two specific forms, Sepp1 and 1β-methylseleno-N-acetyl-D-
galactosamine, but Sepp1 is also expressed by a wide range of tissues (371). Sepp1 has 
two proposed main roles: the first is to supply various tissues with selenium and the 
second is an antioxidant function.  The transport role is thought to be carried out by the 
C-terminal domain of Sepp1 which contains nine selenocysteine residues (372).  Sepp1 
deletion in mice results in severe depletion of Se within the brain and testis as well as in 
other organs to a lesser extent (336).  The antioxidant role is proposed to be carried out 
by a single selenocysteine within a UxxC redox motif in the N-terminal domain (160).  
 93 
 
Two enzymatic activities have been described for the N-terminal selenocysteine: 
phospholipid hydroperoxide glutathione peroxidase and peroxynitrite reductase (159, 
373).  As such, Sepp1 is an effective reductant of reactive oxygen species enabling it to 
prevent damage of cellular lipids, proteins, and nucleic acids (79).  Its antioxidant role 
suggests that Sepp1 could play a significant role in cancer prevention, particularly in the 
context of inflammatory cancers characterized by increased oxidant stress such as colitis-
associated carcinoma (299).  Several epidemiological studies have inversely correlated 
nutritional Se status and cancer risk, particularly in colon cancer (374).  Sepp1 is 
downregulated in colorectal cancers (162) and single nucleotide polymorphisms (SNPs) in 
the selenoprotein P gene (SEPP1) are significantly associated with advanced adenoma risk 
(165).   
Se deficiency can result in stimulation of the Wnt and Nrf2 pathways (125, 130, 
286) which are known to be essential in the pathogenesis of colon cancer (132-134).  
Because Sepp1 serves as the major selenium transport protein, it is likely that it 
contributes to localized Wnt and Nrf2 signaling in target tissues. Furthermore, as the 
gastrointestinal tract is susceptible to oxidative damage resulting from direct contact of 
the colonic epithelium with microbial and food-derived reactive oxygen species, loss of 
Sepp1 might prime the colonic epithelium for increased oxidative damage-induced tumor 
initiation. This potential damage is augmented in the context of inflammatory bowel 
disease (IBD) during which oxidative stress plays a major role (299).  The majority of 
oxidative species generated by the reaction of cellular substrates with nitric oxide during 
IBD result in elevated expression of the inducible form of nitric oxide synthase (NOS2) 
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(338).  NOS2 has been shown to downregulate expression of Sepp1 in a mouse model of 
chronic colitis (171). Sepp1 has also been identified as an IL-10-dependent, alternatively 
activated macrophage-associated gene, linking Sepp1 to a pro-tumorigenic 
microenvironment (375). Thus, not only through reduction of oxidative species, but also 
via modulation of the immune system and Wnt signaling, Sepp1 potentially plays a critical 
role in stem cell pathways and the development of tumors during colitis-associated 
carcinoma. 
The vast majority of Sepp1 is produced by the liver and it is proposed that Sepp1 
activity is solely extracellular in nature.  To date, it is unknown whether Sepp1 made 
within and secreted from extrahepatic cells plays a significant role in antioxidant defense.  
During mouse development spatiotemporal expression of Sepp1 is observed in the 
intestine and is predicted to play a role in both Se transport and antioxidant defense 
during embryogenesis (376).  Sepp1 expression is also regulated in response to 
inflammation (171) and negatively regulated by the glucocorticoid receptor (170), 
suggesting that its cell-specific regulation is important.  Of particular interest, cell culture 
studies in adipocytes have determined that loss of SEPP1 expression results in the 
upregulation of inflammatory cytokines MCP-1 and IL-6 in preadipocytes, leading to the 
inhibition of adipocyte differentiation (172); for the first time implicating extrahepatic 
Sepp1 in the regulation of inflammatory response and differentiation. These data suggest 
that epithelial-derived Sepp1 might also contribute to cellular phenotypes. 
Due to the roles of Sepp1 in Wnt and Nrf2 modulation as well as antioxidant 
defense, we hypothesized that Sepp1 would contribute to stem cell phenotypes, protect 
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from reactive oxygen species, and modify colitis-associated carcinogenesis. In order to 
first establish epithelial cell-autonomous roles for Sepp1 in a closed system, we isolated 
small intestinal organoids (enteroids) from WT and Sepp1-/- mice and analyzed them for 
stem cell properties including plating efficiency, percentage of branching enteroids and 
stem spheroids, and average number of branches within each branching enteroid. 
Concurrent with a role in Wnt signaling, Sepp1-/- enteroids demonstrated increased stem 
cell properties. Moreover, treatment of enteroids with hydrogen peroxide resulted in an 
increase in reactive oxygen species as well as an increase in proliferation which is also 
seen at baseline. Finally, survival is decreased in Sepp1-/- enteroids when treated with 
multiple administrations of hydrogen peroxide over a 4-day period. Because of the 
enteroid stem cell properties and responses to hydrogen peroxide, we wanted to test 
whether Sepp1-/- mice would demonstrate increased inflammatory tumorigenesis. WT, 
Sepp1+/-, and Sepp1-/- mice were subjected to the azoxymethane, repeated dose dextran 
sodium sulfate (AOM/DSS) protocol to model colitis-associated carcinoma. Sepp1+/- mice 
demonstrated increased tumorigenesis compared to WT mice, but surprisingly, Sepp1-/- 
mice displayed decreased tumorigenesis. We hypothesized that this decrease in 
tumorigenesis was due to decreased survival of initiated epithelial cells because of 
augmented inflammatory damage upon complete Sepp1 loss. In support of this 
hypothesis, Sepp1-/- mice subjected to AOM administration alone demonstrated 
increased tumorigenesis and chronic DSS administration resulted in increased mucosal 
injury. Moreover, homozygous loss of either the Se-rich C-terminal region or mutation of 
the N-terminal UXXC redox motif resulted in increased tumorigenesis, suggesting that 
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both domains contribute to the Sepp1 tumor phenotype but when both are lost 
concurrently the stressed placed on the initiated epithelium during the CAC protocol is 
significant enough to kill initiated cells.  
Finally, because absence of Sepp1 in enteroids leads to increased stem cell 
phenotypes and reduced ability to deal with oxidative stress in an epithelial cell 
autonomous manner, we predicted that liver-derived Sepp1 might not contribute 
significantly to the Sepp1-/- tumor phenotype. Conditional knockout of liver Sepp1 
(Sepp1Fl/Fl;Alb-cre) did not alter tumorigenesis in response to the AOM/DSS protocol 
indicating that plasma Sepp1 does not contribute significantly to the Sepp1-/- phenotype. 
This report is the first to utilize enteroids to establish the epithelial cell autonomous 
responses to Sepp1 loss and map the domains of Sepp1 necessary for tumor modification 
in an inflammatory carcinogenesis model. Finally, this study reports that liver-derived 
Sepp1 is not required for the effect that Sepp1 has on tumor modification.  
 
Materials and methods 
Ethics Statement. This study was performed in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Institute of Animal Care and Use 
Committee at Vanderbilt University (protocol number: M/10-355). Every effort was made 
to minimize suffering. 
Murine Inflammatory Carcinogenesis Protocol: Because Sepp1-/- mice exhibit decreased 
survival when not fed a selenium-supplemented diet (301), mice were maintained on 
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diets that were Torula yeast-based and supplemented with 1.0 mg Se as sodium selenite 
per kg. This diet was prepared and pelleted to our specifications (301) by Harlan-Teklad 
(Madison, WI, USA). Eight- to twelve-week old C57BL/6 wild type (WT) (n=13), Sepp1+/- 
(n=9), or Sepp1-/- (n=11) mice (336, 372) (constitutional knockout experiments), WT 
(n=16) or Sepp1Δ240-361/Δ240-361 (n=14) mice (63) (truncation experiments), WT (n=12) or 
Sepp1U40S/U40S (n=15) (redox motif mutant experiments), or Sepp1FL/FL (n=16) or 
Sepp1FL/FL;Alb-cre (n=17) mice (66) (liver-specific knockout experiments) (Figure 4.1A) 
were injected with 12.5 mg/kg of AOM (Sigma-Aldrich, St. Louis, MO, USA) 
intraperitoneally. Three days post-injection, the animals were started on the first of three 
cycles of 3% DSS ad libitum (Figure 4.1B). Each cycle lasted 5 days and was followed by a 
16-day recovery period. During each cycle of recovery, twelve days post-DSS 
administration, colonoscopy (Karl Storz veterinary endoscopy) was performed to assess 
injury, tumor multiplicity, and tumor grade (358). Injury was evaluated based on the 
murine endoscopic index of colitis severity (MEICS) which grades mucosal thickening, 
vasculature pattern, granularity, exudate, and stool consistency (358). Mice were 
subsequently sacrificed on day 70. Tumor counts and measurements were performed in 
a blinded fashion under stereo-dissecting microscope. Histologic analysis was performed 
in a blinded fashion for severity of inflammation (357) and dysplasia on hematoxylin and 
eosin (H&E) stained “Swiss rolled” colons by a gastrointestinal pathologist (MKW). All in 
vivo procedures were carried out in accordance with protocols approved by the 
Vanderbilt Institutional Animal Care and Use Committee. 
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Immunohistochemistry and immunofluorescence staining. For Sepp1 and phalloidin 
staining, mice were exsanguinated and colons and small intestines flash frozen in liquid 
nitrogen. Five-micrometer frozen sections were cut and Sepp1 staining was performed as 
described previously (377).For all other staining, five-micrometer sections of paraffin-
embedded colons were cut and haematoxylin and eosin (H&E) staining was performed by 
the Vanderbilt University Translational Pathology Shared Resource. Cut sections were 
dewaxed, hydrated, and quenched of endogenous peroxidase activity with 0.03% 
hydrogen peroxide in methanol. Antigen retrieval was conducted using Antigen 
Unmasking Reagent (Vector Laboratories, Inc., Burlingame, California, USA) according to 
manufacturer’s instructions. After blocking, primary antibody was added [α-Ki67 
(NeoMarkers), 1:1,000; α-arginase I (ARG1, Santa Cruz), 1:500; α-IL-1β (R&D Systems), 
1:40; α-F4/80 (ABd Serotec) 1:1000; α-8-OHdG (Santa Cruz), 1:500] and incubated 
overnight at 4°C. Isotype-matched antibodies were included as negative controls. 
Identification of intratumoral apoptotic cells was conducted using the ApopTag Plus 
Peroxidase In Situ Apoptosis Kit (Chemicon, Temecula, California, USA) according to the 
manufacturer's protocol. Control slides were obtained by omitting the terminal 
transferase (TnT) enzyme. For immunofluorescence staining of proliferation, 
macrophages, and DNA damage, slides were counterstained and mounted with ProLong 
Gold antifade including 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen, Grand Island, 
New York, USA). Apoptosis, proliferation, DNA damage, and M1 and M2 macrophage 
indices were generated by counting either the number of positive cells per high-powered 
field (HPF; 40x objective) within each tumor or the number of positive cells per crypt in 
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20 crypts per mouse by a blinded observer. The average score was then calculated for 
each Swiss-rolled colon. 
Colonic selenium measurements. The determination of colonic selenium was carried out 
using a modification of the fluorometric assay of Koh and Benson (305) and Sheehan and 
Gao (306). Briefly, tissue was digested in nitric and perchloric acids and Se was complexed 
with diaminonaphthalene. Selenium-diaminonaphthalene was extracted into 
cyclohexane and fluorescence was measured in a Perkin-Elmer LS 55 fluorometer. 
Western blot analysis of apoptosis and WNT pathway proteins. Flash-frozen sections of 
colon (n=6 for each genotype) were lysed in RIPA buffer including 1x protease inhibitor 
cocktail (Sigma) using a rotor homogenizer (Janke & Kunkel IKA-Labortechnik Ultra-Turrax 
T25). Protein quantification was performed using a Pierce BCA Protein Assay Kit (Thermo) 
according to manufacturer’s instructions. Samples were treated with loading buffer, 
boiled, and 40 μg was run on an SDS-PAGE gel for western blot detection. The Apoptosis 
Antibody Sampler (mouse preferred, #9930) and Wnt signaling Antibody Sampler (#2915) 
kits (Cell Signaling Technology, Danvers, MA, USA) were used according to manufacturers’ 
protocol and analyzed using Odyssey imaging software. In short, Western blots were run 
and transferred onto nitrocellulose. Blots were blocked with Odyssey Blocking Buffer (LI-
COR Biosciences, Lincoln, NE, USA) for 1 hour at room temperature with rocking. Blots 
were incubated with primary antibodies from each kit diluted 1:1000 in Odyssey Blocking 
Buffer overnight at 4°C with rocking. Blots were washed three times for five minutes each 
with PBST and then incubated at room temperature for 1 hour in secondary antibody 
(IRDye® 680LT Infrared Dye conjugated to antibodies against either mouse or rabbit) 
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diluted 1:1000 in Odyssey Blocking Buffer. Blots were washed three times for five minutes 
each with PBST, rinsed with PBS, and imaged using the Odyssey quantitative fluorescence 
imaging system. Quantification was performed using Odyssey Imaging Software and 
normalized either to total caspase or β-actin. 
Bone marrow macrophage polarization and analysis. Bone marrow macrophages were 
isolated and activated as has been previously published (378, 379). For the production of 
classically activated macrophages, bone marrow macrophages were primed with 150 
U/ml IFNλ for 6 hours and subsequently stimulated with 10 ng/ml LPS. For the production 
of alternatively activated macrophages, bone marrow macrophages were treated with 20 
U/ml IL13 for 12 hours. Six hours prior to activation of both macrophage types, RNA was 
isolated using the RNEasy MiniKit (Qiagen, Valencia, CA, USA). 1 µg RNA was utilized to 
perform reverse transcription PCR using the iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA, USA). 1 µl of the subsequent cDNA was used for quantitative RT-PCR analysis of the 
targets iNOS, IL-1β, and Ym1 using primers purchased from RealTimePrimers.com.  
Plasma Sepp1 protein determination. Plasma Sepp1 was measured by ELISA. Plasma 
samples were prepared prior to assay by dilution in PBST (PBS with 0.05% Tween-20) 
containing 2% rat plasma cleared of Sepp1 by monoclonal antibody 8F11 (380) 
immunoaffinity purification. 0.1 μl of normal mouse plasma was used in the ELISA assay. 
The monoclonal antibody 9S4 was used as the capture antibody, and the polyclonal 
antibody preparation 695, obtained from a rabbit immunized with rat Sepp1, was used as 
the detection antibody. Wells of a microtiter plate were coated with 9S4 (0.1 μg/well) and 
blocked with Block Ace (Serotec, Ltd., Raleigh, NC, USA). After washing, the plate was 
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incubated with sample (50 μl of pre-prepared plasma) and purified antibody preparation 
695 (50 μl of 1 μg/ml) at 37 °C for 30 min. Horseradish peroxidase-conjugated goat anti-
rabbit IgG was used to detect the amount of 695 bound to Sepp1 captured by 9S4. The 
TMB Microwell Peroxidase Substrate System (KPL, Gaithersburg, MD, USA) was used for 
color development followed by treatment with the stop solution 1 N H2SO4. The 
developed color was measured at 450 nm with a Multiskan Spectrum plate reader 
(ThermoElectron Corporation, Vantaa, Finland). Each assay plate contained a standard 
curve built with 9S4 immunoaffinity-purified mouse Sepp1 (0–7.5 ng).  
Small intestinal organoid culturing. Four inches of the distal small intestine were 
dissected. The small intestinal section was flushed with ice cold PBS and cut open 
lengthwise and dissected into 1cm pieces then transferred into 5ml ice cold PBS. Small 
intestine was vortexed for 3 seconds to pull off loose villi. PBS was removed with a 
pipettor and the villus wash was repeated. Tissue was transferred to 5ml chelation buffer 
(1mM EDTA, made fresh in DPBS) and rocked for 10 minutes at 4°C. Chelation buffer was 
removed from the tissue with a pipettor and tissue was washed twice with 10 ml PBS. 5 
ml PBS was added and shaken gently for 2 minutes. The supernatant from the first shake 
was poured off. 5 ml PBS was added and the shake was repeated for 2 minutes then 
supernatant was poured off. 5 ml fresh chelation buffer was added and chelation was 
performed for 10 minutes at 4°C with rocking. The small intestinal segments were washed 
twice with PBS and then 5 ml PBS PBS was added for 2 minutes of shaking. The 
supernatant was poured off and the shake was repeated with a new aliquot of PBS. Crypts 
were filtered through a 70 m filter into a pre-chilled 50 ml tube. The filter was rinsed 
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with 5 ml cold shaking buffer (PBS with 43.3mM sucrose and 54.9mM Sorbitol). Complete 
crypts were counted and enough volume was transferred for 1200 crypts to a pre-chilled 
5 ml round-bottomed tube. Crypts were centrifuged at 150 xG for 10 minutes at 4°C. 
Shaking buffer was aspirated being careful not to disturb the pellet. Using pre-chilled 
pipette tips, crypts were resuspended in 50 l of Matrigel (BD Bioscience #356237, San 
Jose, CA, USA), per well, containing 50 ng/ml EGF (R&D Systems #2028-EG-200, 
Minneapolis, MN, USA), 100 ng/ml Noggin (R&D Systems #1967-NG-025/CF), 500 ng/ml 
R-Spondin: 500ng/ml (R&D Systems #3474-RS-050), and 50ug/ml Wnt3a (Millipore #GF-
160, Billerica, MA, USA). Using pre-chilled pipette tips, 50 μl Matrigel per well was plated 
with growth factors into 12-well cell culture plates so that the Matrigel formed a 
mounded dome. The plate was placed in an incubator at 37°C for 30 minutes to allow 
Matrigel to polymerize fully. Matrigel was overlayed with 500 l Minigut culture media 
(Advanced DMEM/F12 (Invitrogen #12634-010, Carlsbad, CA, USA), L-Glutamine 
(Invitrogen #25030), Pen-Strep (Invitrogen #15140-148), Hepes (Mediatech #25-060-CI), 
N2 Supplement (R&D Systems #390155), B27 Supplement (Invitrogen #17504044). Every 
4 days, media was replaced with fresh Minigut media plus growth factors. 
Whole-mount 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (Carboxy-H2DCFDA) 
enteroid staining. Enteroids were grown to full maturity, at least 4 days post-plating. The 
morning of hydrogen peroxide treatment, enteroid media was replaced with fresh 
Minigut. Either 0 μM, 400 μM, or 800 μM hydrogen peroxide was added directly to media. 
Two hours post-hydrogen peroxide treatment, growth media was removed from cells. 
Cells were treated with pre- warmed DPBS containing either the probe carboxy-H2DCFDA 
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(Invitrogen #mp-36103) or, as a negative control, carboxy-DCFDA to provide a final 
working concentration of 5 mM. Enteroids were incubated at 37°C in a cell culture 
incubator for 1 hour. Loading buffer was removed and cells were returned to pre-warmed 
Minigut media. Cells were incubated at 37°C for 15 minutes. Media was removed and 
enteroids were fixed overnight at 4°C in 2% formaldehyde with gentle rocking. Fixative 
was removed and enteroids were washed twice with DPBS. Enteroids were imaged with 
a LSM 510 Confocal microscope using the same specifications for imaging of all enteroids. 
Reactive oxygen species were quantified as staining intensity using ImageJ Image Analysis 
software. The graph represents the fold change intensity relative to WT enteroids treated 
with 0 μM hydrogen peroxide. Error bars represent the standard error of the mean for 
three separate experiments performed in duplicate. 
Whole-mount enteroid proliferation staining. Proliferation was determined using the 
Click-iT EdU cell proliferation assay (Invitrogen #C-10337) according to manufacturers’ 
instructions. In short, enteroids were grown to full maturity, at least 4 days post-plating. 
The morning of hydrogen peroxide treatment, enteroid media was replaced with fresh 
Minigut. Either 0 μM or 800 μM hydrogen peroxide was added directly to media. Two 
hours post-hydrogen peroxide treatment, media was replaced with fresh Minigut media 
and a 10 μM working solution of EdU was added to each well of the plate. Enteroids were 
incubated for 15 minutes under normal growth conditions. After incubation, media was 
removed and 1 ml of 2% formaldehyde in PBS was added to each well and incubated 
overnight at 4°C. The fixative was removed and enteroids were washed twice with 1 ml 
3% BSA in PBS. Wash buffer was removed and 1 ml of 0.5% Triton X-100 in PBS was added 
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to each well and incubated at room temperature for 20 minutes. Click-iT reaction cocktail 
was prepared and 0.5 ml was added to each well. The plate was incubated for 30 minutes 
at room temperature, protected from light. The reaction cocktail was removed and 
enteroids were washed once with 1 ml 3% BSA in PBS. The wash solution was removed 
and enteroids were stained with TO-PRO-3 (1:500 in PBS for 15 minutes at room 
temperature). Enteroids were washed twice with 1 ml of PBS for 30 minutes. Enteroids 
were imaged with a LSM 510 Confocal microscope using the same specifications for 
imaging of all enteroids. Proliferation was quantified as EdU+ cells/crypt area where crypt 
area was determined using ImageJ Image Analysis software. The graph represents the fold 
change intensity relative to WT enteroids treated with 0 μM hydrogen peroxide. Error 
bars represent the standard error of the mean for three separate experiments performed 
in duplicate. 
RNAseq assay and analysis. Tumors were dissected from WT and Sepp1-/- mice and 
RNA was isolated using the RNEasy MiniKit (Qiagen, Valencia, CA, USA). RNA integrity was 
determined using Experion RNA StdSens Analysis Kit (Bio-Rad, Hercules, CA, USA). All RNA 
samples had RNA integrity numbers (RINs) >8 and were deemed suitable for 
hybridization. A total of 10 mg of cRNA was used in the second cycle of first strand 
synthesis to generate the correct sense for target hybridization. Mouse gene 1.0 ST arrays 
(Affymetrix, Santa Clara, CA, USA) were scanned the next day. CEL files were imported 
into Partek Express (Partek, St Louis, MI, USA) and Robust Multichip Average (RMA) was 
run across all eight samples. Pivot data was exported and posted. A t-test was run 
between the Sepp1-/- and WT sample groups in Partek. The P-value was multiple testing 
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corrected with Bonferroni and Stepup. Expression array analysis was performed hybrizing 
cRNA to the Mouse gene 1.0 ST chip (Affymetrix). Differentially expressed genes were 
classified using the Ingenuity Pathway Analysis Program 
(http://www.ingenuity.com/products/ipa, Qiagen). 
Statistical Methods: Analyses comparing two groups were analyzed using the Student’s t-
test. One-way ANOVA and Newman-Keuls post-test was used to compare multiple 
groups. Data is presented as the mean +/- the standard error of the mean (SEM) in bar 
graphs and a line identifying the mean is shown when all data points are plotted. 
Percentages of mice displaying altered dysplasia grade were determined using Chi-square 
contingency analysis for each grade. All of these analyses were performed using GraphPad 
Prism®5.0c (San Diego, CA, USA). 
 
Results 
Selenoprotein P is a haploinsufficient tumor suppressor. 
Because Sepp1 has been heavily implicated in protection from reactive oxygen 
species, we hypothesized that Sepp1+/- and Sepp1-/- mice would display increased 
inflammatory tumorigenesis. The inflammatory tumorigenesis model that we used to test 
this hypothesis was the azoxymethane, repeated dose dextran sodium sulfate (AOM/DSS) 
 106 
 
Figure 4.1 Sepp1 haploinsufficiency results in increased inflammatory tumorigenesis in response 
to the AOM/DSS model. A) Table describing the genotypes subjected to the AOM/DSS protocol and 
the symbols used for each genotype. B) Schematic of the AOM/DSS protocol utilized. Mice are 
injected with azoxymethane (AOM) and started on the first of three four-day cycles of DSS 
administration three days post-AOM injection. Mice are analyzed by endoscopy twelve days after 
each DSS administration for tumor burden and injury (black circles). Mice are sacrificed at day 70. 
C) Immunofluorescence staining of Sepp1 (red) within the colon and small intestine of WT and 
Sepp1-/- mice (100x magnification). D) Quantification of colonic selenium in WT, Sepp1+/-, and 
Sepp1-/- mice. E) Tumor number (tumors/mouse, left) and average tumor size (mm2, right) within 
each mouse and F) representative images of Swiss rolled colons from each mouse (25x 
magnification). 
 
colitis-associated carcinoma model (Figure 4.1B).  AOM is a procarcinogen that is 
metabolically activated to a potent alkylating agent forming O6-methyl-guanine (318). Its 
oncogenic potential is augmented in the setting of chronic inflammation, which is induced 
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by repeated cycles of DSS treatment (319). Importantly, Sepp1 expression is seen in the 
colon and small intestine of WT mice (Figure 4.1C), indicating that it exhibits function 
within these tissues. WT, Sepp1+/-, and Sepp1-/- mice were subjected to the AOM/DSS 
protocol and, upon sacrifice, analyzed for tumor burden. As expected, complete loss of 
Sepp1 led to a decrease in colonic Se (Figure 4.1D), though surprisingly, this decrease was 
not severe, indicating that Sepp1 is not the only mechanism of Se transport into the colon. 
Partial loss of Sepp1 led to an increase in tumor number (5.2 ± 0.8 vs 8.3 ± 1.2 
tumors/mouse, P=0.03, Figure 4.1E, left) but no change in tumor size. Unexpectedly, 
complete knockout of Sepp1 led to a decrease in tumor number (2.7 ± 0.7, P=0.02, Figure 
4.1E, left) and size (3.3 ± 0.4 vs 1.8 ± 0.4 mm2, P=0.02, Figure 4.1E, right). As this decrease 
in tumorigenesis was concomitant with increased apoptosis as measured by TUNEL 
staining (34.3 ± 3.1 vs 74.4 ± 10.9 TUNEL+ cells/tumor high-powered field, P<0.01, Figure 
4.2A) and western blotting for markers within the intrinsic apoptosis pathway (Figure 
4.2D), we hypothesized that this decrease might be caused by clearance of initiated cells 
due to oxidative injury beyond that which total Sepp1 loss could compensate. Moreover, 
proliferation was increased in Sepp1+/- tumors (55.6 ± 2.8 vs 85.9 ± 2.9 Ki67+ cells/tumor 
HPF, P<0.0001, Figure 4.2B) and decreased in Sepp1-/- tumors (55.6 ± 2.8 vs 19.0 ± 6.9 
Ki67+ cells/tumor HPF, P<0.0001, Figure 4.2B), further supporting a role of clearance of 
initiated cells in the Sepp1-/- tumor phenotype.  
In order to determine whether Sepp1 absence promotes tumorigenesis utilizing 
either AOM or DSS as single modalities and, thus, understand the impact of Sepp1 on  
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Figure 4.2 Intratumoral apoptosis and DNA damage are increased in response to complete Sepp1 
knockout and proliferation is increased in Sepp1+/- tumors. A) Quantification of intratumoral 
apoptosis as determined by TUNEL+ cells/tumor high-powered field (HPF, 40x magnification). B) 
Quantification of intratumoral proliferation as determined by Ki67+ cells/tumor HPF. C) 
Quantification of intratumoral DNA damage as measured by 8-hydroxyguanine+ cells/tumor HPF. 
D) Quantification of intratumoral canonical apoptosis targets cleaved caspase-3, cleaved caspase-
6, cleaved caspase-9, and cleaved PARP relative to total caspase-3, caspase-6, caspase-9, and β-
actin, respectively. Quantification is shown as fold change relative to WT (top) and representative 
images of blots from three individual tumors from each genotype (bottom). *P<0.05, **P<0.01, 
***P<0.001. 
 
tumorigenesis without the possibility of initiated cell clearance in response to injury, we 
assessed ACF and tumor production as well as injury in response to AOM or DSS 
administration. Endoscopic analysis of tumor burden 15 weeks post-AOM administration 
revealed an increase in tumor number in Sepp1-/- mice compared to WT mice (3.7 ± 0.6 
vs 7.7 ± 2.2 tumors/colon, Figure 4.3A). Moreover, endoscopic injury analysis using the 
MEICS scoring system (302) post-DSS administration revealed increased injury in response 
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to DSS (4.1 ± 0.5 vs 8.1 ± 0.4 MEICS score, P<0.0001, Figure 4.3B). Because tumorigenesis 
is increased in Sepp1-/- mice subjected to AOM alone and injury is increased in Sepp1-/- 
mice subjected to DSS, we suspect that Seep1 loss leads to increased tumorigenic 
potential that is lost when initiated cells are cleared by the increased DSS-induced injury 
in Sepp1-/- mice. 
 
Figure 4.3 Sepp1-/- mice demonstrate increased tumorigenesis and injury in response to AOM and 
DSS as sole agents, respectively. A) Endoscopic tumor score in mice treated with AOM alone. B) 
Endoscopic colitis score (MEICS) in mice treated with DSS alone. 
 
Intratumoral DNA damage increases in a dose-dependent manner with decreased Sepp1 
expression. 
 Se has been identified as a potential contributor to the maintenance of genomic 
stability (129, 136), however the role of selenoprotein P in DNA damage repair is 
unknown. We wanted to test the impact of Sepp1 deficiency on crypt and intratumoral 
DNA damage. 8-hydroxyguanine staining, a measure of oxidative DNA damage, in fact, 
demonstrated that intratumoral DNA damage increases with decreased Sepp1 expression 
(WT: 8.1 ± 0.8, Sepp1+/-: 15.3 ± 1.5, P=0.002, Sepp1-/-: 23.3 ± 3.4 8-hydroxyguanine+ 
cells/tumor HPF, P=0.0007, Figure 2.2C) though crypt DNA damage was not altered when 
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compared to WT mice in response to Sepp1 deficiency. These data suggest that, within 
the tumor microenvironment, decreasing Sepp1 expression leads to an increase in 
oxidative DNA damage. 
 
Pro-tumorigenic M2 macrophage polarization is increased in Sepp1+/- tumors. 
 The most significantly induced gene in response to polarization of macrophages 
to the M2 phenotype is selenoprotein P (375, 381, 382). Moreover, proinflammatory 
cytokines induce NOS2 resulting in down-regulation of Sepp1 (171) indicating that Sepp1 
may play a role in macrophage polarization and inflammation. We, therefore, wanted to 
analyze tumors from WT, Sepp1+/- and Sepp1-/- mice post-AOM/DSS for macrophage 
polarization. Staining for the pan-macrophage marker F4/80 and either the M1 
macrophage marker IL-1β revealed an increase of total macrophages (WT: 13.1 ± 1.3, 
Sepp1+/-: 23.2 ± 3.0, P<0.01, Sepp1-/-: 13.1 ± 0.8 F4/80+ cells/tumor HPF, Figure 4.4A) 
resulting from unaltered M1 macrophages (Figure 4.4B) but increased M2 macrophage 
recruitment (WT: 8.4 ± 0.8, Sepp1+/-: 18.0 ± 3.9, Sepp1-/-: 8.3 ± 1.1 F4/80+/Arginase I+ 
cells/tumor HPF, Figure 4.4C) in Sepp1+/- tumors. Interestingly, Sepp1-/- tumors did not 
demonstrate this increase in M2 polarized macrophage infiltration. In order to determine 
whether this was a recruitment or polarization effect, we isolated bone marrow 
macrophages from WT, Sepp1+/-, and Sepp1-/- mice and activated them to either the M1 
or M2 polarizations using IFNλ and LPS to polarize to the M1 and IL-13 to polarize to the 
M2 phenotype. Analysis of M1 markers iNOS and IL-1β demonstrated decreased M1 
polarization in Sepp1+/- macrophages (iNOS: 19494 ± 593.8 vs 14961 ± 782.3 fold change,  
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Figure 4.4 Sepp1 regulates pro-tumorigenic M2 macrophage polarization. Quantification of A) 
intratumoral total macrophage staining as determined by F4/80+ cells/tumor HPF, B) M1 
macrophage staining as determined by F4/80+/IL-1β+ cells/tumor HPF, and C) M2 macrophage 
staining as determined by F4/80+/Arginase I+ cells/tumor HPF. D) iNOS (left) and IL-1β (right)  and 
E) Ym1 mRNA expression in WT, Sepp1+/-, and Sepp1-/- in vitro-activated bone marrow 
macrophages. Graphs demonstrate fold change in expression relative to unstimulated (US) WT 
macrophages normalized to GAPDH. *P<0.05, **P<0.01, ***P<0.001. 
 
P<0.001, IL-1β: 337.6 ± 0.78 vs 225.1 ± 20.66 fold change, P<0.001, Figure 4.4D) while the 
M2 marker Ym1 demonstrated increased polarization to M2 (13.1 ± 3.3 vs 26.6 ± 0.3, 
P<0.001, Figure 4.4E). Though this is not a complete polarization defect, this data 
indicates that Sepp1 haploinsufficiency may lead to improper macrophage response to 
directed stimulation suggesting that the macrophage phenotype seen in Sepp1+/- tumors 
may be due to increased polarization to the M2 phenotype. 
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Loss of the selenium-rich C-terminal domain of selenoprotein P promotes inflammatory 
tumorigenesis. 
 Selenoprotein P is considered the primary Se transport protein as deletion of the 
Se-rich C-terminal domain (Sepp1Δ240-361/Δ240-361) results in severe Se deficiency in the 
brain and testis of mice (63). In fact we see that, to a lesser extent, loss of this domain 
leads to decreased colonic Se (394.5 ± 19.6 vs 260.2 ± 10.6 ng selenium/g colon, P=0.0001, 
Figure 4.5A) as well suggesting that selenoprotein P contributes to Se delivery to the colon 
but is not the sole source. Because of the role of Se in DNA damage repair, Wnt and Nrf2 
signaling, and links to modification of several cancer types including colorectal, lung, 
laryngeal, hepatic, and prostate (108, 139, 164, 383) to name a few, we wanted to 
determine whether the loss of the Se-rich domain of selenoprotein P would contribute to 
tumorigenesis. We subjected WT and Sepp1Δ240-361/Δ240-361 mice to the AOM/DSS protocol 
and analyzed them for tumor burden. We discovered that Sepp1 truncation leads to an 
increase in tumor number (3.9 ± 0.7 vs 7.9 ± 1.4 tumors/mouse, P=0.02, Figure 4.5B). Also, 
because we have established a role for dietary Se in dysplasia grade (384), we submitted 
H&E stained “Swiss rolled” colons to a gastrointestinal pathologist to determine tumor 
grade and determined that Sepp1 truncation also leads to an increase in tumors 
displaying high-grade dysplasia (P<0.05, Figure 4.5C).  
Concomitant with an increase in tumor number was an increase in intratumoral 
proliferation (13.4 ± 1.7 vs 20.3 ± 2.2 Ki67+ cells/tumor HPF, P=0.04, Figure 4.5D) but no 
change in crypt proliferation or crypt or tumor apoptosis. Consistent with a role of Se in 
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DNA damage repair, crypt (0.7 ± 0.04 vs 1.0 ± 0.08 8-OHdG+ cells/crypt, P=0.02, Figure 
4.5E) and intratumoral (17.1 ± 2.7 vs 29.8 ± 2.8 8-OHdG+ cells/tumor HPF,  
 
 
A B C 
D E F 
G H I 
J K L 
 114 
 
Figure 4.5 Both the selenium-rich region and putative antioxidant domain of selenoprotein P 
protect from inflammatory tumorigenesis. A) Quantification of colonic selenium in WT and 
Sepp1Δ240-361/Δ240-361 mice. B) Number of tumors within each mouse and C) percentage of total 
tumors for each genotype with either high grade dysplasia (HGD, black) or low grade dysplasia 
(LGD, white) (top) and representative images from tumors of the given genotypes (40x 
magnification, bottom). D) Quantification of intratumoral proliferation as measured by Ki67+ 
cells/tumor HPF, E) crypt DNA damage as measured by 8-hydroxyguanine+ cells/crypt averaged 
from 20 crypts within each mouse, and F) intratumoral DNA damage as measured by 8-
hydroxyguanine+ cells/tumor HPF. G) Number of tumors and H) average tumor size within either 
WT or Sepp1U40S/U40S mice. I) Quantification of crypt proliferation as measured by Ki67+ cells/crypt 
averaged from 20 crypts within each mouse, J) intratumoral proliferation as measured by Ki67+ 
cells/tumor HPF, K) crypt DNA damage as measured by 8-hydroxyguanine+ cells/crypt averaged 
from 20 crypts within each mouse, and L) intratumoral DNA damage as measured by 8-
hydroxyguanine+ cells/tumor HPF. *P<0.05, **P<0.01, ***P<0.001. 
 
P=0.01, Figure 4.5F) DNA damage indices are increased in mice lacking the Se-rich C-
terminal domain. These data suggest that the Se-rich domain of Sepp1 might protect from 
tumor initiation by reducing DNA damage in response to AOM and DSS administration. 
 
Mutation of the redox active selenocysteine in Selenoprotein P promotes inflammatory 
tumorigenesis. 
 Within the N-terminal domain of selenoprotein P, residues 40-43, exists a UXXC 
redox motif which possesses phospholipid hydroperoxide glutathione peroxidase activity 
(160). As such, it may be that selenoprotein P is able to contribute to antioxidant activity 
within mice challenged with DSS. In order to test whether loss of this antioxidant domain 
would lead to alterations in tumorigenesis, we subjected Sepp1 mice in which the 
selenocysteine (U) at amino acid 40 was mutated to an enzymatically dead serine (S) 
(Sepp1U40S/U40S) to the AOM/DSS protocol. In response to this inflammatory 
carcinogenesis protocol, Sepp1 mutated mice displayed increased tumor number (3.8 ± 
0.7 vs 7.3 ± 1.1 tumors/mouse, P=0.02, Figure 4.5G) and tumor size (1.6 ± 0.2 vs 3.1 ± 0.3 
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mm2, P=0.002, Figure 4.5H). This increase in tumorigenesis was likely at least partially 
dependent upon an increase in crypt (0.3 ± 0.02 vs 0.5 ± 0.04 Ki67+ cells/crypt, P=0.0009, 
Figure 4.5I) and intratumoral (15.2 ± 1.6 vs 33.5 ± 2.6 Ki67+ cells/tumor HPF, P<0.0001, 
Figure 4.5J) proliferation despite no change in apoptosis. We did note an increase in crypt 
(0.3 ± 0.03 vs 0.6 ± 0.02 8-OHdG+ cells/crypt, P<0.0001, Figure 4.5K) and intratumoral 
(10.8 ± 1.2 vs 28.7 ± 2.6 8-OHdG+ cells/tumor HPF, P<0.0001, Figure 4.5L) DNA damage, 
suggesting that the redox site of Sepp1 contributes to protection from DNA damage. 
 
Hepatic Sepp1 does not contribute to the Sepp1-/- tumorigenic phenotype. 
 Hepatic selenoprotein P expression is essential for Se homeostasis (66) and 
restoration of hepatic Sepp1 can reverse neurological and reproductive phenotypes of 
Sepp1-/- mice (385) indicating that Sepp1 produced by and transported from the liver is 
able to supplement Sepp1 loss in the brain and testes. We wanted to test whether liver-
derived Sepp1 is the major driver of the tumorigenic protection in response to 
inflammatory carcinogenesis. We, therefore, crossed floxed Sepp1 mice with mice 
expressing albumin-driven cre (Sepp1c/c;alb-cre+/-) and subjected these mice to the 
AOM/DSS protocol. As would be expected upon liver-specific knockout of Sepp1, plasma 
levels of Sepp1 were severely reduced compared to those seen in WT mice (31.4 ± 2.1 vs 
3.9 ± 0.6 μg Sepp1/mg plasma, P<0.0001, Figure 4.6A). Despite this decrease in plasma 
Sepp1, tumor number (7.1 ± 1.0 vs 6.5 ± 0.7 tumors/mouse, P=0.6, Figure 4.6B) and size 
(2.4 ± 0.3 vs 2.3 ± 0.2 mm2, P=0.9, Figure 4.6C) were similar between WT and  
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Figure 4.6 Liver-derived Sepp1 does not modify colitis-associated carcinoma. A) Quantification of 
Sepp1 protein within the plasma of either WT or Sepp1c/c/alb-cre+/- mice. B) Number of tumors and 
C) average tumor size within each mouse (mm2). ***P<0.001. 
 
Sepp1c/c;alb-cre+/- mice indicating that loss of liver-derived Sepp1 does not impact the 
tumorigenic phenotype that is seen upon complete Sepp1 knockout. This is especially 
important because it indicates that there is an important function for non-plasma Sepp1 
in anti-tumor properties. 
 
Absence of Selenoprotein P augments stem cell properties and reduces the ability of 
enteroids to survive in response to hydrogen peroxide. 
 Selenoprotein P regulates oxidative stress and toxicity (373, 386) and, consistent 
with a function in Wnt signaling, has been shown to play a role in differentiation and stem 
cell properties (172, 387). Interestingly, we noted that liver-derived Sepp1 does not 
contribute to tumorigenesis in our mouse model, suggesting a potential epithelial 
influence of Sepp1. Of interest, though Sepp1 is not expressed in the colon or enteroids 
to the extent of that in the liver, there is expression which, upon loss, could contribute to 
epithelial phenotypes (Figure 4.7A). We, therefore, wanted to determine whether 
selenoprotein P contributed to epithelial growth and stem cell properties at baseline as 
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well as whether hydrogen peroxide treatment would alter ROS production and survival 
within the epithelial compartment. Recently, a model for epithelial crypt growth has been 
established based on the isolation of stem cells from the small intestinal crypt. From single 
crypts, complex structures can be grown in vitro that closely resemble their in vivo 
counterparts (388). We utilized this model system to determine how the small intestinal 
epithelial compartment responds to selenoprotein P knockout.  
  Enteroids can be grown from a single stem cell or complete crypts (389) and the 
“stemness” of an enteroid can be measured by several growth properties displayed by 
the enteroid. For instance, augmented stem cell survival can be measured by an increase 
in the number of crypts that survive plating versus the total number of crypts plated 
(plating efficiency). Furthermore, the percentage of branching enteroids or stem 
spheroids at a certain time point can establish the capabilities of the stem cells to 
differentiate and the extent of stem cell signaling, respectively. Finally, the number of 
branches within each enteroid exhibit the ability of the stem cells to self-propagate and 
establish new crypts. We analyzed Sepp1-/- enteroids for each of these properties (plating 
efficiency: 96.5 ± 2.4 % enteroids of total crypts plated, branching enteroids: 61.5 ± 1.8 % 
branching enteroids, stem spheroids: 14.5 ± 0.2 % stem spheroids, number of branches: 
3.2 ± 0.2 number of branches per branching enteroid, Figure 4.7B) and discovered an 
increased stem cell fitness and growth abilities compared to WT enteroids (plating 
efficiency: 65.5 ± 2.0 % enteroids of total crypts plated, P<0.0001, branching enteroids: 
42.1 ± 2.4 % branching enteroids, P=0.02, stem spheroids: 7.6 ± 0.9 % stem spheroids, 
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P=0.002, number of branches: 1.9 ± 0.1, P=0.003, Figure 4.7B). We next wanted to 
determine the response of Sepp1-/- enteroids to hydrogen peroxide treatment. Analysis  
 
Figure 4.7 Sepp1-/- enteroids display an increase in stem cell characteristics and increased ROS 
production, proliferation, and decreased survival in response to hydrogen peroxide administration. 
A) Relative Sepp1 mRNA expression in the liver, colon, brain, and enteroids isolated from WT mice. 
The graph displays fold change expression normalized to GAPDH and relative to colonic Sepp1 
expression. B) Enteroid stem cell properties determined based on plating efficiency as measured 
by percentage of surviving enteroids one day post-plating compared to total crypts plated, percent 
of branching enteroids and stem spheroids relative to total enteroids counted three days post-
plating, and average number of branches per branching enteroid at four days post-plating. C) ROS 
quantification as determined by carboxy-H2DCFDA staining intensity measured after 2 hours of 
treatment with 0 μM, 400 μM, and 800 μM hydrogen peroxide. The quantification is displayed as 
the fold change in intensity relative to WT enteroids treated with 0 μM hydrogen peroxide (left). 
Representative images of the single carboxy-H2DCFDA channel and merged carboxy-H2DCFDA and 
TO-PRO3 channels in WT and Sepp1-/- enteroids treated with either 0 μM or 800 μM hydrogen 
peroxide (100x magnification, right). C) Proliferation quantification as determined by EdU+ cells 
per crypt area within WT and Sepp1-/- enteroids after two hours of treatment with either 0 μM or 
800 μM hydrogen peroxide (left) and representative images of EdU staining in WT and Sepp1-/- 
enteroids post-treatment with either 0 μM or 800 μM hydrogen peroxide (100x magnification, 
right). D) Survival curves for WT (red), Sepp1+/- (blue), and Sepp1-/- (black) enteroids after daily 
treatment with 400 μM hydrogen peroxide. *P<0.05, **P<0.01, ***P<0.001. 
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of reactive oxygen species (ROS) produced after treatment with hydrogen peroxide 
revealed a decreased ability of Sepp1-/- mice to respond to oxidative stress as carboxy-
H2DCFDA staining intensity was increased (800 μM H2O2: 1.6 ± 0.4 vs 3.3 ± 0.4 fold-change 
intensity relative to 0 μM H2O2 WT, P=0.04, Figure 4.7C) though there was no change in 
staining intensity of the oxidative-insensitive analogue carboxy-DCFDA. Moreover, 
baseline proliferation was increased in Sepp1-/- enteroids (1.0 ± 0.06 vs 1.4 ± 0.1 fold-
change EdU+ cells/crypt area relative to 0 μM H2O2 WT, P<0.05, Figure 4.7D) and 
treatment with hydrogen peroxide resulted in decreased Sepp1-/- proliferation compared 
to untreated null enteroids (1.4 ± 0.1 vs 0.9 ± 0.09 fold-change EdU+ cells/crypt area 
relative to 0 μM H2O2 WT, P<0.01, Figure 4.7D), but Sepp1-/- enteroids retained increased 
proliferation compared to WT enteroids (0.4 ± 0.09 vs 0.9 ± 0.09 fold-change EdU+ 
cells/crypt area relative to 0 μM H2O2 WT, P<0.05, Figure 4.7D). Finally, Sepp1-/- enteroids 
demonstrated decreased survival in response to multiple daily administrations of 
hydrogen peroxide (P=0.005, Figure 4.7E). These data indicate that absence of Sepp1 
increases baseline stem phenotypes and proliferation but decreases the antioxidant 
potential of enteroids. These data are important because they indicate an epithelial cell-
autonomous role for Sepp1 in processes that would likely contribute to tumorigenesis in 
CAC, a cancer characterized by increased oxidative stress. 
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Wnt signaling and oxidative stress gene signatures are altered in Sepp1-/- epithelium. 
 Enteroids rely on the addition of growth factors EGF, Noggin, and R-spondin in 
order to properly grow and differentiate. As Sepp1 null enteroids demonstrate increased 
stem cell properties and fitness, we wanted to determine whether absence of signaling 
down one of the three pathways required for enteroid establishment and growth would 
reverse the baseline enteroid phenotype. Depletion of EGF, Noggin, and R-spondin 
resulted in similar decreases in survival in all three genotypes indicating that all three 
pathways are important for enteroid persistence (Figure 4.8A), but absence of R-spondin 
is the only condition in which both heterozygous and null enteroids displayed decreased 
survival compared to WT enteroids, though this difference was not statistically significant 
(Figure 4.8A). These data indicate that the stem phenotypes seen upon Sepp1 knockout 
are most dependent on Wnt signaling.  
In order to acquire an unbiased understanding of gene changes within tumors of 
Sepp1-/- tumors, we performed RNAseq analysis of tumors from WT and Sepp1-/- mice 
subjected to the AOM/DSS protocol. Ingenuity pathway analysis indicates that Wnt 
signaling is altered in Sepp1-/- tumors with increases in TGFβR3, APPL2, SFRP-4 and -5, and 
Cdh-2 expression and obvious pathway abnormalities (Figure 4.8B), thus validating results 
seen in enteroids. As further validation of altered Wnt signaling in these tumors, protein 
analysis demonstrates increased expression of the Wnt targets Lef-1, Cyclin D1, and 
Mmp7 upon loss of Sepp1 expression (Figure 4.8C). We also wanted to determine 
whether alterations could be determined within oxidative stress genes. First, we looked 
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for changes in expression of other selenoproteins to determine if compensation was 
taking place and found that expression of selenoproteins were not significantly different  
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Figure 4.8 Wnt signaling plays a pivotal role in the Sepp1-/- phenotype. A) Survival curves in 
response to growth factor depletion in WT, Sepp1+/-, and Sepp1-/- enteroids. B) Ingenuity pathway 
analysis of Sepp1-/- tumor RNAseq data relative to WT data. Select genes from the WNT signaling 
pathway that are overexpressed in Sepp1-/- tumors (top) and WNT pathway alterations 
demonstrated in a pathway map (bottom). Genes highlighted with red are overexpressed and 
genes highlighted with green are suppressed. Intensity of color indicates extent of expression 
where darker color indicates a greater expression change. C) Quantification of WNT proteins Lef-
1, Cyclin D1, and Mmp7 normalized to β-actin. Quantification is shown as fold change relative to 
WT (top) and representative images of blots from three individual tumors from each genotype 
(bottom). 
 
between WT and Sepp1-/- tumors. We did note significant alterations in several 
cytochrome P450 gene family members as well as beta-hydroxysteroid dehydrogenase 
genes (Table 4.1) suggesting that other antioxidant genes are upregulated to attempt to 
compensate for Sepp1 loss.  
 
 
Table 4.1 Significantly up- or down-regulated oxidative stress response genes in Sepp1-/- tumors 
compared to WT tumors. 
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Discussion 
 Selenoprotein P mRNA levels are significantly decreased in colorectal cancer tissue 
relative to normal mucosa (162) and association studies have identified multiple SNPs in 
SEPP1 that are linked to colorectal cancer incidence or risk (99, 165). Perhaps most 
importantly for the purpose of this study, expression of Sepp1 is also significantly 
decreased during progression in tumors resulting from ulcerative colitis (390). This link 
may be dependent upon the role of selenoprotein P in antioxidant activity as it has been 
shown to be a hydroperoxide-reducing enzyme (159) and oxidative stress is a 
characteristic of inflammatory bowel disease (299). This possibility is supported by the 
fact that selenoprotein P is also downregulated in prostate cancer and results in 
decreased protection against oxidative damage (164, 166) and in vitro, Sepp1 protects 
astrocytes (391) and keratinocytes (386) from oxidative damage. These data suggest that 
Sepp1 may protect from colitis-associated carcinoma and its antioxidant activities might 
contribute to this protection. Thus, Sepp1 may serve as a therapeutic target in the 
prevention of CAC in patients with IBD. 
 In support of this proposed role, partial loss of Sepp1 leads to increased 
tumorigenesis concomitant with increased DNA damage, proliferation, and pro-
tumorigenic M2 macrophage infiltration. Interestingly, the macrophage phenotype 
appears to result from improper polarization as activation of Sepp1+/- bone marrow 
macrophages also leads to increase prevalence of M2 characteristics suggesting that 
decreased Sepp1 expression alters macrophage polarization. Moreover, truncation of the 
selenium-rich domain of Sepp1 or mutation of the N-terminal redox active selenocysteine 
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also resulted in increased tumorigenesis, suggesting that both functional domains of 
Sepp1 contribute to protection from inflammatory tumorigenesis. Interestingly, despite 
the fact that the liver produces the majority of Sepp1 which is distributed via the blood 
stream, we present evidence here that implicates epithelial-derived Sepp1 in protection 
from oxidative stress and tumorigenesis. For one, small intestinal organoids isolated from 
Sepp1-/- mice display increased stemness and proliferation, two properties closely linked 
with tumorigenesis. Moreover, they demonstrate a decreased ability to deal with 
oxidative stress as hydrogen peroxide treatment leads to increased ROS production and 
decreased survival. Finally, absence of liver-derived Sepp1 does not alter tumorigenesis. 
While this does not directly implicate epithelial Sepp1 in the Sepp1-/- tumor phenotype, 
coupled with enteroid data, the liver-specific knockout data suggest that epithelial Sepp1 
at least plays a contribution to the phenotype. Additionally, the Se-rich C-terminal domain 
of Sepp1 is considered to primarily function as a Se transport domain but the Sepp1c/c;alb-
cre+/- and Sepp1Δ240-361/Δ240-361 phenotypes do not phenocopy one another suggesting that 
there may be a role for the C-terminal domain of Sepp1 beyond selenium transport. 
Future experiments should focus on epithelial-specific knockout models in order to 
confirm this hypothesis. 
 Induction of several signaling pathways have been linked to Se depletion including 
Nrf2 (125) and Wnt (130), there is little known about the contribution of Sepp1 to these 
pathway alterations or others which might be specific to Sepp1. We, therefore, 
performed an unbiased RNAseq analysis of tumors from WT and Sepp1-/- mice post-
AOM/DSS protocol. Amongst the most severely altered pathways in response to Sepp1 
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loss was the Wnt pathway. While genes were both up- and down-regulated in this 
pathway, some of particular importance including the Wnt ligand, the transcriptional 
effector LEF/TCF, and the Wnt targets Mmp7, which we also validated at the protein level, 
and p14ARF were all decreased at the mRNA level. Genes that demonstrated increases in 
expression included the TGF-β receptor, E-cadherin, and the liver receptor homologue- 1 
(LRH-1) which is important for maintaining stem cell pluripotence during development 
(392). Importantly, Ingenuity analysis identified the Wnt/β-catenin signaling pathway as 
being stimulated in Sepp1-/- tumors despite those genes that were downregulated. This is 
important because Sepp1 is a Se transporter and Se deficiency leads to an increase in Wnt 
signaling suggesting that Sepp1’s selenium transport function may contribute to Wnt 
modulation. 
 We also wanted to survey Sepp1-/- tumors for alterations in redox gene regulation. 
Interestingly, we did not note increased expression of other selenoproteins, indicating 
that there was not compensation upon Sepp1 loss. Amongst some of the most 
significantly upregulated redox genes in response to Sepp1 deficiency in the AOM/DSS 
model were members of the cytochrome P450 family of oxidoreductases. The 
cytochrome P450 (Cyp) superfamily is a group of enzymes that catalyze the oxidation of 
organic substances (393). One Cyp identified, Cyp2e1, can reduce oxygen to produce pro-
oxidant species, which can create oxidative stress particularly when antioxidant reserves 
are depleted (394) as would be seen with Sepp1 deficiency. This upregulation of the Cyp 
gene family likely results from the increased oxidative stress resulting from Sepp1 
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absence and ultimately results in augmentation of the already high oxidative load seen in 
Sepp1-/- mice. 
 We demonstrate that Sepp1 deficiency leads to protumorigenic phenotypes both 
within small intestinal epithelial cells and in response to the AOM/DSS inflammatory 
carcinogenesis protocol. These data utilize a novel stem cell model system as well as 
genetic models of Sepp1 modulation to show that Sepp1 would likely serve as a 
therapeutic target in the prevention and treatment of colitis-associated carcinoma, a 
cancer characterized by high oxidative stress.  
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CHAPTER V 
 
MTGR1 IS REQUIRED FOR TUMORIGENESIS IN THE MURINE AOM/DSS COLITIS-
ASSOCIATED CARCINOMA MODEL3 
 
Introduction 
MTGR1 (Myeloid Translocation Gene, Related-1, CBFA2T2), MTG8 (RUNX1T1) and 
MTG16 (CBFA2T3) are members of a gene family (MTGs) in which MTG8 and MTG16 were 
originally identified as targets of chromosomal translocations in acute myeloid leukemia 
(AML) (178, 190). Translocations involved in cancer identify master regulatory genes often 
affecting cellular proliferation, differentiation and apoptosis. MTGs are transcriptional co-
repressors lacking both enzymatic activity and DNA binding capabilities, and act as 
scaffolding proteins upon which other transcriptional co-repressors (mSin3a, N-CoR, 
SMRT), histone deacetylases, and transcription factors assemble, thus directing 
promoter-specific targeting of repressor complexes (178, 190). The aggregate effect of 
these complexes is chromatin remodeling via post-translational histone modifications.  
In addition to their pivotal role in AML, MTG8 and MTG16 have been implicated in 
epithelial malignancies, with the identification of multiple non-synonymous mutations in 
MTG8 and MTG16 in colorectal carcinoma (228, 229) and more recently additional 
mutations in MTG8 identified in breast and lung cancer (395). Furthermore, MTG16 is 
                                                        
3 This work has been published under Caitlyn W. Barrett, Barbara Fingleton, Amanda Williams, Wei 
Ning, Melissa Steapleton, Mary K. Washington, Rupesh Chaturvedi, Keith T. Wilson, Scott W. Hiebert, 
Christopher S. Williams (2011) Mtgr1 is required for tumorigenesis in the murine AOM/DSS colitis-
associated carcinoma model, Cancer Research, 71, 1302-12 (4). 
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proposed to function as a tumor suppressor in breast cancer (227). Recently, it has been 
demonstrated that MTGs bind to TCF4 and repress its transcriptional activity, thus linking 
MTGs with a stem cell regulatory pathway critical for epithelial homeostasis that is 
frequently targeted in malignancy (209). The role in tumorigenesis of MTGR1, the third 
MTG family member, has yet to be determined. 
Observations made in Mtgr1-/- and Mtg8-/- mice have identified MTGs as participating 
in intestinal developmental and differentiation programs.  Roughly a third of Mtg8-/- mice 
demonstrate a complete deletion of the midgut (214). Mtg16-/- mice revealed that MTG16 
is required for hematopoietic progenitor cell fate decisions and early progenitor 
differentiation (396). Mtgr1-/- mice have increased intestinal proliferation and the 
progressive depletion of the secretory lineage in the small intestine, indicating that 
MTGR1 regulates intestinal proliferation and differentiation programs (217). Additionally, 
Mtgr1-/- mice are sensitive to DSS-induced colitis and exhibit chronic architectural changes 
with this type of injury implicating MTGR1 in epithelial repair programs (226). Collectively, 
the genetic evidence suggests that MTG proteins play key roles in intestinal biologic 
processes and could influence intestinal tumorigenesis.  
Chronic inflammation, as in Ulcerative Colitis and Crohn’s Colitis, predisposes 
malignancy (15, 397, 398), but with an extended latency. While inflammation can be 
linked to tumorigenesis, the long latency makes the molecular basis of these links less 
clear. Moreover, in certain malignancies inflammation may impair tumor growth. This is 
termed “tumor immunoediting” and represents the dynamic nature between the anti-
 130 
 
tumoral and pro-tumoral activities of immunity (399). Thus it is difficult to predict the 
impact a particular gene or pathway may have on tumorigenesis a priori.  
We hypothesized that MTGR1 could modify inflammatory carcinogenesis, but 
whether this would be stimulatory or inhibitory was unclear. In order to test this 
hypothesis, we applied the azoxymethane/dextran sodium sulfate (AOM/DSS) murine 
inflammatory colitis model to Mtgr1-/- mice. This model has been employed to dissect NF-
kB (400), TLR4 (266), and TNFα (401) signaling, innate immune responses (402), and the 
role of intestinal microflora (403) in inflammatory carcinogenesis. We found a striking 
decrease in tumor formation in the absence of MTGR1 coupled with increased intra-
tumoral apoptosis. This phenotype required injury and was non-hematopoietic cell 
autonomous; however, global gene expression analysis revealed that members of WNT 
networks were decreased and genes associated with innate and adaptive immune 
networks upregulated in Mtgr1-/- tumors, implicating tumor immunity as a potential 
mechanism of tumor clearance. Supporting this concept, we observed decreased nuclear 
-catenin and increased CD3+, B220+, NKp46+, and F4/80+ infiltrates in Mtgr1-/- tumors. 
Thus, MTGR1 is required for efficient AOM/DSS-induced tumorigenesis and may promote 
survival of initiated colonocytes perhaps by its influence on suppressing tumor immunity. 
 
Materials and Methods 
Murine Inflammatory Carcinogenesis Protocol: 8-10 week old C57BL/6/129 mixed 
background WT (n=22) or Mtgr1-/- (n=19) mice were injected with 12.5 mg/kg of AOM 
(Sigma-Aldrich) intraperitoneally as described in Greten, et al (265). After a three-day 
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recovery period the animals were started on the first of four cycles of 3% DSS ad libitum 
(See Schematic in Figure 5.1A). Each cycle lasted 5 days and was separated by a 16-day 
recovery period. After the last cycle, animals were sacrificed following a 26-day recovery 
period. Tumor counts and measurements were performed in a blinded fashion under a 
stereo-dissecting microscope. Microscopic analysis was performed for severity of 
inflammation (357)  and dysplasia on (H&E) stained “Swiss rolled” colons by a 
gastrointestinal pathologist (MKW). All in vivo procedures were carried out in accordance 
with protocols approved by the Vanderbilt Institutional Animal Care and Use Committee. 
Mtgr1 expression: Tumors and adjacent non-tumor tissue from four colons were 
dissected from WT mice and RNA was isolated using the RNEasy MiniKit (Qiagen). SYBR 
Green (Bio-Rad) qRT-PCR using Mtgr1 and GAPDH specific primers was performed in 
triplicate as previously described (226). Analysis of fold-change was performed using the 
∆∆Ct method. 
In situ hybridization: The MTGR1-1699T and MTGR1-2020B probe set and protocol of 
Amann et al. were used (217). Images were taken on a Zeiss Axioskope under identical 
conditions.    
Immunohistochemistry: 2-h prior to sacrifice, animals were injected with 16.7 mg/kg 
bromodeoxyuridine. 5-micron sections were cut, dewaxed, hydrated and endogenous 
peroxidase activity quenched with 0.03% hydrogen peroxide in MeOH. Antigen retrieval 
was performed using the boiling sodium citrate method in a microwave (20mM sodium 
citrate pH 6.5) for 16 min at 30% power. After blocking, primary antibody added (--
catenin, (BD Transduction Laboratories), 1:1000; -CD3, (Serotec), 1:1000; -CD45r, (BD 
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Pharmingen), 1:40, monoclonal -BrdU (Accurate Labs) 1:2000), -arginase I (ARG1), 
(Santa Cruz), 1:500; -IL-1, (R&D Systems), 1:50; -NKp46, (Santa Cruz), 1:500; -
matrilysin 338 (404), diluted 1:500) overnight at 4°C. Isotype-matched antibodies were 
included as negative controls. The Vectastain ABC Elite System (Vector Labs) was used to 
visualize staining for IHC. For immunofluorescence slides were counterstained with DAPI 
(Invitrogen) and mounted with ProLong Gold antifade (Invitrogen). Identification of intra-
tumoral apoptotic cells was performed using the ApopTag® Plus Peroxidase in situ 
Apoptosis Kit (Chemicon) according to the manufacturers protocol. Control stains were 
obtained by omitting the terminal transferase (TnT) enzyme. Immune cell, apoptosis, and 
proliferation indices were generated by counting the number of positive cells per high-
powered field (HPF; 40x objective) within each tumor (15 Mtgr1-/- 42 WT tumors) from 9 
Mtgr1-/- and 14 WT tumor bearing mice. A total of 82 Mtgr1-/- and 319 WT high-powered 
fields were examined and the mean positive cells per HPF was calculated. A crypt 
apoptosis and proliferation index was generated by counting twenty crypts per mouse. 
This is presented as the mean number of TUNEL+ or BrdU+ cells per crypt. 
Cell Culture and siRNA transfection: HCT116 cells were obtained from Dr. Robert Coffey 
and have morphologic characteristics consistent with their known identity. Formal 
authentication was not performed. One day prior to siRNA transfection, cells were plated 
at 2x105 cells per well in a 6-well plate. Cells were then transfected with ON-TARGETplus 
SMARTpool siRNA for Mtgr1/CBFA2T2 (Thermo Scientific) using RNAiMax (Invitrogen) 
according to the manufacturer’s protocol. 6 h after transfection, the transfection mixture 
was replaced with complete media. The next day, cells were starved overnight with media 
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containing 1% BSA and the next morning cells were washed and complete media was 
added. After harvesting, cells were analyzed for apoptosis using the TACS Annexin V-FITC 
flow cytometry kit (R&D Systems). Cells were analyzed on the 5-laser BD LSRII analyzer 
and unstained controls were used to establish proper gating. Presented are the average 
percentage of annexin V positive cells per 10,000 cells over three different trials. 
Expression Array Assays: Tumors were dissected from WT and Mtgr1-/- mice and RNA was 
isolated using the RNEasy MiniKit (Qiagen). RNA integrity was determined using an Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). All RNA samples had RNA 
integrity numbers (RINs) >8 and were deemed suitable for hybridization. A total of 10 mg 
of cRNA was used in the second cycle of first strand synthesis to generate the correct 
sense for target hybridization. Mouse gene 1.0 ST arrays (Affymetrix) were scanned the 
next day. CEL files were imported into Partek Express (Partek) and Robust Multichip 
Average (RMA) was run across all 8 samples. Pivot data was exported and posted. A t-test 
was run between the Mtgr1-/- and WT sample groups in Partek. The P-value was multiple 
testing corrected with Bonferroni and Step-up. Expression array analysis was performed 
hybrizing cRNA to the Mouse gene 1.0 ST chip (Affymetrix). Differentially expressed genes 
were classified using the PANTHER (Protein Analysis THrough Evolutionary Relationships) 
classification system (www.pantherdb.org/gen). 
Bone Marrow Transplant: A single cell suspension of bone marrow cells was obtained 
from the tibia and femur of two Mtgr1-/- and four WT 6-week old donor mice, and the red 
blood cells were lysed with erythrocyte lysis buffer (Buffer EL, Qiagen). 0.85 x 106 bone 
marrow cells were injected via the tail vein into 15 Mtgr1-/- and 17 WT lethally irradiated 
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(900 rads) 8 to 12-week old recipient mice. The mice were then fed acidified water 
(0.015% HCl in autoclaved water) supplemented with 1.1 g/L neomycin sulfate and 125 
mg/L polymyxin B sulfate for two weeks post transplantation (modified from Cotta et al. 
(405)). Eight weeks post-transplantation the mice were placed on the Murine 
Inflammatory Carcinogenesis Protocol.   
Statistical Methods: Apoptosis, proliferation, and immune cell indices as well as the tumor 
and burden counts were analyzed using the Student’s-t test using Graphpad Prism® 5.0c, 
unless otherwise indicated.   
 
Results 
Mtgr1 is overexpressed in AOM/DSS tumors.  
Proteins regulating intestinal proliferation and differentiation pathways often 
contribute to oncogenesis. Given the newly discovered role of MTGR1 in regulating these 
processes coupled with the observation that loss of MTGR1 results in sensitization to gut 
injury, we hypothesized that Mtgr1 expression maybe altered in AOM/DSS tumors. For 
these experiments, 8-10 week old mice were injected with AOM and treated with 4 cycles 
of DSS as defined in the Methods and shown in Figure 5.1A. Tumors and adjacent tissue 
were harvested and both qRT-PCR and in situ hybridization for Mtgr1 mRNA expression 
was performed. A 10.7-fold increase (P<0.001) in Mtgr1 mRNA expression was 
demonstrated in tumors compared to adjacent mucosa (Fig. 5.1B) and this expression was 
localized to a majority of the epithelial cells within the tumor whereas in adjacent 
histologically normal appearing colonic crypts it was expressed in only a small population  
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Figure 5.1 Mtgr1 expression is increased in tumors resulting from AOM/DSS colitis-associated 
carcinoma. A, schematic of the AOM/DSS protocol. B, polyps and adjacent normal tissue subjected 
to Taqman qRT-PCR analysis via the delta-delta CT method demonstrated a 10.73-fold increase in 
Mtgr1 expression in tumor versus normal tissue (***P<0.001). Error bar represents the standard 
error for four biological replicates performed in triplicate. C, Mtgr1 in situ hybridization of colonic 
“Swiss Rolls” obtained from WT AOM/DSS. Arrows indicate positive signal within the base of the 
crypt. Scale bar is 5 m. 
 
of epithelial cells within the lower crypt region, consistent with the published expression 
pattern (Fig. 5.1C) (217). We next wanted to determine if MTGR1 levels varied in human 
colon cancer. We were unable to obtain human colitis associated carcinoma samples 
therefore we performed qRT-PCR for MTGR1 on two colorectal cancer sample groups. 
The first consisted of non-matched normal and colorectal carcinoma (CRC) tissues. In this 
group we observed a 2.3 fold increase in MTGR1 expression in the CRC samples (P<0.05) 
(Fig. 5.2A). We then looked at 9 matched normal/colon cancer samples and found  
A 
B C 
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Figure 5.2 MTGR1 is overexpressed in human colorectal cancer. A) Mtgr1 RNA levels in normal 
colon vs. CRC samples. (left) average of 3 normals vs 8 CRC samples, *P<0.05. B) Relationship plot 
of Mtgr1 RNA levels in nine matched normal and CRC samples indicating heterogeneity in Mtgr1 
expression.  
 
heterogeneity in MTGR1 expression, however, 55% of the CRC samples demonstrated an 
increase in MTGR1 expression (Fig. 5.2B). These results suggest that MTGR1 may 
contribute to inflammatory carcinogenesis in the colon and we postulated that deletion 
of MTGR1 may prevent tumor formation.  
 
Mtgr1 is required for efficient inflammatory tumorigenesis.  
Using genetic manipulation in the mouse, we tested whether MTGR1 was required 
for tumorigenesis in the AOM/DSS model. 8-10 week old WT or Mtgr1-/- mice were placed 
on the AOM/DSS protocol (Fig. 5.1A).  Consistent with our prior report (226) Mtgr1-/- mice 
experienced greater weight loss in comparison to WT animals with each DSS treatment. 
Looser stool was evident in both groups, with frank blood frequently seen in the Mtgr1-/- 
mice. Four weeks after the last DSS cycle the animals were sacrificed. Despite the 
increased sensitivity to colitis, the Mtgr1-/- mice actually had significantly fewer polyps  
 
A B 
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Figure 5.3 Mtgr1 functions as a tumor promoter in the murine AOM/DSS inflammatory 
carcinogenesis model. A) polyp frequency and B) polyp size as determined via calculation of the 
surface area of each lesion in each mouse (**P<0.01). C) representative gross specimens from 
three WT and Mtgr1-/- AOM/DSS treated mice with longitudinally opened colons on the far right. 
D) representative H&E demonstrating tumors from WT and Mtgr1-/- mice. Overall, WT tumors 
were larger and displayed more dysplasia than those from Mtgr1-/- mice. Scale bar is 5 m. 
 
compared to WT mice (1.8 ±0.5 vs 7.5 ±0.8, Fig. 5.3A) and decreased tumor size (4.6 ±0.62 
mm2 vs 8.4 ±0.83 mm2, Fig. 5.3), which was apparent upon gross inspection 
(representative colons, Fig. 5.3C). Histologic examination of H&E stained sections from 
colons prepared as “Swiss Rolls” revealed adenomas with high grade dysplasia 
characterized by loss of epithelial polarity and a more complex tumor growth pattern 
frequently present in WT tumors, whereas the adenomas observed in the Mtgr1-/- colons 
(Fig. 5.3D) more often showed only low grade dysplastic changes. WT or Mtgr1-/- mice 
A B 
C 
D 
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treated either with AOM as a single modality, or with multiple exposures to DSS in the 
absence of AOM, did not develop tumors over this time frame (data not shown).  
A decrease in tumor multiplicity in Mtgr1-/- mice suggested that MTGR1 may be 
playing a role in initiated or early tumor progenitor cell survival after injury, as opposed 
to influencing tumor promotion, in which case similar numbers of tumors, but smaller 
tumors would be expected. To determine if epithelial injury was required for this effect, 
we treated animals with AOM as a single agent (12.5 mg/kg IP) and assessed effects 48 
weeks later. At necropsy, there was no difference in polyp or aberrant crypt foci (ACF) 
formation between WT and Mtgr1-/- mice (polyps, 3.5 ±0.2 vs 4.1 ±0.5, P=0.40; ACF, 23.4 
±0.1 vs 27.0 ±2.0, P=0.21, Fig. 5.4A, B). These data indicate that alterations in epithelial 
  
Figure 5.4 AOM-only experiments demonstrate no difference in polyp burden or ACF. A) mice 
treated with AOM and aged for 48 weeks had similar polyp and B) ACF burdens.  
 
injury, either due to DSS itself or to inflammatory infiltration was required for the 
different AOM/DSS phenotype in Mtgr1-/- versus WT mice. Collectively, these 
experiments suggest that MTGR1 could protect early tumor progenitor cells from 
clearance after enterocyte injury.  
A B 
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Altered intratumoral apoptosis in the absence of MTGR1.  
Variations in proliferation or apoptosis may account for the difference in tumor 
burden between Mtgr1-/- and WT mice. Intra-tumoral apoptosis rates were assessed using  
 
Figure 5.5 Mtgr1-/- polyps demonstrate increased apoptosis. Colons were isolated from mice after 
completion of the AOM/DSS protocol. A) apoptosis was measured via TUNEL staining of Swiss 
rolled colons from all tumor bearing mice. Mtrg1-/- polyps, on average, have higher apoptotic cell 
counts than WT polyps (***P<0.001) but there is no difference in apoptosis within crypts. B) siRNA 
knockdown of Mtgr1 in the colon carcinoma line, HCT116, resulted in increased apoptosis 
compared to scrambled siRNA control (*P<0.05). Error bar represents the standard deviation for 
three biological replicates. 
 
in situ TUNEL staining. Mtgr1-/- mice demonstrated an average of 32.0 ±5.1 TUNEL+ 
cells/tumor high-power field (HPF). WT mice, on the other hand, displayed 12.9 ±0.9 
TUNEL+ cells/tumor HPF (P<0.001, Fig. 5.5A), while no differences were seen in apoptotic  
A B 
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indices within crypts. To investigate whether there is a direct link between loss of MTGR1 
and induction of apoptosis, we utilized a cell culture model using the human colon cancer 
cell line HCT116. Knockdown of MTGR1 by siRNA resulted in increased apoptosis as 
measured by annexin V and propidium iodide (PI) flow cytometry (Fig. 5.5B), but no 
change in proliferation (data not shown).  
Next, to analyze proliferation rates, BrdU immunohistochemistry (IHC) was 
performed. BrdU positive cells/crypt were counted and averaged. As observed previously 
(226), non-tumorigenic Mtgr1-/- colonic epithelium showed a modest increase in 
proliferation compared to WT mice. However, intra-tumoral proliferation rates were 
similar between WT and Mtgr1-/- mice, suggesting that the difference in tumor formation 
and/or size was not a function of differences in epithelial proliferation rates between WT 
and Mtgr1-/- animals, but more likely due to differences in intratumoral apoptosis.  
 
Decreased nuclear and total -catenin in Mtgr1-/- tumors.  
All three MTG family members (MTGR1, MTG16, and MTG8) are capable of 
competing with β-catenin for TCF4 occupancy and can repress TCF4 mediated 
transcriptional activity (209). Based on this observation, we stained WT or Mtgr1-/- tumors 
with a β-catenin specific antibody to determine the levels of β-catenin expression and its 
localization. We derived a -catenin staining index, which incorporates the intensity of 
staining and percentage of nuclear β-catenin+ cells/HPF. We found uniformly high nuclear 
and cytoplasmic staining in the WT tumors (252.4 ±24.9, Fig. 5.6A, B). However, the 
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Mtgr1-/- tumors contained lower levels of nuclear β-catenin and there was a more 
heterogeneous staining pattern within the tumor (101.2 ±23.6, Fig. 5.6A, B).  
 
 
Figure 5.6 Decreased expression and heterogeneous distribution of nuclear β-catenin in Mtgr1-/- 
tumors. -catenin expression and localization was determined via immunohistochemistry -
β-catenin as per Methods section. A) representative staining for β-catenin from WT or Mtgr1-/- 
tumors, B) β-catenin index (Percentage of tumor with nuclear β-catenin x expression intensity, 
(N=10 mice, each genotype) **P<0.01). Error bar represents the standard deviation and scale bar 
is 5 m. 
 
Transcriptional network alterations in Mtgr1-/- tumors.  
To address the mechanism by which MTGR1 might act during tumorigenesis, RNA 
was isolated from WT and Mtgr1-/- tumors and hybridized to Affymetrix Mouse Gene 1.0 
ST arrays. After data normalization, expression profiles were uploaded to the PANTHER 
platform (313). Significant decreases in both Wnt (P=.001) and Cadherin (P=.0001) 
pathways in the Mtgr1-/- tumors was evident with the most significant reductions in the  
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Table 5.1 Differential expression of genes in Mtgr1-/- tumors. Tumors were developed according to 
the Murine Inflammatory Carcinogenesis Protocol and dissected from WT and Mtgr1-/- mice. 
Isolated RNA was hybridized to the Mouse gene 1.0 ST arrays and CEL files were imported into 
Partek for differential expression of genes. Among other genes,  
Mmp7 was shown to be downregulated in Mtgr1-/- tumors.  
 
Wnt target Lgr5 (-8.95 fold), consistent with decreased Wnt signaling tone in the Mtgr1-/- 
tumors. Paradoxically, repressors of Wnt signaling (Wif1 -17.9x, Dkk2 -7.6x and Axin2 -
3.8x, Table 5.1) were also down-regulated. Levels of expression of the matrix 
metalloproteinases (Mmp-7 6.8x, Mmp-13 3.9x, Mmp-12 3.5x, and Mmp-14 3.4x) were 
also decreased in Mtgr1-/- tumors (Table 5.1). MMP7 is a known target gene of the Wnt 
pathway (244) and its overexpression has been associated with colon cancer (406). We 
therefore assessed MMP7 at the protein level by immunofluorescence, and observed not 
only decreased expression but also decreased secretion of MMP7 from colonic polyps in 
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the Mtgr1-/- versus WT mice (Fig. 5.7A, B). These findings suggest that decreases in WNT 
signaling and MMP expression may contribute to decreased tumor size in Mtgr1-/- mice. 
 
Figure 5.7 Decreased expression and secretion of Mmp7.  A) immunofluorescence for Mmp7 
demonstrated a decrease in Mmp7 production and secretion. E-cadherin, a downstream target of 
Mmp7 is shown in red. B) Mmp7+ cells were counted per 40x HPF in tumors from WT and Mtgr1-/- 
mice (***P<0.001). Scale bar is 5 m. 
 
Immune pathways are upregulated in Mtgr1-/- tumors.  
PANTHER analysis of the changes in gene expression also revealed increased MHC-I 
(P=.001), MHC-II (P=.003), T-cell (P=6.8x10-11), and B-cell mediated immunity pathways 
(P=.007), indicating that these gene classes are overrepresented in the Mtgr1-/- tumors 
(Table 5.2). To both confirm and extend these observations we performed 
immunohistochemistry on WT and Mtgr1-/- tumors to classify intratumoral inflammation. 
In Mtgr1-/- vs WT tumors (Fig. 5.8A, B), there were increased CD3+ T-lymphocytes (13.6 
±2.5/tumor HPF vs 49.4 ±5.6, P <0.001), B220/CD45r+ B-lymphocytes (15.8 ±2.3 vs 6.0 
±0.8/tumor HPF, P <0.001), and NKp46+ natural killer cells (51.0 ±3.7 vs 36.0 ±3.1/tumor 
HPF, P=0.004). Because Mtgr1-/- tumors were smaller than WT tumors and mononuclear 
phagocytes can exert anti-tumor activity by directly killing tumor cells and eliciting tissue 
A B 
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disruptive reactions (407), we used F4/80 and IL-1β co-staining and observed increased 
M1 macrophages in Mtgr1-/- tumors (29.1 ±3.0 positive cells/tumor HPF vs 11.6 ±1.6,  
 
Table 5.2 Mtgr1-/- tumors have increased adaptive and innate immunologic transcriptional 
networks. Post-normalized expression data was analyzed via PANTHER to map biologic process 
categories. Significant increases in B-, T-cell, MHCII and MHCI were identified in Mtgr1-/- tumors.  
 
P<0.001). Because M2 macrophages are generally considered pro-tumorigenic (407), we 
anticipated that co-staining with F4/80 and ARG1 would identify fewer M2 mononuclear 
cells in the Mtgr1-/- tumors. We were surprised to find increased M2 cells in the Mtgr1-/- 
tumors (15.8 ±2.6 positive cells/tumor HPF vs 7.2 ±1.3, P=0.003, Fig. 5.8A, B).    
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In situ hybridization indicated that Mtgr1 was mainly expressed within the 
epithelium of developing AOM/DSS induced tumors (Fig. 5.1C). However, MTGR1 is 
present in many tissue types, including hematopoietic lineages (198). Given the dramatic  
Figure 5.8 Mtgr1-/- tumors have increased immune infiltration. A & B) WT or Mtgr1-/- tumors were 
stained with NKp46(green), CD3, B220, F4/80 (red), IL-1 (green), and ARG1 (green) 
antibodies and positive cells/tumor HPF were counted showing increased immune infiltrate in 
Mtgr1-/- tumors in comparison to WT tumors (***P<0.001, **P<0.01). Scale bar is 5 m. 
 
changes in inflammatory cell infiltration in the tumors, MTGR1 could be acting in a 
hematopoietic cell autonomous fashion to repress immune infiltration, or alternatively, 
MTGR1 could be acting in the stromal or epithelial compartment to repress immune cell 
recruitment. To test whether the MTGR1 effect is hematopoietic cell autonomous, we 
restored MTGR1 expression in hematopoietic cells in the Mtgr1-/- mouse via bone marrow 
transplantation of WT marrow. In addition, WT mice were transplanted with Mtgr1-/- 
A B 
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marrow and control transplants consisting of WT or Mtgr1-/- mice transplanted with WT 
or Mtgr1-/- marrow, respectively, were also performed (Fig. 5.9A, B). Non-transplanted 
controls did not survive two weeks post irradiation, indicating that the endogenous 
marrow was ablated. Transplanted animals were allowed to recover for three months 
prior to placing the animals on the AOM/DSS protocol.  
 
 
Figure 5.9 Autologous transfer of Mtgr1+/+ marrow does not reverse the Mtgr1-/- AOM/DSS 
phenotype. Bone marrow transplants were performed on WT and Mtgr1-/- mice as indicated. A) 
wild type mice given Mtgr1-/- bone marrow have more polyps per colon than Mtgr1-/- mice given 
WT bone marrow (**P<0.01). B) colonic polyps are larger in WT mice rescued with Mtgr1-/- bone 
marrow than in Mtgr1-/- mice rescued with WT marrow. 
 
WT mice rescued with either WT or Mtgr1-/- bone marrow had equivalent tumor 
burden (2.125 ± 0.693 and 1.5 ± 0.756, polyps/mouse, respectively). No tumors were 
observed in either of the Mtgr1-/- recipient groups. This indicates, at least in this model, 
that it is the absence of MTGR1 in non-hematopoietic cellular compartments that 
protects from AOM/DSS-induced tumorigenesis. This data coupled with increased 
epithelial apoptosis in the HCT-116 cells suggests that MTGR1 promotes tumorigenesis 
through its actions in the epithelium. 
A B 
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Discussion 
Myeloid Translocation Genes (MTGs) are transcriptional co-repressors that were first 
identified in AML where the prototypic event is the 8:21 translocation (408). Considerable 
information has been gained from the creation of constitutional null alleles for each MTG 
family member. Mtgr1-/- mice have increased enterocyte proliferation, mainly localized to 
the lower 1/3 of the crypt, as well as the progressive depletion of the secretory lineage in 
the small intestine (217). The presence of MTGR1 is required for maintenance of epithelial 
integrity after DSS-mediated injury and chronic architectural changes occur after a 
solitary DSS-mediated injury (226).  
In this report, we demonstrate that MTGR1 is required for efficient inflammatory-
associated colonic carcinogenesis. AOM is a procarcinogen and is metabolically activated 
to a potent alkylating agent forming O6-methyl-guanine (318). Its oncogenic potential is 
markedly augmented in the setting of chronic inflammation, such as that induced by 
repeated cycles of DSS treatment (319). The power of this model has recently been 
demonstrated in deciphering the epithelial versus myeloid cell contribution of IKKβ to 
polyp formation in the setting of inflammation (265), and the contributions of IL-6 and its 
downstream mediator, STAT-3 (33). IL-6 and MTGR1 are required for maintenance of 
mucosal integrity after injury (226), (33). Both Mtgr1-/- and IL-6-/- mice are protected from 
tumorigenesis in the AOM/DSS model. In the case of the Mtgr1-/- mice, higher levels of 
intra-tumoral apoptosis, with no appreciable difference in proliferation, may mediate the 
beneficial affect of MTGR1 deletion. Injury is required for the Mtgr1-/-  protective effect, 
as there was no difference in tumor burden when mice were injected with AOM without 
 148 
 
subsequent cycles of DSS. This suggests that MTGR1, similar to IL-6, protects initiated 
epithelial cells from apoptosis. In the case of IL-6, this is mediated via its production by 
lamina propria myeloid cells, and our data indicates that hematopoetic MTGR1 
production does not modify tumorigenesis. 
Alteration in Wnt signaling is a common initiating event in sporadic CRC (25); however, 
it is less common in colitis-associated carcinoma (CAC), and when it does occur, it typically 
does so as a late event (409).  We were surprised to find evidence of low Wnt signaling in 
Mtgr1-/- tumors as it has previously been shown that MTGs bind to TCF4 and compete 
with -catenin for occupancy; thus, at least in certain circumstances, antagonizing WNT 
transduced signals (209). One potential explanation for this apparent paradox is that 
MTGs are known to function as transcriptional co-repressors via diverse interactions with 
multiple transcription factors (i.e. PLZF, BCL6, GFI-1) in addition to TCF4. They also form 
bridging interactions with other transcriptional co-repressors such as N-CoR, SMRT, 
mSin3A and HDACs 1, 2, and 3 (176, 178, 187). Our results suggest that the effect of 
MTGR1 on WNT signaling may be less important than its ability to inhibit apoptosis via 
modulating other pathways.  
Our data suggests that loss of MTGR1 shifts the inflammatory response towards an 
anti-tumorigenic state by increasing expression of tumoricidal immune cells such as 
natural killer cells and M1 macrophage subsets. Perplexingly, there is also a concomitant 
increase in “pro-tumorigenic” M2 polarized macrophages. It is theorized that there is a 
balance between M1 (anti-tumorigenic) and M2 (pro-tumorigenic) within the tumor 
microenvironment and it is proposed that this balance could have different net effects at 
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different stages of tumor progression (407). As the overall observed effect in the absence 
of MTGR1 was smaller and fewer tumors this observation suggests that MTGR1 could 
influence the balance between anti- and pro- tumorigenic macrophage function. 
Furthermore, the fact that WT marrow transplanted into Mtgr1-/- mice failed to prevent 
the reduction in tumorigenesis in the Mtgr1-/- AOM/DSS phenotype indicates that this 
process is not acting in a hematopoietic cell autonomous manner in this tumor model. 
This raises the possibility that MTGR1 suppresses inflammatory recruitment, perhaps via 
regulating production of epithelial derived chemokines and cytokines.  
We observed decreased Mmp-7 (Matrilysin), -12, -13, and -14 in Mtgr1-/- tumors. 
These matrix metalloproteinases are overexpressed in human colorectal carcinomas with 
increased Mmp7 observed early in malignant progression and in 85% of surveyed tumors 
(410). Mmp7-/- mice bred with ApcMin/+ mice have a 50% decrease in polyposis (406, 411). 
MMP7 has pleiotropic effects promoting cancer progression via its proteolytic activity 
against the ectodomain of a number of cell surface proteins. For example, MMP7 cleavage 
of CD45 makes tumor cells resistant to apoptosis (412, 413), MMP7 mediated cleavage of 
proHB-EGF into mature HB-EGD promotes proliferation and angiogenesis (414), and E-
cadherin is cleaved to soluble E-cadherin, promoting invasion (415). The tumor promoting 
effects of increased MMP expression could contribute to tumor growth differences and 
raises the intriguing possibility that MMPs may be important targets of MTGR1-mediated 
repression.  
In conclusion, we demonstrate that removal of MTGR1 enhances inflammation, 
increases intra-tumoral apoptosis, and reduces production of proteins such as MMPs 
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known to be pivotal to tumor growth. Thus, MTGR1 appears to influence the tumor 
microenvironment and in addition to its effects on initiated cell survival may also suppress 
tumor immunosurvelliance. These studies provide insight into disease pathogenesis and 
implicate MTGR1 dysfunction in colitis-associated carcinoma and sporadic colorectal 
carcinoma, thus providing the substrate for translational investigations of MTGR1 in 
colitis-associated carcinoma.  
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CHAPTER VI 
 
KAISO DIRECTS THE TRANSCRIPTIONAL COREPRESSOR MTG16 TO  
THE KAISO BINDING SITE IN TARGET PROMOTERS4 
 
Introduction 
 The myeloid translocation gene proteins (MTGs) are transcriptional corepressors, 
lacking both enzymatic and DNA-binding activities, that act as scaffolding proteins upon 
which other transcriptional corepressors (mSin3a, N-CoR, SMRT), histone deacetylases 
(HDACs), and transcription factors assemble (178, 190). Their modular nature permits 
contributions to multiple promoter-specific repressor complexes, making them master 
regulators of gene expression. MTG8 and MTG16 (CBFA2T3) were originally identified as 
targets of chromosomal translocations in acute myeloid leukemia (178, 190), suggesting 
an important role in cellular growth and development. MTG family proteins have since 
been implicated in the development of colon and breast cancers as well (227-229, 269). 
Because MTG repressive capabilities are dictated via protein-protein interactions with 
transcription factors and other co-repressors it is imperative to identify MTG-interacting 
proteins and understand their functions and specificities in the context of tumorigenesis.  
Zinc fingers, C2H2 and BTB domain containing (ZBTB) family members bind methylated or 
unmethylated DNA in a sequence-specific manner and repress target genes (416). A ZBTB 
                                                        
4 This work has been published under Caitlyn W. Barrett, J. Joshua Smith, Lauren C. Lu, Nicholas 
Markham, Kristy R. Stengel, Sarah P. Short, Baolin Zhang, Aubrey A. Hunt, Barbara M. Fingleton, 
Robert H. Carnahan, Michael E. Engel, Xi Chen, R. Daniel Beauchamp, Keith T. Wilson, Scott W. 
Hiebert, Albert B. Reynolds, Christopher S. Williams (2012) Kaiso directs the transcriptional 
corepressor MTG16 to the Kaiso binding site in target promoters, PLoS One, 7, e51205 (12). 
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family member that has recently been studied in detail for its ability to modulate 
colorectal cancer, Kaiso (ZBTB33), utilizes all three zinc fingers for high affinity binding to 
DNA targets (417). All ZBTB family members likely share this method of DNA binding, as 
homology exists within their zinc finger motifs. Kaiso, like MTGs, forms repression 
complexes that include N-CoR and HDACs (190, 233) and plays a pivotal role in the 
repression of tumor suppression genes such as CDKN2A in colon cancer cell lines (247). 
Kaiso also represses matrix metalloproteinase gene MMP7 expression (241) in addition 
to canonical and non-canonical Wnt targets (418-420). Moreover, Kaiso expression is a 
prognostic indicator in non-small cell lung cancer (420) and its deletion suppresses 
intestinal tumorigenesis in mice (251). ZBTB4 also modulates the cellular responses to 
p53 activation (248) and is downregulated in breast cancer (421). Collectively, these data 
suggest ZBTB proteins, and Kaiso specifically, have multidimensional roles in cancer 
development.  
 Like the ZBTB family of transcription factors, the MTG family of transcriptional 
corepressors has disparate roles in cancer development. For example, MTGs associate 
with TCF4 to repress Wnt signaling (209) and mutations in both MTG8 and MTG16 were 
found in colon and breast cancer (228, 229). Mtgr1 is required for tumorigenesis in a 
murine model of inflammatory carcinogenesis (269), and MTG16 has been identified as a 
putative tumor suppressor in human breast cancer (227). Given that ZBTB16 (also known 
as PLZF) and BCL6 (ZBTB27) associate with MTG8 (192, 199) and that Kaiso and MTG16 
have similar influences in cancer development, we tested for a wider structure-function 
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relationship between the ZBTB and MTG families, which could provide insights into their 
roles in tumorigenesis.  
 Here, we identified the association of Kaiso, ZBTB4, and ZBTB38 with MTG16 in 
yeast two-hybrid assays, which suggests a direct physical interaction between these 
factors. The Kaiso-MTG16 complex specifically binds to Kaiso’s established binding site 
(KBS) on DNA and enhances repression of a KBS-containing reporter and the Kaiso target, 
MMP7 promoter. However, MTG family members did not influence methylation-based 
repression by Kaiso. These data suggest that Kaiso-MTG16 dependent transcriptional 
repression requires the interaction of this complex on the KBS. Moreover, the impact of 
MTG16 on repression of Kaiso target promoters depends on Kaiso DNA binding. Analysis 
of publicly available ChIP-seq datasets showed that MTG family members bind Kaiso-
targeted promoters over 70% of the time, implicating this interaction in the regulation of 
over 100 genes. Lastly we examined a large multi-stage CRC expression array dataset and 
discovered an inverse relationship between Kaiso and MTG16 expression and consistently 
elevated MMP7 expression at all stages of tumorigenesis supporting the hypothesis that 
loss of either Kaiso or MTG16 de-regulates MMP7 expression. 
 
Materials and Methods 
Yeast Two-Hybrid. ZBTB4 and ZBTB38 prey and MTG16 bait plasmids were obtained from 
Hybrigenics. pDONR201-Kaiso (clone ID: HsCD00082434, The ORFeome Collaboration) 
and pDONR221-MTG16 (clone ID: HsCD00079915, HIP) plasmids were obtained from 
Harvard PlasmID and pGAD-GW and pGBT9-GW vectors were provided by ABR. Kaiso and 
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MTG16 were inserted into the pGAD-GW and pGBT9-GW plasmids using the Gateway 
Cloning procedure (422). In short, 150ng of entry vector (Kaiso or MTG16) was mixed with 
150ng of destination vector (pGAD or pGBT9) and the volume was brought to 8μl with TE. 
2μl of LR Clonase II enzyme mix (Invitrogen) was added and the reaction was incubated 
for 1 hour at 25°C. 1μl Proteinase K was then added to each sample and incubated at 37°C 
for 10 minutes. Kaiso was then truncated to include amino acids 298-573 by Agilent 
Quickchange II site-directed mutagenesis (Agilent) according to the manufacturer’s 
protocol. The MTG16 constructs shown in Figure 1 were also developed using the 
Quickchange II site-directed mutagenesis kit. For the yeast two-hybrid, yeast at OD600 
were transformed via the PEG-LiAc-TE method using a 42°C heat shock. Yeast at an OD600 
of 0.6 were centrifuged at 3000 rpm for 5 minutes and resuspended in 10ml of LiAc-TE, 
centrifuged and resuspended in 1ml of LiAc-TE. Transformations were set up using 50ug 
of carrier DNA (sheared salmon sperm DNA, Ambion), 1ug of DNA for each construct 
(pGAD and pGBT9) and 100ul of competent yeast. 0.7ml of sterile 40%PEG-LiAc-TE was 
added and yeast were allowed to recover at 30C for 30 minutes and then heat shocked 
at 42C for 15 minutes. Cells were then washed with sterile TE and the reactions were 
plated on double-dropout selective media plates (-leu, -trp) and grown at 30°C for three 
days. Colonies were then plated on either triple- (for the Hybrigenics system) or 
quadruple-dropout (for the pGAD/pGBT9 system, -leu, -trp, -his, -ala) plates. Empty 
vector bait was used as a negative control. 
Immunofluorescence and Colocalization. K562 human leukemia cells (ATCC CCL-243) were 
plated on poly-l-lysine (Sigma-Aldrich) coated cover slips and allowed to adhere for 30 
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minutes at room temperature. Cells were fixed with ice-cold 2% paraformaldehyde, pH7.4 
for 10 minutes. After three washes, cells were blocked with 1% BSA and then stained with 
MTG16 antibody (1:1000 333, supplied by MEE) and a polyclonal Kaiso antibody (1:1000 
supplied by ABR) overnight at 4C. Cells were washed then stained with anti-rabbit-Cy3 
and anti-mouse-FITC for 1 hour at room temperature and mounted using ProLong Gold 
antifade mounting medium with DAPI (Invitrogen). Slides were visualized using 
Deltavision software (Stress Photonics, Madison, WI) supplied by the Epithelial Biology 
Core (Vanderbilt).  
Cell Culture. Human colon cancer cell lines HCT116 (ATCC CCL-247) and HT29 (ATCC HTB-
38) were maintained in McCoy’s 5A media supplemented with fetal bovine serum (FBS) 
and pen/strep (P/S). HCT116 cells were transfected with Lipofectamine LTX and Plus 
reagent (Invitrogen) and HT29 cells were transfected with Fugene HD (Promega) 
according to manufacturer’s protocol. K562 cells were maintained in DMEM 
supplemented with FBS and P/S.  
Coimmunoprecipitation. HCT116 cells were transfected with Kaiso and each of the Gal- or 
Myc-tagged MTG family members (provided by Mike Engel) using Lipofectamine LTX and 
Plus reagent (Invitrogen) according to manufacturer’s protocol. 48 hours post-
transfection, cells were lysed with coimmunoprecipitation buffer (0.5% Triton-X 100, 0.1% 
DOC, 0.1% SDS, and protease inhibitors in PBS), clarified by centrifugation, and pre-
cleared with protein A/G agarose beads for 1 hour at 4C. 2ug of either anti-Gal (Santa-
Cruz, sc-510), anti-Myc (Santa-Cruz, sc-40) or anti-IgG (Cell Signaling, G3A1) control 
antibodies were then added to pre-cleared lysate and incubated overnight at 4C with 
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rotation. Following removal of input, 40l protein A/G agarose beads were added to each 
sample and incubated at 4C for 1 hour with rotation. Western blotting for Kaiso 
(polyclonal Kaiso antibody supplied by ABR, 1:1000) was then performed. 
Kaiso Knockdown. HEK293T packaging cells (ATCC CRL-11268) were transfected with 
Mission shRNA constructs (Sigma-Aldrich) specific for human Kaiso (clone ID: 
NM_006777.3-2600s1c1 and NM_006777.3-358s1c1) as well as the PAX2 and MDG2 
plasmids using Superfect Transfection Reagent (Qiagen) according to the manufacturer’s 
protocol. 24 hours post-transfection, media was removed from the HEK293T cells and 
passed through a 0.2 M filter. 4g/ml Polybrene (Millipore) was added to the filtered 
media. Growth medium was removed from HCT116 cells and replaced by infection 
medium. After 6 hours, the infection medium was replaced with normal growth medium 
and the infection process was repeated 24 hours later. Cells were selected for knockdown 
using 5g/ml Puromycin (Invitrogen) over a 3-day period. Knockdown was analyzed by 
the delta-delta-CT method following RT-PCR using Kaiso-specific Taqman probes 
(Invitrogen) and by Western blotting using the polyclonal Kaiso antibody (1:1000, 
supplied by ABR).  
Luciferase Reporter Assays. Kaiso and MTG family members were transiently expressed 
in HCT116 cells along with either the Kaiso binding site (4xKBS) reporter, which contains 
four consensus Kaiso binding sites and a luciferase reporter gene (gift from Juliet Daniel, 
McMaster University, Canada), or the mutant Kaiso binding site promoter which contains 
mutant forms of the KBS and a luciferase reporter gene (PGL3 control 4xKBSMT, gift from 
Juliet Daniel). A constitutive reporter plasmid expressing Renilla luciferase (pGL4 TK 
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hRluc) was included to normalize data generated from the Kaiso reporter constructs. Cell 
lysates were subjected to a dual-luciferase assay and presented as adjusted RLUs. For 
human MMP7 (HMAT, gift from BMF) assays, Myc-tagged delta-MTG16 constructs (ME, 
Figure 1C) were co-transfected with activators PEA3, LEF1, C-JUN, and delta -Catenin 
and the human MMP7 promoter fused to the luciferase reporter gene (HMAT-2.3). 
Activation by enforced expression of PEA3, LEF1, C-JUN, and delta β-catenin was required 
to see repression by MTG family members because HCT116 cells express low levels of 
MMP7 endogenously. Mbd2-/- cells (a gift from Pierre-Antoine Defossez) (232) were 
maintained in Advanced MEM supplemented with BCS and P/S and transfected with 
Superfect (Qiagen), according to manufacturer’s protocol. For methylation-dependent 
studies, 5g of pSV40Luc was methylated upon mixture of 1.5l SAM, 30l 10x NEB2, 1l 
SssI methylase (New England Biolabs) and water to 300l.  The mixture was incubated at 
37C for 2 hours followed by addition of 1.5l SAM and continued incubation for 1 hour.  
DNA was then purified using the Qiaquick PCR purification kit (Qiagen). Mbd2-/- cells (gift 
from Pierre-Antoine Defossez) were transfected with MTG family members and either 
methylated or unmethylated promoter according to previously published specifications 
(232).  HMAT and KBS assays were performed as outlined in the Materials and Methods 
section in the main paper. 
MMP7 Repression. HT29 cells were transfected with expression plasmids for Kaiso, an 
MTG family member, or a combination of the two. RNA was isolated using the Qiagen 
RNA Isolation Kit and cDNA was generated from 1 g of total RNA using the iScript cDNA 
Synthesis Kit (BioRad). Taqman qPCR was performed using MMP7-specific probes 
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(Invitrogen), and expression was normalized to GAPDH (Invitrogen). Analysis was 
performed using the delta-delta Ct method. Transfected cells were also treated with 
Protein transport inhibitor containing Brefeldin A (BD GolgiPlug) for 3 hours before lysate 
was collected using RIPA buffer. Lysates were run on Western blots, probed with α-MMP7 
(Santa-Cruz 1:1000) and α-β-actin (Sigma-Aldrich, 1:5000) as a loading control and 
developed using the Odyssey system.  
Chromatin Immunoprecitation. HCT116 cells were fixed using 1% formaldehyde for 20 
minutes at room temperature. Cells were then lysed and chromatin was sheared by 
sonication (4 watts, 10 seconds on, 1 minute off, on ice repeated ten times). Lysate was 
precleared with 20ul protein A/G agarose beads (Santa Cruz, sc-2003) and beads were 
blocked with 2ug sheared salmon sperm DNA (Ambion). Lysate was immunoprecipitated 
with either IgG (Cell Signaling, G3A1), polyclonal MTG16 (333, provided by MEE) or 
monoclonal MTG16 (2D1, provided by SWH) overnight at 4°C with rotation. Protein A/G 
agarose beads were then added for 1 hour at 4°C with rotation. Complexes were eluted 
and crosslinks reversed with NaCl at 65 degrees for 5 hours and DNA isolated using the 
Qiagen PCR purification kit. qRT-PCR was performed using Kaiso binding site-specific 
primers (241). Analysis was performed using the delta-delta Ct method. 
Statistical Methods. Luciferase, ChIP, and expression analyses were analyzed using one-
way ANOVA and a Newman-Keuls post-test in Graphpad Prism 5.0c, unless otherwise 
indicated. 
Microarray experiments—human tissues and microarray platform. Representative 
sections of fresh tissue specimens were flash frozen in liquid nitrogen and stored at -80C 
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until RNA isolation. Quality assessment slides were obtained to verify the diagnosis of 
cancer or normal adjacent mucosa. Stage was assessed using American Joint Commission 
on Cancer guidelines for both cohorts of tumor samples. RNA for human tissue was 
purified using the RNeasy kit (Qiagen). Samples were hybridized to the Human Genome 
U133 Plus 2.0 GeneChip Expression Affymetrix array. The expression array data are 
deposited and the GEO accession number is GSE17538. Complete minimum information 
about a microarray experiment-compliant dataset for analysis are available 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17538). 
Microarray Analysis and Statistics. Microarray data were normalized using the Robust 
MultiChip Averaging (RMA) algorithm as implemented in the Bioconductor package Affy 
as previously described (423-425). Wilcoxon Rank sum test was used to determine 
significance for the normal, adenoma and colorectal cancer comparisons. The gene 
expression data Spearman correlation coefficient was used to assess the association 
between Kaiso and MTG16 (probes 214631_at and 208056_s_at respectively). We next 
compared the differential expression between normal samples and carcinoma samples 
for genes MTG16 and MMP7 using a linear model with an interaction term. More 
specifically, our model included gene expression as the outcome variable, main effects 
group (normal, carcinoma) and gene (e.g., Kaiso, MMP7) as well as the group x gene 
interaction term. The significance of interaction term indicates that differential gene 
expression for normal vs. carcinoma is significantly different for the two genes. This test 
procedure was similarly applied to genes Kaiso versus MMP7.  
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Ethics Statement. The protocols and procedures for this study were approved by the 
Institutional Review Boards at University of Alabama-Birmingham Medical Center, 
Vanderbilt University Medical Center, Veterans Administration Hospital (Nashville, TN) 
and H. Lee Moffitt Cancer Center, and written informed consent was obtained from each 
subject per institutional protocol.  
 
Results 
ZBTB family members interact with MTG16. 
 In order to understand MTG16-mediated intracellular signaling we used yeast-two 
hybrid screening to identify MTG16 binding partners. This approach identified two 
members of a family of zinc-finger transcription factors that repress methylated and non-
methylated DNA: ZBTB4 and ZBTB38. Another member of this family, Kaiso (ZBTB33), is 
of particular interest because, like MTG16, it has been previously linked to Wnt signaling 
and tumorigenesis in the gut (247, 251, 418). Kaiso was not identified in the initial yeast 
two-hybrid screen, likely due to limited expression in the murine brain library that was 
screened. However, the ZBTB4 and ZBTB38 clones that were identified consisted of the 
highly homologous zinc finger region shared by ZBTB family members (Fig. 6.1A) and 
suggested that Kaiso would likely be a third target for MTG16 binding. Directed yeast two-
hybrid validation experiments demonstrated that ZBTB4, ZBTB38, and Kaiso each interact 
with MTG16 via a highly conserved zinc-finger domain (Fig. 6.1B) which is also required 
for ZBTB16 (PLZF) MTG16 interaction (192), but not with ZBTB27 (BCL6) which 
demonstrates MTG16 binding within the fourth zinc finger motif (199). Mapping of the  
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Figure 6.1 ZBTB family members interact with MTG16. A. ZBTB family member alignment based 
on homologous zinc fingers and identification of amino acids used in yeast-two hybrid experiments 
(yeast two-hybrid clones). B. Yeast-two hybrid assay for interactions between ZBTB family 
members and MTG16. C. Mapping of the Kaiso binding site on MTG16. Yeast two-hybrid assays 
were performed in triplicate. 
 
MTG16 binding domain identified the nervy homology region 1 (NHR1) as the component 
of MTG16 that is required for binding to Kaiso as the three constructs lacking the NHR1 
domain (Δ5N, Δ7N, and NHR1) failed to demonstrate an interaction in the yeast two-
hybrid assay (Fig. 6.1C).  
A 
B C 
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Figure 6.2 Kaiso and MTG16 associate and co-localize. A. Immunoprecipitation of overexpressed 
Gal-tagged MTG family members in HCT116 cells. Cell lysates were fractionated and 
immunoprecipitated with anti-Gal or control IgG and analyzed by immunoblotting with Kaiso 
antibody. B. Myc-tagged MTG16 constructs used for immunoprecipitation mapping of MTG16 
binding site. C. Immunoprecipitation of overexpressed Myc-tagged MTG family members in 
HCT116 cells. Cell lysates were fractionated and immunoprecipitated with anti-Myc or control IgG 
and analyzed by immunoblotting with Kaiso antibody. D. K562 cells costained for MTG16 (333, 
FITC) and Kaiso (polyclonal, ABR, Cy3) were imaged using the Deltavision system, and a correlation 
coefficient was determined for Kaiso and MTG16 colocalization (r=0.95±0.04, n=25 cells). 
 
A 
B 
C D 
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Using wild-type and selected mutant constructs for MTG16, we confirmed the 
Kaiso interaction in the HCT116 human colon cancer cell line which has endogenous Kaiso 
expression (Fig. 6.2A, r=0.95±0.04). We then mapped the binding interface to the N-
terminus of MTG16 (Fig. 6.2B,C). We next used immunofluorescence to demonstrate 
endogenous co-localization of Kaiso and MTG16 in the K562 cells, a human leukemia cell 
line with high levels of expression of both proteins (Fig. 6.2D). Furthermore, in silico 
analysis of publicly available ChIP-seq data (UCSC Genome Browser, (426)) identified 101 
promoters with intersecting Kaiso and MTG protein occupancy (Fig. 6.3A), providing 
further evidence that cooperativity between Kaiso and the MTG proteins may occur. 
Furthermore, three targets identified in the in silico ChIP-seq analysis, ATF-2, ATF-7, and 
MAPK14 demonstrate altered expression in response to MTG16 overexpression. ATF-2 
and MAPK14 are repressed by MTG16 (Fig. 6.3B, P<0.0001 ATF-2 and P=0.04 MAPK14) 
while ATF-7 expression is higher in response to MTG16 overexpression (Fig. 6.3C, 
P<0.0001). Though initially surprising, this result still points to a Kaiso and MTG16 complex 
binding the ATF-7 promoter but suggests that either the proteins behave as activators, 
something Kaiso is capable of  on this promoter, or that they are displacing another 
repressor complex that is a more potent repressor than the Kaiso-MTG16 complex. 
Collectively, these findings suggest a direct binding relationship between Kaiso and 
MTG16 with a shared impact in transcriptional control and tumorigenesis.  
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Figure 6.3 Kaiso shares repression targets with MTG16 and MTGR1.  A.  The UCSC genome browser 
ChIP-seq data was used to identify Kaiso targets.  Chip-seq data developed by Soler et al., 2011 
(426) was used to identify MTG16 and MTGR1 targets that overlapped with Kaiso binding sites. B. 
ATF-2, MAPK14, and C. ATF-7 mRNA expression upon overexpression of MTG16. The graph shows 
the fold-change (ΔΔCt) of mRNA compared to an empty vector control. Error bars represent the 
standard error for three replicate experiments performed in triplicate. *P<0.05, ***P<0.001. 
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MTG family members repress the Kaiso binding site promoter. 
 In mammalian cells, Kaiso recognizes both the consensus sequence TCCTGCNA 
(Kaiso binding site, KBS) and methylated CpG dinucleotides (231, 232). We used a  
luciferase-based Kaiso binding site reporter (4xKBS), as well as a mutant form that 
contains a CA transversion that abolishes both Kaiso binding and Kaiso-mediated 
repression (4xKBSMT) (231) to explore cooperation between Kaiso and MTG family 
proteins in transcriptional repression (Fig. 6.4A). We determined that MTGs were capable 
of repressing the 4xKBS reporter construct (Fig. 6.4B) and that this repression was specific 
as it was disrupted when the 4xKBSMT reporter was used in lieu of the 4xKBS reporter 
(Fig. 3C). Additionally, Kaiso knockdown (Fig. 6.4D, left) resulted i a dose-dependent loss 
of 4xKBS repression by MTG16 (Fig. 6.4D, right). Finally, knockdown of both MTG16 and 
Kaiso resulted in decreased repression of the KBS in the HCT 116 cell line that expresses 
high levels of both proteins (Fig. 6.5A & B, P=0.008). 
 Because we determined MTG family members are able to repress the sequence-
specific Kaiso target, we also wanted to determine whether MTGs were able to repress 
the second common Kaiso target, methyl-CpG. We therefore assessed the ability of MTG 
family members to repress a methylated reporter plasmid (232). In this case, we saw little 
repression of the methylated reporter by MTG family members until very high levels of 
MTG8 or MTG16 were used (Fig. 6.4E). This indicates that Kaiso dependent MTG 
repression specificity is directed towards genes containing the KBS as opposed to methyl-
CpG, and suggests a model where MTG16 cooperates with Kaiso in the repression of KBS 
targets, but not to methylated CpG targets (Fig. 6.4F). 
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Figure 6.4 MTG family members repress the Kaiso binding site reporter (4xKBS). A. Composition of 
the KBS reporter constructs. The 4xKBS reporter contains four consensus Kaiso binding site 
sequences followed by a luciferase gene. The mutant reporter (4xKBSMT) contains a CA 
transversion in the Kaiso binding sites which abolishes Kaiso binding. B. 4xKBS artificial promoter 
assays in HCT116 cells upon titration of MTG family members (0ng, 200ng, 400ng, 800ng). The 
graph shows the fold-change in luciferase activity relative to the control reporter, pGL4-TK hRLUC, 
after transfection of expression plasmids encoding MTG family members, MTG8, MTG16, and 
MTGR1. The error bars represent the standard error of the mean for 3 replicate experiments 
performed in triplicate. C. 4xKBS and 4xKBSMT artificial promoter assays in HCT116 cells after 
transfection of 500ng of the indicated MTG family member. The error bars represent the standard 
error of the mean for 4 replicate experiments performed in triplicate. D. Kaiso knockdown by two 
independent Kaiso shRNA constructs compared to a scrambled shRNA control (left). 4xKBS 
artificial promoter assay after knockdown of Kaiso and the transfection of 500ng of MTG16 (right). 
E. Methylated pSV40 artificial promoter assay in Mbd2-/- cells upon titration of MTG family 
members (0ng, 200ng, 400ng, 800ng). The graph shows the fold-change in luciferase activity 
relative to the control reporter, pGL4-TK hRLUC, after transfection of expression plasmids encoding 
MTG family members, MTG8, MTG16, and MTGR1. The error bars represent the standard error of 
the mean for 3 replicate experiments performed in triplicate. F. Model for Kaiso repression of Kaiso 
binding site (KBS) and methyl CpGs (mCpG) on target promoters. *P<0.05, **P<0.01, ***P<0.001. 
Figure 6.5 Repression of 4xKBS, HMAT, and MMP7 is decreased with knockdown of MTG16 and 
Kaiso in HCT116 cells. A. Kaiso or MTG16 mRNA expression after knockdown of Kaiso (sh-Kaiso) 
and MTG16 (si-MTG16) in HCT116 cells. The graph shows the fold-change (ΔΔCt) of mRNA 
compared to a scrambled control (sh-scrambled and si-scrambled). B. 4xKBS and C. HMAT reporter 
activity after knockdown of both Kaiso and MTG16. D. MMP7 expression in response to knockdown 
of Kaiso and MTG16. Error bars represent the standard error for three replicate experiments 
performed in triplicate. **P<0.01, ***P<0.001. 
A B 
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MTG family members repress the MMP7 promoter. 
 MMP7 is an established tumor promoter in colon, prostate, pancreatic, and lung 
cancers (242, 243, 427, 428). It also contributes to tumor progression and metastasis 
(429). Interestingly, two Kaiso binding sites are present in the human MMP7 promoter 
(Fig. 6.6A) that enable Kaiso-mediated repression of MMP7 expression (231). Our data 
suggests that MTGs may cooperate with Kaiso to repress Kaiso targets. Therefore, we 
hypothesized that MTGs would repress the MMP7 promoter. Titration of each MTG family 
member with the full-length human MMP7 reporter (HMAT-2.3, (231)) in the Kaiso-
expressing HCT116 cells resulted in dose-dependent repression (Fig. 6.6B). This 
repression was lost when an MTG16 construct lacking the NHR1 domain (loss of affinity 
mutant) was used, further supporting an interaction with Kaiso that is dependent on the 
NHR1 domain of MTG16 (Fig. 6.6C). Also, Kaiso knockdown resulted in loss of HMAT 
repression, suggesting that Kaiso represses MMP7 via MTG16 recruitment. Moreover, 
knockdown of both MTG16 and Kaiso in the HCT116 cell line resulted in decreased 
repression of the HMAT reporter (Fig. 6.5A & C, P<0.0001). Taken together, these data 
demonstrate that MTG16 and Kaiso repress MMP7 promoter activity. 
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Figure 6.6 MTG family members depend on Kaiso to repress the human MMP7 promoter. A. The 
composition of the full-length MMP7 reporter (HMAT-2.3). The HMAT-2.3 reporter contains two 
Kaiso and two TCF binding sites followed by a luciferase gene. B. HMAT-2.3 artificial promoter 
assays in HCT116 cells upon titration of MTG family members (0ng, 200ng, 400ng, 800ng). The 
graph shows the fold-change in luciferase activity relative to the control reporter, pGL4-TK hRLUC, 
after transfection of expression plasmids encoding MTG family members, MTG8, MTG16, and 
MTGR1. The error bars represent the standard error of the mean for 3 replicate experiments 
performed in triplicate.  C. HMAT-2.3 promoter assay utilizing MTG16 deletion constructs in which 
the indicated nervy homology region is removed. Error bars represent the standard deviation of 
triplicate samples. D. HMAT-2.3 artificial promoter assay after knockdown of Kaiso and the 
transfection of 500ng of MTG16. Error bars represent the standard deviation of triplicate samples. 
*P<0.05, ***P<0.001. 
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Figure 6.7 MTG family members repress endogenous MMP7. A. Primers for the ChIP assay flank 
the -537 Kaiso binding site in the MMP7 promoter. B. ChIP assay performed in HCT116 cells using 
both polyclonal (333, pMTG) and monoclonal (2D1, mMTG16) antibodies for MTG16. The graph 
shows fold-enrichment compared to IgG control. C. Knockdown of Kaiso by three independent 
shRNA constructs compared to a scrambled sh-RNA control. D. Chromatin immunoprecipitation 
assay in HCT116 cells. The graph shows fold enrichment of the -537 Kaiso binding site after 
precipitation with the MTG16 2D1 antibody compared to the IgG control. E. MMP7 mRNA 
expression after transfection of the indicated MTG family member in HT29 cells. The graph shows 
the fold-change (ΔΔCt) of MMP7 mRNA compared to an empty control. Error bars represent the 
standard error for three replicate experiments performed in triplicate (top). Representative 
immunoblotting of MMP7 in HT29 cells after transfection of indicated family members and 
treatment with Brefeldin-A. Protein quantification was performed with the Odyssey Western blot 
developer system. **P<0.01, ***P<0.001. 
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Figure 6.8 MTG16 does not repress the MMP7 reporter via TCF binding sites. A. The composition 
of the truncated MMP7 reporter (HMAT-296) and TCF mutant reporters (HMAT-194, HMAT-109, 
and HMAT-2x). B. HMAT artificial promoter assays in HCT116 cells. HCT116 cells were transfected 
with either 500ng of MTG16 or 500ng of Empty vector as a control. The graph shows the fold-
change in luciferase activity relative to the standard pGL4-TK hRLUC after transfection of 
expression plasmids.  The error bars represent the standard error of four replicate experiments 
performed in triplicate. *P<0.05, **P<0.01. 
 
The human MMP7 promoter also contains two TCF binding sites (Fig. 6.7A). MTGs also 
associate with TCF4 and repress TCF4 targets (209). Thus it was possible that in addition 
A 
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to repressing via an interaction with Kaiso at the KBS, MTG16 could be recruited by TCF4 
to repress MMP7 via TCF response elements. To address this issue of MTG16 specificity 
for Kaiso or TCF binding sites, we performed repression assays using heterologous 
transcriptional reporters composed of minimal MMP7 promoter elements where TCF 
binding sites were mutated individually or in combination (430) (Fig. 6.8A). Mutation of 
either or both of these sites had no effect on MTG16-mediated repression of MMP7 (Fig. 
6.8B). These data indicate that MTG16-dependent MMP7 repression occurs independent 
of TCF binding sites. In concert, these results suggest that MTG16 recruitment by Kaiso to 
the MMP7 KBS is responsible for MTG16:Kaiso mediated MMP7 repression. 
Both MTG16 and Kaiso have been implicated in breast, colon, and lung carcinoma 
(227-229, 247, 431, 432). Each can regulate Wnt signaling (209, 418), a pathway strongly 
associated with colon cancer development. Recently at least five MTG mutations have 
been identified in colon or breast cancer (228, 229), all are non-synonymous and 
predicted to influence MTG function. We therefore wanted to determine whether these 
mutations could influence Kaiso dependent repression of the 4xKBS and HMAT reporters. 
Overexpression of each MTG mutant resulted in no change in repression of either the 
4xKBS (Fig. 6.9A) or HMAT reporters (Fig. 6.9B), indicating that these mutations do not 
influence MTG dependent Kaiso repression.  
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Figure 6.9 Established MTG8 and MTG16 colorectal cancer mutations do not alter repression of 
Kaiso target promoters. A. 4xKBS artificial promoter assays in HCT116 cells. The graph shows the 
fold-change in luciferase activity relative to the standard pGL4-TK hRLUC after transfection of 
expression plasmids encoding the indicated MTG8 mutant constructs. B. HMAT-2.3 artificial 
promoter assays in HCT116 cells. The graph shows the fold-change in luciferase activity relative to 
the standard pGL4-TK hRLUC after transfection of expression plasmids encoding the indicated 
MTG8 mutant constructs. The error bars represent the standard error of three replicate 
experiments performed in triplicate. *P<0.05, **P<0.01. 
 
MTG family members repress endogenous MMP7 expression. 
 Based upon the transcriptional control data described above, we predicted that 
MTG16 should occupy the promoters of Kaiso-regulated genes. To address this 
hypothesis, we used ChIP to probe for MTG16 occupancy of the -537 Kaiso binding site in 
the endogenous MMP7 promoter (Fig.7A). We observed 13.2 or 14.7 fold enrichment 
over IgG when either a polyclonal (333, pMTG) or monoclonal MTG16 (2D1, mMTG16) 
antibody was used (P<0.001, Fig. 6.7B). Importantly, Kaiso knockdown abrogated MTG16 
binding to the MMP7 promoter, showing that Kaiso is essential for MTG16 recruitment 
(Fig. 6.7C, D).  
A B 
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 We next determined whether MTG16 was capable of regulating endogenous 
MMP7 expression by analyzing MMP7 mRNA and protein levels in the context of enforced 
expression of MTG family members. For this experiment, the colon cancer cell line HT29 
was utilized. Overexpression of MTG8, MTG16, and MTGR1 resulted in decreased MMP7 
both at the RNA and protein levels when compared to a vector control (fold-change mRNA 
expression: 0.60 S.E. 0.05 (MTG8), 0.59 S.E. 0.07 (MTG16), 0.71 S.E. 0.09 (MTGR1), P<0.01 
for each, Fig. 6.7E). Considering that HT29 transfection efficiency in these experiments 
was 44.85% ± 6.553, the data likely under-represent the impact of MTGs on MMP7 
expression. Moreover, knockdown of Kaiso and MTG16 in HCT116 cells resulted in 
derepression of endogenous MMP7 expression (Fig. 6.6D, P=0.04). These findings suggest 
that MTGs repress endogenous MMP7 expression via interaction with Kaiso. 
 
MMP7 increased expression is associated with decoupling of the MTG16 and Kaiso 
regulatory axis. 
 We next sought to compare the expression levels of Kaiso, MMP7 and MTG16 in 
patients with colorectal cancer compared with normal adjacent colon tissues and 
adenomas. We observed a significant up-regulation of MMP7 and Kaiso (Fig. 6.10A, B, 
P<0.001 for all stages) while MTG16 is significantly down-regulated for all stages of cancer 
compared with normal adjacent colon samples (Fig. 6.10C, P<0.001). Given the in vitro 
data demonstrating MTG16 played a key role and was required for maximal repression of 
Kaiso-regulated KBS-containing promoters, we reasoned that Kaiso and MTG16 
expression would be inversely related on a per sample basis. We did in fact note a highly 
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significant inverse correlation (Fig. 6.10D, Rho=-0.29, P<0.001). The data presented in this 
paper suggests a model by which both Kaiso and MTG16 are necessary for MMP7  
 
Figure 6.10 MTG16 and Kaiso are negatively correlated in human CRC patient samples and MMP7 
is up-regulated. A) Kaiso expression is significantly up-regulated in adenomas and colorectal 
cancer patients compared with normal adjacent colon tissues (P<0.001, for all comparisons). B) 
MMP7 expression is significantly up-regulated in adenoma and colorectal cancer patients for each 
stage (P<0.001 for all comparisons). C) MTG16 expression is significantly down-regulated in 
colorectal cancers versus normal adjacent samples (P<0.001; *for all comparisons except 
adenoma). Wilcoxon Rank Sum test was used to determine significance for A-C. D) Normalized 
expression of both MTG16 and Kaiso probes (see Methods) were compared in human colorectal 
cancer patients. The graph demonstrates a significant inverse correlation for MTG16 versus Kaiso 
(rho = -0.29, P<0.001, inverse correlation depicted by red line, Spearman correlation coefficient). 
 
repression. This model likely applies to other Kaiso:MTG16 regulated KBS containing 
promoters.  
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Discussion 
Kaiso and MTG16 share several functional similarities, including their abilities to 
repress Wnt signaling, bind co-repressors, and impact processes that influence 
tumorigenesis. Because of these similarities, we postulated that Kaiso and MTGs could 
form complexes and that Kaiso could target MTG repression functions to specific 
promoters. In testing this hypothesis we found that Kaiso and MTG16 interact and that 
this depends on the homologous zinc fingers in Kaiso and the NHR1 domain in MTG16. 
Furthermore, when MTG family members are overexpressed, they enhance repression of 
a KBS reporter. Studies with both heterologous KBS reporters and Kaiso knockdown 
showed that MTG-dependent transcriptional repression on Kaiso targets, such as the 
MMP7 promoter, is Kaiso-dependent. ChIP experiments revealed that the Kaiso-MTG 
interaction occurs endogenously at the KBS in the MMP7 promoter, and reduced MMP7 
expression at both the RNA and protein level show the interaction to be functionally 
significant.  Thus, we have linked two families of transcriptional repressors, both 
previously implicated in oncogenesis. Understanding the nature of this relationship is 
important in understanding transcriptional regulation by these complexes in normal 
biology and how this is perturbed in tumorigenesis.  
 Kaiso is a dual-specificity repressor that can recognize both a consensus sequence 
(KBS, TCCTGCNA) and methyl-CpG dinucleotides (231). Interestingly, though MTG16 is 
important for repression of KBS reporters, it does not repress a methylated reporter, 
suggesting that the Kaiso-MTG16 interaction is specific for promoters that contain the 
Kaiso binding site. Kaiso has been identified as the factor that recruits the N-CoR complex 
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to CpG-rich sequences in a methylation-dependent manner (235), our study 
demonstrates that there is a converse activity with interaction with MTG16, as it is a Kaiso 
cofactor that is dependent solely on Kaiso binding to the canonical KBS. This suggests that 
Kaiso might differentiate between target repression based on the availability of cofactors, 
making these cofactors key in understanding the regulation of Kaiso targets, be they 
methylated or the canonical consensus sequence. We think that this is biologically 
relevant as we noted a strong inverse correlation between MTG16 and Kaiso levels in a 
large human CRC dataset. This could have important implications for the regulation of 
Kaiso:MTG16 targets and may influence the bimodal effect of Kaiso on carcinogenesis 
(247, 251, 418, 432). 
 This interaction is also of great importance as our data directly implicates 
MTG16:Kaiso complexes in the regulation of MMP7 expression. MMP7 plays a significant 
role in all stages of tumor progression and is a key player in a wide variety of cancers 
including, but not limited to, colon, prostate, lung and ovarian (427, 433-436). Indeed, 
metalloproteinases are among the most common targets for anti-cancer drug 
development (437) so understanding their regulation will give insight into mechanisms by 
which their expression might be altered. We have determined that MTG16 binds Kaiso at 
the MMP7 promoter and recruits transcriptional corepressors to attenuate MMP7 
expression. Furthermore, both MTG16 and Kaiso demonstrate coordinate patterns of 
expression when compared with MMP7 in human CRC samples vs. normal adjacent colon 
samples. Decreased repression upon loss of either protein within this complex could 
contribute to tumorigenesis.  
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 In order to better understand the scope of the Kaiso-MTG interaction, we analyzed 
public-domain ChIP-seq datasets (UCSC Genome Browser, (426)) to determine the 
overlap of targets bound by Kaiso and the MTG family members MTG16 and MTGR1. 
Several targets relevant to cancer pathogenesis were revealed using this methodology. 
For example, Kaiso and MTG16 bind the Activating Transcription Factor (ATF)-2 promoter, 
while Kaiso and MTGR1 bind the promoter for ATF7. The ATF family is composed of 
transcription factors that are involved in cellular stress response (438). Aside from being 
activated by the MAPK pathway in response to stress, ATFs 2 and 7 are also involved in 
oncogenesis, as they are able to dimerize with c-Jun to influence Jun-dependent survival, 
apoptosis, and cell cycle progression (439, 440). C-Jun pathway regulation is also seen 
with a third target of MTG-Kaiso binding, MAPK14. Mitogen-activated protein kinase 
(MAPK) p38α (MAPK14) suppresses cellular proliferation through inhibition of the JNK-c-
Jun pathway (441) and plays an essential role in stem and progenitor cell proliferation 
and differentiation in the lung (442). Another MAPK family member, MAP3K7, was also 
identified in this screen. MAP3K7 plays an important role in the modulation of TGF-β 
signaling (443), a pathway highly related to oncogenesis. Importantly, overexpression of 
MTG16 in the HT29 cell line resulted in repression of both ATF2 and MAPK14, consistent 
with MTG16 functioning as a repressor, but also overexpression of the target ATF7, 
suggesting that this target has more complex transcriptional regulation. 
In summary, we identified an association between Kaiso and MTG family 
members. Because Kaiso is the prototypic ZBTB family member, we focused on 
understanding the contribution of MTG16 to Kaiso mediated repression. We determined 
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that the Kaiso-MTG16 complex specifically binds to the KBS and represses the Kaiso 
target, MMP7. We examined a large multi-stage CRC expression array dataset and 
discovered an inverse relationship between Kaiso and MTG16 expression and consistently 
elevated MMP7 expression at all stages of tumorigenesis supporting the hypothesis that 
loss of either Kaiso or MTG16 de-regulates MMP7 expression. Analysis of publicly 
available ChIP-seq datasets showed that MTG family members bind Kaiso-targeted 
promoters over 70% of the time, implicating this interaction in the regulation of over 100 
genes, many of which are involved in cell cycle control and survival programs. 
In conclusion, we report that Kaiso and MTGs interact in inhibitory complexes and 
identify a subset of target genes which are important in oncogenesis. Additional targets 
identified in the ChIP-seq screen include stress and oxidative damage response proteins 
potentially important in inflammatory carcinogenesis. Future experiments should be 
directed towards understanding the role of Kaiso and MTG16 in sporadic and 
inflammatory colon carcinogenesis. 
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CHAPTER VII 
 
KAISO IS REQUIRED FOR MTG16-DEPENDENT EFFECTS ON COLITIS-ASSOCIATED 
CARCINOMA 
 
Introduction 
Kaiso is a p120 catenin binding partner that represses DNA methylation-
dependent targets including several tumor suppressor genes including CDKN2A, HIC1, and 
MGMT (247). As such, Kaiso dysfunction might play a key role in tumorigenesis. In fact, 
Kaiso knockout mice crossed with the tumor-susceptible ApcMin/+ mouse model show 
resistance to intestinal tumorigenesis (251). Moreover, Kaiso represses several genes 
within the canonical WNT signaling pathway including the B-catenin/TCF target gene 
matrix metalloproteinase-7 (Mmp7) (241, 418) which has been implicated in stimulation 
of Wnt signaling as well as tumor progression in several solid malignancies (244, 406, 410, 
428, 429).  
Transcriptional co-repressors recruit other repressors, HDACs, and DNA binding 
transcription factors to repression complexes. The myeloid translocation genes are a 
three-member family of transcriptional corepressors that act as scaffolding proteins upon 
which other transcriptional corepressors, including mSin3a, N-CoR, SMRT, histone 
deacetylases (HDACs), and transcription factors assemble (178, 190). Kaiso is a myeloid 
translocation gene (MTG) family binding partner and the interaction occurs through the 
zinc finger domain of Kaiso and the NHR1 domain of MTG16. Target specificity is achieved 
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via Kaiso vectoring the complex to Kaiso Binding Site (KBS)-containing promoters. The 
functional relevance of the interaction is evident as loss of either protein leads to 
derepression of targets such as Mmp7 (444). MTG family members have been implicated 
in both hematologic and solid malignancies including leukemia and colon and breast 
cancers (227-229) and our lab has shown that MTGR1 is required for tumorigenesis and 
absence of MTG16 leads to increased tumorigenesis in a murine model of colitis-
associated carcinoma, implicating the MTGs in inflammation-driven tumorigenesis (269). 
The impact of Kaiso loss on inflammatory cancer has not yet been established. 
Because Kaiso and MTG16 form a repression complex and MTG16 loss greatly 
exacerbates injury and tumorigenesis in response to the AOM/DSS protocol, the purpose 
of this work was to determine whether Kaiso deficiency modified tumorigenesis and 
whether subsequent loss of MTG16 would modify the Kaiso-/- phenotype. Here, we 
determine that Kaiso deficiency does not lead to altered injury or tumorigenesis in 
response to the AOM/DSS inflammatory carcinogenesis protocol while Mtg16-/- mice, as 
expected, demonstrated increased injury and tumorigenesis in response to AOM/DSS. 
Perhaps most surprisingly, knockout of both MTG16 and Kaiso led to a similar phenotype 
as that seen in WT and Kaiso-/- mice, suggesting that Kaiso loss rescues the Mtg16-/- 
phenotype. Moreover, intratumoral proliferation and apoptosis indices support the 
alterations in tumorigenesis seen in each genotype and, consistent with a pro-
tumorigenic microenvironment, only Mtg16-/- tumors demonstrate increased pro-
tumorigenic M2 macrophages and increased chemokine and cytokine expression. This 
suggests that, though Kaiso and MTG16 share several targets, it is the transcriptional 
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targets that they do not share that distinguish their responses to the AOM/DSS protocol 
and that Kaiso targets are dominant to MTG16 targets where loss of Kaiso leads to rescue 
of the Mtg16-/- phenotype.  
 
Materials and Methods 
Murine inflammatory carcinogenesis protocol. 8-12 week old C57BL/6 wild type (WT) 
(n=14), Mtg16-/- (n=15), Kaiso-/- (n=14), or Kaiso-/-;Mtg16-/- (DKO, n=8) mice were injected 
with 10 mg/kg of azoxymethane (AOM, Sigma-Aldrich, St. Louis, MO, USA) 
intraperitoneally as described by Greten, et al. (265). Three days post-injection, the 
animals were started on the first of two cycles of 2% DSS ad libitum (see schematic in Fig. 
7.1A). Each cycle lasted 5 days and was followed by a 16-day recovery period. Weights 
were obtained throughout the treatment and recovery period and reported as the 
percentage of the original weight one day before DSS administration. In addition, stools 
were examined for consistency and the presence of blood during the treatment period: 
normal stools = 0 points, loose stool = 1 point, diarrhea = 2 points, presence of blood = 2 
points, and excessive blood = 4 points.  During the second cycle of recovery (day 29), 
colonoscopy (Karl Storz veterinary endoscopy, El Segundo, CA, USA) was performed to 
assess injury, tumor multiplicity, and tumor grade. Injury was evaluated based on the 
murine endoscopic index of colitis severity (MEICS) that includes thickening of the colon, 
changes in vasculature, presence of granularity, presence of exudate, and stool 
consistency (302, 358). Mice were subsequently sacrificed on day 40. Colons were 
removed, flushed with PBS, and opened longitudinally and tumor counts and diameter 
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were assessed using calipers. Sections of tumor and normal adjacent colon were collected 
and stored in RNAlater (Qiagen, Valencia, Santa Clarita, CA, USA) and a section of distal 
colon was collected and flash frozen in liquid nitrogen for protein analysis. The remainder 
of the colon was “Swiss Rolled”, formalin fixed overnight, and sectioned for histological 
analysis. All in vivo procedures were carried out in accordance with protocols approved 
by the Vanderbilt Institutional Animal Care and Use Committee. 
Immunohistochemistry and immunofluorescence staining. Five-micrometer sections of 
paraffin-embedded colons were cut and haematoxylin and eosin (H&E) staining was 
performed by the Vanderbilt University Translational Pathology Shared Resource. Cut 
sections were dewaxed, hydrated, and quenched of endogenous peroxidase activity with 
0.03% hydrogen peroxide in methanol. Antigen retrieval was conducted using Antigen 
Unmasking Reagent (Vector Laboratories, Inc., Burlingame, CA, USA) according to 
manufacturer’s instructions. After blocking, primary antibody was added [α-Ki67 
(NeoMarkers, Fremont, CA, USA), 1:1,000; α-arginase I (ARG1, Santa Cruz, Dallas, TX, 
USA), 1:500; α-IL-1β (R&D Systems, Minneapolis, MN, USA), 1:40; α-F4/80 (AbD Serotec, 
Raleigh, NC, USA) 1:1000] and incubated overnight at 4°C. Isotype-matched antibodies 
were included as negative controls. Identification of intratumoral apoptotic cells was 
conducted using the ApopTag Plus Peroxidase In Situ Apoptosis Kit (Chemicon, Temecula, 
CA, USA) according to the manufacturer's protocol. Control slides were obtained by 
omitting the terminal transferase (TnT) enzyme. For immunofluorescence staining of 
proliferation and macrophages, slides were counterstained and mounted with ProLong 
Gold antifade including 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen, Grand Island, 
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NY, USA). Apoptosis, proliferation, and M1 and M2 macrophage indices were generated 
by counting either the number of positive cells per high-powered field (HPF; 40x 
objective) within each tumor or the number of positive cells per crypt in 20 crypts per 
mouse by a blinded observer. The average score was then calculated for each Swiss-rolled 
colon. 
Wnt pathway analysis. Flash-frozen sections of colon (n=6 for each genotype) were lysed 
in RIPA buffer including 1x protease inhibitor cocktail (Sigma-Aldrich) using a rotor 
homogenizer (Janke & Kunkel IKA-Labortechnik Ultra-Turrax T25). Protein quantification 
was performed using a Pierce BCA Protein Assay Kit (Thermo, Hudson, NH, USA) according 
to manufacturer’s instructions. Samples were treated with loading buffer, boiled, and 40 
μg was run on an SDS-PAGE gel for western blot detection using the Odyssey western blot 
system (LI-COR, Lincoln, NE, USA). A Wnt/β-catenin Activated Targets Antibody Sampler 
Kit (Cell Signaling Technology, Boston, MA, USA) was used to probe for Wnt targets 
according to the manufacturer’s protocol with the exception of using Odyssey-specific 
secondary antibodies for detection. Bands were quantified using Odyssey software and 
normalized to β-actin.  
Cytokine array analysis. RNA from tumors of WT (n=4), Kaiso-/- (n=4), Mtg16-/- (n=4), and 
DKO (n=4) was isolated using the RNeasy Mini Kit (Qiagen). cDNA was synthesized using 
the iScript cDNA synthesis kit (Bio-rad, Hercules, CA, USA) and 1 μg of total RNA. 1 μl of 
the 20 μl cDNA produced through the iScript reaction was used as a template in each 
subsequent PCR reaction. SYBR green qRT-PCR was performed using mouse cytokine 
array libraries I and II from RealTimePrimers.com (Elkins Park, PA, USA) according to 
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manufacturer’s instructions. Individual cytokines were analyzed using the delta-delta Ct 
method and those showing significant differences can be seen in Supplementary Figure 
3. The networks were generated through the use of IPA (Ingenuity® Systems, 
www.ingenuity.com). 
Statistical methods. Statistical analysis comparing all four groups was performed utilizing 
Graphpad Prism and analysis with the one-way ANOVA and Newman-Keuls Multiple 
Comparison post-test. Differences in stool scores and percentage weight loss were 
determined using two-way ANOVA for repeated measurements over time. 
 
Results 
Kaiso is required for enhanced mucosal injury in Mtg16-/- mice after AOM/DSS treatment. 
 Mtg16-/- mice demonstrate increased mucosal injury in response to the AOM/DSS 
protocol resulting in increased weight loss, stool scores, and morbidity (McDonough et 
al., submitted). Because we have determined that Kaiso and MTG16 form a repression 
complex, we wanted to determine whether absence of Kaiso influenced AOM/DSS-
induced injury. We utilized 10mg/kg azoxymethane (AOM) in order to initiate DNA 
damage and treated mice with cyclical administration of 2% DSS for five days followed by 
16 days of recovery (Figure 7.1A). Absence of MTG16 resulted in exacerbated injury as 
evidenced by increased stool scores which take into account stool consistency and 
presence of frank blood (P<0.0001 2-way ANOVA, Figure 7.1B) as well as increased weight 
loss (P<0.0001 2-way ANOVA, Figure 7.1C), both of which were most prominent during 
the second cycle of DSS administration. In support of these clinical metrics, endoscopy  
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Figure 7.1 Kaiso knockout rescues the Mtg16-/- injury phenotype observed in response to the 
AOM/DSS protocol. A. Schematic of AOM/DSS inflammatory carcinogenesis protocol. B. Stool 
scores as determined using the scoring system described in the “materials and methods” section 
and C. percent weight change throughout the course of the AOM/DSS protocol. D. Endoscopic 
colitis scoring (MEICS scale) determined at day 29 of the AOM/DSS protocol. *P<0.05, **P<0.01. 
 
performed at day 29 demonstrated an increase in colitis severity as measured by the 
MEICS scoring system (302) (WT: 7.3±1.0, Mtg16-/-: 11.7±0.6, P<0.01, Figure 7.1D). Kaiso-
/- mice, however, did not show increased injury in response to the AOM/DSS protocol 
above that of WT mice (Kaiso-/-: 9.4±0.7). In fact, Kaiso-/-;Mtg16-/- double knockout (DKO) 
mice demonstrated injury equivalent to that seen in Kaiso-/- mice (MEICS DKO: 8.7±1.1, 
A 
B C 
D 
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Figure 7.1) indicating Kaiso was required for this Mtg16-null phenotype. Thus Mtg16-/- 
mice have worse injury after AOM/DSS treatment, which is Kaiso dependent. 
 
Knockout of Kaiso rescues Mtg16-/--dependent increases in tumorigenesis. 
We next evaluated for modified tumor burden in Mtg16-/-, Kaiso-/-, or DKO mice 
compared to WT mice in response to the AOM/DSS CAC protocol. Tumor development 
tracked very closely with severity of injury with Mtg16-/- mice displaying increased tumor 
number (9.9±0.8 tumors/mouse, P<0.001) compared to both the WT (5.4±0.8 
tumors/mouse) and Kaiso-/- (4.9±0.6 tumors/mouse) mice and the MTG16 effect on 
tumorigenesis was partially rescued by subsequent Kaiso knockout (7.5±1.1 
tumors/mouse, Figure 7.2A & B). Furthermore, consistent with an increase in injury 
extent, an increased number of Mtg16-/- tumors were identified in the more proximal 
region within the colon compared to those seen in the other three genotypes (Figure 
7.2C). These data suggest that, while MTG16 loss serves to promote tumorigenesis, at 
least in part through increasing mucosal injury and inflammation, Kaiso loss has no impact 
on inflammatory tumorigenesis by itself, but in fact, rescues the Mtg16-/- phenotype.  
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Figure 7.2 Knockout of Kaiso rescues the Mtg16-/- tumor phenotype. A. Number of tumors within 
each mouse of the indicated genotypes. B. Representative images of Swiss rolled colons and 
tumors from WT, Mtg16-/-, Kaiso-/-, and DKO mice (left 25x, right 100x) C. Graphical depictions of 
tumor locations within mice post-AOM/DSS protocol. Each dot represents the number of tumors 
found within the given region of the colon in a single mouse. ***P<0.001. 
 
Crypt and intratumoral proliferation and apoptosis rates support alterations in 
tumorigenesis between the genotypes. 
Alterations in proliferation and apoptosis, among other growth parameters, could 
contribute to differences in tumor size and number. As we identified increased tumor 
A B 
C 
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multiplicity in Mtg16-/- mice, we wanted to determine whether crypt or intratumoral 
proliferation or apoptosis indices were altered in these mice and if Kaiso absence reversed 
any of these parameters. Proliferation, as determined by Ki67 staining, was only increased 
in crypts of Mtg16-/- mice (1.2±0.2 Ki67+/crypt, P<0.01) compared to WT (0.7±0.02 
Ki67+/crypt), Kaiso-/- (0.6±0.07 Ki67+/crypt), and DKO mice (0.7±0.06 Ki67+/crypt, Figure 
7.3A). Intratumoral proliferation, on the other hand, was increased in both Mtg16-/- 
(34.0±3.4 Ki67+/tumor high-powered field (HPF)) and Kaiso-/- (25.0±4.3 Ki67+/tumor HPF) 
mice compared to WT mice (8.7±1.3 Ki67+/tumor HPF, Figure 7.3B). This increase in Kaiso-
/- intratumoral proliferation was balanced by a marked increase in apoptosis (WT: 
12.5±2.3, Kaiso-/-: 25.7±3.5, P<0.01, Mtg16-/-: 20.9±1.2, P<0.05, DKO: 15.3±2.7 
TUNEL+/tumor HPF, Figure 7.3D). Crypt apoptosis is increased in Mtg16-/- (0.8±0.04 
TUNEL+/crypt, P<0.05), Kaiso-/- (0.7±0.08 TUNEL+/crypt, P<0.05), and DKO (0.7±0.08 
TUNEL+/crypt, P<0.05) mice compared to WT mice (0.5±0.03 TUNEL+/crypt, Figure 7.3C), 
and thus does not likely contribute to alterations in tumorigenesis. Therefore, Mtg16-/- 
mice likely demonstrate increased tumorigenesis compared to the other genotypes due 
to an increase in proliferation and, though Kaiso-/- mice display increased proliferation as 
well, they do not display increased tumorigenesis because the effects of this proliferation 
are reversed by a concomitant increase in apoptosis. 
 
Wnt target expression is increased in tumors lacking Kaiso, MTG16, or both proteins. 
 Kaiso and MTG16 repress canonical Wnt signaling (209, 418) and our lab has 
shown that Kaiso recruits MTG16 to the Mmp7 promoter and represses its expression 
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(444). We, therefore, wanted to determine whether Kaiso and MTG16 contributed to Wnt 
repression in vivo. Tumor lysates from WT, Kaiso-/-, Mtg16-/-, and DKO mice were 
immunoblotted to determine expression of WNT pathway targets. As expected, absence 
of Kaiso, MTG16, or both resulted in an increase in Mmp7 protein levels (WT: 1.6±0.3, 
Kaiso-/-: 3.2±0.8, P<0.01, Mtg16-/-: 2.8±0.7, P<0.05, DKO: 2.4±0.3 relative fold change 
compared to WT and normalized to β-actin, P<0.05). Moreover, c-Myc was also increased 
with loss of these proteins in vivo (WT: 0.7±0.3, Kaiso-/-: 3.6±1.5, P<0.05, Mtg16-/-: 3.1±0.8, 
P<0.05, DKO: 2.5±0.5 relative fold change compared to WT and normalized to β-actin, 
P<0.05, Figure 7.4A & B). These data suggest that Kaiso and MTG16 cooperate to repress 
at least a component of Wnt signaling and the loss of either protein increases Mmp7 and 
c-Myc levels.  
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Figure 7.3 Proliferation is increased in tumors and crypts of Mtg16-/- mice and apoptosis is 
increased in tumors of Kaiso-/- mice.  α-Ki67 immunohistochemistry was conducted to identify 
actively proliferating cells and TUNEL staining was performed to identify apoptotic cells. A. Ki67+ 
cells/crypt determined as averaged positive cells/crypt within 20 crypts per mouse (left) and 
representative images shown for each genotype (right). B. Ki67+ cells/tumor high-powered field 
(HPF, 40x) averaged for each tumor (left) and representative images of each genotype (right) 
where red shows Ki67 staining and blue is DAPI nuclear stain. C. TUNEL+ cells/crypt determined as 
averaged positive cells/crypt within 20 crypts per mouse (left) and representative images shown 
for each genotype (right). D. TUNEL+ cells/tumor high-powered field (HPF, 40x) averaged for each 
tumor (left) and representative images of each genotype (right). *P<0.05, **P<0.01, ***P<0.001. 
 
 
Figure 7.4 Wnt targets are upregulated in Kaiso-/- and Mtg16-/- mice. A. Quantification of tumor 
protein expression of matrix metalloproteinase-7 (Mmp7) and c-Myc normalized to β-actin and B. 
representative western blots from three tumors within each genotype. *P<0.05, **P<0.01, 
***P<0.001. 
 
Kaiso is required for recruitment of tumor-promoting M2 macrophages in Mtg16-/- 
tumors. 
Macrophage polarization to the M2 phenotype is associated with a pro-
tumorigenic microenvironment (368). Because we have previously identified an 
A 
B 
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upregulation of M2 macrophages in Mtg16-/- tumors (McDonough et al., submitted), we 
wanted to determine whether Kaiso was required for this phenotype. Co-staining for 
F4/80 and Arginase 1 revealed a relative paucity of M2 macrophages in Kaiso-/- (17.0±3.1 
F4/80+/Arginase I+/tumor HPF) and DKO (13.3±1.2 F4/80+/Arginase I+/tumor HPF) tumors 
with their numbers equaling those of WT tumors (10.2±1.2 F4/80+/Arginase I+/tumor 
HPF), but a substantial increase in M2 macrophages in Mtg16-/- tumors (36.0±3.4 
F4/80+/Arginase I+/tumor HPF, P<0.001, Figure 7.5 A & B) suggesting that the presence of 
Kaiso is required for recruitment or polarization of M2 macrophages in Mtg16-/- mice.  
 
Figure 7.5 Pro-tumorigenic M2 macrophage infiltrate is increased in Mtg16-/- tumors. α-F4/80 
(green) and α-Arginase I (red) immunofluorescence was conducted to identify M2 macrophages. 
A. Intratumoral M2 macrophage index calculated from number of F4/80/Arginase I-double 
positive cells per high-powered field (HPF, 40x) and B. Representative images from tumors of each 
genotype. ***P<0.0001. 
 
 
 
A B 
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Absence of Kaiso rescues increased tumor-promoting microenvironment seen in Mtg16-/- 
tumors. 
Absence of MTG family members leads to an increase in pro-inflammatory and 
pro-tumorigenic cytokines in response to injury (269). We, therefore, performed cytokine 
and chemokine expression analysis from WT, Kaiso-/-, Mtg16-/-, and DKO colons after 
AOM/DSS treatment. Interestingly, we noted that the inflammatory microenvironment is  
 
Figure 7.6 TGF and TNF signaling is increased in Mtg16-/- tumors but not in WT, Kaiso-/-, or DKO 
tumors. A. Spider plot demonstrating alterations in cytokine and chemokine mRNA expression in 
WT (red), Kaiso-/- (green), Mtg16-/- (blue), and DKO (purple) tumors where each concentric circle 
represents the log fold change in expression for each gene. B. Quantification of tumor protein 
expression of phosphorylated Smad-2 normalized to total Smad-2 (left) and immunohistochemical 
staining of tumors from WT, Kaiso-/-, Mtg16-/-, and DKO mice for phosphorylated Smad-2. 
A 
B 
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very similar between WT and DKO mice (Figure 7.6A) with minimal alterations seen in 
chemokine and cytokine expression. Moreover, as has been demonstrated previously, the 
Mtg16-/- tumor inflammatory milieu is increased substantially compared to WT mice. 
Specifically, the fibroblast growth factor (FGF), transforming growth factor (TGF), bone 
morphogenic protein (BMP), and interleukin families are upregulated specifically in 
Mtg16-/- mice compared to WT and Kaiso-/- mice. Moreover, DKO mice show a partial 
rescue of the increased inflammation seen in Mtg16-/- mice (Figure 7.6A).  
Because Ingenuity Pathway Analysis identified components of the TGF-β pathway 
as increased specifically in Mtg16-/- tumors compared to tumors from the other 
genotypes, we wanted to test the expression of a downstream TGF-β target, 
phosphorylated Smad-2. Analysis of phospho-Smad-2 by both western blot and IHC 
corroborated an increase in TGF-β signaling in Mtg16-/- tumors (WT: 1.0±0.2, Kaiso-/-: 
1.9±0.4, Mtg16-/-: 5.8±1.3, P<0.01, DKO: 4.2±0.7, relative fold change compared to WT 
and normalized to total Smad-2, P<0.05, Figure 7.6B). Interestingly, based on 
immunohistochemical staining, this increase looks to be associated with the epithelial 
cells within the tumor and not the immune cells, suggesting that this is an epithelial cell-
autonomous effect. 
 
Discussion 
Kaiso is a transcriptional repressor that recognizes both methylated DNA and a 
sequence-specific consensus sequence by utilizing its three zinc fingers for high-affinity 
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DNA binding (445). Moreover, the interaction between MTG16 and Kaiso has been 
mapped to this domain. MTG16 is a transcriptional co-repressor and serves as a 
scaffolding protein upon which repressor complexes are nucleated (444). As such, MTG16 
and Kaiso are required for repression of several targets including Mmp7 (418, 444). A 
great deal has been learned about these proteins through the generation of Kaiso-/- and 
Mtg16-/- mice. Though Kaiso is reported to be a transcriptional repressor of S100A4, 
MTA2, Mmp7 (241, 446, 447), and an activator of Rapsyn (447) and is proposed to be a 
tumor modifier through its ability to repress tumor suppressor genes in a DNA 
methylation-dependent manner (247), Kaiso-/- mice demonstrate no overt phenotype. A 
phenotype is unmasked, though, when the mice are crossed with the ApcMin/+ sporadic 
tumor model and resistance to intestinal polyposis is demonstrated (251). MTG16 
knockout mice, on the other hand, display some very specific gut and stem cell 
phenotypes. Mtg16-/- mice demonstrate increased enterocyte proliferation at baseline 
and in response to DSS, Mtg16-/- mice demonstrate severe colitis (216), and display 
increased tumorigenesis when subjected to the AOM/DSS inflammatory tumorigenesis 
protocol (McDonough et al., submitted). Furthermore, Mtg16-/- mice also demonstrate 
hematopoietic stem cell defects (215). These data suggest that, though Kaiso and MTG16 
share a subset of targets, loss of repression of exclusive, non-overlapping, targets of each 
might also influence tumorigenesis. 
Because Kaiso and MTG16 cooperate in regulating Wnt signaling and have been 
implicated in intestinal tumorigenesis, we wanted to determine the requirement for Kaiso 
in the development of colitis-associated cancer in the absence of Mtg16. In this report, 
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we demonstrate that absence of Kaiso rescues the pro-injury and tumorigenesis 
phenotypes observed in Mtg16-/- mice after AOM/DSS treatment. This appears to occur 
via an increase in intratumoral apoptosis and a decrease in pro-inflammatory chemokines 
and cytokines that normally produce a pro-tumorigenic microenvironment. These data 
suggest that there is a subset of Kaiso targets that are normally repressed by Kaiso and 
block tumorigenesis an when Kaiso is lost these genes are activated, masking the Mtg16 
phenotype. 
Because MTG16 and Kaiso form a repression complex that binds the Mmp7 
promoter and impacts its expression (444) and because both proteins have been 
implicated in Wnt regulation (209, 241), we analyzed Wnt targets Mmp7 and c-Myc for 
expression changes in the tumors of WT, Kaiso-/-, Mtg16-/-, and DKO mice. Wnt signaling 
is especially important in colitis-associated carcinoma as Wnt pathway gene methylation 
is an early event seen in IBD and methylation of several Wnt targets are proposed to serve 
as biomarkers for IBD-associated neoplasia (448). Interestingly, though, we have 
demonstrated that Kaiso-dependent methylation binding was not dependent on Mtg16 
(444), suggesting differential methylation targets for the two proteins. As expected, we 
determined that knockout of either MTG16, Kaiso, or both resulted in an increase in 
Mmp7 and c-Myc expression in the tumors of the respective mice. Interestingly, these 
Wnt signaling changes do not contribute to the phenotypes seen in response to AOM and 
DSS administration as the expected increase in tumorigenesis with augmented Wnt 
signaling does not result in an increase in tumorigenesis in Kaiso-/- or DKO tumorigenesis 
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relative to WT mice. We therefore wanted to establish the role of injury and inflammation 
in the observed tumor phenotypes. 
In order to analyze the pathways and genes that contribute most significantly to 
the injury phenotypes seen in Kaiso-/-, Mtg16-/-, and DKO mice we performed chemokine 
and cytokine expression analysis. Several interesting targets were increased in Mtg16-/-
tumors but not tumors isolated from WT, Kaiso-/-, or DKO mice. Ingenuity pathway 
analysis of these genes identified several pathways modified specifically in Mtg16-/-
tumors. Amongst some of the most interesting targets were genes within a FGF, TGF, and 
IL18 signaling axis as well as genes within the BMP, TNF, and IFN signaling axis. Because 
of the complex role of TGF-β in tumor modulation as well as its central position in the 
signaling axis identified, we wanted to determine whether the canonical TGF-β target 
phosphorylated Smad-2 was altered in tumors of Mtg16-/- mice compared to WT, Kaiso-/-
, and DKO mice. Western blotting of tumors from WT, Kaiso-/-, Mtg16-/-, and DKO mice 
demonstrated that TGF-β signaling is significantly increased in Mtg16-/- mice and partially 
rescued in DKO tumors. Immunohistochemical staining corroborates Western blotting 
and suggests that increased TGF-β signaling is specific for the epithelial compartments of 
Mtg16-/- tumors. While TGF-β signaling has recently been implicated in tumor 
suppression, there are instances in which this pathway can contribute to tumorigenesis, 
especially in the context of severe inflammation as is seen in colitis-associated 
tumorigenesis. TGF-β is a key immunosuppressor and tumors often produce high levels 
in order to evade immune surveillance (449). TGF-β released by Mtg16-/- tumors, coupled 
with increased M2 macrophage infiltrate, may enable tumors to survive despite massive 
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inflammatory cytokine expression while also allowing for the pro-tumorigenic properties 
of that inflammation to contribute to tumorigenesis. 
Kaiso and MTG16 interact within a repression complex and share a wide variety 
of targets, but they also target a separate set of genes. This is made clear by the fact that 
Mtg16-/- and Kaiso-/- mice display very different baseline phenotypes and, as reported 
here, demonstrate very different responses to the AOM/DSS initiation-promotion model. 
Moreover, knockout of both proteins leads to rescue of the increased tumorigenesis 
phenotype seen in Mtg16-/- mice. These data suggest that Kaiso targets act downstream 
or are dominant to MTG16 targets in this model system. This report is the first to establish 
the Kaiso-/- response to the AOM/DSS inflammatory carcinogenesis protocol and shows 
that Kaiso deficiency can rescue the Mtg16-/- phenotype.  
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CHAPTER VIII 
 
SUMMARY, CONCLUSIONS, AND IMPLICATIONS 
 
Selenium as a potential therapeutic target in colitis-associated carcinoma 
 Amongst important considerations regarding the beneficial supplementation of Se 
is baseline Se status. Patients presenting with optimal Se levels, 124 ng/ml Se, are unlikely 
to benefit from Se supplementation. In fact, supranutritional Se levels can be detrimental. 
Importantly, patients with IBD demonstrate Se deficiency as measured by both plasma Se 
and Sepp1 levels. While healthy controls have plasma Se levels of 0.84 ± 0.13 mmol/L, 
patients with UC display Se levels of 0.63 ± 0.25 mmol/L and patients with CD have levels 
of 0.69 ± 0.25 mmol/L (283). Furthermore, the expression of Sepp1 in healthy controls is 
3.4 ± 0.8 µg/ml while expression in patients with CD is 1.8 ± 0.5 µg/ml, a decrease of 53% 
in the most accurate determinant of Se status (274). This suggests that patients with IBD 
are Se deficient to an extent where Se supplementation would be beneficial should Se 
contribute to protection from inflammation, oxidative injury, and tumorigenesis in 
patients with IBD. It is for this reason that we tested the impact of dietary Se modulation 
as well as plasma selenoprotein loss in the development of colitis-associated carcinoma. 
We determine that Se and selenoproteins are protective against injury and tumor 
development in our model system suggesting that Se supplementation would be 
beneficial in patients with IBD that demonstrate low Se levels.  
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Selenium supplementation in reduction of inflammatory injury and cancer risk resulting 
from IBD. 
 We have shown that Se deficiency leads to increased morbidity, weight loss, stool 
scores, and colonic injury as well as increased DNA damage, likely resulting from increased 
oxidative stress, in response to DSS-induced injury compared to mice fed a Se-sufficient 
diet. This suggests that Se is protective against oxidative stress and inflammation. 
Moreover, it indicates that patients with IBD concomitant with low Se levels might have 
more severe colitis. Ultimately, the question that was posed was whether this increased 
injury, inflammation, and oxidative stress led to increased tumorigenesis. In response to 
the AOM/DSS protocol, we observed increased tumor number and progression to high-
grade dysplasia. Taken together, these data indicate that Se supplementation could 
benefit patients with risk of CAC and Se-low status and, importantly, this supplementation 
might be able to not only decrease IBD disease severity, but also decrease risk of cancer. 
It is most likely through impact on selenoprotein expression that Se protects against 
inflammation and tumorigenesis, so we sought to determine the impact of loss of the 
plasma selenoproteins on development of CAC. 
 
Selenoproteins in colitis-associated carcinoma 
 Sepp1 expression is decreased as much as 50% in IBD compared to healthy 
controls (274). We note that Sepp1 haploinsufficiency leads to a dramatic increase in 
tumorigenesis indicating that Se alterations already seen in patients with IBD could be 
actively contributing to CAC through the decreased expression of a single selenoprotein. 
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As we also note that Gpx3 loss leads to increased tumorigenesis and there is strong 
evidence to indicate that other selenoproteins contribute to tumor promotion, 
selenoprotein expression alterations could be significant contributors to CAC. 
Selenoproteins likely protect from tumorigenesis through protection from DNA damage, 
reduction of oxidative stress, and modulation of signaling pathways such as the Wnt 
pathway to which Sepp1 deficiency contributes significantly. A more detailed 
understanding of the impact of other selenoproteins on CAC or other cancers in which Se 
deficiency is commonplace would greatly benefit the design and development of 
intervention trials. 
 Contrary to expectations, complete Sepp1 loss leads to decreased tumor burden 
despite increased DNA damage and inflammatory injury. Because AOM-only experiments 
demonstrate that Sepp1 loss leads to increased ACF formation and DSS as a single 
modality leads to increased injury in Sepp1-/- mice, we predict that the decreased 
tumorigenesis observed in Sepp1-/- mice is the result of increased clearance of initiated 
epithelial cells. This indicates to us that complete Sepp1 loss is not necessarily detrimental 
to tumorigenesis, but instead overwhelms the antioxidant system making cell survival 
problematic in response to stress. We predict that, if there was a condition in humans in 
which Sepp1 was completely lost, the effects on cell survival in response to stress would 
be catastrophic. As decreased, but not completely lost, Sepp1 expression is observed in 
people with IBD and genetic variants, the Sepp1+/- phenotype is the more applicable 
model in this situation and best demonstrates the impact of Sepp1 loss on IBD and CAC.  
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 Finally, we have noted an increase in Wnt signaling in mice lacking Sepp1 and a 
dependence upon Wnt signaling for the increased “stemness” that is seen in Sepp1-/- 
enteroids. This suggests that the Wnt pathway, a signaling pathway that is commonly 
upregulated in CRC and CAC, plays an integral role in the pro-tumorigenic phenotype in 
response to Sepp1 loss. It is possible that patients with SNPs in the promoter regions of 
SEPP1 may not benefit from Se supplementation due to inability to promote transcription 
despite an influx of Se. In these cases, disruption of the signaling pathway that is activated 
might be beneficial. Unfortunately, until recently, the Wnt pathway has been a very 
difficult anti-cancer target. Pan-Wnt inhibitors inhibit both canonical and non-canonical 
Wnt signaling leading to far-reaching and detrimental non-specific effects. Even targeting 
some of the most downstream processes in Wnt signaling, such as inhibiting β-catenin, 
impact the binding of β-catenin to α-catenin and E-cadherin, disrupting cell adhesion 
(274). Notably, Gonsalves et al. have developed inhibitors of the β-catenin-TCF4 
interaction that display minimal to no impact on non-canonical Wnt signaling or the 
Hedgehog, JAK/STAT, or Notch signaling pathways (450). Depending on the feasibility of 
use of these inhibitors on humans, they might preferentially benefit patients with IBD and 
SEPP1 SNPs. 
 
The impact of Mtgr1 on gut homeostasis and its misregulation in colitis-associated 
carcinoma 
 We have observed that Mtgr1 is expressed in the crypt base and overexpressed in 
the tumors of mice subjected to the AOM/DSS protocol compared to “normal” adjacent 
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tissue. Moreover, we note an increase in MTGR1 expression in CRC samples compared to 
normal controls indicating that Mtgr1 expression might be tumor supportive. 
Interestingly, Mtgr1-/- mice are protected from inflammatory tumorigenesis, due at least 
in part to a significant increase in colonic apoptosis. This increase in cellular death is likely 
due to severe epithelial injury and inflammation typified by increased CD3+ and natural 
killer T cells as well as macrophages. These phenotypes are dependent on epithelial injury 
as there is no difference in ACF when animals were treated with AOM as a single modality 
and the effect is not hematopoietic cell-autonomous because bone marrow 
transplantation does not impact the phenotype. Similar to results seen in Sepp1-/- mice, 
we predict that Mtgr1 is required for the survival of initiated epithelial cells in response 
to inflammation. Contrary to what is seen with complete loss of Sepp1, Mtgr1 expression 
is increased in tumors of mice subjected to the AOM/DSS protocol as well as in human 
CRC samples. This suggests that, while at its core loss of Sepp1 expression is tumor-
promoting, loss of Mtgr1 is tumor-suppressing. Thus, disruption of Mtgr1 skews the 
inflammatory microenvironment to the extent that anti-tumorigenic inflammatory cell 
recruitment is increased and damaged epithelial cells are destroyed. Through its potential 
impact on tumor immunosurveillance, Mtgr1 disruption could serve as a therapeutic 
approach in treatment of inflammatory cancers such as CAC.   
 
The Kaiso-MTG16 interaction and how it modifies colitis-associated carcinoma 
Kaiso and MTG16 share several functional similarities, including their abilities to 
repress Wnt signaling, bind co-repressors, and impact processes that influence 
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tumorigenesis. We, therefore, wanted to determine whether these two proteins could 
interact and, ultimately, whether this interaction had a functional impact on AOM/DSS-
induced tumorigenesis. We found that Kaiso and MTGs interact in inhibitory complexes 
and target genes that are important in oncogenesis, including Mmp7. We expected 
knockout of either of the proteins alone or in tandem would result in similar AOM/DSS-
induced tumor burdens as loss of either of the proteins in the complex should have 
destroyed the entire complex and released targets from repression.  
Contrary to these expectations, knockout of either one or both of these proteins 
resulted in very different phenotypes suggesting that the Kaiso-MTG16 complex is not the 
only factor that controls tumorigenesis. Specifically, we see in this model system that, 
while Mtg16-/- mice display increased injury and tumorigenesis, Kaiso loss does not impact 
tumorigenesis in AOM/DSS mice relative to WT mice. Significantly, knockout of both 
Mtg16 and Kaiso results in rescue of the Mtg16-/- phenotype suggesting that, though Kaiso 
and Mtg16 share several targets, it is the transcriptional targets that they do not share 
that distinguish their responses to the AOM/DSS protocol. There is likely a subset of Kaiso 
targets that are normally repressed by Kaiso and block tumorigenesis which, when Kaiso 
is lost, are activated, masking the Mtg16 phenotype. Further exploration into these genes 
could provide important targets for anti-tumorigenic therapeutics, especially in people 
that express one of the 4 identified MTG mutations or demonstrate decreased 
intratumoral MTG16 expression. These data establish a foundation for further research 
into the genes that may contribute to the protective effect of Kaiso in a subset of patients 
with decreased MTG16 expression or activity.    
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CHAPTER IX 
 
FUTURE DIRECTIONS 
 
Selenium and selenoproteins in modification of sporadic colorectal cancer 
 We hypothesized that, as important regulators of reactive oxygen species and 
inflammation, selenoproteins would play a critical role in protection against CAC. 
Interestingly, inflammation is not only important in the development of CAC, but it is also 
associated with pathogenesis of sporadic CRC (451). Moreover, our work has shown that 
Se and Sepp1 depletion induces Wnt signaling, a key contributor in colonic tumorigenesis. 
Both lines of evidence point toward a potential role for Se and selenoproteins in 
development of sporadic CRC. As Se and Sepp1 modulation of tumorigenesis is partially 
dependent on Wnt signaling, the commonly utilized Apcmin/+ model of sporadic 
tumorigenesis, which relies on mutagenesis of the murine homolog of the Apc gene, is 
not an ideal model as it could mask some of the impact of Se deficiency or Sepp1 loss. 
Recently, a genetic model of intestinal polyposis that is independent of dysregulated 
canonical Wnt signaling was developed by the lab of Robert Coffey utilizing the leucine-
rich repeats and immunoglobin-like domains 1 (Lrig1) protein. Lrig1 is a transmembrane 
protein that inhibits ErbB signaling in an inducible manner (452). Lrig1 marks a subset of 
intestinal stem cells that are relatively quiescent until they are mobilized to repopulate 
the colonic crypt in response to tissue damage. The Lrig1-CreERT2/CreERT2 mouse model 
results in low-grade adenomas within the duodenum by 5 to 6 months of age with 88% 
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penetrance (453). This model system is especially applicable to the analysis of phenotypes 
in response to dietary Se deficiency or Sepp1 knockout because, though it is not a model 
of CAC, the Lrig1 knockout mouse displays significant intratumoral inflammation 
(correspondence with Robert Coffey) which will model the inflammation commonly seen 
during the development of sporadic CRC. Monitoring the effect of dietary Se deficiency 
and Sepp1 depletion in this model will allow us to determine whether Se and Sepp1 can 
protect against sporadic CRC as well as inflammatory cancer, expanding the list of cancer 
types impacted by the essential micronutrient Se and one of the predominant plasma 
selenoproteins. In addition, this model system would allow other selenoproteins, such as 
Gpx3, to be studied, potentially establishing an important link between selenoproteins 
and CRC.  
 
Hematopoietic and epithelial cell-autonomous effects of selenoprotein P modulation 
on cancer development 
 To our surprise, our data indicate that, despite the preponderance of hepatic 
Sepp1 within the body, liver-derived Sepp1 does not impact tumorigenesis in response to 
the AOM/DSS protocol. Studies in intestinal organoids suggest that epithelial Sepp1 loss 
has an effect on several tumorigenic properties, including increased stem cell 
characteristics, augmented proliferation, and increased ROS production in response to 
oxidative stress. Enteroid studies suggest that it might be through the epithelial 
compartment that Sepp1 loss is having an impact on tumorigenesis. It is for this reason 
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that epithelial-specific knockout models would benefit the understanding of the role of 
Sepp1 in CAC development.  
The villin-cre-ERT2 model of tissue-specific and inducible cre-mediated 
recombination allows for epithelial-specific knockout of genes of interest (454). Crossing 
the Sepp1Fl/Fl mouse onto this background will enable epithelial knockout of Sepp1. These 
mice could then be subjected to the AOM/DSS protocol and monitored for tumorigenesis, 
establishing the first evidence that non-hepatic Sepp1 is essential for tumor modification 
in vivo. 
 Sepp1 is one of the most highly induced genes in response to polarization of M2 
and tumor –associated macrophages (375, 381) suggesting that Sepp1 may play a role in 
macrophage polarization. We identified a mild polarization defect in bone marrow 
macrophages isolated from Sepp1+/- mice, supporting the hypothesis that Sepp1 has an 
impact on macrophage activity. In addition, Sepp1 knockdown leads to amplified 
inflammation (172) which may be the result of more than just alterations in macrophage 
polarization. Sepp1 might be acting within the inflammatory compartment to modify 
tumorigenesis. In order to test this hypothesis, crossing the floxed Sepp1 mouse with the 
Mx1-cre mouse (455) would enable the cre-mediated inducible inactivation of Sepp1 in 
the bone marrow as well as several tissues including the liver, heart, spleen, and kidney. 
In order to avoid the complex effects of Sepp1 deletion in other tissues, bone marrow 
transplant could be used to insure that recombination only occurs within the bone 
marrow compartment, thus resulting in knockout of Sepp1 in the hematopoietic lineages. 
This tool will not only enable the analysis of the effects of Sepp1 loss in the hematopoietic 
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compartment on AOM/DSS carcinogenesis, but also allow for the characterization of 
immune cell function alterations in vivo.  
 
Pathway alterations in response to modulation of selenoprotein P expression in 
normal physiology and response to oxidative stress 
We have identified increased Wnt signaling in Sepp1-/- tumors and a potential 
dependence on Wnt signaling in the stem cell phenotype of Sepp1-/- enteroids. Wnt 
inhibitors will enable us to solidify the role of Wnt signaling in Sepp1-/- phenotypes. The 
monoclonal antibody OMP-18R5 binds to Frizzled, the receptor through which the Wnt/β-
catenin pathway is initiated and can be utilized in vivo to inhibit Wnt signaling (456). The 
utilization of the OMP-18R5 inhibitor prior to and post-AOM/DSS protocol in Sepp1+/- and 
Sepp1-/- mice would enable the determination of the role of Wnt signaling in tumor 
initiation and promotion, respectively, in these genotypes. The use of this antibody would 
also establish a role for Wnt signaling in Sepp1-/- enteroid phenotypes, both during 
initiation of enteroids and upon establishment of fully differentiated enteroid cultures. 
Enteroid experiments also suggest that Notch and EGF signaling may contribute 
to Sepp1-/- phenotypes. In order to gain unbiased insight into pathways modulated by 
Sepp1 loss, it would be beneficial to perform RNAseq analysis of enteroids isolated from 
WT and Sepp1-/- mice. We have performed this analysis in tumors from these mice, but 
the tumor microenvironment is incredibly complex, containing a plethora of cell types 
that might skew RNAseq results. The benefit of RNAseq analysis in enteroids is that it will 
analyze pathway changes in the epithelial compartment alone. Based on the pathway and 
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gene alterations identified, experiments can be designed that test for the impact of those 
pathways on Sepp1-/- phenotypes both in vitro and in vivo using either inhibitors or 
overexpression of essential pathway components, depending on the identified changes 
of the pathway of interest. Additionally, the enteroid system allows for the analysis of 
gene changes in response to events such as oxidative stress. RNAseq analysis if hydrogen 
peroxide or diquat-treated enteroids could establish pathways that are altered in Sepp1-
/- epithelial cells in response to oxidative stress compared to WT epithelial cells.  
 
Myeloid translocation gene modulation in intestinal organoids: stem cell properties 
and mechanisms for altered cellular activities 
 The identification of MTGs in leukemia translocations suggests that the MTGs play 
roles in stem cell properties.  In addition, we have noted alterations in apoptosis and 
proliferation in cells with MTG knockdown. While we have dismissed a hematopoetic cell-
autonomous effect of MTG knockout on CAC development, we have not established that 
the effect is epithelial in nature. The intestinal organoid model that we have leveraged to 
establish a role for Sepp1 in epithelial phenotypes will be an exceptional system with 
which to monitor the effects of Mtgr1 loss on epithelial phenotypes. Monitoring of stem 
cell properties including plating efficiency, stem spheroid percentage, percentage of 
branching enteroids and number of branches per enteroid will  establish a role for Mtgr1 
in stem cell fitness and/or characteristics. Moreover, analysis of cell types within the fully 
differentiated enteroid will confirm the effect of Mtgr1 on lineage allocation when 
microenvironmental influence is no longer a contributing factor in cellular differentiation. 
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Finally, enteroids will be used to monitor proliferation and apoptosis as well as pathway 
dependence in Mtgr1-/- epithelial cells. Taken together, these analyses will determine the 
mechanisms by which Mtgr1 loss is able to suppress tumorigenesis or, if upon taking the 
severe inflammation resulting from DSS out of the equation, Mtgr1 loss actually promotes 
tumorigenic properties. 
 Absence of Mtgr1 in the AOM/DSS model results in a multilineage inflammatory 
cell infiltrate. This influx of inflammatory cells is not due to a hematopoietic cell 
autonomous effect, suggesting that it is recruitment that controls this phenotype. To 
date, there have been no attempts to culture enteroids with immune cell subtypes, but 
the enteroid culturing parameters make this a feasible option. For one, immune cells, like 
enteroids, can be plated in Matrigel and monitored for alterations in motility and activity. 
Secondly, as enteroids are isolated from mice, immune cells can also be isolated from 
mice of the same strain, or even the same mouse from which the enteroids are derived, 
and cross-species immunity can be avoided. Finally, enteroids and immune cells can be 
isolated from WT or knockout mice, again of the same background, and mixed to monitor 
how loss of the protein of interest in either compartment contributes to the observed 
phenotypes. Co-culturing a combination of WT and Mtgr1-/- enteroids and immune cells, 
such as naïve macrophages, will give significant insight into the mechanism of increased 
infiltration and altered macrophage polarization in Mtgr1-/- tumors. 
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Mtgr1 in sporadic colorectal cancer 
 We have shown that Mtgr1-/- mice are protected from tumorigenesis in response 
to the AOM/DSS inflammatory carcinogenesis protocol, and that this protection is likely 
the result of clearance of initiated cells by an anti-tumorigenic microenvironment. 
Furthermore, we have identified an increase in Mtgr1 expression in human CRC. These 
data beg the question, what is the impact of Mtgr1 loss on development of sporadic CRC? 
Similar to Sepp1-/- experiments outlined above, the Lrig1-CreERT2/CreERT2 mouse will 
serve as an optimal background for the Mtgr1-/- cross. For one, the MTGs are repressors 
of canonical Wnt signaling making the ApcMin/+ model less than ideal as it relies on 
augmented Wnt signaling for the development of intestinal polyps. If MTGs repress Wnt, 
knockout of Mtgr1 will result in increased Wnt signaling which will be masked by the Apc 
mutational activation of Wnt signaling. Lrig1 knockout, on the other hand, will allow for 
the induction of tumorigenesis in a Wnt-independent manner with the added benefit of 
smoldering inflammation. The determination of a Mtgr1-/- phenotype in a sporadic CRC 
model will expand the role of Mtgr1 into a realm beyond just CAC and will add insight into 
the role of DSS-induced injury in the Mtgr1-/- AOM/DSS phenotype. 
 
The impacts of MTG colorectal cancer mutations on cancer risk and cellular properties 
 As mentioned in the Introduction, there are several non-synonymous mutations 
that have been identified in MTG8 and MTG16 in colorectal and breast cancer (228, 229). 
Preliminary work in our lab has demonstrated decreased TCF4 binding and decreased 
TOPFLASH Wnt inhibition with several of these MTG mutations, indicating severe 
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functional abnormalities in the repression capabilities of these mutants. It will be very 
interesting to develop a transgenic mouse model expressing the most severe mutation 
based on Wnt repressive capabilities, but in the short term, enteroids will serve as a great 
model for MTG mutant analysis. Overexpression of the Mtg16 mutants in Mtg16-/- 
enteroids will enable analysis of epithelial phenotypes including lineage allocation, 
proliferation, apoptosis, and stem cell characteristics in response to abnormal Mtg16 
function. Importantly, this will give insight into the mechanisms by which these mutations 
might be beneficial to tumorigenesis within a closed and well-controlled system. An 
understanding of the molecular mechanisms by which these mutations promote 
tumorigenesis will likely open avenues for specific therapeutic interventions in patients 
with MTG mutations. 
 
Additional future directions 
 Determine the receptor for Sepp1 in enterocytes. 
 Establish the isoforms of Sepp1 made within enterocytes and hematopoietic cells. 
Subsequently, determine the activity/roles of each isoform in enteroids. 
 Develop Gpx3-/-;Sepp1-/- double knockout mice so that there is complete absence 
of plasma selenoproteins. Analyze mice and enteroids at baseline and in response 
to stress for intestinal phenotypes including proliferation changes, DNA damage, 
apoptosis, and macrophage polarization. 
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 Irradiate enteroids from Sepp1-/- mice and determine DNA damage and establish 
alterations in repair pathways. 
 Treat Sepp1-/- enteroids with H2O2 or diquat. Determine if this alters DNA damage 
and, if so, perform RNAseq to determine genes mutated and the functional 
significance of these mutations (i.e. overexpression, underexpression). 
 Isolate enteroids from Sepp1U40S and Sepp1Δ240-361 mice and establish which 
domains are important for the identified Sepp1-/- phenotypes in enteroids. 
 We have found that the truncation of Sepp1 leads to alterations in tumorigenesis 
in response to AOM and DSS but that loss of the liver-specific form of Sepp1 does 
not show a phenotype, suggesting that the selenium-rich C-terminal domain 
serves a function aside from delivery of selenium to enterocytes and that this 
function is important for the inhibition of inflammatory tumorigenesis. Utilize 
Sepp1Δ240-361 enteroids to determine pathway and functional changes that result 
from truncation. These enteroids can also be compared with Sepp1-/- enteroids by 
RNAseq to identify the pathway alterations that are dependent upon the 
selenium-rich region as opposed to the other domain of Sepp1.  
 
 
 
 
  
 216 
 
REFERENCES 
 
 
 
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. 
CA Cancer J Clin. 2008;58(2):71-96. Epub 2008/02/22. doi: 10.3322/CA.2007.0010. 
PubMed PMID: 18287387. 
2. Quante M, Wang TC. Inflammation and stem cells in gastrointestinal 
carcinogenesis. Physiology (Bethesda). 2008;23:350-9. Epub 2008/12/17. doi: 
10.1152/physiol.00031.2008. PubMed PMID: 19074742; PubMed Central PMCID: 
PMC2705777. 
3. Loftus EV, Jr., Sandborn WJ. Epidemiology of inflammatory bowel disease. 
Gastroenterol Clin North Am. 2002;31(1):1-20. Epub 2002/07/19. PubMed PMID: 
12122726. 
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 
2009;361(21):2066-78. Epub 2009/11/20. doi: 10.1056/NEJMra0804647. PubMed 
PMID: 19923578; PubMed Central PMCID: PMC3491806. 
5. Nieminen U, Jussila A, Nordling S, Mustonen H, Farkkila MA. Inflammation 
and disease duration have a cumulative effect on the risk of dysplasia and carcinoma 
in IBD: A case-control observational study based on registry data. Int J Cancer. 2013. 
Epub 2013/06/26. doi: 10.1002/ijc.28346. PubMed PMID: 23797639. 
6. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of 
colorectal high-grade dysplasia and cancer in a prospective observational cohort of 
patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166-75 
e8. Epub 2013/04/02. doi: 10.1053/j.gastro.2013.03.044. PubMed PMID: 
23541909. 
7. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of 
intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort 
studies. Am J Gastroenterol. 2005;100(12):2724-9. Epub 2006/01/06. doi: 
10.1111/j.1572-0241.2005.00287.x. PubMed PMID: 16393226. 
8. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with 
ulcerative colitis: a meta-analysis of population-based cohort studies. Clin 
Gastroenterol Hepatol. 2012;10(6):639-45. Epub 2012/02/01. doi: 
10.1016/j.cgh.2012.01.010. PubMed PMID: 22289873. 
9. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. 
Decreasing risk of colorectal cancer in patients with inflammatory bowel disease 
over 30 years. Gastroenterology. 2012;143(2):375-81 e1; quiz e13-4. Epub 
2012/04/24. doi: 10.1053/j.gastro.2012.04.016. PubMed PMID: 22522090. 
 217 
 
10. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and 
mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease 
from 1998 to 2010. Gastroenterology. 2012;143(2):382-9. Epub 2012/05/23. doi: 
10.1053/j.gastro.2012.04.054. PubMed PMID: 22609382. 
11. Neumann H, Vieth M, Langner C, Neurath MF, Mudter J. Cancer risk in IBD: 
how to diagnose and how to manage DALM and ALM. World J Gastroenterol. 
2011;17(27):3184-91. Epub 2011/09/14. doi: 10.3748/wjg.v17.i27.3184. PubMed 
PMID: 21912466; PubMed Central PMCID: PMC3158393. 
12. Nguyen GC, Bressler B. A tale of two cohorts: are we overestimating the risk 
of colorectal cancer in inflammatory bowel disease? Gastroenterology. 
2012;143(2):288-90. Epub 2012/06/26. doi: 10.1053/j.gastro.2012.06.027. 
PubMed PMID: 22727998. 
13. Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery 
EA, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 
5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 
2008;14(2):265-74. Epub 2007/10/13. doi: 10.1002/ibd.20297. PubMed PMID: 
17932965. 
14. Quante M, Varga J, Wang TC, Greten FR. The gastrointestinal tumor 
microenvironment. Gastroenterology. 2013;145(1):63-78. Epub 2013/04/16. doi: 
10.1053/j.gastro.2013.03.052. PubMed PMID: 23583733. 
15. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in 
inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest 
Liver Physiol. 2004;287(1):G7-17. Epub 2004/06/15. doi: 
10.1152/ajpgi.00079.2004 
287/1/G7 [pii]. PubMed PMID: 15194558. 
16. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial 
infections to chronic inflammation and cancer. Cell. 2006;124(4):823-35. Epub 
2006/02/25. doi: 10.1016/j.cell.2006.02.016. PubMed PMID: 16497591. 
17. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The 
NLRP3 inflammasome functions as a negative regulator of tumorigenesis during 
colitis-associated cancer. J Exp Med. 2010;207(5):1045-56. Epub 2010/04/14. doi: 
10.1084/jem.20100050. PubMed PMID: 20385749; PubMed Central PMCID: 
PMC2867287. 
18. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 
2003;3(4):276-85. Epub 2003/04/03. doi: 10.1038/nrc1046. PubMed PMID: 
12671666. 
 218 
 
19. Mangerich A, Knutson CG, Parry NM, Muthupalani S, Ye W, Prestwich E, et al. 
Infection-induced colitis in mice causes dynamic and tissue-specific changes in 
stress response and DNA damage leading to colon cancer. Proc Natl Acad Sci U S A. 
2012;109(27):E1820-9. Epub 2012/06/13. doi: 10.1073/pnas.1207829109. 
PubMed PMID: 22689960; PubMed Central PMCID: PMC3390855. 
20. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, et al. DNA 
damage induced by chronic inflammation contributes to colon carcinogenesis in 
mice. J Clin Invest. 2008;118(7):2516-25. Epub 2008/06/04. doi: 
10.1172/JCI35073. PubMed PMID: 18521188; PubMed Central PMCID: 
PMC2423313. 
21. Olipitz W, Wiktor-Brown D, Shuga J, Pang B, McFaline J, Lonkar P, et al. 
Integrated molecular analysis indicates undetectable change in DNA damage in mice 
after continuous irradiation at ~ 400-fold natural background radiation. Environ 
Health Perspect. 2012;120(8):1130-6. Epub 2012/04/28. doi: 
10.1289/ehp.1104294. PubMed PMID: 22538203; PubMed Central PMCID: 
PMC3440074. 
22. Kraus S, Arber N. Inflammation and colorectal cancer. Current opinion in 
pharmacology. 2009;9(4):405-10. Epub 2009/07/11. doi: 
10.1016/j.coph.2009.06.006. PubMed PMID: 19589728. 
23. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related 
inflammation, the seventh hallmark of cancer: links to genetic instability. 
Carcinogenesis. 2009;30(7):1073-81. Epub 2009/05/27. doi: 
10.1093/carcin/bgp127. PubMed PMID: 19468060. 
24. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., Sjoblom T, et al. The 
colorectal microRNAome. Proc Natl Acad Sci U S A. 2006;103(10):3687-92. Epub 
2006/03/01. doi: 10.1073/pnas.0511155103. PubMed PMID: 16505370; PubMed 
Central PMCID: PMC1450142. 
25. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal 
cancer pathogenesis. Gastroenterology. 2008;135(4):1079-99. Epub 2008/09/09. 
doi: S0016-5085(08)01451-0 [pii] 
10.1053/j.gastro.2008.07.076. PubMed PMID: 18773902; PubMed Central PMCID: 
PMC2866182. 
26. Oving IM, Clevers HC. Molecular causes of colon cancer. Eur J Clin Invest. 
2002;32(6):448-57. Epub 2002/06/13. PubMed PMID: 12059991. 
27. Perucho M. Tumors with microsatellite instability: many mutations, targets 
and paradoxes. Oncogene. 2003;22(15):2223-5. Epub 2003/04/18. doi: 
10.1038/sj.onc.1206580. PubMed PMID: 12700658. 
 219 
 
28. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer 
H, et al. Transcriptome profile of human colorectal adenomas. Molecular cancer 
research : MCR. 2007;5(12):1263-75. Epub 2008/01/04. doi: 10.1158/1541-
7786.MCR-07-0267. PubMed PMID: 18171984. 
29. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated 
neoplasia. Seminars in immunopathology. 2013;35(2):229-44. Epub 2012/11/20. 
doi: 10.1007/s00281-012-0352-6. PubMed PMID: 23161445; PubMed Central 
PMCID: PMC3568220. 
30. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to 
cancer development and progression. Nat Rev Immunol. 2005;5(10):749-59. Epub 
2005/09/22. doi: 10.1038/nri1703. PubMed PMID: 16175180. 
31. Li J, Liu Y, Wang B, Xu Y, Ma A, Zhang F, et al. Myeloid TGF-beta signaling 
contributes to colitis-associated tumorigenesis in mice. Carcinogenesis. 2013. Epub 
2013/05/23. doi: 10.1093/carcin/bgt172. PubMed PMID: 23695722. 
32. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et 
al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-
cycle progression during colitis-associated tumorigenesis. Cancer Cell. 
2009;15(2):91-102. Epub 2009/02/03. doi: 10.1016/j.ccr.2009.01.002. PubMed 
PMID: 19185844. 
33. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 
and Stat3 are required for survival of intestinal epithelial cells and development of 
colitis-associated cancer. Cancer Cell. 2009;15(2):103-13. Epub 2009/02/03. doi: 
S1535-6108(09)00002-6 [pii] 
10.1016/j.ccr.2009.01.001. PubMed PMID: 19185845; PubMed Central PMCID: 
PMC2667107. 
34. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 
promotes tumour incidence and growth. Nature. 2006;442(7101):461-5. Epub 
2006/05/12. doi: 10.1038/nature04808. PubMed PMID: 16688182. 
35. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. IL-
23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and 
IL-6. J Clin Invest. 2006;116(5):1310-6. Epub 2006/05/04. doi: 10.1172/JCI21404. 
PubMed PMID: 16670770; PubMed Central PMCID: PMC1451201. 
36. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by 
inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1(1):11-21. Epub 
2002/03/20. doi: 10.1038/35094017. PubMed PMID: 11900248. 
37. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, et al. MyD88-
mediated signaling prevents development of adenocarcinomas of the colon: role of 
 220 
 
interleukin 18. J Exp Med. 2010;207(8):1625-36. Epub 2010/07/14. doi: 
10.1084/jem.20100199. PubMed PMID: 20624890; PubMed Central PMCID: 
PMC2916129. 
38. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. 
Gastroenterology. 2010;138(6):2101-14 e5. Epub 2010/04/28. doi: 
10.1053/j.gastro.2010.01.058. PubMed PMID: 20420949. 
39. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell 
Cycle. 2009;8(20):3267-73. Epub 2009/09/23. PubMed PMID: 19770594; PubMed 
Central PMCID: PMC3702728. 
40. Klampfer L. The role of signal transducers and activators of transcription in 
colon cancer. Front Biosci. 2008;13:2888-99. Epub 2007/11/06. PubMed PMID: 
17981761. 
41. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation 
and colorectal cancer. Cell Mol Immunol. 2009;6(5):327-34. Epub 2009/11/06. doi: 
10.1038/cmi.2009.43. PubMed PMID: 19887045. 
42. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by 
NF-kappaB is required for inflammation-induced cell migration and invasion. 
Cancer Cell. 2009;15(5):416-28. Epub 2009/05/05. doi: 10.1016/j.ccr.2009.03.016. 
PubMed PMID: 19411070; PubMed Central PMCID: PMC2881229. 
43. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer 
cells converts inflammation- induced tumor growth mediated by TNFalpha to 
TRAIL-mediated tumor regression. Cancer Cell. 2004;6(3):297-305. Epub 
2004/09/24. doi: 10.1016/j.ccr.2004.08.012. PubMed PMID: 15380520. 
44. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal 
cancer. Cancer Metastasis Rev. 2004;23(1-2):101-17. Epub 2004/03/06. PubMed 
PMID: 15000152. 
45. Emsley J. Nature's building blocks: an A-Z guide to te elements. Oxford, UK: 
Oxford University Press; 2011 2011. 720 p. 
46. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. 
Selenium: biochemical role as a component of glutathione peroxidase. Science. 
1973;179(4073):588-90. Epub 1973/02/09. PubMed PMID: 4686466. 
47. Hawkes WC, Wilhelmsen EC, Tappel AL. Abundance and tissue distribution of 
selenocysteine-containing proteins in the rat. J Inorg Biochem. 1985;23(2):77-92. 
Epub 1985/02/01. PubMed PMID: 3156209. 
 221 
 
48. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, et al. 
Characterization of mammalian selenoproteomes. Science. 2003;300(5624):1439-
43. Epub 2003/05/31. doi: 10.1126/science.1083516. PubMed PMID: 12775843. 
49. Driscoll DM, Copeland PR. Mechanism and regulation of selenoprotein 
synthesis. Annu Rev Nutr. 2003;23:17-40. Epub 2003/01/14. doi: 
10.1146/annurev.nutr.23.011702.073318 
011702.073318 [pii]. PubMed PMID: 12524431. 
50. Heider J, Baron C, Bock A. Coding from a distance: dissection of the mRNA 
determinants required for the incorporation of selenocysteine into protein. EMBO J. 
1992;11(10):3759-66. Epub 1992/10/01. PubMed PMID: 1396569; PubMed Central 
PMCID: PMC556836. 
51. Berry MJ, Banu L, Harney JW, Larsen PR. Functional characterization of the 
eukaryotic SECIS elements which direct selenocysteine insertion at UGA codons. 
EMBO J. 1993;12(8):3315-22. Epub 1993/08/01. PubMed PMID: 8344267; PubMed 
Central PMCID: PMC413599. 
52. Hill KE, Lloyd RS, Burk RF. Conserved nucleotide sequences in the open 
reading frame and 3' untranslated region of selenoprotein P mRNA. Proc Natl Acad 
Sci U S A. 1993;90(2):537-41. Epub 1993/01/15. PubMed PMID: 8421687; PubMed 
Central PMCID: PMC45698. 
53. Martin GW, 3rd, Harney JW, Berry MJ. Selenocysteine incorporation in 
eukaryotes: insights into mechanism and efficiency from sequence, structure, and 
spacing proximity studies of the type 1 deiodinase SECIS element. RNA. 
1996;2(2):171-82. Epub 1996/02/01. PubMed PMID: 8601283; PubMed Central 
PMCID: PMC1369361. 
54. Lee BJ, Rajagopalan M, Kim YS, You KH, Jacobson KB, Hatfield D. 
Selenocysteine tRNA[Ser]Sec gene is ubiquitous within the animal kingdom. Mol Cell 
Biol. 1990;10(5):1940-9. Epub 1990/05/01. PubMed PMID: 2139169; PubMed 
Central PMCID: PMC360540. 
55. Leinfelder W, Forchhammer K, Zinoni F, Sawers G, Mandrand-Berthelot MA, 
Bock A. Escherichia coli genes whose products are involved in selenium metabolism. 
J Bacteriol. 1988;170(2):540-6. Epub 1988/02/01. PubMed PMID: 2962989; 
PubMed Central PMCID: PMC210687. 
56. Low SC, Harney JW, Berry MJ. Cloning and functional characterization of 
human selenophosphate synthetase, an essential component of selenoprotein 
synthesis. J Biol Chem. 1995;270(37):21659-64. Epub 1995/09/15. PubMed PMID: 
7665581. 
 222 
 
57. Squires JE, Berry MJ. Eukaryotic selenoprotein synthesis: mechanistic insight 
incorporating new factors and new functions for old factors. IUBMB Life. 
2008;60(4):232-5. Epub 2008/03/18. doi: 10.1002/iub.38. PubMed PMID: 
18344183. 
58. Low SC, Grundner-Culemann E, Harney JW, Berry MJ. SECIS-SBP2 
interactions dictate selenocysteine incorporation efficiency and selenoprotein 
hierarchy. EMBO J. 2000;19(24):6882-90. Epub 2000/12/16. doi: 
10.1093/emboj/19.24.6882. PubMed PMID: 11118223; PubMed Central PMCID: 
PMC305907. 
59. Fradejas N, Carlson BA, Rijntjes E, Becker NP, Tobe R, Schweizer U. 
Mammalian Trit1 is a tRNA([Ser]Sec)-isopentenyl transferase required for full 
selenoprotein expression. Biochem J. 2013;450(2):427-32. Epub 2013/01/08. doi: 
10.1042/BJ20121713. PubMed PMID: 23289710. 
60. Esaki N, Nakamura T, Tanaka H, Soda K. Selenocysteine lyase, a novel enzyme 
that specifically acts on selenocysteine. Mammalian distribution and purification 
and properties of pig liver enzyme. J Biol Chem. 1982;257(8):4386-91. Epub 
1982/04/25. PubMed PMID: 6461656. 
61. Kobayashi Y, Ogra Y, Ishiwata K, Takayama H, Aimi N, Suzuki KT. 
Selenosugars are key and urinary metabolites for selenium excretion within the 
required to low-toxic range. Proc Natl Acad Sci U S A. 2002;99(25):15932-6. Epub 
2002/11/21. doi: 10.1073/pnas.252610699. PubMed PMID: 12441402; PubMed 
Central PMCID: PMC138542. 
62. Bopp BA, Sonders RC, Kesterson JW. Metabolic fate of selected selenium 
compounds in laboratory animals and man. Drug metabolism reviews. 
1982;13(2):271-318. Epub 1982/01/01. doi: 10.3109/03602538209030000. 
PubMed PMID: 7047128. 
63. Hill KE, Zhou J, Austin LM, Motley AK, Ham AJ, Olson GE, et al. The selenium-
rich C-terminal domain of mouse selenoprotein P is necessary for the supply of 
selenium to brain and testis but not for the maintenance of whole body selenium. J 
Biol Chem. 2007;282(15):10972-80. Epub 2007/02/22. doi: M700436200 [pii] 
10.1074/jbc.M700436200. PubMed PMID: 17311913. 
64. Olson GE, Winfrey VP, Nagdas SK, Hill KE, Burk RF. Apolipoprotein E 
receptor-2 (ApoER2) mediates selenium uptake from selenoprotein P by the mouse 
testis. J Biol Chem. 2007;282(16):12290-7. Epub 2007/02/23. doi: 
10.1074/jbc.M611403200. PubMed PMID: 17314095. 
65. Burk RF, Hill KE, Olson GE, Weeber EJ, Motley AK, Winfrey VP, et al. Deletion 
of apolipoprotein E receptor-2 in mice lowers brain selenium and causes severe 
neurological dysfunction and death when a low-selenium diet is fed. J Neurosci. 
 223 
 
2007;27(23):6207-11. Epub 2007/06/08. doi: 10.1523/JNEUROSCI.1153-07.2007. 
PubMed PMID: 17553992. 
66. Hill KE, Wu S, Motley AK, Stevenson TD, Winfrey VP, Capecchi MR, et al. 
Production of selenoprotein P (Sepp1) by hepatocytes is central to selenium 
homeostasis. J Biol Chem. 2012;287(48):40414-24. Epub 2012/10/06. doi: 
10.1074/jbc.M112.421404. PubMed PMID: 23038251; PubMed Central PMCID: 
PMC3504756. 
67. Kim JY, Carlson BA, Xu XM, Zeng Y, Chen S, Gladyshev VN, et al. Inhibition of 
selenocysteine tRNA[Ser]Sec aminoacylation provides evidence that aminoacylation 
is required for regulatory methylation of this tRNA. Biochem Biophys Res Commun. 
2011;409(4):814-9. Epub 2011/06/01. doi: 10.1016/j.bbrc.2011.05.096. PubMed 
PMID: 21624347; PubMed Central PMCID: PMC3124823. 
68. Brigelius-Flohe R. Tissue-specific functions of individual glutathione 
peroxidases. Free Radic Biol Med. 1999;27(9-10):951-65. Epub 1999/11/24. doi: 
S0891-5849(99)00173-2 [pii]. PubMed PMID: 10569628. 
69. Burk RF, Hill KE. Selenoprotein P-expression, functions, and roles in 
mammals. Biochim Biophys Acta. 2009;1790(11):1441-7. Epub 2009/04/07. doi: 
10.1016/j.bbagen.2009.03.026. PubMed PMID: 19345254; PubMed Central PMCID: 
PMC2763998. 
70. Chen J. An original discovery: selenium deficiency and Keshan disease (an 
endemic heart disease). Asia Pacific journal of clinical nutrition. 2012;21(3):320-6. 
Epub 2012/06/19. PubMed PMID: 22705420. 
71. Yao Y, Pei F, Kang P. Selenium, iodine, and the relation with Kashin-Beck 
disease. Nutrition. 2011;27(11-12):1095-100. Epub 2011/10/05. doi: 
10.1016/j.nut.2011.03.002. PubMed PMID: 21967994. 
72. Schoenmakers E, Agostini M, Mitchell C, Schoenmakers N, Papp L, 
Rajanayagam O, et al. Mutations in the selenocysteine insertion sequence-binding 
protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J 
Clin Invest. 2010;120(12):4220-35. Epub 2010/11/19. doi: 10.1172/JCI43653. 
PubMed PMID: 21084748; PubMed Central PMCID: PMC2993594. 
73. Rayman MP. The importance of selenium to human health. Lancet. 
2000;356(9225):233-41. Epub 2000/08/30. doi: 10.1016/S0140-6736(00)02490-
9. PubMed PMID: 10963212. 
74. Ashrafi MR, Shams S, Nouri M, Mohseni M, Shabanian R, Yekaninejad MS, et 
al. A probable causative factor for an old problem: selenium and glutathione 
peroxidase appear to play important roles in epilepsy pathogenesis. Epilepsia. 
2007;48(9):1750-5. Epub 2007/06/09. doi: 10.1111/j.1528-1167.2007.01143.x. 
PubMed PMID: 17555528. 
 224 
 
75. Zhang S, Rocourt C, Cheng WH. Selenoproteins and the aging brain. 
Mechanisms of ageing and development. 2010;131(4):253-60. Epub 2010/03/12. 
doi: 10.1016/j.mad.2010.02.006. PubMed PMID: 20219520. 
76. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. 
Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 
2011;364(20):1920-31. Epub 2011/05/20. doi: 10.1056/NEJMoa1012985. PubMed 
PMID: 21591944. 
77. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, et al. 
Selenium in human health and disease. Antioxidants & redox signaling. 
2011;14(7):1337-83. Epub 2010/09/04. doi: 10.1089/ars.2010.3275. PubMed 
PMID: 20812787. 
78. Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and 
immunity: from molecular mechanisms to therapeutic opportunities. Antioxidants & 
redox signaling. 2012;16(7):705-43. Epub 2011/10/01. doi: 
10.1089/ars.2011.4145. PubMed PMID: 21955027; PubMed Central PMCID: 
PMC3277928. 
79. Steinbrenner H, Sies H. Protection against reactive oxygen species by 
selenoproteins. Biochim Biophys Acta. 2009;1790(11):1478-85. Epub 2009/03/10. 
doi: S0304-4165(09)00043-9 [pii] 
10.1016/j.bbagen.2009.02.014. PubMed PMID: 19268692. 
80. Nuttall KL. Evaluating selenium poisoning. Annals of clinical and laboratory 
science. 2006;36(4):409-20. Epub 2006/11/28. PubMed PMID: 17127727. 
81. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et 
al. Effects of long-term selenium supplementation on the incidence of type 2 
diabetes: a randomized trial. Ann Intern Med. 2007;147(4):217-23. Epub 
2007/07/11. PubMed PMID: 17620655. 
82. Steinbrenner H, Speckmann B, Pinto A, Sies H. High selenium intake and 
increased diabetes risk: experimental evidence for interplay between selenium and 
carbohydrate metabolism. J Clin Biochem Nutr. 2011;48(1):40-5. Epub 2011/02/08. 
doi: 10.3164/jcbn.11-002FR. PubMed PMID: 21297910; PubMed Central PMCID: 
PMC3022062. 
83. Czech MP, Lawrence JC, Jr., Lynn WS. Evidence for the involvement of 
sulfhydryl oxidation in the regulation of fat cell hexose transport by insulin. Proc 
Natl Acad Sci U S A. 1974;71(10):4173-7. Epub 1974/10/01. PubMed PMID: 
4372610; PubMed Central PMCID: PMC434352. 
84. Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-stimulated hydrogen 
peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances 
 225 
 
the early insulin action cascade. J Biol Chem. 2001;276(24):21938-42. Epub 
2001/04/12. doi: 10.1074/jbc.C100109200. PubMed PMID: 11297536. 
85. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, Kurita S, 
et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. 
Cell Metab. 2010;12(5):483-95. Epub 2010/11/03. doi: 
10.1016/j.cmet.2010.09.015. PubMed PMID: 21035759. 
86. Pinto A, Speckmann B, Heisler M, Sies H, Steinbrenner H. Delaying of insulin 
signal transduction in skeletal muscle cells by selenium compounds. J Inorg 
Biochem. 2011;105(6):812-20. Epub 2011/04/19. doi: 
10.1016/j.jinorgbio.2011.03.010. PubMed PMID: 21497580. 
87. Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO, et al. 
Selenoprotein P expression is controlled through interaction of the coactivator PGC-
1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. 
Hepatology. 2008;48(6):1998-2006. Epub 2008/10/31. doi: 10.1002/hep.22526. 
PubMed PMID: 18972406. 
88. Gromadzinska J, Reszka E, Bruzelius K, Wasowicz W, Akesson B. Selenium 
and cancer: biomarkers of selenium status and molecular action of selenium 
supplements. Eur J Nutr. 2008;47 Suppl 2:29-50. Epub 2008/06/17. doi: 
10.1007/s00394-008-2005-z. PubMed PMID: 18458833. 
89. Chiang EC, Shen S, Kengeri SS, Xu H, Combs GF, Morris JS, et al. Defining the 
Optimal Selenium Dose for Prostate Cancer Risk Reduction: Insights from the U-
Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis. Dose-
response : a publication of International Hormesis Society. 2009;8(3):285-300. 
Epub 2009/01/01. doi: 10.2203/dose-response.09-036.Chiang. PubMed PMID: 
20877485; PubMed Central PMCID: PMC2939616. 
90. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin 
C, vitamin E, selenium, and carotenoids. J Am Diet Assoc. 2000;100(6):637-40. Epub 
2000/06/23. doi: 10.1016/S0002-8223(00)00189-9. PubMed PMID: 10863565. 
91. Rayman MP. Food-chain selenium and human health: emphasis on intake. Br 
J Nutr. 2008;100(2):254-68. Epub 2008/03/19. doi: 10.1017/S0007114508939830. 
PubMed PMID: 18346308. 
92. Duffield AJ, Thomson CD, Hill KE, Williams S. An estimation of selenium 
requirements for New Zealanders. Am J Clin Nutr. 1999;70(5):896-903. Epub 
1999/10/28. PubMed PMID: 10539752. 
93. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, et al. 
Establishing optimal selenium status: results of a randomized, double-blind, 
placebo-controlled trial. Am J Clin Nutr. 2010;91(4):923-31. Epub 2010/02/26. doi: 
 226 
 
10.3945/ajcn.2009.28169. PubMed PMID: 20181815; PubMed Central PMCID: 
PMC2844680. 
94. Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium 
supplements in a low-selenium area of China. Am J Clin Nutr. 2005;81(4):829-34. 
Epub 2005/04/09. PubMed PMID: 15817859. 
95. Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, et al. Optimization of 
selenoprotein P and other plasma selenium biomarkers for the assessment of the 
selenium nutritional requirement: a placebo-controlled, double-blind study of 
selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin 
Nutr. 2010;92(3):525-31. Epub 2010/06/25. doi: 10.3945/ajcn.2010.29642. 
PubMed PMID: 20573787; PubMed Central PMCID: PMC2921536. 
96. Hu Y, McIntosh GH, Le Leu RK, Upton JM, Woodman RJ, Young GP. The 
influence of selenium-enriched milk proteins and selenium yeast on plasma 
selenium levels and rectal selenoprotein gene expression in human subjects. Br J 
Nutr. 2011;106(4):572-82. Epub 2011/04/01. doi: 10.1017/S0007114511000420. 
PubMed PMID: 21450115. 
97. Karunasinghe N, Han DY, Zhu S, Yu J, Lange K, Duan H, et al. Serum selenium 
and single-nucleotide polymorphisms in genes for selenoproteins: relationship to 
markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr. 
2012;7(2):179-90. Epub 2011/12/06. doi: 10.1007/s12263-011-0259-1. PubMed 
PMID: 22139612; PubMed Central PMCID: PMC3316745. 
98. Al-Taie OH, Seufert J, Mork H, Treis H, Mentrup B, Thalheimer A, et al. A 
complex DNA-repeat structure within the Selenoprotein P promoter contains a 
functionally relevant polymorphism and is genetically unstable under conditions of 
mismatch repair deficiency. Eur J Hum Genet. 2002;10(9):499-504. Epub 
2002/08/13. doi: 10.1038/sj.ejhg.5200811. PubMed PMID: 12173025. 
99. Meplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, et al. 
Genetic variants in selenoprotein genes increase risk of colorectal cancer. 
Carcinogenesis. 2010;31(6):1074-9. Epub 2010/04/10. doi: 
10.1093/carcin/bgq076. PubMed PMID: 20378690. 
100. Sutherland A, Kim DH, Relton C, Ahn YO, Hesketh J. Polymorphisms in the 
selenoprotein S and 15-kDa selenoprotein genes are associated with altered 
susceptibility to colorectal cancer. Genes Nutr. 2010;5(3):215-23. Epub 
2010/11/06. doi: 10.1007/s12263-010-0176-8. PubMed PMID: 21052528; PubMed 
Central PMCID: PMC2935533. 
101. Zhang J, Dhakal IB, Lang NP, Kadlubar FF. Polymorphisms in inflammatory 
genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control. 
2010;21(9):1437-44. Epub 2010/05/01. doi: 10.1007/s10552-010-9571-0. PubMed 
PMID: 20431935; PubMed Central PMCID: PMC3207491. 
 227 
 
102. Zhuo P, Goldberg M, Herman L, Lee BS, Wang H, Brown RL, et al. Molecular 
consequences of genetic variations in the glutathione peroxidase 1 selenoenzyme. 
Cancer Res. 2009;69(20):8183-90. Epub 2009/10/15. doi: 10.1158/0008-
5472.CAN-09-1791. PubMed PMID: 19826042; PubMed Central PMCID: 
PMC2763328. 
103. Steinbrenner H, Speckmann B, Sies H. Toward understanding success and 
failures in the use of selenium for cancer prevention. Antioxidants & redox signaling. 
2013;19(2):181-91. Epub 2013/02/21. doi: 10.1089/ars.2013.5246. PubMed PMID: 
23421468; PubMed Central PMCID: PMC3689159. 
104. Stadtman TC. Selenium biochemistry. Mammalian selenoenzymes. Ann N Y 
Acad Sci. 2000;899:399-402. Epub 2000/06/23. PubMed PMID: 10863556. 
105. Stadtman TC. Selenocysteine. Annual review of biochemistry. 1996;65:83-
100. Epub 1996/01/01. doi: 10.1146/annurev.bi.65.070196.000503. PubMed 
PMID: 8811175. 
106. Brozmanova J, Manikova D, Vlckova V, Chovanec M. Selenium: a double-
edged sword for defense and offence in cancer. Archives of toxicology. 
2010;84(12):919-38. Epub 2010/09/28. doi: 10.1007/s00204-010-0595-8. PubMed 
PMID: 20871980. 
107. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M. 
Selenium for preventing cancer. Cochrane Database Syst Rev. 2011(5):CD005195. 
Epub 2011/05/13. doi: 10.1002/14651858.CD005195.pub2. PubMed PMID: 
21563143; PubMed Central PMCID: PMC3692366. 
108. Jaworska K, Gupta S, Durda K, Muszynska M, Sukiennicki G, Jaworowska E, et 
al. A low selenium level is associated with lung and laryngeal cancers. PLoS One. 
2013;8(3):e59051. Epub 2013/03/22. doi: 10.1371/journal.pone.0059051. PubMed 
PMID: 23516596; PubMed Central PMCID: PMC3596323. 
109. Meyer HA, Endermann T, Stephan C, Stoedter M, Behrends T, Wolff I, et al. 
Selenoprotein P status correlates to cancer-specific mortality in renal cancer 
patients. PLoS One. 2012;7(10):e46644. Epub 2012/10/12. doi: 
10.1371/journal.pone.0046644. PubMed PMID: 23056383; PubMed Central PMCID: 
PMC3467258. 
110. Jung HJ, Seo YR. Current issues of selenium in cancer chemoprevention. 
Biofactors. 2010;36(2):153-8. Epub 2010/03/25. doi: 10.1002/biof.81. PubMed 
PMID: 20333751. 
111. Mugesh G, du Mont WW, Sies H. Chemistry of biologically important synthetic 
organoselenium compounds. Chemical reviews. 2001;101(7):2125-79. Epub 
2001/11/17. PubMed PMID: 11710243. 
 228 
 
112. Wang D, Taylor EW, Wang Y, Wan X, Zhang J. Encapsulated 
nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms 
for nanochemoprevention. International journal of nanomedicine. 2012;7:1711-21. 
Epub 2012/05/24. doi: 10.2147/IJN.S29341. PubMed PMID: 22619522; PubMed 
Central PMCID: PMC3356175. 
113. Clark LC, Dalkin B, Krongrad A, Combs GF, Jr., Turnbull BW, Slate EH, et al. 
Decreased incidence of prostate cancer with selenium supplementation: results of a 
double-blind cancer prevention trial. Br J Urol. 1998;81(5):730-4. Epub 
1998/06/20. PubMed PMID: 9634050. 
114. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. 
Selenium supplementation, baseline plasma selenium status and incidence of 
prostate cancer: an analysis of the complete treatment period of the Nutritional 
Prevention of Cancer Trial. BJU Int. 2003;91(7):608-12. Epub 2003/04/18. PubMed 
PMID: 12699469. 
115. Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, et al. 
Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst. 
2004;96(22):1669-75. Epub 2004/11/18. doi: 10.1093/jnci/djh310. PubMed PMID: 
15547179. 
116. Fernandez-Banares F, Cabre E, Esteve M, Mingorance MD, Abad-Lacruz A, 
Lachica M, et al. Serum selenium and risk of large size colorectal adenomas in a 
geographical area with a low selenium status. Am J Gastroenterol. 2002;97(8):2103-
8. Epub 2002/08/23. doi: 10.1111/j.1572-0241.2002.05930.x. PubMed PMID: 
12190184. 
117. Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, et al. High 
serum selenium and reduced risk of advanced colorectal adenoma in a colorectal 
cancer early detection program. Cancer Epidemiol Biomarkers Prev. 
2006;15(2):315-20. Epub 2006/02/24. doi: 10.1158/1055-9965.EPI-05-0471. 
PubMed PMID: 16492922. 
118. Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et 
al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT). JAMA. 2011;306(14):1549-56. Epub 2011/10/13. doi: 
10.1001/jama.2011.1437. PubMed PMID: 21990298. 
119. Wallace K, Byers T, Morris JS, Cole BF, Greenberg ER, Baron JA, et al. 
Prediagnostic serum selenium concentration and the risk of recurrent colorectal 
adenoma: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 
2003;12(5):464-7. Epub 2003/05/17. PubMed PMID: 12750244. 
120. Papaioannou D, Cooper KL, Carroll C, Hind D, Squires H, Tappenden P, et al. 
Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas 
in the general population: a systematic review and meta-analysis. Colorectal Dis. 
 229 
 
2011;13(10):1085-99. Epub 2010/04/24. doi: 10.1111/j.1463-1318.2010.02289.x. 
PubMed PMID: 20412095. 
121. Lee EH, Myung SK, Jeon YJ, Kim Y, Chang YJ, Ju W, et al. Effects of selenium 
supplements on cancer prevention: meta-analysis of randomized controlled trials. 
Nutr Cancer. 2011;63(8):1185-95. Epub 2011/10/19. doi: 
10.1080/01635581.2011.607544. PubMed PMID: 22004275. 
122. Zhang J, Wang L, Li G, Anderson LB, Xu Y, Witthuhn B, et al. Mouse prostate 
proteomes are differentially altered by supranutritional intake of four selenium 
compounds. Nutr Cancer. 2011;63(5):778-89. Epub 2011/05/27. doi: 
10.1080/01635581.2011.563029. PubMed PMID: 21614726. 
123. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of 
carcinogenesis. Biochim Biophys Acta. 2009;1790(11):1555-68. Epub 2009/03/18. 
doi: 10.1016/j.bbagen.2009.03.006. PubMed PMID: 19289149. 
124. Muller M, Banning A, Brigelius-Flohe R, Kipp A. Nrf2 target genes are induced 
under marginal selenium-deficiency. Genes Nutr. 2010;5(4):297-307. Epub 
2010/12/31. doi: 10.1007/s12263-010-0168-8. PubMed PMID: 21189866; PubMed 
Central PMCID: PMC2989369. 
125. Burk RF, Hill KE, Nakayama A, Mostert V, Levander XA, Motley AK, et al. 
Selenium deficiency activates mouse liver Nrf2-ARE but vitamin E deficiency does 
not. Free Radic Biol Med. 2008;44(8):1617-23. Epub 2008/02/19. doi: S0891-
5849(08)00038-5 [pii] 
10.1016/j.freeradbiomed.2008.01.016. PubMed PMID: 18279678; PubMed Central 
PMCID: PMC2346531. 
126. Burk RF, Lawrence RA, Lane JM. Liver necrosis and lipid peroxidation in the 
rat as the result of paraquat and diquat administration. Effect of selenium 
deficiency. J Clin Invest. 1980;65(5):1024-31. Epub 1980/05/01. doi: 
10.1172/JCI109754. PubMed PMID: 7364936; PubMed Central PMCID: PMC371432. 
127. Burk RF, Hill KE, Awad JA, Morrow JD, Kato T, Cockell KA, et al. Pathogenesis 
of diquat-induced liver necrosis in selenium-deficient rats: assessment of the roles 
of lipid peroxidation and selenoprotein P. Hepatology. 1995;21(2):561-9. Epub 
1995/02/01. doi: S0270913995000760 [pii]. PubMed PMID: 7843731. 
128. Hill KE, McCollum GW, Boeglin ME, Burk RF. Thioredoxin reductase activity is 
decreased by selenium deficiency. Biochem Biophys Res Commun. 
1997;234(2):293-5. Epub 1997/05/19. doi: 10.1006/bbrc.1997.6618. PubMed 
PMID: 9177261. 
 230 
 
129. Ferguson LR, Karunasinghe N, Zhu S, Wang AH. Selenium and its' role in the 
maintenance of genomic stability. Mutat Res. 2012;733(1-2):100-10. Epub 
2012/01/12. doi: 10.1016/j.mrfmmm.2011.12.011. PubMed PMID: 22234051. 
130. Brigelius-Flohe R, Kipp AP. Selenium in the redox regulation of the nrf2 and 
the wnt pathway. Methods Enzymol. 2013;527:65-86. Epub 2013/07/09. doi: 
10.1016/B978-0-12-405882-8.00004-0. PubMed PMID: 23830626. 
131. Halliwell B. Free radicals and antioxidants - quo vadis? Trends Pharmacol Sci. 
2011;32(3):125-30. Epub 2011/01/11. doi: 10.1016/j.tips.2010.12.002. PubMed 
PMID: 21216018. 
132. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, et al. NRF2 blockade 
suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of 
HIF-1alpha. Cancer Res. 2011;71(6):2260-75. Epub 2011/02/01. doi: 
10.1158/0008-5472.CAN-10-3007. PubMed PMID: 21278237. 
133. Chang LC, Fan CW, Tseng WK, Chen JR, Chein HP, Hwang CC, et al. 
Immunohistochemical Study of the Nrf2 Pathway in Colorectal Cancer: Nrf2 
Expression is Closely Correlated to Keap1 in the Tumor and Bach1 in the Normal 
Tissue. Appl Immunohistochem Mol Morphol. 2013. Epub 2013/03/05. doi: 
10.1097/PAI.0b013e318282ac20. PubMed PMID: 23455180. 
134. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 
2005;434(7035):843-50. Epub 2005/04/15. doi: 10.1038/nature03319. PubMed 
PMID: 15829953. 
135. Kipp AP, Muller MF, Goken EM, Deubel S, Brigelius-Flohe R. The 
selenoproteins GPx2, TrxR2 and TrxR3 are regulated by Wnt signalling in the 
intestinal epithelium. Biochim Biophys Acta. 2012;1820(10):1588-96. Epub 
2012/06/12. doi: 10.1016/j.bbagen.2012.05.016. PubMed PMID: 22683372. 
136. Bera S, De Rosa V, Rachidi W, Diamond AM. Does a role for selenium in DNA 
damage repair explain apparent controversies in its use in chemoprevention? 
Mutagenesis. 2013;28(2):127-34. Epub 2012/12/04. doi: 10.1093/mutage/ges064. 
PubMed PMID: 23204505; PubMed Central PMCID: PMC3570792. 
137. Jiang C, Jiang W, Ip C, Ganther H, Lu J. Selenium-induced inhibition of 
angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog. 
1999;26(4):213-25. Epub 1999/11/24. doi: 10.1002/(SICI)1098-
2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z [pii]. PubMed PMID: 10569799. 
138. Chen YC, Prabhu KS, Mastro AM. Is selenium a potential treatment for cancer 
metastasis? Nutrients. 2013;5(4):1149-68. Epub 2013/04/10. doi: 
10.3390/nu5041149. PubMed PMID: 23567478; PubMed Central PMCID: 
PMC3705340. 
 231 
 
139. Kasaikina MV, Turanov AA, Avanesov A, Schweizer U, Seeher S, Bronson RT, 
et al. Contrasting roles of dietary selenium and selenoproteins in chemically induced 
hepatocarcinogenesis. Carcinogenesis. 2013;34(5):1089-95. Epub 2013/02/08. doi: 
10.1093/carcin/bgt011. PubMed PMID: 23389288; PubMed Central PMCID: 
PMC3643414. 
140. Moustafa ME, Carlson BA, Anver MR, Bobe G, Zhong N, Ward JM, et al. 
Selenium and selenoprotein deficiencies induce widespread pyogranuloma 
formation in mice, while high levels of dietary selenium decrease liver tumor size 
driven by TGFalpha. PLoS One. 2013;8(2):e57389. Epub 2013/03/06. doi: 
10.1371/journal.pone.0057389. PubMed PMID: 23460847; PubMed Central PMCID: 
PMC3583866. 
141. Krehl S, Loewinger M, Florian S, Kipp AP, Banning A, Wessjohann LA, et al. 
Glutathione peroxidase-2 and selenium decreased inflammation and tumors in a 
mouse model of inflammation-associated carcinogenesis whereas sulforaphane 
effects differed with selenium supply. Carcinogenesis.33(3):620-8. Epub 
2011/12/20. doi: bgr288 [pii] 
10.1093/carcin/bgr288. PubMed PMID: 22180572; PubMed Central PMCID: 
PMC3291858. 
142. Tsuji PA, Carlson BA, Naranjo-Suarez S, Yoo MH, Xu XM, Fomenko DE, et al. 
Knockout of the 15 kDa selenoprotein protects against chemically-induced aberrant 
crypt formation in mice. PLoS One. 2012;7(12):e50574. Epub 2012/12/12. doi: 
10.1371/journal.pone.0050574. PubMed PMID: 23226526; PubMed Central PMCID: 
PMC3514276. 
143. Hu Y, Benya RV, Carroll RE, Diamond AM. Allelic loss of the gene for the GPX1 
selenium-containing protein is a common event in cancer. J Nutr. 2005;135(12 
Suppl):3021S-4S. Epub 2005/12/01. PubMed PMID: 16317164. 
144. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of 
heterozygosity and allelic differences in the response to selenium. Cancer Res. 
2003;63(12):3347-51. Epub 2003/06/18. PubMed PMID: 12810669. 
145. Hu YJ, Dolan ME, Bae R, Yee H, Roy M, Glickman R, et al. Allelic loss at the 
GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res. 2004;101(2):97-
106. Epub 2004/11/24. doi: 10.1385/BTER:101:2:097. PubMed PMID: 15557674. 
146. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, et 
al. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's 
tumorigenesis. Neoplasia. 2005;7(9):854-61. Epub 2005/10/19. PubMed PMID: 
16229808; PubMed Central PMCID: PMC1501938. 
147. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional 
epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 
 232 
 
2005;65(10):4218-27. Epub 2005/05/19. doi: 10.1158/0008-5472.CAN-04-4407. 
PubMed PMID: 15899813. 
148. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: 
synthesis, identity, and their role in human health. Antioxidants & redox signaling. 
2007;9(7):775-806. Epub 2007/05/19. doi: 10.1089/ars.2007.1528. PubMed PMID: 
17508906. 
149. Speckmann B, Bidmon HJ, Pinto A, Anlauf M, Sies H, Steinbrenner H. 
Induction of Glutathione Peroxidase 4 Expression during Enterocytic Cell 
Differentiation. J Biol Chem.286(12):10764-72. Epub 2011/01/22. doi: 
M110.216028 [pii] 
10.1074/jbc.M110.216028. PubMed PMID: 21252226; PubMed Central PMCID: 
PMC3060527. 
150. Davis CD, Tsuji PA, Milner JA. Selenoproteins and cancer prevention. Annu 
Rev Nutr. 2012;32:73-95. Epub 2012/03/13. doi: 10.1146/annurev-nutr-071811-
150740. PubMed PMID: 22404120. 
151. Meplan C, Hesketh J. The influence of selenium and selenoprotein gene 
variants on colorectal cancer risk. Mutagenesis.27(2):177-86. Epub 2012/02/02. 
doi: ger058 [pii] 
10.1093/mutage/ger058. PubMed PMID: 22294765. 
152. Meplan C, Crosley LK, Nicol F, Horgan GW, Mathers JC, Arthur JR, et al. 
Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the 
glutathione peroxidase 4 gene: interaction with sex. Am J Clin Nutr. 
2008;87(4):1019-27. Epub 2008/04/11. PubMed PMID: 18400727. 
153. Bermano G, Pagmantidis V, Holloway N, Kadri S, Mowat NA, Shiel RS, et al. 
Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is 
functional and is associated with susceptibility to colorectal cancer. Genes Nutr. 
2007;2(2):225-32. Epub 2008/10/14. doi: 10.1007/s12263-007-0052-3. PubMed 
PMID: 18850177; PubMed Central PMCID: PMC2474949. 
154. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, et al. Common 
germline genetic variation in antioxidant defense genes and survival after diagnosis 
of breast cancer. J Clin Oncol. 2007;25(21):3015-23. Epub 2007/07/20. doi: 
10.1200/JCO.2006.10.0099. PubMed PMID: 17634480. 
155. Bermano G, Smyth E, Goua M, Heys SD, Wahle KW. Impaired expression of 
glutathione peroxidase-4 gene in peripheral blood mononuclear cells: a biomarker 
of increased breast cancer risk. Cancer biomarkers : section A of Disease markers. 
2010;7(1):39-46. Epub 2010/11/04. doi: 10.3233/CBM-2010-0146. PubMed PMID: 
21045263. 
 233 
 
156. Sengupta A, Lichti UF, Carlson BA, Cataisson C, Ryscavage AO, Mikulec C, et al. 
Targeted disruption of glutathione peroxidase 4 in mouse skin epithelial cells 
impairs postnatal hair follicle morphogenesis that is partially rescued through 
inhibition of COX-2. J Invest Dermatol. 2013;133(7):1731-41. Epub 2013/02/01. 
doi: 10.1038/jid.2013.52. PubMed PMID: 23364477; PubMed Central PMCID: 
PMC3652900. 
157. Liu J, Du J, Zhang Y, Sun W, Smith BJ, Oberley LW, et al. Suppression of the 
malignant phenotype in pancreatic cancer by overexpression of phospholipid 
hydroperoxide glutathione peroxidase. Hum Gene Ther. 2006;17(1):105-16. Epub 
2006/01/18. doi: 10.1089/hum.2006.17.105. PubMed PMID: 16409129. 
158. Heirman I, Ginneberge D, Brigelius-Flohe R, Hendrickx N, Agostinis P, 
Brouckaert P, et al. Blocking tumor cell eicosanoid synthesis by GP x 4 impedes 
tumor growth and malignancy. Free Radic Biol Med. 2006;40(2):285-94. Epub 
2006/01/18. doi: 10.1016/j.freeradbiomed.2005.08.033. PubMed PMID: 16413410. 
159. Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M, Saito E, et al. 
Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide 
glutathione peroxidase. Isolation and enzymatic characterization of human 
selenoprotein p. J Biol Chem. 1999;274(5):2866-71. Epub 1999/01/23. PubMed 
PMID: 9915822. 
160. Burk RF, Hill KE. Selenoprotein P: an extracellular protein with unique 
physical characteristics and a role in selenium homeostasis. Annu Rev Nutr. 
2005;25:215-35. Epub 2005/07/14. doi: 10.1146/annurev.nutr.24.012003.132120. 
PubMed PMID: 16011466. 
161. Dreher I, Schmutzler C, Jakob F, Kohrle J. Expression of selenoproteins in 
various rat and human tissues and cell lines. J Trace Elem Med Biol. 1997;11(2):83-
91. Epub 1997/06/01. doi: 10.1016/S0946-672X(97)80031-4. PubMed PMID: 
9285888. 
162. Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mork H, Scheurlen M, et al. 
Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP 
in colorectal carcinogenesis. Nutr Cancer. 2004;48(1):6-14. Epub 2004/06/19. doi: 
10.1207/s15327914nc4801_2. PubMed PMID: 15203372. 
163. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in 
gene expression profiles during prostate cancer progression: functional correlations 
to tumorigenicity and down-regulation of selenoprotein-P in mouse and human 
tumors. Cancer Res. 2002;62(18):5325-35. Epub 2002/09/18. PubMed PMID: 
12235003. 
164. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, et 
al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate 
cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers 
 234 
 
Prev. 2010;19(11):2958-68. Epub 2010/09/21. doi: 10.1158/1055-9965.EPI-10-
0364. PubMed PMID: 20852007. 
165. Peters U, Chatterjee N, Hayes RB, Schoen RE, Wang Y, Chanock SJ, et al. 
Variation in the selenoenzyme genes and risk of advanced distal colorectal 
adenoma. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1144-54. Epub 
2008/05/17. doi: 10.1158/1055-9965.EPI-07-2947. PubMed PMID: 18483336. 
166. Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, Endermann 
T, et al. Selenoprotein-P is down-regulated in prostate cancer, which results in lack 
of protection against oxidative damage. Prostate. 2011;71(8):824-34. Epub 
2011/04/02. doi: 10.1002/pros.21298. PubMed PMID: 21456065. 
167. Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, et al. 
Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in 
human colon carcinoma. Eur J Cancer. 2001;37(2):224-33. Epub 2001/02/13. 
PubMed PMID: 11166150. 
168. Mostert V, Dreher I, Kohrle J, Abel J. Transforming growth factor-beta1 
inhibits expression of selenoprotein P in cultured human liver cells. FEBS Lett. 
1999;460(1):23-6. Epub 1999/11/26. doi: S0014-5793(99)01298-3 [pii]. PubMed 
PMID: 10571054. 
169. Dreher I, Jakobs TC, Kohrle J. Cloning and characterization of the human 
selenoprotein P promoter. Response of selenoprotein P expression to cytokines in 
liver cells. J Biol Chem. 1997;272(46):29364-71. Epub 1997/11/20. PubMed PMID: 
9361018. 
170. Rock C, Moos PJ. Selenoprotein P regulation by the glucocorticoid receptor. 
Biometals. 2009;22(6):995-1009. Epub 2009/06/11. doi: 10.1007/s10534-009-
9251-2. PubMed PMID: 19513589; PubMed Central PMCID: PMC3039700. 
171. Speckmann B, Pinto A, Winter M, Forster I, Sies H, Steinbrenner H. 
Proinflammatory cytokines down-regulate intestinal selenoprotein P biosynthesis 
via NOS2 induction. Free Radic Biol Med.49(5):777-85. Epub 2010/06/15. doi: 
S0891-5849(10)00354-0 [pii] 
10.1016/j.freeradbiomed.2010.05.035. PubMed PMID: 20542496. 
172. Zhang Y, Chen X. Reducing selenoprotein P expression suppresses adipocyte 
differentiation as a result of increased preadipocyte inflammation. Am J Physiol 
Endocrinol Metab.300(1):E77-85. Epub 2010/10/21. doi: ajpendo.00380.2010 [pii] 
10.1152/ajpendo.00380.2010. PubMed PMID: 20959537; PubMed Central PMCID: 
PMC3023214. 
 235 
 
173. Look AT. Oncogenic transcription factors in the human acute leukemias. 
Science. 1997;278(5340):1059-64. Epub 1997/11/14. PubMed PMID: 9353180. 
174. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) 
breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a 
limited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88(23):10431-
4. Epub 1991/12/01. PubMed PMID: 1720541; PubMed Central PMCID: PMC52942. 
175. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, et al. 
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic 
mouse model. Blood. 2000;96(6):2108-15. Epub 2000/09/09. PubMed PMID: 
10979955. 
176. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in 
t(8;21) acute myeloid leukemia, represses transcription by interaction with the 
human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A. 
1998;95(18):10860-5. Epub 1998/09/02. PubMed PMID: 9724795; PubMed Central 
PMCID: PMC27986. 
177. Lutterbach B, Sun D, Schuetz J, Hiebert SW. The MYND motif is required for 
repression of basal transcription from the multidrug resistance 1 promoter by the 
t(8;21) fusion protein. Mol Cell Biol. 1998;18(6):3604-11. Epub 1998/06/20. 
PubMed PMID: 9584201; PubMed Central PMCID: PMC108942. 
178. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, et al. 
ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 
corepressors. Mol Cell Biol. 1998;18(12):7176-84. Epub 1998/11/20. PubMed 
PMID: 9819404; PubMed Central PMCID: PMC109299. 
179. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, et al. The 
t(8;21) translocation in acute myeloid leukemia results in production of an AML1-
MTG8 fusion transcript. EMBO J. 1993;12(7):2715-21. Epub 1993/07/01. PubMed 
PMID: 8334990; PubMed Central PMCID: PMC413521. 
180. Fracchiolla NS, Colombo G, Finelli P, Maiolo AT, Neri A. EHT, a new member 
of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute 
myeloid leukemias. Blood. 1998;92(9):3481-4. Epub 1998/10/27. PubMed PMID: 
9787195. 
181. Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, et al. The 
partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the 
MTG8(ETO) family. Blood. 1998;91(11):4028-37. Epub 1998/05/30. PubMed PMID: 
9596646. 
182. Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K, et al. 
The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of 
 236 
 
the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol. 1998;18(2):846-58. Epub 
1998/02/03. PubMed PMID: 9447981; PubMed Central PMCID: PMC108796. 
183. Davis JN, Williams BJ, Herron JT, Galiano FJ, Meyers S. ETO-2, a new member 
of the ETO-family of nuclear proteins. Oncogene. 1999;18(6):1375-83. Epub 
1999/02/18. doi: 10.1038/sj.onc.1202412. PubMed PMID: 10022820. 
184. McGhee L, Bryan J, Elliott L, Grimes HL, Kazanjian A, Davis JN, et al. Gfi-1 
attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase 
proteins, and represses transcription using a TSA-sensitive mechanism. J Cell 
Biochem. 2003;89(5):1005-18. Epub 2003/07/23. doi: 10.1002/jcb.10548. PubMed 
PMID: 12874834. 
185. Hoey T, Weinzierl RO, Gill G, Chen JL, Dynlacht BD, Tjian R. Molecular cloning 
and functional analysis of Drosophila TAF110 reveal properties expected of 
coactivators. Cell. 1993;72(2):247-60. Epub 1993/01/29. PubMed PMID: 7678780. 
186. Wei Y, Liu S, Lausen J, Woodrell C, Cho S, Biris N, et al. A TAF4-homology 
domain from the corepressor ETO is a docking platform for positive and negative 
regulators of transcription. Nat Struct Mol Biol. 2007;14(7):653-61. Epub 
2007/06/19. doi: 10.1038/nsmb1258. PubMed PMID: 17572682. 
187. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, et al. ETO, a 
target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone 
deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol. 
2001;21(19):6470-83. Epub 2001/09/05. PubMed PMID: 11533236; PubMed 
Central PMCID: PMC99794. 
188. Hildebrand D, Tiefenbach J, Heinzel T, Grez M, Maurer AB. Multiple regions of 
ETO cooperate in transcriptional repression. J Biol Chem. 2001;276(13):9889-95. 
Epub 2001/01/21. doi: 10.1074/jbc.M010582200. PubMed PMID: 11150306. 
189. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant 
recruitment of the nuclear receptor corepressor-histone deacetylase complex by the 
acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 1998;18(12):7185-91. 
Epub 1998/11/20. PubMed PMID: 9819405; PubMed Central PMCID: PMC109300. 
190. Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. Gene. 
2003;303:1-10. PubMed PMID: 12559562. 
191. Sacchi N, Tamanini F, Willemsen R, Denis-Donini S, Campiglio S, Hoogeveen 
AT. Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells. 
Oncogene. 1998;16(20):2609-15. Epub 1998/06/19. doi: 10.1038/sj.onc.1201824. 
PubMed PMID: 9632137. 
192. Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, et al. The 
ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a 
 237 
 
corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol. 
2000;20(6):2075-86. Epub 2000/02/25. PubMed PMID: 10688654; PubMed Central 
PMCID: PMC110824. 
193. Fukuyama T, Sueoka E, Sugio Y, Otsuka T, Niho Y, Akagi K, et al. MTG8 proto-
oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent 
protein kinase in lymphocytes. Oncogene. 2001;20(43):6225-32. Epub 2001/10/11. 
doi: 10.1038/sj.onc.1204794. PubMed PMID: 11593431. 
194. Wolford JK, Prochazka M. Structure and expression of the human MTG8/ETO 
gene. Gene. 1998;212(1):103-9. Epub 1998/07/14. PubMed PMID: 9661669. 
195. Erickson PF, Dessev G, Lasher RS, Philips G, Robinson M, Drabkin HA. ETO 
and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: 
implications for t(8;21) leukemogenesis and monitoring residual disease. Blood. 
1996;88(5):1813-23. Epub 1996/09/01. PubMed PMID: 8781439. 
196. Okumura AJ, Peterson LF, Lo MC, Zhang DE. Expression of AML/Runx and 
ETO/MTG family members during hematopoietic differentiation of embryonic stem 
cells. Experimental hematology. 2007;35(6):978-88. Epub 2007/05/30. doi: 
10.1016/j.exphem.2007.03.002. PubMed PMID: 17533052. 
197. Calabi F, Cilli V. CBFA2T1, a gene rearranged in human leukemia, is a 
member of a multigene family. Genomics. 1998;52(3):332-41. Epub 1998/10/29. 
doi: 10.1006/geno.1998.5429. PubMed PMID: 9790752. 
198. Morohoshi F, Mitani S, Mitsuhashi N, Kitabayashi I, Takahashi E, Suzuki M, et 
al. Structure and expression pattern of a human MTG8/ETO family gene, MTGR1. 
Gene. 2000;241(2):287-95. Epub 2000/02/16. doi: S0378111999004813 [pii]. 
PubMed PMID: 10675041. 
199. Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, Bardwell VJ, et al. 
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. 
Blood. 2004;103(4):1454-63. Epub 2003/10/11. doi: 10.1182/blood-2003-06-2081 
2003-06-2081 [pii]. PubMed PMID: 14551142. 
200. Fischer MA, Moreno-Miralles I, Hunt A, Chyla BJ, Hiebert SW. Myeloid 
translocation gene 16 is required for maintenance of haematopoietic stem cell 
quiescence. EMBO J.31(6):1494-505. Epub 2012/01/24. doi: emboj2011500 [pii] 
10.1038/emboj.2011.500. PubMed PMID: 22266796; PubMed Central PMCID: 
PMC3321173. 
201. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer 
Biol Ther. 2002;1(5):466-76. Epub 2002/12/24. PubMed PMID: 12496471. 
 238 
 
202. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control 
and signal integration in development. Science. 1999;284(5415):770-6. Epub 
1999/04/30. PubMed PMID: 10221902. 
203. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annual review of 
pathology. 2008;3:587-613. Epub 2007/11/28. doi: 
10.1146/annurev.pathmechdis.3.121806.154300. PubMed PMID: 18039126. 
204. Gridley T. Notch signaling and inherited disease syndromes. Hum Mol Genet. 
2003;12 Spec No 1:R9-13. Epub 2003/04/02. PubMed PMID: 12668592. 
205. Jundt F, Schwarzer R, Dorken B. Notch signaling in leukemias and 
lymphomas. Current molecular medicine. 2008;8(1):51-9. Epub 2008/02/22. 
PubMed PMID: 18289013. 
206. Miele L, Golde T, Osborne B. Notch signaling in cancer. Current molecular 
medicine. 2006;6(8):905-18. Epub 2006/12/16. PubMed PMID: 17168741. 
207. Engel ME, Nguyen HN, Mariotti J, Hunt A, Hiebert SW. Myeloid translocation 
gene 16 (MTG16) interacts with Notch transcription complex components to 
integrate Notch signaling in hematopoietic cell fate specification. Mol Cell Biol. 
2010;30(7):1852-63. Epub 2010/02/04. doi: 10.1128/MCB.01342-09. PubMed 
PMID: 20123979; PubMed Central PMCID: PMC2838074. 
208. Kumar P, Sharoyko VV, Spegel P, Gullberg U, Mulder H, Olsson I, et al. The 
transcriptional co-repressor myeloid translocation gene 16 inhibits glycolysis and 
stimulates mitochondrial respiration. PLoS One. 2013;8(7):e68502. Epub 
2013/07/11. doi: 10.1371/journal.pone.0068502. PubMed PMID: 23840896; 
PubMed Central PMCID: PMC3698176. 
209. Moore AC, Amann JM, Williams CS, Tahinci E, Farmer TE, Martinez JA, et al. 
Myeloid translocation gene family members associate with T-cell factors (TCFs) and 
influence TCF-dependent transcription. Mol Cell Biol. 2008;28(3):977-87. PubMed 
PMID: 18039847. 
210. Costa FF. Non-coding RNAs: lost in translation? Gene. 2007;386(1-2):1-10. 
Epub 2006/11/23. doi: 10.1016/j.gene.2006.09.028. PubMed PMID: 17113247. 
211. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15 Spec No 
1:R17-29. Epub 2006/05/03. doi: 10.1093/hmg/ddl046. PubMed PMID: 16651366. 
212. Storz G. An expanding universe of noncoding RNAs. Science. 
2002;296(5571):1260-3. Epub 2002/05/23. doi: 10.1126/science.1072249. 
PubMed PMID: 12016301. 
213. Rossetti S, van Unen L, Sacchi N, Hoogeveen AT. Novel RNA-binding 
properties of the MTG chromatin regulatory proteins. BMC Mol Biol. 2008;9:93. 
 239 
 
Epub 2008/10/28. doi: 10.1186/1471-2199-9-93. PubMed PMID: 18950503; 
PubMed Central PMCID: PMC2579434. 
214. Calabi F, Pannell R, Pavloska G. Gene targeting reveals a crucial role for MTG8 
in the gut. Mol Cell Biol. 2001;21(16):5658-66. Epub 2001/07/21. doi: 
10.1128/MCB.21.16.5658-5666.2001. PubMed PMID: 11463846; PubMed Central 
PMCID: PMC87286. 
215. Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, Engel 
M, et al. Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell 
proliferation and lineage allocation. Mol Cell Biol. 2008;28(20):6234-47. Epub 
2008/08/20. doi: 10.1128/MCB.00404-08. PubMed PMID: 18710942; PubMed 
Central PMCID: PMC2577421. 
216. Williams CS, Bradley AM, Chaturvedi R, Singh K, Piazuelo MB, Chen X, et al. 
MTG16 contributes to colonic epithelial integrity in experimental colitis. Gut. 2012. 
Epub 2012/07/27. doi: 10.1136/gutjnl-2011-301439. PubMed PMID: 22833394; 
PubMed Central PMCID: PMC3663894. 
217. Amann JM, Chyla BJ, Ellis TC, Martinez A, Moore AC, Franklin JL, et al. Mtgr1 is 
a transcriptional corepressor that is required for maintenance of the secretory cell 
lineage in the small intestine. Mol Cell Biol. 2005;25(21):9576-85. Epub 
2005/10/18. doi: 25/21/9576 [pii] 
10.1128/MCB.25.21.9576-9585.2005. PubMed PMID: 16227606; PubMed Central 
PMCID: PMC1265807. 
218. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, et al. 
Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of 
a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, 
runt. Blood. 1992;80(7):1825-31. Epub 1992/10/01. PubMed PMID: 1391946. 
219. Acute myelogenous leukemia with an 8;21 translocation. A report on 148 
cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet 
Cytogenet. 1990;44(2):169-79. Epub 1990/02/01. PubMed PMID: 2297675. 
220. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute 
and chronic myeloid leukemia. Blood. 1995;86(1):1-14. Epub 1995/07/01. PubMed 
PMID: 7795214. 
221. Langabeer SE, Walker H, Rogers JR, Burnett AK, Wheatley K, Swirsky D, et al. 
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML 
trials. MRC Adult Leukaemia Working Party. Br J Haematol. 1997;99(4):925-8. Epub 
1998/01/31. PubMed PMID: 9432044. 
222. Goardon N, Lambert JA, Rodriguez P, Nissaire P, Herblot S, Thibault P, et al. 
ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. 
 240 
 
EMBO J. 2006;25(2):357-66. Epub 2006/01/13. doi: 10.1038/sj.emboj.7600934. 
PubMed PMID: 16407974; PubMed Central PMCID: PMC1383517. 
223. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. E protein silencing by 
the leukemogenic AML1-ETO fusion protein. Science. 2004;305(5688):1286-9. Epub 
2004/08/31. doi: 10.1126/science.1097937. PubMed PMID: 15333839. 
224. Hiebert SW, Lutterbach B, Amann J. Role of co-repressors in transcriptional 
repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins. 
Curr Opin Hematol. 2001;8(4):197-200. Epub 2001/09/19. PubMed PMID: 
11561155. 
225. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone 
deacetylase relieve ETO-mediated repression and induce differentiation of AML1-
ETO leukemia cells. Cancer Res. 1999;59(12):2766-9. Epub 1999/06/26. PubMed 
PMID: 10383127. 
226. Martinez JA, Williams CS, Amann JM, Ellis TC, Moreno-Miralles I, Washington 
MK, et al. Deletion of Mtgr1 sensitizes the colonic epithelium to dextran sodium 
sulfate-induced colitis. Gastroenterology. 2006;131(2):579-88. Epub 2006/08/08. 
doi: S0016-5085(06)01238-8 [pii] 
10.1053/j.gastro.2006.06.009. PubMed PMID: 16890610. 
227. Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, et al. 
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast 
cancer loss of heterozygosity region at 16q24.3. Cancer Res. 2002;62(16):4599-604. 
Epub 2002/08/17. PubMed PMID: 12183414. 
228. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic 
landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-
13. Epub 2007/10/13. doi: 1145720 [pii] 
10.1126/science.1145720. PubMed PMID: 17932254. 
229. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The 
consensus coding sequences of human breast and colorectal cancers. Science. 
2006;314(5797):268-74. PubMed PMID: 16959974. 
230. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome 
integrates intrinsic and environmental signals. Nat Genet. 2003;33 Suppl:245-54. 
Epub 2003/03/01. doi: 10.1038/ng1089. PubMed PMID: 12610534. 
231. Daniel JM, Spring CM, Crawford HC, Reynolds AB, Baig A. The p120(ctn)-
binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a 
sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res. 
 241 
 
2002;30(13):2911-9. Epub 2002/06/28. PubMed PMID: 12087177; PubMed Central 
PMCID: PMC117053. 
232. Prokhortchouk A, Hendrich B, Jorgensen H, Ruzov A, Wilm M, Georgiev G, et 
al. The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional 
repressor. Genes Dev. 2001;15(13):1613-8. Epub 2001/07/11. doi: 
10.1101/gad.198501. PubMed PMID: 11445535; PubMed Central PMCID: 
PMC312733. 
233. Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA. A 
family of human zinc finger proteins that bind methylated DNA and repress 
transcription. Mol Cell Biol. 2006;26(1):169-81. Epub 2005/12/16. doi: 26/1/169 
[pii] 
10.1128/MCB.26.1.169-181.2006. PubMed PMID: 16354688; PubMed Central 
PMCID: PMC1317629. 
234. Daniel JM, Reynolds AB. The catenin p120(ctn) interacts with Kaiso, a novel 
BTB/POZ domain zinc finger transcription factor. Mol Cell Biol. 1999;19(5):3614-
23. Epub 1999/04/17. PubMed PMID: 10207085; PubMed Central PMCID: 
PMC84161. 
235. Yoon HG, Chan DW, Reynolds AB, Qin J, Wong J. N-CoR mediates DNA 
methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol 
Cell. 2003;12(3):723-34. Epub 2003/10/07. PubMed PMID: 14527417. 
236. Futamura M, Nishimori H, Shiratsuchi T, Saji S, Nakamura Y, Tokino T. 
Molecular cloning, mapping, and characterization of a novel human gene, MTA1-L1, 
showing homology to a metastasis-associated gene, MTA1. J Hum Genet. 
1999;44(1):52-6. Epub 1999/02/04. doi: 10.1007/s100380050107. PubMed PMID: 
9929979. 
237. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect 
on cell growth and apoptosis. Nature. 2000;408(6810):377-81. Epub 2000/12/01. 
doi: 10.1038/35042612. PubMed PMID: 11099047. 
238. Defossez PA, Kelly KF, Filion GJ, Perez-Torrado R, Magdinier F, Menoni H, et 
al. The human enhancer blocker CTC-binding factor interacts with the transcription 
factor Kaiso. J Biol Chem. 2005;280(52):43017-23. Epub 2005/10/19. doi: 
10.1074/jbc.M510802200. PubMed PMID: 16230345. 
239. Fiorentino FP, Giordano A. The tumor suppressor role of CTCF. J Cell Physiol. 
2012;227(2):479-92. Epub 2011/04/06. doi: 10.1002/jcp.22780. PubMed PMID: 
21465478. 
 242 
 
240. Iioka H, Doerner SK, Tamai K. Kaiso is a bimodal modulator for Wnt/beta-
catenin signaling. FEBS Lett. 2009;583(4):627-32. Epub 2009/01/27. doi: 
10.1016/j.febslet.2009.01.012. PubMed PMID: 19166851. 
241. Spring CM, Kelly KF, O'Kelly I, Graham M, Crawford HC, Daniel JM. The 
catenin p120ctn inhibits Kaiso-mediated transcriptional repression of the beta-
catenin/TCF target gene matrilysin. Exp Cell Res. 2005;305(2):253-65. Epub 
2005/04/09. doi: 10.1016/j.yexcr.2005.01.007. PubMed PMID: 15817151. 
242. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of 
matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut. 
1999;45(2):252-8. Epub 1999/07/14. PubMed PMID: 10403738; PubMed Central 
PMCID: PMC1727600. 
243. Bloomston M, Zervos EE, Rosemurgy AS, 2nd. Matrix metalloproteinases and 
their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann 
Surg Oncol. 2002;9(7):668-74. Epub 2002/08/09. PubMed PMID: 12167581. 
244. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis 
P, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation 
in intestinal tumors. Oncogene. 1999;18(18):2883-91. Epub 1999/06/11. doi: 
10.1038/sj.onc.1202627. PubMed PMID: 10362259. 
245. Del Valle-Perez B, Casagolda D, Lugilde E, Valls G, Codina M, Dave N, et al. 
Wnt controls the transcriptional activity of Kaiso through CK1epsilon-dependent 
phosphorylation of p120-catenin. J Cell Sci. 2011;124(Pt 13):2298-309. Epub 
2011/06/15. doi: 10.1242/jcs.082693. PubMed PMID: 21670201. 
246. Kelly KF, Daniel JM. POZ for effect--POZ-ZF transcription factors in cancer 
and development. Trends Cell Biol. 2006;16(11):578-87. Epub 2006/09/26. doi: 
10.1016/j.tcb.2006.09.003. PubMed PMID: 16996269. 
247. Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, et al. Kaiso 
contributes to DNA methylation-dependent silencing of tumor suppressor genes in 
colon cancer cell lines. Cancer Res. 2008;68(18):7258-63. Epub 2008/09/17. doi: 
10.1158/0008-5472.CAN-08-0344. PubMed PMID: 18794111. 
248. Weber A, Marquardt J, Elzi D, Forster N, Starke S, Glaum A, et al. Zbtb4 
represses transcription of P21CIP1 and controls the cellular response to p53 
activation. EMBO J. 2008;27(11):1563-74. Epub 2008/05/03. doi: emboj200885 
[pii] 
10.1038/emboj.2008.85. PubMed PMID: 18451802; PubMed Central PMCID: 
PMC2426723. 
249. Soubry A, van Hengel J, Parthoens E, Colpaert C, Van Marck E, Waltregny D, et 
al. Expression and nuclear location of the transcriptional repressor Kaiso is 
 243 
 
regulated by the tumor microenvironment. Cancer Res. 2005;65(6):2224-33. Epub 
2005/03/23. doi: 10.1158/0008-5472.CAN-04-2020. PubMed PMID: 15781635. 
250. Jiang G, Wang Y, Dai S, Liu Y, Stoecker M, Wang E. P120-catenin isoforms 1 
and 3 regulate proliferation and cell cycle of lung cancer cells via beta-catenin and 
Kaiso respectively. PLoS One. 2012;7(1):e30303. Epub 2012/01/26. doi: 
10.1371/journal.pone.0030303. PubMed PMID: 22276175; PubMed Central PMCID: 
PMC3262806. 
251. Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina 
D, et al. Kaiso-deficient mice show resistance to intestinal cancer. Mol Cell Biol. 
2006;26(1):199-208. Epub 2005/12/16. doi: 26/1/199 [pii] 
10.1128/MCB.26.1.199-208.2006. PubMed PMID: 16354691; PubMed Central 
PMCID: PMC1317619. 
252. Vermeulen JF, van de Ven RA, Ercan C, van der Groep P, van der Wall E, Bult 
P, et al. Nuclear Kaiso expression is associated with high grade and triple-negative 
invasive breast cancer. PLoS One. 2012;7(5):e37864. Epub 2012/06/05. doi: 
10.1371/journal.pone.0037864. PubMed PMID: 22662240; PubMed Central PMCID: 
PMC3360634. 
253. Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, Sitaraman SV, et al. 
Temporal and spatial analysis of clinical and molecular parameters in dextran 
sodium sulfate induced colitis. PLoS One. 2009;4(6):e6073. Epub 2009/06/30. doi: 
10.1371/journal.pone.0006073. PubMed PMID: 19562033; PubMed Central PMCID: 
PMC2698136. 
254. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg. 
1998;22(4):382-9. Epub 1998/04/02. PubMed PMID: 9523521. 
255. Kennedy RJ, Hoper M, Deodhar K, Erwin PJ, Kirk SJ, Gardiner KR. Interleukin 
10-deficient colitis: new similarities to human inflammatory bowel disease. Br J 
Surg. 2000;87(10):1346-51. Epub 2000/10/24. doi: 10.1046/j.1365-
2168.2000.01615.x. PubMed PMID: 11044159. 
256. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. 
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 
2000;289(5483):1352-5. Epub 2000/08/26. PubMed PMID: 10958782. 
257. Hofstetter C, Kleen M, Habler O, Allmeling AM, Krombach F, Zwissler B. 
Recombinant human interleukin-10 attenuates TNFalpha production by porcine 
monocytes. European journal of medical research. 1998;3(6):299-303. Epub 
1998/06/11. PubMed PMID: 9620892. 
258. Kim IW, Myung SJ, Do MY, Ryu YM, Kim MJ, Do EJ, et al. Western-style diets 
induce macrophage infiltration and contribute to colitis-associated carcinogenesis. J 
 244 
 
Gastroenterol Hepatol. 2010;25(11):1785-94. Epub 2010/11/03. doi: 
10.1111/j.1440-1746.2010.06332.x. PubMed PMID: 21039842. 
259. Miyazawa F, Olijnyk OR, Tilley CJ, Tamaoki T. Interactions between dextran 
sulfate and Escherichia coli ribosomes. Biochim Biophys Acta. 1967;145(1):96-104. 
Epub 1967/08/22. PubMed PMID: 4861264. 
260. Fellig J, Wiley CE. The inhibition of pancreatic ribonuclease by anionic 
polymers. Arch Biochem Biophys. 1959;85:313-6. Epub 1959/12/01. PubMed 
PMID: 13822112. 
261. Philipson L, Zetterqvist O. The Presence of DNA in Human Erythrocyte 
Membranes. Biochim Biophys Acta. 1964;91:171-3. Epub 1964/09/11. PubMed 
PMID: 14227268. 
262. Laroui H, Ingersoll SA, Liu HC, Baker MT, Ayyadurai S, Charania MA, et al. 
Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes 
with medium-chain-length fatty acids in the colon. PLoS One. 2012;7(3):e32084. 
Epub 2012/03/20. doi: 10.1371/journal.pone.0032084. PubMed PMID: 22427817; 
PubMed Central PMCID: PMC3302894. 
263. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. Dysplasia and 
carcinoma development in a repeated dextran sulfate sodium-induced colitis model. 
J Gastroenterol Hepatol. 2002;17(10):1078-83. Epub 2002/08/31. PubMed PMID: 
12201867. 
264. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel 
inflammation-related mouse colon carcinogenesis model induced by azoxymethane 
and dextran sodium sulfate. Cancer Sci. 2003;94(11):965-73. Epub 2003/11/13. 
PubMed PMID: 14611673. 
265. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links 
inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 
2004;118(3):285-96. Epub 2004/08/06. doi: 10.1016/j.cell.2004.07.013 
S0092867404006713 [pii]. PubMed PMID: 15294155. 
266. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. 
Toll-like receptor-4 promotes the development of colitis-associated colorectal 
tumors. Gastroenterology. 2007;133(6):1869-81. Epub 2007/12/07. doi: S0016-
5085(07)01649-6 [pii] 
10.1053/j.gastro.2007.09.008. PubMed PMID: 18054559; PubMed Central PMCID: 
PMC2180834. 
267. Lowe EL, Crother TR, Rabizadeh S, Hu B, Wang H, Chen S, et al. Toll-like 
receptor 2 signaling protects mice from tumor development in a mouse model of 
 245 
 
colitis-induced cancer. PLoS One.5(9):e13027. Epub 2010/10/05. doi: 
10.1371/journal.pone.0013027. PubMed PMID: 20885960; PubMed Central PMCID: 
PMC2946405. 
268. Barrett CW, Ning W, Chen X, Smith JJ, Washington MK, Hill KE, et al. Tumor 
suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated 
carcinoma. Cancer Res. 2013;73(3):1245-55. Epub 2012/12/12. doi: 10.1158/0008-
5472.CAN-12-3150. PubMed PMID: 23221387; PubMed Central PMCID: 
PMC3563732. 
269. Barrett CW, Fingleton B, Williams A, Ning W, Fischer MA, Washington MK, et 
al. MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated 
carcinoma model. Cancer Res.71(4):1302-12. Epub 2011/02/10. doi: 0008-
5472.CAN-10-3317 [pii] 
10.1158/0008-5472.CAN-10-3317. PubMed PMID: 21303973; PubMed Central 
PMCID: PMC3150168. 
270. Kuroki F, Matsumoto T, Iida M. Selenium is depleted in Crohn's disease on 
enteral nutrition. Dig Dis. 2003;21(3):266-70. Epub 2003/10/23. doi: 73346. 
PubMed PMID: 14571102. 
271. Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ. Circulating antioxidant 
concentrations in children with inflammatory bowel disease. Am J Clin Nutr. 
1997;65(5):1482-8. Epub 1997/05/01. PubMed PMID: 9129480. 
272. Rannem T, Ladefoged K, Hylander E, Hegnhoj J, Jarnum S. Selenium status in 
patients with Crohn's disease. Am J Clin Nutr. 1992;56(5):933-7. Epub 1992/11/01. 
PubMed PMID: 1415013. 
273. Reimund JM, Hirth C, Koehl C, Baumann R, Duclos B. Antioxidant and immune 
status in active Crohn's disease. A possible relationship. Clin Nutr. 2000;19(1):43-8. 
Epub 2000/03/04. doi: 10.1054/clnu.1999.0073. PubMed PMID: 10700533. 
274. Andoh A, Hirashima M, Maeda H, Hata K, Inatomi O, Tsujikawa T, et al. Serum 
selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition. 
2005;21(5):574-9. Epub 2005/04/27. doi: 10.1016/j.nut.2004.08.025. PubMed 
PMID: 15850963. 
275. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, 
prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-17. 
Epub 2004/05/29. PubMed PMID: 15168363. 
276. Kirsner JB. Inflammatory bowel disease. Part II: Clinical and therapeutic 
aspects. Disease-a-month : DM. 1991;37(11):669-746. Epub 1991/11/01. PubMed 
PMID: 1935537. 
 246 
 
277. Kirsner JB. Inflammatory bowel disease. Part I: Nature and pathogenesis. 
Disease-a-month : DM. 1991;37(10):605-66. Epub 1991/10/01. PubMed PMID: 
1893828. 
278. Vatn MH. Natural history and complications of IBD. Current gastroenterology 
reports. 2009;11(6):481-7. Epub 2009/11/12. PubMed PMID: 19903424. 
279. Kirsner JB. The local and systemic complications of inflammatory bowel 
disease. JAMA. 1979;242(11):1177-83. Epub 1979/09/14. PubMed PMID: 470073. 
280. Ringstad J, Kildebo S, Thomassen Y. Serum selenium, copper, and zinc 
concentrations in Crohn's disease and ulcerative colitis. Scand J Gastroenterol. 
1993;28(7):605-8. Epub 1993/07/01. PubMed PMID: 8362213. 
281. Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR. Nutrition and 
inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28(2):423-43, ix. 
Epub 1999/06/18. PubMed PMID: 10372275. 
282. Sturniolo GC, Mestriner C, Lecis PE, D'Odorico A, Venturi C, Irato P, et al. 
Altered plasma and mucosal concentrations of trace elements and antioxidants in 
active ulcerative colitis. Scand J Gastroenterol. 1998;33(6):644-9. Epub 
1998/07/21. PubMed PMID: 9669638. 
283. Ojuawo A, Keith L. The serum concentrations of zinc, copper and selenium in 
children with inflammatory bowel disease. The Central African journal of medicine. 
2002;48(9-10):116-9. Epub 2003/10/18. PubMed PMID: 14562534. 
284. Mannick EE, Bonomolo JC, Horswell R, Lentz JJ, Serrano MS, Zapata-Velandia 
A, et al. Gene expression in mononuclear cells from patients with inflammatory 
bowel disease. Clin Immunol. 2004;112(3):247-57. Epub 2004/08/17. doi: 
10.1016/j.clim.2004.03.014. PubMed PMID: 15308118. 
285. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, et al. 
Challenges in IBD research: update on progress and prioritization of the CCFA's 
research agenda. Inflamm Bowel Dis. 2013;19(4):677-82. Epub 2013/03/02. doi: 
10.1097/MIB.0b013e31828134b3. PubMed PMID: 23448796. 
286. Kipp A, Banning A, van Schothorst EM, Meplan C, Schomburg L, Evelo C, et al. 
Four selenoproteins, protein biosynthesis, and Wnt signalling are particularly 
sensitive to limited selenium intake in mouse colon. Mol Nutr Food Res. 
2009;53(12):1561-72. Epub 2009/10/08. doi: 10.1002/mnfr.200900105. PubMed 
PMID: 19810021. 
287. Yin F, Sancheti H, Cadenas E. Mitochondrial thiols in the regulation of cell 
death pathways. Antioxidants & redox signaling. 2012;17(12):1714-27. Epub 
2012/04/26. doi: 10.1089/ars.2012.4639. PubMed PMID: 22530585; PubMed 
Central PMCID: PMC3474184. 
 247 
 
288. Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer 
mortality in U.S. counties. Arch Environ Health. 1991;46(1):37-42. Epub 
1991/01/01. doi: 10.1080/00039896.1991.9937427. PubMed PMID: 1992931. 
289. Combs GF, Jr., Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 
1998;79(3):179-92. Epub 1998/10/17. PubMed PMID: 9776375. 
290. Jaworska K, Gupta S, Durda K, Muszynska M, Sukiennicki G, Jaworowska E, et 
al. A low selenium level is associated with lung and laryngeal cancers. PLoS One. 
2013;8(3):e59051. Epub 2013/03/22. doi: 10.1371/journal.pone.0059051. PubMed 
PMID: 23516596; PubMed Central PMCID: PMC3596323. 
291. Schrauzer GN. Trace elements, nutrition and cancer: perspectives of 
prevention. Adv Exp Med Biol. 1977;91:323-44. Epub 1977/01/01. PubMed PMID: 
605853. 
292. Irons R, Carlson BA, Hatfield DL, Davis CD. Both selenoproteins and low 
molecular weight selenocompounds reduce colon cancer risk in mice with 
genetically impaired selenoprotein expression. J Nutr. 2006;136(5):1311-7. Epub 
2006/04/15. doi: 136/5/1311 [pii]. PubMed PMID: 16614422. 
293. Florian S, Wingler K, Schmehl K, Jacobasch G, Kreuzer OJ, Meyerhof W, et al. 
Cellular and subcellular localization of gastrointestinal glutathione peroxidase in 
normal and malignant human intestinal tissue. Free Radic Res. 2001;35(6):655-63. 
Epub 2002/01/29. PubMed PMID: 11811519. 
294. Mork H, al-Taie OH, Bahr K, Zierer A, Beck C, Scheurlen M, et al. Inverse 
mRNA expression of the selenocysteine-containing proteins GI-GPx and SeP in 
colorectal adenomas compared with adjacent normal mucosa. Nutr Cancer. 
2000;37(1):108-16. Epub 2000/08/31. doi: 10.1207/S15327914NC3701_14. 
PubMed PMID: 10965527. 
295. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular 
diagnosis of colorectal tumors by expression profiles of 50 genes expressed 
differentially in adenomas and carcinomas. Oncogene. 2002;21(26):4120-8. Epub 
2002/05/31. doi: 10.1038/sj.onc.1205518. PubMed PMID: 12037668. 
296. Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, et al. 
Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. 
Cancer Res. 2004;64(3):962-8. Epub 2004/02/12. PubMed PMID: 14871826. 
297. Krehl S, Loewinger M, Florian S, Kipp AP, Banning A, Wessjohann LA, et al. 
Glutathione peroxidase-2 and selenium decreased inflammation and tumors in a 
mouse model of inflammation-associated carcinogenesis whereas sulforaphane 
effects differed with selenium supply. Carcinogenesis. 2012;33(3):620-8. Epub 
2011/12/20. doi: 10.1093/carcin/bgr288. PubMed PMID: 22180572; PubMed 
Central PMCID: PMC3291858. 
 248 
 
298. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, et al. 
Aberrant expression of selenoproteins in the progression of colorectal cancer. 
Cancer Lett. 2008;259(2):218-30. Epub 2007/12/07. doi: 
10.1016/j.canlet.2007.10.019. PubMed PMID: 18054426. 
299. Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, Akcay T. Oxidative DNA 
damage and antioxidant activity in patients with inflammatory bowel disease. Dig 
Dis Sci. 2007;52(7):1636-41. Epub 2007/03/30. doi: 10.1007/s10620-006-9386-8. 
PubMed PMID: 17393334. 
300. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal 
cancer. A population-based study. N Engl J Med. 1990;323(18):1228-33. Epub 
1990/11/01. PubMed PMID: 2215606. 
301. Hill KE, Zhou J, McMahan WJ, Motley AK, Burk RF. Neurological dysfunction 
occurs in mice with targeted deletion of the selenoprotein P gene. J Nutr. 
2004;134(1):157-61. Epub 2004/01/06. PubMed PMID: 14704310. 
302. Becker C, Fantini MC, Wirtz S, Nikolaev A, Kiesslich R, Lehr HA, et al. In vivo 
imaging of colitis and colon cancer development in mice using high resolution 
chromoendoscopy. Gut. 2005;54(7):950-4. Epub 2005/06/14. doi: 
10.1136/gut.2004.061283. PubMed PMID: 15951540; PubMed Central PMCID: 
PMC1774595. 
303. Washington MK, Powell AE, Sullivan R, Sundberg JP, Wright N, Coffey RJ, et al. 
Pathology of rodent models of intestinal cancer: progress report and 
recommendations. Gastroenterology. 2013;144(4):705-17. Epub 2013/02/19. doi: 
10.1053/j.gastro.2013.01.067. PubMed PMID: 23415801; PubMed Central PMCID: 
PMC3660997. 
304. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, et al. 
Pathology of mouse models of intestinal cancer: consensus report and 
recommendations. Gastroenterology. 2003;124(3):762-77. Epub 2003/03/04. doi: 
10.1053/gast.2003.50094. PubMed PMID: 12612914. 
305. Koh TS, Benson TH. Critical re-appraisal of fluorometric method for 
determination of selenium in biological materials. J Assoc Off Anal Chem. 
1983;66(4):918-26. Epub 1983/07/01. PubMed PMID: 6885699. 
306. Sheehan TM, Gao M. Simplified fluorometric assay of total selenium in plasma 
and urine. Clin Chem. 1990;36(12):2124-6. Epub 1990/12/01. PubMed PMID: 
2253359. 
307. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient 
rat liver. Biochem Biophys Res Commun. 1976;71(4):952-8. Epub 1976/08/23. doi: 
0006-291X(76)90747-6 [pii]. PubMed PMID: 971321. 
 249 
 
308. Paglia DE, Valentine WN. Studies on the quantitative and qualitative 
characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 
1967;70(1):158-69. Epub 1967/07/01. PubMed PMID: 6066618. 
309. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-
isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2(1):221-6. Epub 
2007/04/03. doi: 10.1038/nprot.2006.375. PubMed PMID: 17401357. 
310. Koller FL, Dozier EA, Nam KT, Swee M, Birkland TP, Parks WC, et al. Lack of 
MMP10 exacerbates experimental colitis and promotes development of 
inflammation-associated colonic dysplasia. Lab Invest. 2012;92(12):1749-59. Epub 
2012/10/10. doi: 10.1038/labinvest.2012.141. PubMed PMID: 23044923; PubMed 
Central PMCID: PMC3510327. 
311. Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, et al. 
Selenium, selenoprotein genes and Crohn's disease in a case-control population 
from Auckland, New Zealand. Nutrients. 2012;4(9):1247-59. Epub 2012/11/01. doi: 
10.3390/nu4091247. PubMed PMID: 23112913; PubMed Central PMCID: 
PMC3475235. 
312. Circu ML, Aw TY. Intestinal redox biology and oxidative stress. Semin Cell 
Dev Biol. 2012;23(7):729-37. Epub 2012/04/10. doi: 
10.1016/j.semcdb.2012.03.014. PubMed PMID: 22484611; PubMed Central PMCID: 
PMC3396776. 
313. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. 
PANTHER: a library of protein families and subfamilies indexed by function. 
Genome Res. 2003;13(9):2129-41. Epub 2003/09/04. doi: 10.1101/gr.772403. 
PubMed PMID: 12952881; PubMed Central PMCID: PMC403709. 
314. Beckett GJ, Arthur JR. Selenium and endocrine systems. J Endocrinol. 
2005;184(3):455-65. Epub 2005/03/08. doi: 10.1677/joe.1.05971. PubMed PMID: 
15749805. 
315. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-
associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 
2003;24(3):353-62. Epub 2003/03/29. PubMed PMID: 12663492. 
316. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. 
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, 
and DNA markers of CCl4 poisoning? Free Radic Biol Med. 2005;38(6):698-710. 
Epub 2005/02/22. doi: 10.1016/j.freeradbiomed.2004.09.017. PubMed PMID: 
15721980. 
317. Ferguson LR, Karunasinghe N, Zhu S, Wang AH. Selenium and its' role in the 
maintenance of genomic stability. Mutat Res.733(1-2):100-10. Epub 2012/01/12. 
doi: S0027-5107(11)00325-3 [pii] 
 250 
 
10.1016/j.mrfmmm.2011.12.011. PubMed PMID: 22234051. 
318. Pegg AE. Methylation of the O6 position of guanine in DNA is the most likely 
initiating event in carcinogenesis by methylating agents. Cancer Invest. 
1984;2(3):223-31. Epub 1984/01/01. PubMed PMID: 6733565. 
319. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal 
neoplasia in experimental murine ulcerative colitis. Gut. 1996;39(1):87-92. Epub 
1996/07/01. PubMed PMID: 8881816; PubMed Central PMCID: PMC1383238. 
320. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel 
method in the induction of reliable experimental acute and chronic ulcerative colitis 
in mice. Gastroenterology. 1990;98(3):694-702. Epub 1990/03/01. PubMed PMID: 
1688816. 
321. Hong MY, Turner ND, Carroll RJ, Chapkin RS, Lupton JR. Differential response 
to DNA damage may explain different cancer susceptibility between small and large 
intestine. Exp Biol Med (Maywood). 2005;230(7):464-71. Epub 2005/06/30. 
PubMed PMID: 15985621. 
322. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-
17C promotes Th17 cell responses and autoimmune disease via interleukin-17 
receptor E. Immunity. 2011;35(4):611-21. Epub 2011/10/11. doi: 
10.1016/j.immuni.2011.09.010. PubMed PMID: 21982598. 
323. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 
2007;13(1):26-8. Epub 2007/01/09. doi: 10.1038/nm0107-26. PubMed PMID: 
17206128. 
324. Damiani CR, Benetton CA, Stoffel C, Bardini KC, Cardoso VH, Di Giunta G, et al. 
Oxidative stress and metabolism in animal model of colitis induced by dextran 
sulfate sodium. J Gastroenterol Hepatol. 2007;22(11):1846-51. Epub 2007/05/11. 
doi: 10.1111/j.1440-1746.2007.04890.x. PubMed PMID: 17489966. 
325. Trivedi PP, Jena GB. Ulcerative colitis-induced hepatic damage in mice: 
studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. 
Chem Biol Interact. 2013;201(1-3):19-30. Epub 2012/12/25. doi: 
10.1016/j.cbi.2012.12.004. PubMed PMID: 23261717. 
326. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J, et al. NK-1 
antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-
induced colitis in rats. Am J Physiol Gastrointest Liver Physiol. 2000;279(6):G1298-
306. Epub 2000/11/30. PubMed PMID: 11093954. 
327. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases 
disease activity and vitamin E ameliorates the effect in rats with dextran sulfate 
 251 
 
sodium-induced colitis. J Nutr. 2002;132(10):3146-50. Epub 2002/10/09. PubMed 
PMID: 12368409. 
328. Ying Y, Liu XM, Marble A, Lawson KA, Zhao GQ. Requirement of Bmp8b for 
the generation of primordial germ cells in the mouse. Mol Endocrinol. 
2000;14(7):1053-63. Epub 2000/07/14. PubMed PMID: 10894154. 
329. Frierson HF, Jr., El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, et al. 
Large scale molecular analysis identifies genes with altered expression in salivary 
adenoid cystic carcinoma. Am J Pathol. 2002;161(4):1315-23. Epub 2002/10/09. 
doi: 10.1016/S0002-9440(10)64408-2. PubMed PMID: 12368205; PubMed Central 
PMCID: PMC1867312. 
330. Langenskiold M, Holmdahl L, Falk P, Angenete E, Ivarsson ML. Increased TGF-
beta 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol. 
2008;97(5):409-15. Epub 2008/01/08. doi: 10.1002/jso.20961. PubMed PMID: 
18176914. 
331. Saltzman BS, Yamamoto JF, Decker R, Yokochi L, Theriault AG, Vogt TM, et al. 
Association of genetic variation in the transforming growth factor beta-1 gene with 
serum levels and risk of colorectal neoplasia. Cancer Res. 2008;68(4):1236-44. Epub 
2008/02/19. doi: 10.1158/0008-5472.CAN-07-2144. PubMed PMID: 18281501. 
332. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. 
ONCOMINE: a cancer microarray database and integrated data-mining platform. 
Neoplasia. 2004;6(1):1-6. Epub 2004/04/08. PubMed PMID: 15068665; PubMed 
Central PMCID: PMC1635162. 
333. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, et al. 
Modeling oncogenic signaling in colon tumors by multidirectional analyses of 
microarray data directed for maximization of analytical reliability. PLoS One. 
2010;5(10). Epub 2010/10/20. doi: 10.1371/journal.pone.0013091. PubMed PMID: 
20957034; PubMed Central PMCID: PMC2948500. 
334. Modjtahedi H, Dean C. The receptor for EGF and its ligands - expression, 
prognostic value and target for therapy in cancer (review). Int J Oncol. 
1994;4(2):277-96. Epub 1994/02/01. PubMed PMID: 21566922. 
335. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling 
and beyond. Nat Rev Cancer. 2010;10(3):165-80. Epub 2010/02/25. doi: 
10.1038/nrc2806. PubMed PMID: 20179713; PubMed Central PMCID: 
PMC2921274. 
336. Hill KE, Zhou J, McMahan WJ, Motley AK, Atkins JF, Gesteland RF, et al. 
Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem. 
2003;278(16):13640-6. Epub 2003/02/08. doi: 10.1074/jbc.M300755200 
 252 
 
M300755200 [pii]. PubMed PMID: 12574155. 
337. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies--
III: statistical associations with dietary selenium intakes. Bioinorg Chem. 
1977;7(1):23-31. Epub 1977/01/01. PubMed PMID: 856291. 
338. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky 
DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in 
ulcerative colitis and Crohn's disease. Gut. 1995;36(5):718-23. Epub 1995/05/01. 
PubMed PMID: 7541008; PubMed Central PMCID: PMC1382676. 
339. Hudson TS, Carlson BA, Hoeneroff MJ, Young HA, Sordillo L, Muller WJ, et al. 
Selenoproteins reduce susceptibility to DMBA-induced mammary carcinogenesis. 
Carcinogenesis. Epub 2012/03/23. doi: bgs129 [pii] 
10.1093/carcin/bgs129. PubMed PMID: 22436612. 
340. Maiorino M, Aumann KD, Brigelius-Flohe R, Doria D, van den Heuvel J, 
McCarthy J, et al. Probing the presumed catalytic triad of selenium-containing 
peroxidases by mutational analysis of phospholipid hydroperoxide glutathione 
peroxidase (PHGPx). Biol Chem Hoppe Seyler. 1995;376(11):651-60. Epub 
1995/11/01. PubMed PMID: 8962674. 
341. Olson GE, Whitin JC, Hill KE, Winfrey VP, Motley AK, Austin LM, et al. 
Extracellular glutathione peroxidase (Gpx3) binds specifically to basement 
membranes of mouse renal cortex tubule cells. Am J Physiol Renal 
Physiol.298(5):F1244-53. Epub 2009/12/18. doi: 00662.2009 [pii] 
10.1152/ajprenal.00662.2009. PubMed PMID: 20015939; PubMed Central PMCID: 
PMC2867408. 
342. Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K. 
Analysis of an expression profile of genes in the human adipose tissue. Gene. 
1997;190(2):227-35. Epub 1997/05/06. doi: S0378-1119(96)00730-5 [pii]. 
PubMed PMID: 9197538. 
343. Chu FF, Esworthy RS, Doroshow JH, Doan K, Liu XF. Expression of plasma 
glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast 
in humans and rodents. Blood. 1992;79(12):3233-8. Epub 1992/06/15. PubMed 
PMID: 1339300. 
344. Tham DM, Whitin JC, Kim KK, Zhu SX, Cohen HJ. Expression of extracellular 
glutathione peroxidase in human and mouse gastrointestinal tract. Am J Physiol. 
1998;275(6 Pt 1):G1463-71. Epub 1998/12/09. PubMed PMID: 9843785. 
 253 
 
345. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, et al. Human 
kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J 
Physiol. 1994;266(2 Pt 1):C367-75. Epub 1994/02/01. PubMed PMID: 8141250. 
346. Burk RF, Olson GE, Winfrey VP, Hill KE, Yin D. Glutathione peroxidase-3 
produced by the kidney binds to a population of basement membranes in the 
gastrointestinal tract and in other tissues. Am J Physiol Gastrointest Liver 
Physiol.301(1):G32-8. Epub 2011/04/16. doi: ajpgi.00064.2011 [pii] 
10.1152/ajpgi.00064.2011. PubMed PMID: 21493731; PubMed Central PMCID: 
PMC3280860. 
347. Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z. GPx3 promoter 
hypermethylation is a frequent event in human cancer and is associated with 
tumorigenesis and chemotherapy response. Cancer Lett.309(1):37-45. Epub 
2011/06/21. doi: S0304-3835(11)00279-5 [pii] 
10.1016/j.canlet.2011.05.013. PubMed PMID: 21684681. 
348. Zhang X, Yang JJ, Kim YS, Kim KY, Ahn WS, Yang S. An 8-gene signature, 
including methylated and down-regulated glutathione peroxidase 3, of gastric 
cancer. Int J Oncol.36(2):405-14. Epub 2010/01/01. PubMed PMID: 20043075. 
349. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, et al. Glutathione 
peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer 
growth and metastasis. Cancer Res. 2007;67(17):8043-50. Epub 2007/09/07. doi: 
67/17/8043 [pii] 
10.1158/0008-5472.CAN-07-0648. PubMed PMID: 17804715. 
350. Esworthy RS, Aranda R, Martin MG, Doroshow JH, Binder SW, Chu FF. Mice 
with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol 
Gastrointest Liver Physiol. 2001;281(3):G848-55. Epub 2001/08/24. PubMed PMID: 
11518697. 
351. Chu FF, Esworthy RS, Doroshow JH. Role of Se-dependent glutathione 
peroxidases in gastrointestinal inflammation and cancer. Free Radic Biol Med. 
2004;36(12):1481-95. Epub 2004/06/09. doi: 
10.1016/j.freeradbiomed.2004.04.010 
S0891584904003132 [pii]. PubMed PMID: 15182851. 
352. D'Odorico A, D'Inca R, Mestriner C, Di Leo V, Ferronato A, Sturniolo GC. 
Influence of disease site and activity on peripheral neutrophil function in 
inflammatory bowel disease. Dig Dis Sci. 2000;45(8):1594-600. Epub 2000/09/28. 
PubMed PMID: 11007111. 
 254 
 
353. Eaden J. Review article: colorectal carcinoma and inflammatory bowel 
disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:24-30. Epub 2004/09/09. doi: 
10.1111/j.1365-2036.2004.02046.x 
APT2046 [pii]. PubMed PMID: 15352890. 
354. Mayer R, Wong WD, Rothenberger DA, Goldberg SM, Madoff RD. Colorectal 
cancer in inflammatory bowel disease: a continuing problem. Dis Colon Rectum. 
1999;42(3):343-7. Epub 1999/05/01. PubMed PMID: 10223754. 
355. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. 
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with 
chronic colitis. J Clin Invest. 2008;118(2):560-70. Epub 2008/01/26. doi: 
10.1172/JCI32453. PubMed PMID: 18219394; PubMed Central PMCID: 
PMC2213370. 
356. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. 
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer 
susceptibility. PLoS One. 2009;4(6):e6026. Epub 2009/06/25. doi: 
10.1371/journal.pone.0006026. PubMed PMID: 19551144; PubMed Central PMCID: 
PMC2696084. 
357. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, et al. 
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is 
characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114(3):385-91. 
Epub 1998/12/09. PubMed PMID: 9844047; PubMed Central PMCID: PMC1905133. 
358. Becker C, Fantini MC, Neurath MF. High resolution colonoscopy in live mice. 
Nat Protoc. 2006;1(6):2900-4. Epub 2007/04/05. doi: nprot.2006.446 [pii] 
10.1038/nprot.2006.446. PubMed PMID: 17406549. 
359. Chaturvedi R, Asim M, Romero-Gallo J, Barry DP, Hoge S, de Sablet T, et al. 
Spermine oxidase mediates the gastric cancer risk associated with Helicobacter 
pylori CagA. Gastroenterology.141(5):1696-708 e1-2. Epub 2011/08/16. doi: 
S0016-5085(11)01080-8 [pii] 
10.1053/j.gastro.2011.07.045. PubMed PMID: 21839041; PubMed Central PMCID: 
PMC3202654. 
360. Carlson BA, Yoo MH, Sano Y, Sengupta A, Kim JY, Irons R, et al. Selenoproteins 
regulate macrophage invasiveness and extracellular matrix-related gene expression. 
BMC Immunol. 2009;10:57. Epub 2009/10/30. doi: 1471-2172-10-57 [pii] 
10.1186/1471-2172-10-57. PubMed PMID: 19863805; PubMed Central PMCID: 
PMC2774298. 
 255 
 
361. Yasui Y, Tanaka T. Protein expression analysis of inflammation-related colon 
carcinogenesis. J Carcinog. 2009;8:10. Epub 2009/06/06. doi: 
JCarcinog_2009_8_1_10_51851 [pii] 
10.4103/1477-3163.51851. PubMed PMID: 19491504; PubMed Central PMCID: 
PMC2699605. 
362. Bartsch H, Nair J. Potential role of lipid peroxidation derived DNA damage in 
human colon carcinogenesis: studies on exocyclic base adducts as stable oxidative 
stress markers. Cancer Detect Prev. 2002;26(4):308-12. Epub 2002/11/15. PubMed 
PMID: 12430635. 
363. Fridovich I. Fundamental aspects of reactive oxygen species, or what's the 
matter with oxygen? Ann N Y Acad Sci. 1999;893:13-8. Epub 2000/02/15. PubMed 
PMID: 10672226. 
364. Muscoli C, Cuzzocrea S, Riley DP, Zweier JL, Thiemermann C, Wang ZQ, et al. 
On the selectivity of superoxide dismutase mimetics and its importance in 
pharmacological studies. Br J Pharmacol. 2003;140(3):445-60. Epub 2003/10/03. 
doi: 10.1038/sj.bjp.0705430 
140/3/445 [pii]. PubMed PMID: 14522841; PubMed Central PMCID: PMC1574047. 
365. Dix TA, Hess KM, Medina MA, Sullivan RW, Tilly SL, Webb TL. Mechanism of 
site-selective DNA nicking by the hydrodioxyl (perhydroxyl) radical. Biochemistry. 
1996;35(14):4578-83. Epub 1996/04/09. doi: 10.1021/bi952010w 
bi952010w [pii]. PubMed PMID: 8605208. 
366. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an 
abundant form of oxidative DNA damage, causes G----T and A----C substitutions. J 
Biol Chem. 1992;267(1):166-72. Epub 1992/01/05. PubMed PMID: 1730583. 
367. Hussain SP, Harris CC. Molecular epidemiology of human cancer: 
contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 
1998;58(18):4023-37. Epub 1998/09/29. PubMed PMID: 9751603. 
368. Sica A, Bronte V. Altered macrophage differentiation and immune 
dysfunction in tumor development. J Clin Invest. 2007;117(5):1155-66. Epub 
2007/05/04. doi: 10.1172/JCI31422. PubMed PMID: 17476345; PubMed Central 
PMCID: PMC1857267. 
369. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. 
Regulation of cellular immune responses by selenium. Biol Trace Elem Res. 
1992;33:23-35. Epub 1992/04/01. PubMed PMID: 1379457. 
 256 
 
370. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. 
Supplementation with selenium and human immune cell functions. II. Effect on 
cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res. 1994;41(1-
2):115-27. Epub 1994/04/01. PubMed PMID: 7946899. 
371. Burk RF, Hill KE. Selenoprotein P. A selenium-rich extracellular glycoprotein. 
J Nutr. 1994;124(10):1891-7. Epub 1994/10/01. PubMed PMID: 7931697. 
372. Schomburg L, Schweizer U, Holtmann B, Flohe L, Sendtner M, Kohrle J. Gene 
disruption discloses role of selenoprotein P in selenium delivery to target tissues. 
Biochem J. 2003;370(Pt 2):397-402. Epub 2003/01/11. doi: 10.1042/BJ20021853 
BJ20021853 [pii]. PubMed PMID: 12521380; PubMed Central PMCID: PMC1223208. 
373. Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, Sies H. Protection by 
selenoprotein P in human plasma against peroxynitrite-mediated oxidation and 
nitration. Biol Chem. 1998;379(8-9):1201-5. Epub 1998/10/29. PubMed PMID: 
9792455. 
374. Shamberger RJ, Willis CE. Selenium distribution and human cancer mortality. 
CRC Crit Rev Clin Lab Sci. 1971;2(2):211-21. Epub 1971/06/01. PubMed PMID: 
4950948. 
375. Bosschaerts T, Guilliams M, Noel W, Herin M, Burk RF, Hill KE, et al. 
Alternatively activated myeloid cells limit pathogenicity associated with African 
trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol. 
2008;180(9):6168-75. Epub 2008/04/22. PubMed PMID: 18424738. 
376. Lee SR, Yon JM, Baek IJ, Kim MR, Park CG, Lee BJ, et al. Spatiotemporal 
expression of the selenoprotein P gene in postimplantational mouse embryos. Int J 
Dev Biol. 2008;52(7):1005-11. Epub 2008/10/29. doi: 082656sl [pii] 
10.1387/ijdb.082656sl. PubMed PMID: 18956332. 
377. Olson GE, Winfrey VP, Hill KE, Burk RF. Megalin mediates selenoprotein P 
uptake by kidney proximal tubule epithelial cells. J Biol Chem. 2008;283(11):6854-
60. Epub 2008/01/05. doi: 10.1074/jbc.M709945200. PubMed PMID: 18174160. 
378. Zhang X, Goncalves R, Mosser DM. The isolation and characterization of 
murine macrophages. Curr Protoc Immunol. 2008;Chapter 14:Unit 14 1. Epub 
2008/11/20. doi: 10.1002/0471142735.im1401s83. PubMed PMID: 19016445; 
PubMed Central PMCID: PMC2834554. 
379. Mosser DM, Zhang X. Activation of murine macrophages. Curr Protoc 
Immunol. 2008;Chapter 14:Unit 14 2. Epub 2008/11/20. doi: 
10.1002/0471142735.im1402s83. PubMed PMID: 19016446; PubMed Central 
PMCID: PMC2822273. 
 257 
 
380. Read R, Bellew T, Yang JG, Hill KE, Palmer IS, Burk RF. Selenium and amino 
acid composition of selenoprotein P, the major selenoprotein in rat serum. J Biol 
Chem. 1990;265(29):17899-905. Epub 1990/10/15. PubMed PMID: 2211667. 
381. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, et al. 
Tumor-conditioned macrophages secrete migration-stimulating factor: a new 
marker for M2-polarization, influencing tumor cell motility. J Immunol.185(1):642-
52. Epub 2010/06/10. doi: jimmunol.1000413 [pii] 
10.4049/jimmunol.1000413. PubMed PMID: 20530259. 
382. Ghassabeh GH, De Baetselier P, Brys L, Noel W, Van Ginderachter JA, 
Meerschaut S, et al. Identification of a common gene signature for type II cytokine-
associated myeloid cells elicited in vivo in different pathologic conditions. Blood. 
2006;108(2):575-83. Epub 2006/03/25. doi: 10.1182/blood-2005-04-1485. 
PubMed PMID: 16556895. 
383. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, Sandler RS. 
Selenium, folate, and colon cancer. Nutr Cancer. 2009;61(2):165-78. Epub 
2009/02/24. doi: 10.1080/01635580802404188. PubMed PMID: 19235033; 
PubMed Central PMCID: PMC2743456. 
384. Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, et al. 
Dietary Selenium Deficiency Exacerbates DSS-Induced Epithelial Injury and 
AOM/DSS-Induced Tumorigenesis. PLoS One. 2013;8(7):e67845. Epub 2013/07/19. 
doi: 10.1371/journal.pone.0067845. PubMed PMID: 23861820; PubMed Central 
PMCID: PMC3701622. 
385. Renko K, Werner M, Renner-Muller I, Cooper TG, Yeung CH, Hollenbach B, et 
al. Hepatic selenoprotein P (SePP) expression restores selenium transport and 
prevents infertility and motor-incoordination in Sepp-knockout mice. Biochem J. 
2008;409(3):741-9. Epub 2007/10/27. doi: 10.1042/BJ20071172. PubMed PMID: 
17961124. 
386. Xiao W, Zhu Y, Sarsour EH, Kalen AL, Aykin-Burns N, Spitz DR, et al. 
Selenoprotein P regulates 1-(4-Chlorophenyl)-benzo-2,5-quinone-induced oxidative 
stress and toxicity in human keratinocytes. Free Radic Biol Med. 2013;65C:70-7. 
Epub 2013/06/19. doi: 10.1016/j.freeradbiomed.2013.06.010. PubMed PMID: 
23770201. 
387. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, Jansen-Durr P, et al. 
ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the 
diseased prostatic stroma. Mol Endocrinol. 2011;25(3):503-15. Epub 2011/01/29. 
doi: 10.1210/me.2010-0340. PubMed PMID: 21273445. 
 258 
 
388. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal 
stem cell: mechanism and applications. Science. 2013;340(6137):1190-4. Epub 
2013/06/08. doi: 10.1126/science.1234852. PubMed PMID: 23744940. 
389. Fuller MK, Faulk DM, Sundaram N, Shroyer NF, Henning SJ, Helmrath MA. 
Intestinal crypts reproducibly expand in culture. J Surg Res. 2012;178(1):48-54. 
Epub 2012/05/09. doi: 10.1016/j.jss.2012.03.037. PubMed PMID: 22564827; 
PubMed Central PMCID: PMC3654833. 
390. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, et al. 
Aberrant expression of selenoproteins in the progression of colorectal cancer. 
Cancer Lett. 2008;259(2):218-30. Epub 2007/12/07. doi: 
10.1016/j.canlet.2007.10.019. PubMed PMID: 18054426. 
391. Steinbrenner H, Alili L, Bilgic E, Sies H, Brenneisen P. Involvement of 
selenoprotein P in protection of human astrocytes from oxidative damage. Free 
Radic Biol Med. 2006;40(9):1513-23. Epub 2006/04/25. doi: S0891-
5849(05)00759-8 [pii] 
10.1016/j.freeradbiomed.2005.12.022. PubMed PMID: 16632112. 
392. Gu P, Goodwin B, Chung AC, Xu X, Wheeler DA, Price RR, et al. Orphan nuclear 
receptor LRH-1 is required to maintain Oct4 expression at the epiblast stage of 
embryonic development. Mol Cell Biol. 2005;25(9):3492-505. Epub 2005/04/16. 
doi: 10.1128/MCB.25.9.3492-3505.2005. PubMed PMID: 15831456; PubMed 
Central PMCID: PMC1084298. 
393. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution 
and drug metabolism in humans. Current drug metabolism. 2002;3(6):561-97. Epub 
2002/10/09. PubMed PMID: 12369887. 
394. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and 
steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol 
Gastrointest Liver Physiol. 2001;281(5):G1135-9. Epub 2001/10/23. PubMed PMID: 
11668021. 
395. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse 
somatic mutation patterns and pathway alterations in human cancers. 
Nature.466(7308):869-73. Epub 2010/07/30. doi: nature09208 [pii] 
10.1038/nature09208. PubMed PMID: 20668451. 
396. Chyla B, Moreno-Miralles I, Steapleton M, Thompson M, Bhaskara S, Engel M, 
et al. Deletion of Mtg16, a target of the t(16;21), alters hematopoietic progenitor cell 
proliferation and lineage allocation. Mol Cell Biol. 2008. doi: MCB.00404-08 [pii] 
10.1128/MCB.00404-08. PubMed PMID: 18710942. 
 259 
 
397. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking 
inflammation and cancer. J Immunol. 2009;182(8):4499-506. Epub 2009/04/04. 
doi: 182/8/4499 [pii] 
10.4049/jimmunol.0802740. PubMed PMID: 19342621; PubMed Central PMCID: 
PMC2810498. 
398. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. 
Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci. 
2009;1155:206-21. Epub 2009/03/03. doi: NYAS03704 [pii] 
10.1111/j.1749-6632.2009.03704.x. PubMed PMID: 19250206. 
399. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 
2007;117(5):1137-46. Epub 2007/05/04. doi: 10.1172/JCI31405. PubMed PMID: 
17476343; PubMed Central PMCID: PMC1857231. 
400. Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, et al. IKKbeta 
links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. 
Cell. 2004;118(3):285-96. doi: 10.1016/j.cell.2004.07.013. PubMed PMID: 
15294155. 
401. Popivanova B, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking 
TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. 
J Clin Invest. 2008;118(2):560-70. doi: 10.1172/JCI32453. PubMed PMID: 
18219394. 
402. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, et al. IL-
6 and Stat3 are required for survival of intestinal epithelial cells and development of 
colitis-associated cancer. Cancer Cell. 2009;15(2):103-13. doi: 
10.1016/j.ccr.2009.01.001. PubMed PMID: 19185845. 
403. Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C, et al. 
Modulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer 
Susceptibility. PLoS ONE. 2009;4(6):e6026. doi: 
10.1371/journal.pone.0006026.g007. 
404. Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM. A rat 
monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized 
expression in vivo. Hybridoma (Larchmt). 2007;26(1):22-7. Epub 2007/02/24. doi: 
10.1089/hyb.2006.028. PubMed PMID: 17316082. 
405. Cotta CV, Zhang Z, Kim HG, Klug CA. Pax5 determines B- versus T-cell fate 
and does not block early myeloid-lineage development. Blood. 2003;101(11):4342-
6. Epub 2003/02/01. doi: 10.1182/blood-2002-10-3139 
2002-10-3139 [pii]. PubMed PMID: 12560221. 
 260 
 
406. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal 
tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc 
Natl Acad Sci U S A. 1997;94(4):1402-7. Epub 1997/02/18. PubMed PMID: 
9037065; PubMed Central PMCID: PMC19803. 
407. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-
associated macrophages in neoplastic progression and immune surveillance. 
Immunol Rev. 2008;222:155-61. doi: 10.1111/j.1600-065X.2008.00607.x. PubMed 
PMID: 18364000. 
408. Kozu T, Komori A, Sueoka E, Fujiki H, Kaneko Y, Matsui T, et al. Significance of 
MTG8 in leukemogenesis. Leukemia. 1997;11 Suppl 3:297-8. Epub 1997/04/01. 
PubMed PMID: 9209371. 
409. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for 
the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009;6(5):297-
305. Epub 2009/05/01. doi: nrgastro.2009.44 [pii] 
10.1038/nrgastro.2009.44. PubMed PMID: 19404270. 
410. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in 
colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004;23(1-
2):119-35. Epub 2004/03/06. PubMed PMID: 15000153. 
411. Sinnamon MJ, Carter KJ, Fingleton B, Matrisian LM. Matrix metalloproteinase-
9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli 
multiple intestinal neoplasia mouse. Int J Exp Pathol. 2008;89(6):466-75. Epub 
2009/01/13. doi: IEP621 [pii] 
10.1111/j.1365-2613.2008.00621.x. PubMed PMID: 19134056; PubMed Central 
PMCID: PMC2669608. 
412. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] 
expression selects for cells with reduced sensitivity to apoptosis. Neoplasia. 
2001;3(6):459-68. Epub 2002/01/05. doi: 10.1038/sj/neo/7900190. PubMed 
PMID: 11774028; PubMed Central PMCID: PMC1506562. 
413. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The 
metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and 
potentiates epithelial cell apoptosis. Curr Biol. 1999;9(24):1441-7. Epub 
1999/12/23. doi: S0960-9822(00)80113-X [pii]. PubMed PMID: 10607586. 
414. Yu WH, Woessner JF, Jr., McNeish JD, Stamenkovic I. CD44 anchors the 
assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor 
precursor and ErbB4 and regulates female reproductive organ remodeling. Genes 
Dev. 2002;16(3):307-23. Epub 2002/02/05. doi: 10.1101/gad.925702. PubMed 
PMID: 11825873; PubMed Central PMCID: PMC155329. 
 261 
 
415. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, et al. 
Release of an invasion promoter E-cadherin fragment by matrilysin and 
stromelysin-1. J Cell Sci. 2001;114(Pt 1):111-8. Epub 2000/12/12. PubMed PMID: 
11112695. 
416. Sasai N, Nakao M, Defossez PA. Sequence-specific recognition of methylated 
DNA by human zinc-finger proteins. Nucleic Acids Res.38(15):5015-22. Epub 
2010/04/21. doi: gkq280 [pii] 
10.1093/nar/gkq280. PubMed PMID: 20403812; PubMed Central PMCID: 
PMC2926618. 
417. Bethany A. Buck-Koehntop MAM-Y, H. Jane Dyson, Peter E. Wright. Kaiso uses 
all three zinc fingers and adjacent sequence motifs for high affinity binding to 
sequence-specific and methyl-CpG DNA targets. FEBS J. 2012;586:734-9. Epub 30 
January 2012. 
418. Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K, et al. Kaiso/p120-catenin 
and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. 
Dev Cell. 2005;8(6):843-54. Epub 2005/06/07. doi: S1534-5807(05)00141-3 [pii] 
10.1016/j.devcel.2005.04.010. PubMed PMID: 15935774. 
419. Del Valle-Perez B, Casagolda D, Lugilde E, Valls G, Codina M, Dave N, et al. 
Wnt controls the transcriptional activity of Kaiso through CK1epsilon-dependent 
phosphorylation of p120-catenin. J Cell Sci.124(Pt 13):2298-309. Epub 2011/06/15. 
doi: 124/13/2298 [pii] 
10.1242/jcs.082693. PubMed PMID: 21670201. 
420. Dai SD, Wang Y, Zhang JY, Zhang D, Zhang PX, Jiang GY, et al. Upregulation of 
delta-catenin is associated with poor prognosis and enhances transcriptional 
activity through Kaiso in non-small-cell lung cancer. Cancer Sci.102(1):95-103. Epub 
2010/11/13. doi: 10.1111/j.1349-7006.2010.01766.x. PubMed PMID: 21070476. 
421. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, et al. 
Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in 
breast cancer. Oncogene.31(8):1034-44. Epub 2011/07/19. doi: onc2011296 [pii] 
10.1038/onc.2011.296. PubMed PMID: 21765466; PubMed Central PMCID: 
PMC3288192. 
422. Hartley JL, Temple, G.F., Brasch, M.A. DNA Cloning Using In Vitro Site-Specific 
Recombination. Genome Res. 2000(10):1788-95. doi: 10.1101/gr.143000. 
423. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. 
Experimentally derived metastasis gene expression profile predicts recurrence and 
 262 
 
death in patients with colon cancer. Gastroenterology.138(3):958-68. Epub 
2009/11/17. doi: S0016-5085(09)01964-7 [pii] 
10.1053/j.gastro.2009.11.005. PubMed PMID: 19914252. 
424. Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, et al. BVES 
regulates EMT in human corneal and colon cancer cells and is silenced via promoter 
methylation in human colorectal carcinoma. J Clin Invest.121(10):4056-69. Epub 
2011/09/14. doi: 44228 [pii] 
10.1172/JCI44228. PubMed PMID: 21911938; PubMed Central PMCID: 
PMC3195453. 
425. Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, et al. Claudin-1 
up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer 
cells. Gastroenterology.141(6):2140-53. Epub 2011/09/01. doi: S0016-
5085(11)01221-2 [pii] 
10.1053/j.gastro.2011.08.038. PubMed PMID: 21878201. 
426. Soler E, Andrieu-Soler C, de Boer E, Bryne JC, Thongjuea S, Stadhouders R, et 
al. The genome-wide dynamics of the binding of Ldb1 complexes during erythroid 
differentiation. Genes Dev.24(3):277-89. Epub 2010/02/04. doi: 24/3/277 [pii] 
10.1101/gad.551810. PubMed PMID: 20123907; PubMed Central PMCID: 
PMC2811829. 
427. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, et al. MMP-7 
promotes prostate cancer-induced osteolysis via the solubilization of RANKL. 
Cancer Cell. 2005;7(5):485-96. Epub 2005/05/17. doi: S1535-6108(05)00124-8 
[pii] 
10.1016/j.ccr.2005.04.013. PubMed PMID: 15894268. 
428. Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, et al. 
Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor 
proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer. 
2007;58(3):384-91. Epub 2007/08/31. doi: S0169-5002(07)00414-X [pii] 
10.1016/j.lungcan.2007.07.005. PubMed PMID: 17728005. 
429. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase 
expression in tumor invasion. FASEB J. 1999;13(8):781-92. Epub 1999/05/04. 
PubMed PMID: 10224222. 
430. Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell 
JA, et al. The PEA3 subfamily of Ets transcription factors synergizes with beta-
 263 
 
catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol. 
2001;21(4):1370-83. PubMed PMID: 11158322. 
431. Jiang G, Wang Y, Dai S, Liu Y, Stoecker M, Wang E. P120-catenin isoforms 1 
and 3 regulate proliferation and cell cycle of lung cancer cells via beta-catenin and 
Kaiso respectively. PLoS One.7(1):e30303. Epub 2012/01/26. doi: 
10.1371/journal.pone.0030303 
PONE-D-11-19390 [pii]. PubMed PMID: 22276175; PubMed Central PMCID: 
PMC3262806. 
432. van Roy FM, McCrea PD. A role for Kaiso-p120ctn complexes in cancer? Nat 
Rev Cancer. 2005;5(12):956-64. Epub 2005/11/19. doi: nrc1752 [pii] 
10.1038/nrc1752. PubMed PMID: 16294216. 
433. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. beta-catenin regulates the 
expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J 
Pathol. 1999;155(4):1033-8. Epub 1999/10/09. doi: S0002-9440(10)65204-2 [pii]. 
PubMed PMID: 10514384; PubMed Central PMCID: PMC1867011. 
434. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ, et al. Fibulin-3 promoter 
methylation alters the invasive behavior of non-small cell lung cancer cell lines via 
MMP-7 and MMP-2 regulation. Int J Oncol.40(2):402-8. Epub 2011/09/09. doi: 
10.3892/ijo.2011.1191. PubMed PMID: 21901248. 
435. Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, Mao TL, et al. Mesothelin 
enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and 
JNK pathways. Biochem J.442(2):293-302. Epub 2011/10/18. doi: BJ20110282 [pii] 
10.1042/BJ20110282. PubMed PMID: 21999204. 
436. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic 
remodeling of the extracellular matrix. Am J Pathol. 1996;148(5):1345-50. Epub 
1996/05/01. PubMed PMID: 8623905; PubMed Central PMCID: PMC1861572. 
437. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors 
and cancer: trials and tribulations. Science. 2002;295(5564):2387-92. Epub 
2002/03/30. doi: 10.1126/science.1067100 
295/5564/2387 [pii]. PubMed PMID: 11923519. 
438. Hai T, Hartman MG. The molecular biology and nomenclature of the 
activating transcription factor/cAMP responsive element binding family of 
transcription factors: activating transcription factor proteins and homeostasis. 
Gene. 2001;273(1):1-11. Epub 2001/08/03. doi: S0378-1119(01)00551-0 [pii]. 
PubMed PMID: 11483355. 
 264 
 
439. van Dam H, Castellazzi M. Distinct roles of Jun : Fos and Jun : ATF dimers in 
oncogenesis. Oncogene. 2001;20(19):2453-64. Epub 2001/06/13. doi: 
10.1038/sj.onc.1204239. PubMed PMID: 11402340. 
440. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P, DeRaemy-Schenk AM, 
Chen BP, Hai T, et al. Cyclic AMP-independent ATF family members interact with NF-
kappa B and function in the activation of the E-selectin promoter in response to 
cytokines. Mol Cell Biol. 1993;13(11):7180-90. Epub 1993/11/01. PubMed PMID: 
7692236; PubMed Central PMCID: PMC364779. 
441. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. 
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-
c-Jun pathway. Nat Genet. 2007;39(6):741-9. Epub 2007/05/01. doi: ng2033 [pii] 
10.1038/ng2033. PubMed PMID: 17468757. 
442. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. 
p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and 
differentiation. Nat Genet. 2007;39(6):750-8. Epub 2007/05/01. doi: ng2037 [pii] 
10.1038/ng2037. PubMed PMID: 17468755. 
443. Kajino T, Omori E, Ishii S, Matsumoto K, Ninomiya-Tsuji J. TAK1 MAPK kinase 
kinase mediates transforming growth factor-beta signaling by targeting SnoN 
oncoprotein for degradation. J Biol Chem. 2007;282(13):9475-81. Epub 
2007/02/06. doi: M700875200 [pii] 
10.1074/jbc.M700875200. PubMed PMID: 17276978; PubMed Central PMCID: 
PMC2175395. 
444. Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, et al. Kaiso 
directs the transcriptional corepressor MTG16 to the Kaiso binding site in target 
promoters. PLoS One. 2012;7(12):e51205. Epub 2012/12/20. doi: 
10.1371/journal.pone.0051205. PubMed PMID: 23251453; PubMed Central PMCID: 
PMC3521008. 
445. . !!! INVALID CITATION !!! 
446. Kim SW, Park JI, Spring CM, Sater AK, Ji H, Otchere AA, et al. Non-canonical 
Wnt signals are modulated by the Kaiso transcriptional repressor and p120-catenin. 
Nat Cell Biol. 2004;6(12):1212-20. Epub 2004/11/16. doi: 10.1038/ncb1191. 
PubMed PMID: 15543138. 
447. Rodova M, Kelly KF, VanSaun M, Daniel JM, Werle MJ. Regulation of the 
rapsyn promoter by kaiso and delta-catenin. Mol Cell Biol. 2004;24(16):7188-96. 
Epub 2004/07/30. doi: 10.1128/MCB.24.16.7188-7196.2004. PubMed PMID: 
15282317; PubMed Central PMCID: PMC479716. 
 265 
 
448. Dhir M, Montgomery EA, Glockner SC, Schuebel KE, Hooker CM, Herman JG, et 
al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel 
disease (IBD) associated neoplasia. Journal of gastrointestinal surgery : official 
journal of the Society for Surgery of the Alimentary Tract. 2008;12(10):1745-53. 
Epub 2008/08/22. doi: 10.1007/s11605-008-0633-5. PubMed PMID: 18716850. 
449. Massague J. A very private TGF-beta receptor embrace. Mol Cell. 
2008;29(2):149-50. Epub 2008/02/05. doi: 10.1016/j.molcel.2008.01.006. PubMed 
PMID: 18243107. 
450. Gonsalves FC, Klein K, Carson BB, Katz S, Ekas LA, Evans S, et al. An RNAi-
based chemical genetic screen identifies three small-molecule inhibitors of the 
Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011;108(15):5954-63. 
Epub 2011/03/12. doi: 10.1073/pnas.1017496108. PubMed PMID: 21393571; 
PubMed Central PMCID: PMC3076864. 
451. Moossavi S, Bishehsari F. Inflammation in sporadic colorectal cancer. Arch 
Iran Med. 2012;15(3):166-70. Epub 2012/03/01. doi: 012153/AIM.0012. PubMed 
PMID: 22369306. 
452. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, 3rd, et al. 
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family 
receptor tyrosine kinases. J Biol Chem. 2004;279(45):47050-6. Epub 2004/09/04. 
doi: 10.1074/jbc.M409703200. PubMed PMID: 15345710. 
453. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, et al. The pan-
ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a 
tumor suppressor. Cell. 2012;149(1):146-58. Epub 2012/04/03. doi: 
10.1016/j.cell.2012.02.042. PubMed PMID: 22464327; PubMed Central PMCID: 
PMC3563328. 
454. el Marjou F, Janssen KP, Chang BH, Li M, Hindie V, Chan L, et al. Tissue-
specific and inducible Cre-mediated recombination in the gut epithelium. Genesis. 
2004;39(3):186-93. Epub 2004/07/30. doi: 10.1002/gene.20042. PubMed PMID: 
15282745. 
455. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. 
Science. 1995;269(5229):1427-9. Epub 1995/09/08. PubMed PMID: 7660125. 
456. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, et al. Wnt 
pathway inhibition via the targeting of Frizzled receptors results in decreased 
growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 
2012;109(29):11717-22. Epub 2012/07/04. doi: 10.1073/pnas.1120068109. 
PubMed PMID: 22753465; PubMed Central PMCID: PMC3406803. 
 
 266 
 
 
